---
document_datetime: 2023-09-21 17:28:48
document_pages: 131
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/tagrisso-h-c-4124-ii-0019-epar-assessment-report-variation_en.pdf
document_name: tagrisso-h-c-4124-ii-0019-epar-assessment-report-variation_en.pdf
version: success
processing_time: 222.231175
conversion_datetime: 2025-12-14 21:33:00.509773
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

26 April 2018 EMA/396618/2018 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## TAGRISSO

International non-proprietary name: osimertinib

Procedure No. EMEA/H/C/004124/II/0019

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................6                                                           |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation                                                                                                      | ..................................................................................................6       |
| 1.2. Steps taken for the assessment of the product.........................................................7                |                                                                                                           |
| 2. Scientific discussion ................................................................................8                  |                                                                                                           |
| 2.1. Introduction.........................................................................................................8 |                                                                                                           |
| 2.2. Non-clinical aspects                                                                                                   | ..............................................................................................9           |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | ...........................................................9                                              |
| 2.2.2. Discussion on non-clinical aspects......................................................................10           |                                                                                                           |
| 2.2.3. Conclusion on the non-clinical aspects................................................................10             |                                                                                                           |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................11      |
| 2.3.1. Introduction....................................................................................................11   |                                                                                                           |
| 2.3.2. Pharmacokinetics.............................................................................................12      |                                                                                                           |
| 2.3.3. Pharmacodynamics..........................................................................................24         |                                                                                                           |
| 2.3.4. PK/PD modelling..............................................................................................26      |                                                                                                           |
| 2.3.5. Discussion on clinical                                                                                               | pharmacology...................................................................29                         |
| 2.3.6. Conclusions on clinical pharmacology.................................................................31              |                                                                                                           |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................31      |
| 2.4.1. Dose response study(ies)                                                                                             | .................................................................................31                       |
| 2.4.2. Main study......................................................................................................32   |                                                                                                           |
| 2.4.3. Discussion on clinical efficacy............................................................................69        |                                                                                                           |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................74          |                                                                                                           |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................75    |
| 2.5.1. Discussion on clinical safety ............................................................................           | 117                                                                                                       |
| 2.5.2. Conclusions on clinical safety ..........................................................................            | 120                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                           | ................................................................................................... 120   |
| 2.6. Risk management plan......................................................................................             | 120                                                                                                       |
| 2.7. Update of the Product information                                                                                      | ...................................................................... 126                                |
| 2.7.1. User consultation...........................................................................................         | 126                                                                                                       |
| 3. Benefit-Risk Balance............................................................................127                      |                                                                                                           |
| 3.1. Therapeutic Context                                                                                                    | ......................................................................................... 127             |
| 3.1.1. Disease or condition.......................................................................................          | 127                                                                                                       |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 127                                                                                                       |
| 3.1.3. Main clinical studies                                                                                                | ....................................................................................... 128               |
| 3.2. Favourable effects                                                                                                     | ............................................................................................ 128          |
| 3.3. Uncertainties and limitations about favourable effects...........................................                      | 128                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................          | 129                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | ....................................... 129                                                               |
| 3.6. Effects Table....................................................................................................      | 130                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                  | 130                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                        | 130                                                                                                       |
| 3.7.2. Balance of benefits and risks...........................................................................             | 131                                                                                                       |
| 3.8. Conclusions                                                                                                            | ..................................................................................................... 131 |

<div style=\"page-break-after: always\"></div>

4. Recommendations ...............................................................................  131

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AE

Adverse event

AESI

Adverse events of special interest

ALT

Alanine aminotransferase

AST

Aspartate aminotransferase

AUC

Area under the curve

AUCss

Area under the concentration-time curve at steady-state

BBB

Blood brain barrier

BICR

Blinded independent central review

cEFR

CNS evaluable-for-response analysis set

cFAS

CNS full analysis set

CI

Confidence interval

Cmax:Cmin

Maximum plasma concentration: minimum plasma concentration

Css,max

Mean maximum plasma concentration at steady state

CNS

Central nervous system

CNS

MTS CNS metastases subgroup of the study FAS

CTCAE

Common Terminology Criteria for Adverse Events

ctDNA

Circulating tumour deoxyribonucleic acid

DCO

Data cut-off

DCR

Disease control rate

DoR

Duration of response

EGFR

Epidermal growth factor receptor

EGFRm

Epidermal growth factor receptor-tyrosine kinase inhibitor sensitising mutation,

including exon 19 deletion and exon 21 L858R substitution

EGFR-TKI

Epidermal growth factor receptor-tyrosine kinase inhibitor

EMA

European Medicines Agency

ERA

Environmental Risk Assessment

Ex19del

Deletion in Exon 19

FAS

Full analysis set

FDA

Food and Drug Administration (US Department of Health and Human Sciences)

GCP

Good Clinical Practice

HR

Hazard ratio

HRQL

Health-related quality of life

ICH

International Conference on Harmonisation

ILD

Interstitial lung disease

ITT

Intention-to-treat

L858R

Sensitising mutation in the EGFR gene with substitution of a leucine with an arginine at

position 858 in exon 21

LLN

Lower limit of normal

LVEF

Left ventricular ejection fraction

NCCN

National Comprehensive Cancer Network

NL

New lesion

NSCLC

Non-small cell lung cancer

NTL

Non-target lesion

OR

Odds ratio

ORR

Objective response rate

OS

Overall survival

<div style=\"page-break-after: always\"></div>

| PD         | Progressive disease                                                                                                                     |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| PFS        | Progression-free survival                                                                                                               |
| PFS2       | Time from randomisation to second progression on subsequent anti-cancer therapy                                                         |
| PRO        | Patient reported outcomes                                                                                                               |
| PRO-CTCAE  | Patient-reported outcomes version of the Common Terminology Criteria for Adverse Events                                                 |
| PS         | Performance status                                                                                                                      |
| PT         | Preferred term                                                                                                                          |
| QD         | Once daily                                                                                                                              |
| QoL        | Quality of life                                                                                                                         |
| QT         | ECG interval measured from the onset of the QRS complex to the end of the T wave                                                        |
| QTc        | QT interval corrected for heart rate                                                                                                    |
| RECIST 1.1 | Response Evaluation Criteria in Solid Tumours version 1.1                                                                               |
| SAE        | Serious adverse event                                                                                                                   |
| SD         | Stable disease                                                                                                                          |
| SMQ        | Standardised MedDRA query                                                                                                               |
| SoC        | Standard of Care                                                                                                                        |
| SOC        | System organ class                                                                                                                      |
| T790M      | Second-site EGFR point mutation that results in substitution of threonine with methionine at amino acid position 790 (T790M) in exon 20 |
| TdP        | Torsade de pointes                                                                                                                      |
| TDT        | Time from randomisation to discontinuation of randomised treatment or death                                                             |
| TFST       | Time from randomisation to first subsequent therapy or death                                                                            |
| TL         | Target lesion                                                                                                                           |
| TSST       | Time from randomisation to second subsequent therapy or death                                                                           |
| ULN        | Upper limit of normal                                                                                                                   |
| WHO        | World Health Organisation                                                                                                               |
| WT         | Wild-type                                                                                                                               |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, AstraZeneca AB submitted to the European Medicines Agency on 26 October 2017 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, IIIB and IV     |

Extension of Indication to include first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer whose tumours have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations, based on data from the FLAURA study (D5160C00007): a phase III, double-blind, randomised study to assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor-Tyrosine Kinase Inhibitor as firstline treatment in patients with epidermal growth factor receptor mutation-positive, locally-advanced or metastatic non-small-cell lung cancer; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 of the SmPC were proposed to be updated and the Package Leaflet was proposed to be updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC and Package Leaflet.

As part of this application the MAH is requesting an additional year of market protection for a new indication in accordance with Article 14(11) of Regulation (EC) No 726/2004.

An updated RMP version 8 was submitted as part of the application.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0222/2017 on the granting of a (product-specific) waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication.

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Jorge Camarero Jiménez

Co-Rapporteur:

Bjorg Bolstad

| Timetable                                                                                                                                                                                                                                                                                       | Actual dates     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Submission date                                                                                                                                                                                                                                                                                 | 26 October 2017  |
| Start of procedure                                                                                                                                                                                                                                                                              | 25 November 2017 |
| CHMP Rapporteur Assessment Report                                                                                                                                                                                                                                                               | 19 January 2018  |
| CHMP Co-Rapporteur Assessment Report                                                                                                                                                                                                                                                            | 19 January 2018  |
| PRAC Rapporteur Assessment Report                                                                                                                                                                                                                                                               | 25 January 2018  |
| PRAC members comments                                                                                                                                                                                                                                                                           | 31 January 2018  |
| Updated PRAC Rapporteur Assessment Report                                                                                                                                                                                                                                                       | N/A              |
| PRAC Outcome                                                                                                                                                                                                                                                                                    | 08 February 2018 |
| CHMP members comments                                                                                                                                                                                                                                                                           | 12 February 2018 |
| Updated CHMP Rapporteur joint Assessment Report                                                                                                                                                                                                                                                 | 15 February 2018 |
| Request for Supplementary Information (RSI)                                                                                                                                                                                                                                                     | 22 February 2018 |
| PRAC Rapporteur response Assessment Report                                                                                                                                                                                                                                                      | 03 April 2018    |
| CHMP Rapporteur joint response Assessment Report                                                                                                                                                                                                                                                | 11 April 2018    |
| CHMP Rapporteur Assessment Report on one additional year of Marketing Protection                                                                                                                                                                                                                | 11 April 2018    |
| PRAC Outcome                                                                                                                                                                                                                                                                                    | 12 April 2018    |
| CHMP members comments                                                                                                                                                                                                                                                                           | 19 April 2018    |
| Updated CHMP Rapporteur joint response Assessment Report                                                                                                                                                                                                                                        | 20 April 2018    |
| CHMP opinion                                                                                                                                                                                                                                                                                    | 26 April 2018    |
| The CHMP adopted a report on the novelty of the indication/significant clinical benefit for Tagrisso in comparison with existing therapies (Appendix 1) for the purpose of granting an additional year of marketing protection in accordance with Article 14(11) of Regulation (EC) No 726/2004 | 26 April 2018    |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

Osimertinib  (TAGRISSO™2)  is  an  epidermal  growth  factor  receptor-tyrosine  kinase  inhibitor  (EGFRTKI), first approved by the EMA in 2016 for the treatment of adult patients with locally advanced or metastatic  epidermal  growth  factor  receptor  (EGFR)  T790M  mutation-positive  non-small  cell  lung cancer (NSCLC).

This application is being submitted to support the additional indication for use of osimertinib 80 mg (40 mg and 80 mg oral tablets) once daily (QD), as first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have EGFR exon 19 deletions (Ex19del) or substitution of a leucine with an arginine at position 858 in exon 21 (L858R) mutations.

## Disease background

Despite progress in early detection and treatment, in 70% to 80% of patients, NSCLC is diagnosed at a locally  advanced  or  metastatic  stage  (AJCC  Stage  IIIB  and  IV;  referred  to  as  advanced  hereafter), when it is no longer amenable to curative surgery or chemoradiation (Besse et al 2014). Furthermore, a  significant  percentage  of  early-stage  NSCLC  patients  who  have  undergone  surgery  subsequently have recurrence with distant metastases and die as a result of their lung cancer, with 30% to 49% of early-stage  patients  surviving  for  5  years  (Carnio  et  al  2011,  Hung  et  al  2012,  Uramoto  &amp;  Tanaka 2014, Varela &amp; Thomas 2014) and a much lower 5- year survival rate was observed for patients who did not undergo surgery (Rosen et al 2016). In summary, advanced NSCLC is an incurable condition.

Recent  advances  in  the  knowledge  of  tumour-specific  genomic  abnormalities  have  enabled  the identification of specific molecular targets for NSCLC treatment in the current clinical practice (Keedy et al 2011, Leighl et al 2014, NCCN 2017, Novello et al 2016, Travis et al 2011). Several biomarkers have shown to be predictive of therapeutic efficacy of molecularly targeted agents and immune-oncology agents, including the presence of sensitising EGFR mutations, anaplastic lymphoma kinase (ALK) gene rearrangement,  ROS  proto-oncogene  1  receptor  tyrosine  kinase  (ROS1)  gene  rearrangement  and overexpression of programmed cell death-ligand 1 (PD-L1) and all these biomarkers are now routinely tested to establish the optimal treatment choice.

The  EGFR  is  a  member  of  the  ErbB  family  of  receptors  tyrosine  kinases  that  are  essential  to  cell proliferation and survival (Shea et al 2016). The sensitising mutations in the kinase domain of EGFR increase  the  affinity  of  EGFR  towards  EGFR-TKIs  over  ATP  and  are  found  in  approximately  15%  of patients  with  lung  cancer  in  the  US  (Keedy  et  al  2011),  10%  of  patients  with  lung  cancer  in  the European Economic Area (Barlesi et al 2013, Esteban et al 2015, Gahr et al 2013, Herbst et al 2008, Rosell et al 2009), and 30% to 50% of patients with lung cancer in Asia (Ahn et al. 2015, Han et al 2015, Shi et al 2014, Tokumo et al 2005, Yoshida et al 2007).

In addition to the higher prevalence of EGFR mutations in Asian patients, overall, EGFR mutations have been  found  to  be  more  frequent  in  never-smokers,  patients  with  the  adenocarcinoma  histological subtype, and in women (Marchetti et al 2005, Novello et al 2016).

The two most frequent sensitising mutations are Ex19del and L858R that account for 85-90% of EGFRTKI-sensitising mutations found in NSCLC (Lynch et al 2004; Paez et al 2004). Tumours harbouring these  mutations  are  particularly  sensitive  towards  EGFR-TKIs  and  undergo  significant  apoptosis  in response  to  exposure  to  these  agents  (Mitsudomi  and  Yatabe  2010).  Multiple  randomised  clinical

<div style=\"page-break-after: always\"></div>

studies  have  shown  that  the  presence  of  common  sensitising  EGFR  mutations  in  patients  with advanced NSCLC is predictive of response and improved treatment outcome to EGFR-TKIs. Patients with  less  common  sensitising  EGFR  mutations  such  as  L861Q  or  G719X,  while  still  benefitting  from EGFR-TKIs, have a lesser magnitude of benefit.

## Current standard of care in the proposed indication

Molecular testing of tumours in patients with advanced NSCLC is now established practice to determine the preferred choice as first-line therapy.

Epidermal  growth  factor  receptor-  TKIs  such  as  such  as  gefitinib,  erlotinib,  afatinib  are  the  current standard of care (SoC) as first-line therapy for EGFR mutation-positive NSCLC (NCCN 2017, Novello et al 2016).

Though most tumours initially respond well systemically to the currently approved EGFRTKIs in firstline setting, the vast majority of patients develop TKI resistance with a median PFS of 9 to 13 months. In approximately 50% to 65% of the patients the resistance is due to the development of a secondsite  EGFR-TKI  resistance-conferring  'gatekeeper'  point  mutation,  T790M  leading  to  treatment  failure and disease progression (Jackman et al 2009, Maemondo et al 2010, Mitsudomi et al 2010, Mok et al 2009, Oxnard et al 2011, Rosell et al 2012, Sebastian et al 2014).

Patients who develop, or are diagnosed with, central nervous system (CNS) metastases currently have limited treatment options resulting in poorer outcomes (Mak et al 2015). Limited data are available on the efficacy of EGFR-TKIs against CNS metastases in first-line setting, given that CNS metastases have been a typical exclusion criterion in historical studies involving these agents (Bartolotti et al 2012). A selection  of  trials  studying  the  activity  of  EGFR-TKIs  in  patients  with  NSCLC  harbouring  EGFR mutations and CNS metastases report response rates of 70-85% (Zimmermann et al 2014).

Despite significant  progress  achieved  since  the  introduction  of  EGFR-TKIs  into  clinical  practice  more than  a  decade  ago,  there  is  still  a  considerable  unmet  medical  need  for  new  treatment  options  for patients in this disease setting. Inevitably, a majority of patients develop resistance to EGFR-TKIs with the  most  common  resistance  being  associated  with  secondary  T790M  mutation.  In  sites  of  very common metastatic disease such as the CNS, the suboptimal exposure provided by currently approved EGFR-TKIs allows the disease to spread into the CNS and the formation of CNS metastases.

The applicant requested the approval for the following indication:

TAGRISSO is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small  cell  lung  cancer  (NSCLC)  whose  tumours  have  epidermal  growth  factor  receptor  (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

The indication approved by the CHMP was as follows: TAGRISSO as monotherapy is indicated for the first-line  treatment  of  adult  patients  with  locally  advanced  or  metastatic  non-small  cell  lung  cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

The MAH submitted an update of the ERA (Environmental Risk Assessment).

<div style=\"page-break-after: always\"></div>

Table 2: Summary of main study results

| Substance (INN/Invented Name): Osimertinib (Tagrisso)   | Substance (INN/Invented Name): Osimertinib (Tagrisso)   | Substance (INN/Invented Name): Osimertinib (Tagrisso)       | Substance (INN/Invented Name): Osimertinib (Tagrisso)   |
|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------|
| CAS-number: 1421373-66-1                                | CAS-number: 1421373-66-1                                | CAS-number: 1421373-66-1                                    | CAS-number: 1421373-66-1                                |
| PBT screening                                           |                                                         | Result                                                      | Conclusion                                              |
| Bioaccumulation potential- log K ow                     | OECD107                                                 | pH 4 log Dow = 1.77 pH 7 log Dow = 2.45 pH 9 log Dow = 2.69 | Potential PBT (N)                                       |
| Phase I                                                 | Phase I                                                 | Phase I                                                     | Phase I                                                 |
| Calculation                                             | Value                                                   | Unit                                                        | Conclusion                                              |
| PEC surfacewater , refined with prevalence data         | 0.0023                                                  | µ g/L                                                       | > 0.01 threshold (N)                                    |

## 2.2.2. Discussion on non-clinical aspects

No new non-clinical data have been submitted with this new indication of Tagrisso, which is considered acceptable.

In relation to the ERA, due to the lack of robust epidemiology data available for the prevalence of exon 19  deletions  and  exon  21  (L858R)  substitution  mutations,  the  prevalence  rate  was  not  refined  for mutation status of EGFR NSCLC and the revised assessment uses a worst-case scenario and is based on the incidence of all EGFR mutations (7-13%).

Thus, the highest reported incidence rates of NSCLC (89%) and EGFR mutation (13%) were applied to the overall prevalence rate of lung cancer for Hungary (European member state with the highest single year prevalence of lung cancer) to calculate the market penetration factor (Fpen = 0.000058).

The data show that the refined PECsurfacewater value for osimertinib mesylate is below the action limit of 0.01 µg/L and it is not a PBT substance, as log Dow does not exceed the trigger value of 4.5. The octanol-water partition values indicate that the risk of bioaccumulation is low.

Thus, osimertinib mesylate is not expected to pose a risk to the environment.

In  addition,  as  required  by  Directive  2001/83/EC  and  EMA  Quality  Review  Document,  the  following statement has been included in the Tagrisso package leaflet: Do  not  throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

## 2.2.3. Conclusion on the non-clinical aspects

The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of osimertinib.

Considering the above data, osimertinib is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

Table 1: Summary of studies included in the current analysis

| Study number                   | Study deseription                                                                                                                                                                                                                                                                                                                                                                                               | Number of patients with PK information   | PK sampling schedule*                                                                                                                                                                                                                                                                                                              |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D5160C0000 1 (AURA)            | Phase I component in EGFR mutation positive advanced NSCLC patients. Doses: 20, 40, 80, 160 and 240 mg (capsule) S0 mg (tablet)                                                                                                                                                                                                                                                                                 | 402b                                     | Following a single dose: pre-dose, (0.5). 1, 1.5, 2, (3).4, 6,8, 10, 12,24, 48, (72) and (120) hours post dosing Following multiple doses: Cycle 1 Day 8: predose, 0.5, 1, 1.5,2,3,4,6,8,10,12 and 24 hours post dosing, or Cycle 2 Day 1: predose,1,1.5,2,4, 6, 8, 10, 12 and 24 hours post dosing and predose on Cycle 1 day 15. |
| D5160C:0000 1 (AURA extension) | Phase IIinEGFR T790M positive advanced NSCLC patients who have progressed following either l prior therapy with an EGFR TKI agent or following teatment with at least 1 EGFR TKI and atleast l prior platinum-based doublet chemotherapy.Dose: S0 mg (tablet)                                                                                                                                                   | 201                                      | Cycle 2 Day l: predose, 1, 1.5, 2, 4, 6, 8, 10, 12 and 24 hous post dosing and predose on Cyele 1 days l, 8 and 15.                                                                                                                                                                                                                |
| D5160C:0000 2 (AURA2)          | Phase II component in EGFR T790M positive advanced NSCLC patients who have progressed following either l prior therapy with an EGFR TKI agent or following treatment with both EGFR TKI and at least 1 other prior line of therapy, such as cytotoxic doublet chemotherapy or immunmotherapy. Dose: S0 mg (tablet)                                                                                              | 210                                      | Following a single dose: predose, 1, 2,4,6 and 8 hous post dosing. Following multiple doses on Cycle 2 Day 1 : predose and on Cycle 3 Day l: predose,1,2,4,6,8, 10, 12 and 24 hours post dosing. Dose reductions were allowed.                                                                                                     |
| D5160C0000 3 (AURA3)           | A Phase Ill, open label, randomized study of AZD9291 Vs platinum-based doublet chemotherapy for patients with locally advanced or metastatic non-small cell lumg cancer whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy and whose tumours harbour a T790M mutation within the epidermal growth factor receptor gene (AURA3). Dose: 80 mg (tablet) | 2794                                     | Plasma samples were collected at predose, between 0.5 to 1.5 hows and between 2 and 4 hours after dosing on first day of dosing in cycle 1, 3, 5, 7, 9, 11, and 13. Dose reductions Were allowed.                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

## D5160C:0000 7 (FLAURA)

A Phase Ill, double-blind randomised study to assess the efficacy and safety of AZD9291 Vs a standard of care epidermal growth factor receptor tyrosine kinase inhibitor as first-line treatment in patients with epidermal growth factorreceptor mutation positive, locally advanced or metastatic non-small cell lumg camcer. Dose: S0 mg (tablet)

279

Plasma samples were collected at pre-dose, between 0.5 to 2 hows and behween 3 and 5 hours after dosing at Day 1 Cycle l and every other cycle thereafter up to and including Cycle 13. Dose reductions Were allowed.

In AURA the PK sampling scheme was updated based on emerging PK data and hence single dose samples in brackets Were not collected in all patieuts and multiple dose samples were collected on either Cycle 1 Smsop teio Aep aomo pieadai sem suisop yd asop adgmm :t ea t apt o g Aea

Two patienis from each of these studies were not included in the master dataset. ../Output/01\\_BasicStatistics/ TAB\\_02\\_summary\\_shudies.txt

2017-Sep-08 10:58

## 2.3.2. Pharmacokinetics

The pharmacokinetic (PK) of osimertinib and its main metabolite (AZ5104) in NSCLC patients with the T790M mutation have been characterised in the initial MA and variations submitted post authorisation. This submission provides an updated population PK analysis where the FLAURA data have been added to the data set. As in the previous submissions, data from paediatric subjects were not available.

Plasma  samples  for  osimertinib  and  AZ5104  were  assayed  using  a  liquid  chromatographic-tandem mass  spectrometric  (LC-MS/MS)  method.  The  lower  limit  of  quantification  (LLOQ)  was  0.05  nM  for osimertinib and 0.0515 nM for AZ5104. The bioanalytical methods used in FLAURA were appropriately validated and the results were consistent with the previous analysis.

The objectives of the updated analysis were to

- Characterize  the  PK  of  osimertinib  and  its  main  metabolite  of  interest  (AZ5104)  in  NSCLC patients, following oral once daily administration.
- Evaluate the impact of line of therapy on the PK of osimertinib.
- Update the impact of selected intrinsic and extrinsic covariates of interest on the PK variability of osimertinib.

Nonlinear  mixed  effects  modelling  was  performed  using  NONMEM  v  7.3  (SAEM  estimation  method). Model  development  and  final  model  selection  was  driven  by  data  and  based  on  goodness-of-fit indicators,  including  visual  inspection  of  diagnostic  and  covariate  scatter  plots,  parameter  estimate precision and minimum objective function value.

Osimeritinib and its main metabolite (AZ5104) have been characterized by a linear 1-compartmental disposition model for both parent and metabolite, with first order oral absorption of osimeritinib into the central compartment and the formation of AZ5104 from osimeritinib (Figure 2).

<div style=\"page-break-after: always\"></div>

Figure 1: Structure of previous osimertinib population PK model

<!-- image -->

The characteristics of the final model included:

- Linear 1 compartmental distribution model for each analyte
- Fraction of osimertinib metabolized to AZ5104 (FM) was fixed to 0.25
- First-order absorption of parent into the parent's central compartment
- Linear elimination from parent and metabolite from their central compartments
- Between-subject variability considered on all PK parameters (ka, CL/F, CLM/F,
- V/F, VM/F)
- Correlation of random effects of CL/F and CLM/F
- Additive-proportional residual error models for both analytes
- The covariate/parameter pairs, included in the final model are the following:
- Bodyweight (WT) on CL/F, CLM/F, V/F
- Baseline albumin (BALB) on CL/F, CLM/F, V/F, and VM/F
- Grouped ethnicity (ETHL) on CLM/F

<div style=\"page-break-after: always\"></div>

Table 2: Population parameter estimates for final model

| Parameter                                             | Typical value   | RSE (%)   | Shrinkage (%)   |
|-------------------------------------------------------|-----------------|-----------|-----------------|
| CL/F (L/hou)                                          | 14.3            | 1.39#     |                 |
| CLM/F (L/hour)                                        | 31.3            | 2         |                 |
| FM (faction)                                          | 0.25 (FIX)      |           |                 |
| VF (L)                                                | 918             | 3.3       |                 |
| VMF (L)                                               | 143             | 4.224     |                 |
| ka (l/hou)                                            | 0.196           | 5.09*     |                 |
| Between-subject variability (as % CV)                 |                 |           |                 |
| Omega (CL/F)                                          | 44.9            | 1.86      | 3.8             |
| Omega (CLM/F)                                         | 49.7            | 1.85      | 3.5             |
| Omega (FM)                                            | 0 (FIX)         |           |                 |
| Omega (V/F)                                           | 90.9            | 1.58      | 28.9            |
| Omega (VM/F)                                          | 78.2            | 3.24      | 38.1            |
| Omega (ka)                                            | 109             | 2.14      | 38.6            |
| Correlation of random effects                         |                 |           |                 |
| Conrelation (CL/F and CLM/F)                          | 0.885           | 0.732     |                 |
| Parameter-covariate estimates                         |                 |           |                 |
| Baseline albumin on CL/F                              | 0.825           | 11.7      |                 |
| Baseline bodyweight on CL/F                           | 0.421           | 13.9      |                 |
| Baseline albumin on CLM/F                             | 0.928           | 11.4      |                 |
| Asian (non-Chinese, non-Japanese) on CLM/F            | 0.182           | 11.2      |                 |
| Chinese on CLM/F                                      | 0.0763          | 27.2      |                 |
| Japanese on CLMF                                      | 0.184           | 13.1      |                 |
| Non-Asian, non-White on CLMF                          | 0.0903          | 26.4      |                 |
| Baseline bodyweight on CLM/F                          | 0.822           | 8.01      |                 |
| Baseline albumin on V/F                               | 2.27            | 9.82      |                 |
| Baseline bodyweight on V/F                            | 0.814           | 16.9      |                 |
| Baseline albumin on VMF                               | -0.831          | 28.6      |                 |
| Residual variability                                  |                 |           |                 |
| Additive eror osimertinib (nM)                        | 30.1            | 1         |                 |
| Additive enror AZ5104 (mM)                            | 0.516           | 2.48      |                 |
| Proportional error osimertinib (fraction)             | 0.205           | 0.424     |                 |
| Proportional elror AZ5104 (fiaction)                  | 0.215           | 0.357     |                 |
| Objective function valueb                             | 299461.2        |           |                 |
| Condition number -FULL                                | 274.8           |           |                 |
| Condition number -fixed effects                       | 43.83           |           |                 |
| Condition number -random effects and error parameters | 11.72           |           |                 |

Relative standard errors for the fixed effect parameters have been obtained by sampling in the log domain and back transfonmation into the nommal domain (due to use of MU referencing).

Abbreviations: RSE: Relative standard error; CLF: Apparent osimertinib clearance; V/F: Apparent osimertinib volume of distibution; CLM/F: Apparent clearance of metabolite AZ5104; VM/F: Apparent volume of distribution of metabolite AZ5104; ka: First-order absorption rate constant; CV%6: Percent coefficient of variation; nM: Nano molar.

The objective fimction was detemmined using importance sampling (IMP) with settings EONL Y=1 and MAPITER=0, as suggested in (ICON 2014).

./Output/16\\_FINALmodel/parameter\\_table.txt Main analysis file: \"SCRIPT\\_17\\_FINALmodel m\" 2017-Aug-25 11:15

<div style=\"page-break-after: always\"></div>

## Results from the GOF plots are represented in the following figures.

<!-- image -->

/Output/16\\_FINALmodel/Final\\_Model/RESULTS/GOF\\_OUTPUT\\_1\\_CP/03\\_GOF\\_Plots.pdf C:/PROJECTS/AZ\\_A24\\_Tagrisso\\_FLAURA/Work/01\\_PopPK/Scripts/SCRIPT\\_18\\_FINALmodel\\_WIN.m 2017-Aug-23 11:25 Page 1

<!-- image -->

Output/16\\_FINALmodel/Final\\_Model/RESULTS/GOF\\_OUTPUT\\_1\\_CP/03\\_GOF\\_Plots.pdf 2017-Aug-23 11:25 Page 2

<!-- image -->

/Output/16\\_FINALmodel/Final\\_Model/RESULTS/GOF\\_OUTPUT\\_1\\_CP/03\\_GOF\\_Plots.pdf 2017-Aug-23 11:25 Page 3

<!-- image -->

/Output/16\\_FINALmodel/Final\\_Model/RESULTS/GOF\\_OUTPUT\\_1\\_CP/03\\_GOF\\_Plots.pdf C/PROJECTS/AZ\\_A24\\_Tagrisso\\_FLAURA/Work/01\\_PopPK/Scripts/SCRIPT\\_18\\_FINALmodel\\_WIN.m 2017-Aug-2311:25 Page 5

Figure 2: Goodness-of-fit plots osimertinib final model

<!-- image -->

/Output/16\\_FINALmodel/Final\\_Model/RESULTS/GOF\\_OUTPUT\\_2\\_CM/03\\_GOF\\_Plots.pdf C:/PROJECTS/AZ\\_A24\\_Tagrisso\\_FLAURA/Work/01\\_PopPK/Scripts/SCRIPT\\_18\\_FINALmodel\\_WINm 2017-Aug-23 11:47 Page 1

<!-- image -->

/Output/16\\_FINALmodel/Final\\_Model/RESULTS/GOF\\_OUTPUT\\_2\\_CM/03\\_GOF\\_Plots.pdf 2017-Aug-23 11:47 Page 2

<!-- image -->

/Output/16\\_FINALmodel/Final\\_Model/RESULTS/GOF\\_OUTPUT\\_2\\_CM/03\\_GOF\\_Plots.pdf 2017-Aug-23 11:47 Page 3

<!-- image -->

/Output/16\\_FINALmodel/Final\\_Model/RESULTS/GOF\\_OUTPUT\\_2\\_CM/03\\_GOF\\_Plots.pdf C/PROJECTS/AZ\\_A24\\_Tagrisso\\_FLAURA/Work/01\\_PopPK/Scripts/SCRIPT\\_18\\_FINALmodel\\_WINm 2017-Aug-23 11:47 Page 5

Figure 3: Goodness-of-fit plots AZ5104 final model

<div style=\"page-break-after: always\"></div>

Diagnostics of the final model showed that the random effects were adequately normally distributed and  the  predicted  and  observed  individual  concentrations  were  generally  symmetrically  distributed around  the  line  of  identity.  The  different  residuals  and  the  normalized  prediction  distribution  errors (NPDE)  did  not  show  any  trends,  both  over  time  and  over  the  population  prediction.  The  VPCs suggested that the final model reasonably described the main part of the observed data. The VPCs also showed that observations in second-line patients are slightly overpredicted. This is as expected, as it already had been seen in Figure 5 that pre-dose steady-state concentrations at 80 mg were lower in second-line patients than in third-line patients. Additionally, the covariate analysis showed that line of therapy as a covariate on CL/F and CLM/F was not statistically significant and that the median effect was clearly below 20%. The typical predicted half-life of osimertinib was calculated with a median of 44.4 hours (95% confidence interval: [41.2, 47.7] hours), which is consistent with the results from the previous analysis (Johnson and Schmidt 2016), in which 48 hours was determined.

A  non-parametric  bootstrap  analysis  using  1000  bootstrapped  datasets  was  performed.  In  this bootstrap  analysis,  all  the  models  converged  successfully.  The  median  and  confidence  intervals  of parameter  estimates  derived  from  this  bootstrap  analysis  were  consistent  with  the  parameter estimates and confidence intervals (CI) derived from the final population PK model.

<div style=\"page-break-after: always\"></div>

Table 3: Non-parametric bootstrap analysis

| Parameter                                   | Final Model estimate          | Bootstrap analysis median     | Final Model 95% CI            | Bootstrap analysis 95% CI     |
|---------------------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| CL/F (L/hour)                               | 14.34                         | 14.34                         | [ 13.95, 14.73]               | [ 14, 14.69]                  |
| CLM/F (L/hour)                              | 31.31                         | 31.28                         | [ 30.08, 32.54]               | [ 30.21, 32.39]               |
| ka (1/hour)                                 | 0.1962                        | 0.2047                        | [ 0.1767, 0.2158]             | [ 0.1738, 0.2396]             |
| V/F (L)                                     | 918.5                         | 934.8                         | [ 859.1, 977.8]               | [ 845.3, 1029]                |
| VM/F (L)                                    | 143.4                         | 144.5                         | [ 131.6, 155.3]               | [ 133.5, 156.7]               |
| Between Subject Variability a               | Between Subject Variability a | Between Subject Variability a | Between Subject Variability a | Between Subject Variability a |
| omega(CL/F)                                 | 0.4485                        | 0.4485                        | [ 0.4322, 0.4649]             | [ 0.4254, 0.4738]             |
| omega(CLM/F)                                | 0.4972                        | 0.4959                        | [ 0.4792, 0.5153]             | [ 0.4734, 0.5222]             |
| omega(ka)                                   | 1.088                         | 1.044                         | [ 1.043, 1.134]               | [ 0.8507, 1.221]              |
| omega(V/F)                                  | 0.9091                        | 0.8981                        | [ 0.8809, 0.9374]             | [ 0.8076, 0.993]              |
| omega(VM/F)                                 | 0.782                         | 0.7775                        | [ 0.7324, 0.8317]             | [ 0.6818, 0.8802]             |
| Correlation of random effects               | Correlation of random effects | Correlation of random effects | Correlation of random effects | Correlation of random effects |
| Correlation (CL/F and CLM/F)                | 0.8853                        | 0.8859                        | [ 0.8726, 0.8981]             | [ 0.8713, 0.9001]             |
| Parameter-Covariate Estimates               | Parameter-Covariate Estimates | Parameter-Covariate Estimates | Parameter-Covariate Estimates | Parameter-Covariate Estimates |
| Baseline bodyweight on CL/F                 | 0.4212                        | 0.4225                        | [ 0.3063, 0.5362]             | [ 0.3128, 0.5289]             |
| Baseline albumin on CL/F                    | 0.8255                        | 0.8178                        | [ 0.6358, 1.015]              | [ 0.639, 0.9931]              |
| Baseline bodyweight on V/F                  | 0.8144                        | 0.7802                        | [ 0.5446, 1.084]              | [ 0.4979, 1.049]              |
| Baseline albumin on V/F                     | 2.266                         | 2.243                         | [ 1.83, 2.703]                | [ 1.797, 2.736]               |
| Baseline bodyweight on CLM/F                | 0.8223                        | 0.8237                        | [ 0.6932, 0.9514]             | [ 0.6966, 0.9565]             |
| Baseline albumin on CLM/F                   | 0.9281                        | 0.9197                        | [ 0.7207, 1.135]              | [ 0.7166, 1.115]              |
| Baseline albumin on VM/F                    | -0.8309                       | -0.7629                       | [ -1.297, -0.3648]            | [ -1.304, -0.2178]            |
| Asian (non-Chinese, non- Japanese) on CLM/F | 0.1822                        | 0.1834                        | [ 0.1421, 0.2223]             | [ 0.1453, 0.2203]             |
| Chinese on CLM/F                            | 0.07629                       | 0.07613                       | [ 0.03558, 0.117]             | [ 0.03541, 0.1202]            |
| Japanese on CLM/F                           | 0.1835                        | 0.1848                        | [ 0.1366, 0.2305]             | [ 0.1424, 0.2282]             |
| Non-Asian, non-White on CLM/F               | 0.09031                       | 0.09072                       | [ 0.04356,                    | [ 0.04123, 0.1415]            |
| Residual Variability                        | Residual Variability          | Residual Variability          | Residual Variability          | Residual Variability          |
| Additive error Osimertinib (nM)             | 30.08                         | 30.65                         | [ 29.49, 30.67]               | [ 26.7, 34.9]                 |
| Additive error AZ5104 (nM)                  | 0.2051                        | 0.2035                        | [ 0.2034, 0.2068]             | [ 0.1934, 0.2142]             |
| Proportional error Osimertinib (fraction)   | 0.5161                        | 0.5275                        | [ 0.491, 0.5413]              | [ 0.41, 0.7072]               |
| Proportional error AZ5104 (fraction)        | 0.2152                        | 0.2145                        | [ 0.2137, 0.2167]             | [ 0.2073, 0.2225]             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

../Output/VPCs/FIG\\_VPC\\_DAY22\\_AZD9291\\_80mg\\_First-line.pdf

- C:/PROJECTS/A52\\_Tagrisson\\_Questions/WorkHenning/Scripts/SCRIPT\\_20\\_VPCs.m

All data-points,considered inthisVPChavebeensampled in steady-state conditions,meaning that at least 10 dosesof 80 mg had been given in the last 250 hours before sampling of concentrations.Data points sampled before day 22 have been excluded. Data is plotted over actual time after last dose, as nominal profile sampling timeswerenotavailableinthedataset.The timeaxiswaslimited tomax.3ohours.Simulationsfor theVPChave been conducted by simulating a dosing regimen of 80 mg daily for 6 weeks to reach steady-state conditions and plotting only results for the last 24 hour profile. Residual variability was considered in this VPC.

Figure 4: Steady-state VPC, first-line patients for osimertinib following 80 mg dose

<!-- image -->

PK sampling in AuRA3 (second-line satients)

All data-points, considered in this VPC have been sampled in steady-state conditions, meaning that at least 10 doses of 80 mg had been given in the last 250 hours before sampling of concentrations. Data points sampled the 2 post-dose samples from the last 24 hour profile. Residual variability was cousidered in this VPC. /home/iqrun/PROJECTS/AZ\\_A24\\_Tagrisso\\_FLAURA/Work/01\\_PopPK/Scripts/SCRIPT\\_19\\_FINALmodel\\_VP Cs.m 2017-Sep-04 16:35

Figure 5: Steady-state VPC, second-line patients, Day 22 for osimertinib following 80 mg dose

<div style=\"page-break-after: always\"></div>

<!-- image -->

All data-points, considered in this VPC have been sampled in steady-state conditions, meaning that at least 10 doses of 80 mg had been given in the last 250 hours before sampling of coucentrations. Data points sampled before Day 22 have been excluded. Data are plotted over achual time after last dose, as nominal profile sampling times were not available in the dataset. The time axis was limited to maximum 30 howrs. Simmlations for the VPC have been conducted by simulating a dosing regimen of 80 mg daily for 6 weeks to reach steady-state conditions and ploting only results for the last 24 hour profile. Residual variability was considered in this VPC. /Output/16\\_FINALmodel/Final\\_Model/../FIG\\_VPC\\_DAY22\\_AZD9291\\_80mg\\_Greaterorequalthird-line.pdf /home/iqrum/PROJECTS/AZ\\_A24\\_Tagisso\\_FLAURA/Work/01l\\_PopPK/Scripts/SCRIPT\\_19\\_FINALmodel\\_VP Cs.m

2017-Sep-04 16:43

Figure 6: Steady-state VPC, ≥third-line patients, Day 22 for osimertinib following 80 mg dose

30

<!-- image -->

All data-points, considered in this VPC have been sampled in steady-state conditions, meaning that at least 10 doses of 80 mg had been given in the last 250 hours before sampling of conceutrations. Data points sampled before Day 22 have been excluded. Data are plotted over achual time after last dose, as nominal profile sampling times were not available in the dataset. The time axis was limited to maximum 30 howrs. Simulations for the VPC have been conducted by simulating a dosing regimen of 80 mg daily for 6 weeks to reach steady-state conditions and plotting only results for the last 24 hour profile. Residual variability was considered in this VPC. ./Output/16\\_FINALmodel/Final\\_Model/..FIG\\_VPC\\_DAY22\\_AZ5104\\_80mg\\_Allpatients.pdf /home/iqrun/PROJECTS/AZ\\_A24\\_Tagrisso\\_FLAURA/Work/01\\_PopPK/Scripts/SCRIPT\\_19\\_FINALmodel\\_VF Cs.m 2017-Sep-04 17:33

Figure 7: Steady-state VPC, all studies, Day 22 for AZ5104 following 80 mg dose

<div style=\"page-break-after: always\"></div>

<!-- image -->

All data-points, considered in this VPC have been sampled in steady-state conditions, meaning that at least 10 doses of 80 mg had been given in the last 250 hours before sampling of concentrations. Data points sampled before Day 22 have been excluded. Simulations for the VPC have been conducted by simulating a dosing regimen of 80 mg daily for 6 weeks to reach steady-state conditions and plotting only results for the pre-dose and the 2 post-dose samples from the last 24 hour profile. Residual variability was considered in this VPC. ./Output/16\\_FINALmodelFinal\\_Model../FIG\\_VPC\\_DAY22\\_AZ5104\\_80mg\\_First-line.pdf /home/iqnm/PROJECTS/AZ\\_A24\\_Tagrisso\\_FLAURA/Work/01\\_PopPK/Scripts/SCRIPT\\_19\\_FINALmodel\\_VP Cs.m 2017-Sep-04 16:26

Figure 8: Steady-state VPC, first-line patients, Day 22 for AZ5104 following 80 mg dose

<!-- image -->

All data-points, considered in this VPC have been sampled in steady-state conditions, meaning that at least 10 doses of 80 mg had been given in the last 250 hours before sampling of concentrations. Data points sampled before Day 22 have been excluded. Simulations for the VPC have been conducted by simulating a dosing regimen of 80 mg daily for 0 weeks to reach steady-state conditions and plotting only results for the pre-dose and the 2 post-dose samples from the last 24 howr profile. Residual variability was considered in this VPC. /home/iqnm/PROJECIS/AZ\\_A24\\_Tagrisso\\_FLAURA/Work/01\\_PopPK/Scripts/SCRIPT\\_19\\_FINALmodel\\_VP Cs.m

2017-Sep-04 16:35

Figure 9: Steady-state VPC, second-line patients, Day 22 for AZ5104 following 80 mg dose

<div style=\"page-break-after: always\"></div>

<!-- image -->

All data-points, considered in this VPC have been sampled in steady-state conditions, meaning that at least 10 doses of 80 mg had been given in the last 250 hours before sampling of concentrations. Data points sampled before Day 22 have been excluded. Data are plotted over achual time after last dose, as nominal profile sampling times were not available in the dataset. The time axis was limited to maximum 30 hours. Simulations for the VPC have been conducted by simulating a dosing regimen of 80 mg daily for 6 weeks to reach steady-state

Cs.m

2017-Sep-04 16:43

## Figure 10: Steady-state VPC, ≥third-line patients, Day 22 for AZ5104 following 80 mg dose

Simulations  were  conducted  to  assess  the  impact  of  identified  important  covariate/parameter relationships  in  the  final  PK  model.  These  simulations  considered  only  the  80  mg  dose  level.  The simulation  based  analysis  suggested  that  at  typical  patient  level  the  changes  in  exposure  metrics related  to  covariates  are  not  expected  to  show  clinically  impactful  differences.  Considering  the therapeutic dose (80 mg once daily), the worst-case combination of covariates (worst-case selected based on safety considerations to obtain the highest values for osimertinib Cmax) consists of patients that  have  a  low  bodyweight  and  low  albumin  levels  and  are  of  Asian  (no  Chinese,  no  Japanese) ethnicity. The  worst-case  combination  of covariates considering the 5th percent of covariate distribution  of  bodyweight  (43  kg)  and  baseline  albumin  (29.3  g/L)  in  the  dataset,  predicted  an increase  in  median  steady-state  osimertinib  Cmaxss  and  AUCss  of  approximately  59%  and  49%, respectively, in relation to the typical patient.

<div style=\"page-break-after: always\"></div>

<!-- image -->

This figure is a graphical representation of the infommation in Table 8. A prediction interval of 90% means that the final model predicts that 90%6 of the population will fall into the indicated ramge (relative to the typical patient) for a given covariate setting. Typical patient: White, 61 kg bodyweight, 39 g/L baseline senum albumin.

Figure 11: Effect of covariates on osimertinib PK

<!-- image -->

Typical patient: White, 60 kg bodyweight, 39 g/L baseline senum albumin. Worst case: White, 43 kg and 160 mg daily doses for reference.

.Output/16\\_FINALmodel/Final\\_Model../FIG\\_SIM\\_02\\_simulation\\_Forest\\_Metabolite.pdf /home/iqnm/PROJECTS/AZ\\_A24\\_Tagrisso\\_FLAURA/Work/01\\_PopPK/Scripts/SCRIPT\\_20\\_STEP5\\_Simulatio

115.1m1

2017-Aug-23 14:09

Figure 12: Effect of covariates on AZ5104 PK

A comparison of osimertinib PK endpoints was performed, when possible, in order to demonstrate the adequacy of the model to characterize the observed exposure of osimertinib for the different studies.

Table 4: Comparison of osimertinib PK parameters between observed and model predicted

| PK parameter   | Study a        |   n | Observed GeoMean (CV%)   | Model predicted (95%PI) b   |
|----------------|----------------|-----|--------------------------|-----------------------------|
| AUC ss         | AURA Phase I   |  60 | 11410 (55)               | 11990 (5535, 37187)         |
| [nM*h]         | AURA extension | 183 | 11980 (46)               | 11893 (4949, 36332)         |
|                | AURA2          | 192 | 10180 (42)               | 10712 (4570, 22797)         |
|                | AURA3          | 235 | NA                       | 9744.5 (4723, 23819)        |
|                | FLAURA         | 183 | NA                       | 10915 (4897, 23614)         |

<div style=\"page-break-after: always\"></div>

| PK parameter   | Study a        |   n | Observed GeoMean (CV%)   | Model predicted (95%PI) b   |
|----------------|----------------|-----|--------------------------|-----------------------------|
| C ssmax        | AURA Phase I   |  60 | 602 (58%)                | 540 (244, 1532)             |
| [nM]           | AURA extension | 183 | 631 (45)                 | 526 (221, 1488)             |
|                | AURA2          | 192 | 533 (43)                 | 510 (210, 1140)             |
|                | AURA3          | 235 | NA                       | 440 (210, 1022)             |
|                | FLAURA         | 183 | NA                       | 511 (248, 1100)             |
| C ssmin        | AURA Phase I   |  60 | 367 (61)                 | 417 (194,1467)              |
| [nM]           | AURA extension | 183 | 384 (51)                 | 438 (175, 1406)             |
|                | AURA2          | 192 | 332 (49)                 | 373 (163, 833)              |
|                | AURA3          | 235 | 357 (53) c               | 340 (161, 864)              |
|                | FLAURA         | 183 | 394 (44) c               | 360 (147, 866)              |

Only patients having received 80 mg as first dose have been considered.

PI: Prediction Interval based on individual model predicted exposures.

predose value from Cycle 3 Day 1 shown

## Dose proportionality and time dependencies

Both  population  pharmacokinetic  models  supported  dose  proportionality  of  the  dose-concentration relationship  (parent  and metabolite)  across the  20  to  240  mg  dose  range that  was  available  in  the previous analysis.

Dose-proportionality  of  the  pharmacokinetics  of  osimertinib  and  AZ5104  was  already  assessed  in previous reports (Comisar et al 2015, Johnson and Schmidt 2016) and is not repeated in this analysis, as the only change was to add data from FLAURA with a planned single dose level of 80 mg.

## Special populations

Based on in vitro data and the human ADME study (Study D5160C00011), osimertinib has been shown to  undergo  significant  metabolic  clearance  via  the  liver  and  hence,  a  clinical  study  to  evaluate  the impact of hepatic impairment (mild and moderate hepatic impairment) on osimertinib exposure has been completed  (study D5160C00008). The MAH has  submitted the CSR of study D5160C00008 CSR which is currently under evaluation (EMEA/H/C/004124/II/0024).

Renal elimination contributes minimally to total osimertinib clearance; however, at the request of EMA, and  based  on  renal  impairment  maybe  affecting  some  pathways  of  hepatic  metabolism,  a  reduced design study to evaluate the impact of severe renal impairment on osimertinib exposure is ongoing (Study D5160C00035) as reflected in the RMP.

Furthermore,  at  the  request  of  EMA,  a  study  to  evaluate  the  single  and  multiple  dose  effect  of osimertinib on the exposure of a non-CYP3A4 mediated Pregnane X receptor substrate (P-glycoprotein [P-gp] substrate, fexofenadine) (D5160C00036) has been submitted and is currently under assessment (EMEA/H/C/004124/II/0021).

## Pharmacokinetic interaction studies

No additional studies have been submitted.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetics using human biomaterials

No additional or updated human in vitro studies have been completed to those already presented with the previous submissions.

## 2.3.3. Pharmacodynamics

## Mechanism of action

Osimertinib is an oral, potent, irreversible central nervous system active EGFR-TKI, effective against NSCLC with both EGFR-TKI-sensitizing mutations (EGFRm+) as well as T790M mutation positive (TKI resistance conferring mutation) forms of EGFR, but designed to have limited activity against wild type (WT) EGFR at clinically relevant doses. As a result, osimertinib can effectively block EGFR signaling both  in  EGFRm+  and  EGFRm+/T790M  mutation  positive  cells.  In  Phase  I,  II,  and  III  studies, osimertinib  has  shown  to  provide  clinically  meaningful  benefit  to  patients  with  advanced  NSCLC harboring the EGFR T790M resistance mutation after prior treatment with an EGFR-TKI.

## Primary and secondary pharmacology

## Relation between PK and efficacy

<!-- image -->

- ./Output/21\\_PFS\\_SOC\\_AUC/FIG\\_01\\_KM\\_PFS\\_AUC\\_AZD9291\\_SOC\\_EFFICACY\\_population.png C:/PROJECTS/AZ\\_A24\\_Tagrisso\\_FLAURA/Work/03\\_Efficacy/Scripts/SCRIPT\\_21\\_PFS\\_SOC\\_AUC.m 2017-Sep-18 14:12

Figure 13: Kaplan-Meier representation of PFS stratified by quartiles of osimertinib AUCss and SoC FLAURA studies

<div style=\"page-break-after: always\"></div>

Table 5: Median PFS and 95% CI for the FLAURA SoC group and the osimertinib AUCss quartiles

| Exposure Metrics               |   Number patients |   Number uncensored events |   Median PFS (months) | 95% CI (months)   |
|--------------------------------|-------------------|----------------------------|-----------------------|-------------------|
| Standard of care               |               277 |                        204 |                   9.8 | 8.6, 11.2         |
| Quartile 1 of osimertinibAUCs  |                85 |                         48 |                  18.1 | 15.2,26.5         |
| Quartile 2 of osimertinib AUC  |                84 |                         42 |                  19.2 | 13.9, NaN         |
| Quartile 3 of osimertinib AUC  |                85 |                         41 |                  19.2 | 13.7, 33.6        |
| Quartile 4 of osimertinib AUCs |                84 |                         51 |                  15.4 | 11.2, 21.7        |

../Output/21\\_PFS\\_SOC\\_AUC/TAB\\_01\\_PFS\\_survivalTime50\\_CI\\_SOC\\_AZD9291\\_AUCss\\_EFFICACY\\_popula tion.txt

C:/PROJECTS/AZ\\_A24\\_Tagrisso\\_FLAURA/Work/03\\_Efficacy/Scripts/SCRIPT\\_21\\_PFS\\_SOC\\_AUC.m 2017-Sep-18 14:12

Abbreviation: NaN not a number, meaning that this value is undefined as information is missing in the data to compute the 50% survival time.

## Relation between PK and safety

Left ventricular ejection fraction (LVEF) is considered the most important measurement of ventricular function  for  distinguishing  patients  with  cardiac  systolic  dysfunction  from  patients  with  preserved systolic function (Swedberg et al 2005).

The below analysis demonstrated that there is no evidence of any quantifiable exposure-related effects on change from baseline LVEF value and incidence of LVEF event.

Table 6: Number of patients within intervals of baseline LVEF values for each dose group

| Treatment group       | LVEFO -50   | LVEFO 50 to <70   | LVEF0 >= 70   | LVEFin 50   | LVEFmin 50 to ≤70   | LVEFin ≥70   | LVEFmx 50   | LVEFm 50 to <70   | LVEFmar ≥70   |
|-----------------------|-------------|-------------------|---------------|-------------|---------------------|--------------|-------------|-------------------|---------------|
| AURA3 Chemotherapy    |             | 67 (71.3%)        | 27 (28.7%)    | 1 (1.06%)   | 75 (79.8%)          | 18 (19.1%)   |             | 62 (66%)          | 32 (34%)      |
| FLAURA SoC            | 4 (1.56%)   | 168 (65.6%)       | 84 (32.8%)    | 10 (3.91%)  | 210 (82%)           | 36 (14.1%)   | 2 (0.781%)  | 108 (42.2%)       | 146 (57%)     |
| Osimertinib 40 mg     |             | 4 (100%)          |               |             | 4 (100%)            |              |             | 3 (75%)           | 1 (25%)       |
| Osimertinib 80 mg     | 9 (0.99%)   | 664 (73%)         | 236 (26%)     | 50 (5.5%)   | 797 (87.7%)         | 62 (6.82%)   | 9(0.99%)    | 563 (61.9%)       | 337 (37.1%)   |
| Osimertinib 160mg     | 1 (4.76%)   | 19 (90.5%)        | 1 (4.76%)     | 2 (9.52%)   | 17 (81%)            | 2 (9.52%)    | 1 (4.76%)   | 15 (71.4%)        | 5 (23.8%)     |
| Osimertinib 240 mg    |             | 2 (100%)          |               |             | 2 (100%)            |              |             | 2 (100%)          |               |
| Osimertinib All Doses | 10 (1.07%)  | 689 (73.6%)       | 237 (25.3%)   | 52 (5.56%)  | 820 (87.6%)         | 64 (6.84%)   | 10 (1.07%)  | 583 (62.3%)       | 343 (36.6%)   |
| All Groups            | 14 (1.09%)  | 924 (71.9%)       | 348 (27.1%)   | 63 (4.9%)   | 1105 (85.9%)        | 118 (9.18%)  | 12 (0.933%) | 753 (58.6%)       | 521 (40.5%)   |

LVEFO LVEF at baseline, LVEFmw Maximum post-baseline LVEF; LVEFmn Minimum post-baseline LVEF, N Number of patients.

Percentages of patients per group provided in parentheses.

C:/PROJECTS/A24 -Tagrisso FLAURA/Work/05\\_LVEF/Scripts/SCRIPT\\_11\\_stats\\_All\\_LVEF.m

2017-Sep-13 15:50

Further  analysis  indicated  no  time  dependent  trend  in  the  change  in  LVEF  over  the  study  days observed.

Rash and diarrhoea are the most common side effects observed with EGFR-TKIs due to wild-type EGFR activity.

Table 7: Summary of the number of first-line patients for each maximum rash CTCAE grade by first dose for osimertinib treated patients and SoC treated patients (safety population)

<div style=\"page-break-after: always\"></div>

|        | Total number of patients   | Number (%o) of Patients   | Number (%o) of Patients   | Number (%o) of Patients   | Number (%o) of Patients   |
|--------|----------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Dose   | (N=615)                    | No event                  | Grade 1                   | Grade 2                   | Grade 3                   |
| 80 mg  | 308                        | 124 (40.26)               | 151 (49.03)               | 30 (9.74)                 | 3 (0.97)                  |
| 160 mg | 30                         | 4 (13.33)                 | 13 (43.33)                | 12 (40.00)                | 1 (3.33)                  |
| SoC    | 277                        | 60 (21.66)                | 109 (39.35)               | 89 (32.13)                | 19 (6.86)                 |

m suaned ou ane araul sasauuared u papoid dnona rad suanedjo saeearad suaged jo raqumn N CTCAE Grade ≥4.

./Output/15\\_Rash\\_Diamhoea\\_Severity\\_stats\\_firstline/TAB\\_01\\_summary\\_mumber\\_patients\\_RASH\\_GRADES DOSE\\_SAFETY \\_population.txt

FLAURA/Work/04\\_Safety/Scripts/SCRIPT\\_15 Rash\\_Diahoea\\_Severity\\_stats\\_firstline.m 2017-Sep-15 10:52

C:/PROJECTS/A24 - Tagriss0

Table 8: Summary of the number of first-line patients for each maximum diarrhoea CTCAE grade by first dose for osimertinib treated patients and SoC treated patients (safety population)

|        | Total number of patients   | Nunber (%o) of Patients   | Nunber (%o) of Patients   | Nunber (%o) of Patients   | Nunber (%o) of Patients   | Nunber (%o) of Patients   | Nunber (%o) of Patients   |
|--------|----------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Dose   | (N=615)                    | No event                  | Grade 1                   | Grade 2                   | Grade 3                   | Grade 4                   | Grade 5                   |
| 80 mg  | 308                        | 129 (41.88)               | 132 (42.86)               | 41 (13.31)                | 6 (1.95)                  | 0                         | 0                         |
| 160 mg | 30                         | 4 (13.33)                 | 16 (53.33)                | 8 (26.67)                 | 2 (6.67)                  | 0                         | 0                         |
| SoC    | 277                        | 118 (42.60)               | 117 (42.24)               | 35 (12.64)6 (2.17)        |                           | 0                         | 1 (0.36)                  |

../Output/15\\_Rash\\_Dianhoea\\_Severity\\_stats\\_firstline/TAB\\_02\\_summary\\_number\\_patients\\_DIAR\\_GRADES\\_D OSE\\_SAFETY\\_population.txt

C:/PROJECTS/A24 - Tagrisso FLAURA/Work/04\\_Safety/Scripts/SCRIPT\\_15\\_Rash\\_Dianhoea\\_Severity\\_stats firstline.m

2017-Sep-15 10:52

## 2.3.4. PK/PD modelling

## Efficacy analysis

Although profound efficacy (BRS, DoR, BPCT and PFS) was observed upon treatment with osimertinib, the  magnitude  of  this  efficacy  was  generally  not  found  to  be  related  to  drug  exposure  (osimertinib AUCss  or  AZ5104  AUCss)  observed  in  FLAURA  and  AURA  Phase  1  studies.  This  may  possibly  be explained by the limited AUCss range in the analysis data. For both osimertinib and AZ5104, the AUCss range is predominantly determined by patients receiving the 80 mg dose.

In  order  to  further  investigate  the  magnitude  of  efficacy  in  relation  to  drug  exposure,  a  Coxproportional  hazard  model  has  been  used  to  assess  the  relative  HRs  between  SoC  treatment,  and AUCss quartiles of osimertinib. A similar analysis for AZ5104 has been conducted for AZ5104, showing HRs range from 0.37 to 0.42 for the lower 3 AZ5104 AUCss quartiles and 0.64 for the highest AZ5104 AUCss quartile.

Table 9: Hazard ratios and 95% CI for each osimertinib AUCss quartile vs, SoC arm in FLAURA for the efficacy endpoint PFS

<div style=\"page-break-after: always\"></div>

| Comparison                  | HR (95% CI)       | p-value   |
|-----------------------------|-------------------|-----------|
| Osimertinib AUCss Q1 vs SoC | 0.44 (0.32, 0.61) | p=0.001   |
| Osimertinib AUCss Q2 vs SoC | 0.44 (0.32,0.62)  | p<0.001   |
| Osimertinib AUCss Q3 vs SoC | 0.4 (0.29, 0.57)  | p=0.001   |
| Osimertinib AUCss Q4 vs SoC | 0.53 (0.39, 0.73) | p=0.001   |

../Output/22\\_PFS\\_AUC\\_COX/TAB\\_02\\_HRs\\_95CI\\_AUCss\\_quartile\\_SOC\\_AZD9291.txt

C:/PROJECTS/AZ\\_A24\\_Tagrisso\\_FLAURA/Work/03\\_Efficacy/Scripts/SCRIPT\\_22\\_PFS\\_AUC\\_COX.m 2017-Sep-18 13:21

A  Cox  regression  analysis  was  performed,  considering  these  covariates  one-by-one  and  the  most important ones in combination with AUCss of both osimertinib and AZ5104. With respect to the predefined level for detection of statistical significance in the analysis plan of p&lt;0.001, only baseline sum of longest tumour diameter was retained in the covariate model.

The relationship between PFS vs osimertinib Cssmax or Cssmin as a predictor variable was assessed and is shown in the below table.

Table 10: Protocol of Cox regressions for PFS (osimertinib)

| Predictor                       | Coefficients   | 95% CI of coefficients   | OFV (-2xLL)   | Change in OFV (to nominal)*   |
|---------------------------------|----------------|--------------------------|---------------|-------------------------------|
| -                               | -              | 1878.5                   | 0             | No predictor (nominal)        |
| AUCss) 0.458                    | [-0.217 1.13]  |                          | 1876.7 -1.73  | log10(osimertinib             |
| log10(osimertinib               | [-0.146 1.24]  |                          | 1876.1 -2.35  | Cmaxss) 0.545                 |
| log10(osimertinib Cminss) 0.255 | [-0.374        | 0.884]                   | 1877.8        | -0.623                        |

* For a single tested covariate, a drop in objective function value of &gt;=10.83 indicates a statistically significant effect with a p-value of p&lt;=0.001.

OFV: Objective function value; LL: log-likelihood CI: confidence interval

Parameter estimates, confidence intervals, and the change in objective function value are shown with 3 significant digits.

Objective function value was shown with 5 significant digits.

- ../Output/05\\_PFS\\_BaseModels\\_Cmax/TAB\\_01\\_COX\\_protocol\\_BaseModel.txt

C:/PROJECTS/A52 - Tagrisso Questions/WorkMikael/Scripts/SCRIPT\\_05\\_PFS\\_BaseModels\\_Cmax.m 2018-Jan-29 12:01

Overall,  this  analysis  indicates  that  there  is  no  evidence  that  increasing  exposure  (AUCss)  of osimertinib and AZ5104 is associated with increased efficacy (PFS, BPCT, DoR and BRS).

## Safety analysis

A model based analysis was conducted to assess the potential exposure dependency of LVEF events and  a  potential  influence  of  covariates.  This  analysis  did  not  support  an  AUC  dependency  of  LVEF events  on  the  pre-defined  significance  level  (p&lt;0.001).  The  only  identified  statistically  significant covariate  was  baseline  LVEF.  The  models  using  log-transformed  osimertinib  or  AZ5104  AUCss  with baseline  LVEF  as  covariate  were  chosen  as  final  models.  These  models  indicated  an  exposure dependency of LVEF events even if not meeting the pre-defined level of significance.

Table 11: Final models

<div style=\"page-break-after: always\"></div>

| Model                   | Intercept          | Intercept   | Slope on AUC.      | Slope on AUC.   | Baseline LVEF on intercept   | Baseline LVEF on intercept   |
|-------------------------|--------------------|-------------|--------------------|-----------------|------------------------------|------------------------------|
|                         | (95% CI)           | p-value     | (95% CI)           | p-value         | (95% CI)                     | p-value                      |
| Final model osimertinib | -6.36 (-13.6,1.01) | 0.0901      | 0.921 (0.209,1.61) | 0.0116          | -0.087 (-0.134,-0.0419)      | 0.000155                     |
| Final model AZ5104      | -4.38 (-9.88,1.07) | 0.115       | 0.927 (0.292,1.56) | 0.00431         | -0.0867 (-0.134,-0.0412)     | 0.000181                     |

CI Confidence interval.

../Output/22b\\_finalModelTable/TAB\\_01\\_finalModel.txt

SCRIPT 22b finalModelTable.R

2017-09-13 15:52:38

Since the graphical analysis suggested a relationship between osimertinib exposure and ILD events, model based analysis  was  conducted.  This  analysis  showed  that  increasing  osimertinib  (or  AZ5104) exposure  increases  the  probability  to  develop  ILD-like  events.  However,  this  relationship  was  not statistically  significant  (according  to  the  pre-defined  criterion;  p&lt;0.001).  None  of  the  additional covariates  (age,  weight,  BMI,  gender,  WHO  performance  status,  history  of  hypertension,  line  of therapy, nicotine use and statin use) showed any statistically significant effect on the occurrence of ILD events.

The final models included AUCss (for osimertinib or AZ5104), Japanese, and Asian non-Japanese as predictive  variables.  Visual  predictive  checks  suggested  that  both  final  models  (osimertinib  and AZ5104) are able to well describe the observed occurrence of ILD across various subpopulations.

The parameter estimates for the final model of the relationship between osimertinib AUCss or Cssmax and ILD are shown in the table below.

Table 12: Comparison of the final model with osimertinib AUCss and Cmaxss as predictor variables for ILD events

| Model    | Intercept (95% CI)       | Slope parameter on exposure (log(AUCss+1) or log(Cmaxss+1)) (95% CI)   | Japanese (95% CI)*   | Asian, non- Japanese (95% CI)*   |   Change in OBJ** |   Required change in OBJ for p < 0.001*** |
|----------|--------------------------|------------------------------------------------------------------------|----------------------|----------------------------------|-------------------|-------------------------------------------|
| 1 AUCss  | -9.350 (-13.800,- 4.760) | 0.628 (0.149,1.090)                                                    | 1.140 (0.510,1.800)  | -0.567 (-1.380,0.206)            |             -34.3 |                                      16.3 |
| 2 Cmaxss | -7.860 (-11.100,- 4.600) | 0.698 (0.198,1.190)                                                    | 1.140 (0.512,1.800)  | -0.555 (-1.370,0.219)            |             -35.1 |                                      16.3 |
| 3 Cminss | -6.930 (-9.810,- 4.030)  | 0.576 (0.113,1.020)                                                    | 1.130 (0.499,1.790)  | -0.571 (-1.390,0.202)            |             -33.6 |                                      16.3 |

*As covariate on the intercept parameter.

**OBJ=objective function value (-2xLL). LL referred to the penalized fitted log-likelihood function (Firth). Change in OBJ compares the restricted model (model with intercept only) to the full model (model with intercept and variables for exposure and ethnicity covariates).

***Referring to the likelihood ratio test.

../Output/02\\_ILD\\_final\\_model\\_AZD9291\\_Cmax/TAB\\_01\\_comparison\\_Osimertinib.txt

SCRIPT\\_02\\_final\\_model\\_AZD9291\\_Cmax.R

2018-01-29 11:37:2

<div style=\"page-break-after: always\"></div>

Figure 14: Visual predictive checks for the frequency of ILD events in different populations - for the (osimertinib) final model accounting for ethnicity differences (left), and for the (osimertinib) base model not accounting for ethnicity differences (right)

<!-- image -->

The  incidence  and  severity  of  rash  appears  to  increase  with  increasing  dose  (and  exposure)  of osimertinib.

Similar to  the  observation  for  rash,  the  incidence  and  severity  of  diarrhoea  appear  to  increase  with increasing dose (and exposure) of osimertinib. In the group of first-line 160 mg osimertinib treated patients 86.7% of the patients experienced diarrhoea as compared to 58.1% in the first-line 80 mg osimertinib treated patients.

The relationship between corrected QT interval (QTc) and plasma concentrations upon multiple dosing was assessed via modelling intensive digital electrocardiogram and PK data generated in AURA2 and was included in the previous submissions.

## 2.3.5. Discussion on clinical pharmacology

The population pharmacokinetic model describes the concentration-time course profiles of osimertinib and its metabolite (AZ5104) orally administered at 80 mg. The same structural pharmacokinetic model as  in  the  previous  clinical  trials  has  been  proposed  in  order  to  characterize  the  experimental observations from all available clinical trial. Linear absorption, distribution and elimination processes were  assumed  in  a  one-compartment  model  for  the  parent  and  metabolite  analyte.  Inter-individual

<div style=\"page-break-after: always\"></div>

variability was incorporated in all PK parameters (ka, V/F, CL/F, CLM/F and VM/F). Several covariates were  included  in  CL/F,  CLM/F,  V/F,  VM/F  with  the  aim  of  partially  explaining  the  inter-individual variability  on  osimertinib's  PK.  Model  evaluation  was  performed  through  prediction-corrected  VPC, showing the population PK model developed is able to reproduce in general the observations after the administration  of  osimertinib  at  80  mg.  All  parameters  in  the  model  were  adequately  qualified  as indicated by the 95% confidence interval from the non-parametric bootstrap. All experimental/predicted  ratios  obtained  from  the  osimertinib  PK  parameters  (AUCss,  Cminss,  and Cmaxss) were within the ±20% range.

Then, a dose-exposure response analysis on efficacy and several safety endpoints (LVEF and ILD) have been performed investigating the relationship between osimertinib exposure and PFS or the incidence of safety events for osimertinib treated patients. Once the results from the exposure-response analysis were  obtained,  AUCss  was  selected  as  the  most  relevant  PK  variable.  A  covariate  analysis  was performed on each exposure-safety model in order to better explain individual differences on safety based on the studied population.

Data management, model development, and model evaluation/qualification procedures seem adequate and acceptable. Condition number of 274.8 indicates no over-parametrization and model stability and the shrinkage values (ETA- and EPS-shrinkage) were low, except for ka and VM/F (38.6 and 38.1%, respectively).

## Population PK model

-Line  of  therapy  was  not  considered  as  a  covariate  on  absorption  rate  or  bioavailability.  During  the absorption phase the median observation in 1st line patients is below the 95% confidence interval of the model-predicted median, indicating that the model slightly overpredicts the central tendency. Due to the sparse PK sampling in FLAURA, the absorption profile could not be fully characterized in 1st line patients.  The  observed  prediction  bias  is  acceptable  considering  the  low  regulatory  impact  of  the modelling results.

## Simulation of the impact of covariate differences on osimertinib exposure

- The impact of the identified covariates in typical patients is too small to be clinically relevant. This supports  that  the  initial  fixed  dose  approach  is  appropriate.  However,  due  to  large,  unexplained variability in osimertinib PK, a considerable proportion of patients weighing 43 kg, and even more of the 'worst-case' patient group (with baseline albumin equal to 29.3 g/L), will have exposures above the suggested target range (approximately Cmaxss and AUCss of 59% and 49%, respectively), defined by the applicant as exposure between the mean expected exposure at 40 and 160 mg. Patients with low body weight (&lt;50 kg) may be at increased risk of developing adverse events of Grade 3 or higher. Close monitoring is therefore recommended in these patients

## Special populations

-Studies  investigating  severe  renal  impaired  population  and  P-gp  interaction  study  are  ongoing. Therefore,  no  specific  recommendations  can  be  made  on  these  special  populations  until  results  are available.

-No specific dose recommendations can be derived on moderate and severe hepatic population based on  the  low  number  of  individuals  included  in  the  dataset  (moderate=8  individuals,  severe=0 individuals).

No interaction studies have been submitted which is acceptable as osimertinib exposure is consistent between 1st and ≥2nd line of therapy. The results of the previous interaction studies are applicable for all lines of therapy.

<div style=\"page-break-after: always\"></div>

## Exposure-safety relationship

-The  exposure-safety  model  that  accounts  for  the  relationship  between  AUC-LVEF  levels  is  able  to characterize the proportion of patients with LVEF events at 80mg, but no information is provided on 40 and  160  mg.  Additionally,  the  95%  CI  of  the  intercept  includes  the  zero,  which  indicates  lack  of significance. Therefore, the model should not be used for simulation or extrapolation purposes.

## 2.3.6. Conclusions on clinical pharmacology

The population PK model is in general adequate.

Based  on  results  from  osimertinib  and  metabolite  (AZ5104)  exposure  (PK)  and  efficacy/safety relationship  from  studies AURA1,  AURA2,  AURA3, and FLAURA, the recommended dose of 80 mg is acceptable. In terms of efficacy,  no exposure-efficacy relationship could be detected, which reduces the impact of model-based predictions in future assessments (dose selections, special populations). An evaluation  of  other  exposure  metrics did  not  increase  the  prediction  of  the  model  in  regards  to  the efficacy endpoints selected.

A model-based assessment was performed to detect any relationship between exposure and incidence of  LVEF  events,  but  failed  to  achieve  the  significance  criterion.  The  Applicant,  however,  applied  the model in order to simulate different dose regimens and scenarios since the significance of the AUCss as a predictor was borderline non-significant. This approach is fully endorsed as it provides more accurate conclusions and allows for a model-informed drug development process. The incidence of ILD, rash and diarrhoea  is  low  and,  in  general,  comparable  to  EGFR-TKI  SoC  treated  patients.  For  ILD  events, Japanese and Asian  non-Japanese  populations  were  included  as  significant  covariates  in  the  model, and differences between those sub-groups of populations might be explained due to constitutional and environmental factors. Additionally, the more intensive monitoring for ILD and ILD-like incidences in Japanese population could have also contributed to identify more incidences of ILD events.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

No dose response studies specifically in 1st line NSCLC patients were conducted. Using the same dose as the registered dose in ≥2nd line patients is reasonable.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study

A Phase III, Double-blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor as First-line Treatment in Patients with Epidermal Growth Factor Receptor Mutation-positive, Locally-advanced or Metastatic Non-small-cell Lung Cancer (FLAURA)

<!-- image -->

EGFR-TKI=epidermal growth factorreceptor-tyrosinekinaseinhibitor.NSCLC=non-small celllung cancer:OS=overall survival:PFS2=second progression-fee survival:QD-once daily,RECISTv1.1 -ResponseEvaluation Cniteria inSolid Tumorsversion 1.1;SoC-standardof care.

- Eithergefitinib(250mg)orerlotinib(150mg).
- Patients in theSoCEGFR-TKI arm who had objective disease progression according toRECIST1.1 based onInvestigator assessment,that was confirmed by independentcentralimagingreview,andwhohadtumourspositiveforT790Mmutationfollowingprogression,afterbeingunblindedweregiventheopportunityto crossoverandbegintreatmentwithosimertinib80mg,oncedaily.
- Patientswhodiscontinued treatment prior todiseaseprogression continuedhadRECIsTv1.1 assessments until objectiveprogression.Patientswho continued treafment afier objective progression due toclinical benefit were to be followed asper standard practice post-progression.

Figure 15 : Flow chart of study design.

Efficacy  and  safety  data  from  FLAURA  presented  in  this  submission  are  from  the  556  patients randomised globally. As per protocol amendment 1, a China extension cohort of 136 patients was also enrolled  in  FLAURA  to  meet  China  regulatory  requirements:  this  cohort  included  19  patients randomised in the global study prior to the end of global recruitment as well as 117 additional patients to be recruited as part of the China extension cohort. Data for the 19 patients randomised in the global study prior to the end of global recruitment are included in the global analysis set. Data for the entire 136-  patient  China  extension  cohort  will  be  analysed  separately  once  the  PFS  data  for  the  China extension cohort has reached similar maturity to that used in the primary analysis of PFS based on Investigator  assessment  in  the  globally-recruited  patients    and  will  be  submitted  to  the  Chinese regulatory authority only.

## Methods

## Study participants

The key inclusion and exclusion criteria are:

## Inclusion criteria

For inclusion in the study, patients had to fulfil all the following criteria;

1. Informed consent prior to any study-specific procedures, sampling, and analyses;

<div style=\"page-break-after: always\"></div>

2. Male or female, aged at least 18 years. Patients from Japan aged at least 20 years;

3. Pathologically-confirmed adenocarcinoma of the lung (eg, this could occur as systemic recurrence after prior surgery for early stage disease or patients could be newly diagnosed with Stage IIIB/IV disease). Patients with mixed histology were eligible if adenocarcinoma was the predominant histology;

4. Locally-advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy;

5. The tumour harboured 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations, as assessed by a CLIA-certified (US sites) or an accredited (outside the US) local laboratory or by central testing;

6. Mandatory provision of an unstained, archived tumour tissue sample in a quantity sufficient to allow for central analysis of EGFR mutation status;

7. Patients had to be treatment-naïve for locally-advanced or metastatic NSCLC and eligible to receive first-line treatment with gefitinib or erlotinib as selected by the participating centre. Prior adjuvant and neo-adjuvant therapy was permitted (chemotherapy, radiotherapy, investigational agents) provided all other entry criteria were satisfied;

8. World Health Organization PS of 0 to 1, with no clinically significant deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks;

9. At least 1 lesion, not previously irradiated and not chosen for biopsy during the study screening period, that could be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which had to have a short axis of ≥15 mm) with computerised tomography (CT) or magnetic resonance imaging (MRI), and which was suitable for accurate repeated measurements. If only 1 measurable lesion existed, it was acceptable to be used as a target lesion (TL) as long as it had not been previously irradiated and baseline tumour assessment scans were done at least 14 days after the screening biopsy was performed;

10. Female patients were to be using adequate contraceptive measures, were not to breast feed, and had to have a negative pregnancy test prior to first dose of study drug; or female patients had to have an evidence of non-child-bearing potential;

11. Male patients were to be willing to use barrier contraception, ie, condoms;

12. For inclusion in the optional genetics research study, patients had to provide informed consent for genetic research.

## 5.3.2 Exclusion criteria

Patients could not enter the study if any of the following exclusion criteria were fulfilled:

1. Involvement in the planning and/or conduct of the study (applied to both AstraZeneca staff and/or staff at the study site);

2. Treatment with any of the following:

- Prior treatment with any systemic anti-cancer therapy for locally advanced/ metastatic NSCLC including chemotherapy, biologic therapy, immunotherapy or any investigational drug;

- Prior treatment with an EGFR-TKI;

- Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study drug;

- Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug;

<div style=\"page-break-after: always\"></div>

- Patients who were currently receiving (or unable to stop using at least 1 week prior to receiving the first dose of study drug) medications or herbal supplements known to be potent inducers of cytochrome P450 (CYP) 3A4 (see CSP Amendment 2 Appendix B in Appendix 12.1.1);

- Alternative anti-cancer treatment;

- Treatment with an investigational drug within 5 half-lives of the compound or any of its related material, if known;

3. Any concurrent and/or other active malignancy that had required treatment within 2 years of first dose of study drug;

4. Any unresolved toxicities from prior systemic therapy (eg, adjuvant chemotherapy) greater than CTCAE grade 1 at the time of starting study drug, except for alopecia and grade 2, priorchemotherapy-induced neuropathy;

5. Spinal cord compression, symptomatic and unstable brain metastases (BM) except for those patients who had completed definitive therapy, were not on steroids, and had a stable neurological status for at least 2 weeks after completion of the definitive therapy and steroids;

6. Any evidence of severe or uncontrolled systemic disease. Screening for chronic conditions was not required;

7. Refractory nausea and vomiting, chronic gastrointestinal (GI) diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib;

8. Any of the following cardiac criteria:

- Mean resting corrected QT interval (QTc) &gt;470 milliseconds (msec);
- Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG;
- Any factors that increased the risk of QTc prolongation or risk of arrhythmic events;
9. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment or any evidence of clinically-active ILD;
10. Inadequate bone marrow reserve or organ function;
11. Women who were breast feeding;

12. History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib;

13. Judgment by the Investigator that the patient should not participate in the study if the patient was unlikely to comply with study procedures, restrictions, and requirements.

## Treatments

After randomization, the investigational products osimertinib 80 mg or the SoC EGFR-TKI (either gefitinib [250 mg] or erlotinib [150 mg]) were administered orally once daily.

Patients were to continue their randomised treatment until disease progression (RECIST v1.1), or until a treatment discontinuation criterion was met. However, patients could continue to receive their randomised treatment beyond RECIST v1.1-defined progression if the Investigator judged the patient was continuing to show clinical benefit on treatment. As per protocol Amendment 1 (13-Apr-2015) after Investigator-assessed objective disease progression, patients randomised to the SoC arm had the

<div style=\"page-break-after: always\"></div>

option to crossover to treatment with open-label osimertinib provided they met predefined criteria (confirmation of disease progression by BICR prior to unblinding; no subsequent intervention therapy following discontinuation of randomised treatment; and tissue or plasma confirmation that the tumour was T790M mutation-positive after disease progression).

## Objectives

## Primary objective:

To assess the efficacy of single-agent osimertinib compared with SoC EGFR-TKI therapy as measured by PFS, by investigator.

## Key secondary objectives:

To assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy by assessment of PFS in patients with EGFR Ex19del or L858R mutations, and with EGFRm (Ex19del or L858R) detectable in plasma-derived  ctDNA;  to  further  assess  the  efficacy  of  osimertinib  compared  with  SoC  EGFR-TKI therapy in terms of ORR, DoR, DCR, depth of response, and OS; to characterise the pharmacokinetics (PK) of osimertinib and its metabolites; and to assess the impact of osimertinib compared to SoC on patient-reported outcomes.

To  compare  the  efficacy  of  osimertinib  with  SoC  EGFR-TKIs  based  on  presence  or  absence  of  CNS metastases at study entry (CNS MTS subgroup analysis)

The safety objective was to assess the safety and tolerability profile of osimertinib compared with SoC EGFR-TKI therapy.

## Key exploratory objectives:

To  further  assess  the  efficacy  of  osimertinib  compared  to  SoC  EGFR-TKI  on  post-progression outcomes; to assess the agreement between local and central EGFR tumour tissue testing results; and to compare the baseline tumour EGFR mutation status in all screened patients with evaluable results from baseline plasma in all screened patients. Furthermore, CNS efficacy analyses were pre-specified in the SAP finalised prior to database lock for the primary PFS analysis.

## Outcomes/endpoints

The primary efficacy endpoint was PFS based on Investigator assessment of radiological data with a sensitivity analysis based on BICR assessment using RECIST v1.1.

The main secondary endpoints were:

- overall survival compared to SoC EGFR-TKI therapy,
- ORR, DoR, DCR, and depth of response compared to SoC EGFR-TKI therapy. All according to RECIST v1.1 using Investigator assessments
- To compare the efficacy of osimertinib with SoC EGFR-TKIs based on presence or absence of CNS metastases at study entry (CNS MTS subgroup analysis). Systemic PFS by Investigator assessment; reason for systemic progression (TL, NTL [CNS NTL or non-CNS NTL], NL [new CNS lesion or no new CNS lesion]); reason for CNS progression, systemic ORR by Investigator assessment; and systemic DoR and onset of response by Investigator assessment.

<div style=\"page-break-after: always\"></div>

- Patient reported outcomes, as measured via the EORTC QLQ-C30 and the complementary lung cancer questionnaire EORTC QLQ-LC13.

The main exploratory endpoints were:

- efficacy of osimertinib compared to SoC EGFR-TKI post-progression as measured by PFS2 and time to subsequent treatments, including time from randomisation to discontinuation of any EGFR-TKI or death.
- Tumour and ctDNA were gathered to explore biomarker effects on efficacy of both osimertinib and SoC, these data will be reported at a later time.

## Sample size

Per protocol, approximately 530 patients (265 per treatment arm) were to be randomised globally. In order to randomise 530 patients, it is estimated that 980 EGFRm+ patients will need to be screened.

The DCO1 for the primary analysis of PFS was pre-specified to occur after approximately 359 PFS events had occurred in the 530 patients randomised globally, representing approximately 65% maturity.

If the true PFS HR for the comparison of osimertinib and SoC EGFR-TKI is 0.71, 359 PFS events would provide 90% power to demonstrate a statistically significant difference in PFS at a 5% two-sided significance level, translating into an approximate improvement in median PFS from 10 months to 14.1 months assuming exponential data distribution and proportional hazards. The minimum critical HR is 0.81 (e.g. 10 to 12 months).

For the key secondary endpoint of PFS in patients with T790M+ NSCLC confirmed using a highly sensitive assay, there will be approximately 72% power to detect a PFS HR=0.55 (i.e. 10 to 18 months), assuming a prevalence of 20%.

For the OS analysis, there will be approximately 72% power to demonstrate a HR &lt;0.75 (i.e. 25 to 33.3 months) with two-sided 5% significance level. If the 4 month improvement as detailed for PFS is maintained for OS, then there will be approximately 27% power to demonstrate a HR of 0.86 (median OS of 25 months for SOC and 29 months for AZD9291) with two-sided 5% significance level.

Following randomisation of 530 patients in the global portion of the study, additional mainland China patients (until approximately 120 in total) will be randomized to facilitate the China-only analysis dataset.

## Randomisation

Eligible patients were centrally randomised in a 1:1 ratio, using the IVRS/IWRS, to receive either osimertinib 80 mg orally once daily or the EGFR-TKI chosen by the site based on site preference and marketing authorisation in the particular country (ie, gefitinib 250 mg orally once daily or erlotinib 150 mg orally once daily). The actual EGFR-TKI had to be selected at a site/country level according to the country's marketing authorisation prior to the site initiation.

Patients were stratified at randomisation based on EGFR mutation status (Ex19del or L858R) and ethnicity (Asian or Non-Asian).

<div style=\"page-break-after: always\"></div>

## Blinding (masking)

This  was  a  double-dummy  study  wherein  each  patient  received  either  the  active  AZD9291  plus comparator-matching placebo (SoC) or the active comparator (SoC) plus AZD9291-matching placebo. The active and placebo tablets were identical and presented in the same packaging to ensure blinding of the medication. The treatment code could be broken if the appropriate management of the patient required knowledge of the treatment randomisation for medical emergencies or for treatment decisions (eg, cross-over). Study sites were required to select either gefitinib or erlotinib as the sole comparator prior to site initiation, except for the US where all sites used erlotinib (the most commonly used EGFRTKI for first-line EGFRm NSCLC in the US at the time of study start, in 2014).

The primary efficacy endpoint of the study was PFS based on Investigator assessment according to RECIST v1.1, with a sensitivity analysis based on  blinded independent central review (BICR) of the imaging data.

## Statistical methods

The primary efficacy endpoint was PFS based on Investigator assessment according to RECIST v1.1. One analysis of the primary endpoint of PFS was planned. The DCO for the primary analysis of PFS was pre-specified to occur after approximately 359 PFS events had occurred in the planned 530 patients to be  randomised  globally,  representing  approximately  65%  maturity.  Progression-free  survival  was established  from  programmatically  calculated  response  based  on  the  Investigator  assessment  for patients  in  the  full  analysis  set  (FAS)  using  a  log-rank  test  stratified  by  mutation  type  (Ex19del  or L858R) and ethnicity (Asian vs. Non- Asian) to generate p-value and using the Breslow approach for handling ties. The HR and its confidence interval (CI) were obtained directly from the U and V statistics from a stratified log-rank test.

A sensitivity analysis of PFS based on assessment of response by BICR according to RECIST v1.1 was also  conducted.  Other  PFS  sensitivity  analyses  included  the  possibility  of  bias  in  assessment  and measurements  by  Investigators  (ascertainment  bias);  the  possible  bias  in  evaluation-time  if  scans were not performed at the protocol-scheduled time points (evaluation-time bias); attrition bias; and a post-hoc analysis to assess the potential impact of change in scanning schedule at Month 18 falling close to the median PFS. A posthoc sensitivity analysis was added to assess the impact of change in scanning  schedule  at  Month  18  falling  close  to  the  median  PFS.  Sensitivity  analyses  were  to  be performed as per the primary reporting of PFS.

In  addition  to  the  primary  analysis  of  PFS,  subgroup  analyses  were  conducted  by  comparing  PFS between treatment arms using a Cox-proportional hazards model in the following subgroups: gender (male/female); ethnicity (Asian/Non-Asian); age at screening (&lt;65 years/≥65 years); CNS metastases (CNS  MTS)  status  at  study  entry  (Yes/No);  smoking  history  (Yes/No);  baseline  WHO  performance status  (0  or  1);  pre-treatment  T790M  status  (positive/negative);  EGFR  mutation  (Ex19del/L858R); EGFR mutation-positive by ctDNA (Yes/No); and centrally-confirmed EGFR mutation-positive (Yes/No).

The analyses of the secondary endpoints of ORR, DoR, DCR, and depth of response also occurred at the time of the primary PFS analysis.

Two OS analyses are planned: an initial interim analysis at the time of the primary PFS analysis and a final  analysis  when  the  OS  data  are  approximately  60%  mature  (approximately  318  deaths).  In addition, an analysis of PROs was conducted.

An analysis to establish any efficacy benefit of osimertinib on the CNS (CNS BICR) was also added to the SAP (Amendment to the SAP dated 16 December 2016) and occurred at the time of the primary analysis  of  PFS.  The  following  variables  were  evaluated  by  CNS  BICR  on  the  CNS  full  analysis  set

<div style=\"page-break-after: always\"></div>

(cFAS)  and  CNS  evaluable-for-response  (cEFR)  analysis  sets:  CNS  PFS  on  the  cFAS;  CNS  PFS  by number of CNS lesions at baseline on cFAS; CNS ORR on the cFAS and cEFR; CNS DoR and onset of response  on  the  cFAS  and  cEFR;  CNS  DCR  on  the  cFAS  and  cEFR;  and  CNS  ORR  by  prior  brain radiotherapy on cFAS.

A hierarchical procedure was used to adjust for multiplicity in testing the key endpoints of PFS, OS, and CNS PFS. To provide strong control of the Type I error rate (5% two-sided), the primary endpoint of  PFS,  and  the  endpoints  of  OS  and  CNS  PFS  were  tested in  this  sequential  order.  If  any  previous analysis  in  the  sequence  was  not  statistically  significant,  the  alpha  was  not  to  be  transferred  to subsequent analyses. If the OS analysis was statistically significant at the time of the PFS analysis or the final OS analysis, then the significance testing of CNS PFS was to be performed at the full alpha (5% two-sided) significance level.

If  the  OS  analysis  was  not  statistically  significant  at  the  time  of  the  PFS  analysis  or  the  final  OS analysis, then the significance testing of CNS PFS was not to be performed. Only 1 CNS BICR statistical analysis  was  to  be  performed:  either  at  the  time  of  the  primary  PFS  analysis  or  at  the  later  OS analysis. A 2-sided 5% alpha was used in all testing, except for the OS endpoint. Since 2 analyses of OS  are  planned,  the  Lan  DeMets  approach  that  approximates  the  O'Brien  and  Fleming  spending function was used to maintain an overall 2-sided 5% Type I error across the 2 planned OS analyses. Any non-statistically significant OS analysis at the time of the primary PFS analysis did not preclude further testing of OS.

The China extension cohort enrolled 136 patients: 19 patients from China who were randomised in the global study prior to the end of global recruitment and an additional 117 patients recruited in China specifically  for  the  China  extension  cohort.  Data  for  the  19  patients  randomised  in  the  global  study prior to the end of global recruitment are included in the global analysis set presented in this report. Data for the entire 136-patient China extension cohort (ie, the 19 China patients in the global study and the additional 117 China extension cohort patients) will be analysed separately and submitted to the  Chinese  regulatory  authority  only  once  the  PFS  data  for  the  entire  China  extension  cohort  has reached similar maturity to that used in the primary analysis of PFS based on Investigator assessment in  the  globally-recruited  patients  (ie,  approximately  65%).  Thus,  data  from  the  19  Chinese  patients randomised prior to the end of global enrolment will be part of both the main global analysis and the China extension cohort analysis.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Figure 16 : Disposition of patients

<!-- image -->

## Recruitment

A  total  of  556  patients  were  randomised  to  treatment  at  132  study  centres  in  29  countries  (global recruitment). An additional 17 centres in China enrolled patients into the China extension cohort only.

The first patient was randomised in the global study and dosed on 19 February 2015. The last patient's first dose was administered on 11 March 2016.

## Conduct of the study

## Protocol amendments:

The study protocol was amended two times. In addition to minor clarifications, the main amendments are described below.

Amendment 1 (13 Apr 2015) was introduced due to advice from the FDA, regulatory requirements from Chinese authorities and emerging data from use of osimertinib after treatment with other EGFRTKIs. The main changes were:

- Addition of option to continue recruitment in mainland China, following achievement of global recruitment target of 650
- Allow post-progression cross-over for patients receiving SoC to open-label osimertinib provided specific criteria are satisfied.
- Removal of efficacy interim analysis

<div style=\"page-break-after: always\"></div>

Amendment 2 (24 Sep 2015) was introduced due to data from the phase I trial. The main changes were:

- Sample size has been reduced from 650 to 530 patients
- The number of patients in each treatment group has been updated based on the change in the sample size
- Disease  Control  Rate  (DCR)  has  been  added  to  the  list  of  RECIST-based  endpoints  for completeness.

## Protocol deviations

The most frequent of the important protocol deviations in both treatment arms was the nonadherence to a protocol-required procedure, including, in decreasing order of frequency:

- Missing  RECIST  assessments  for  efficacy:  67  (12.1%)  patients  overall  (osimertinib:  41 [14.7%]; SoC: 26 [9.4%]). This was the most frequently reported protocol deviation in both treatment arms. None of the missing scans were baseline scans and the majority were single missing assessments.
- RECIST scan performed outside the visit window on more than 2 occasions: 27 (4.9%) patients overall (osimertinib: 18 [6.5%]; SoC: 9 [3.2%])
- Baseline tumour RECIST assessments performed more than 28 days before randomisation: 15 (2.7%) patients overall (osimertinib: 7 [2.5%]; SoC: 8 [2.9%])
- Tumour assessment methods and procedures not compliant with protocol or RECIST v1.1: 14 (2.5%) patients overall (osimertinib: 7 [2.5%]; SoC: 7 [2.5%])
- Administration of prohibited other anti-cancer agents, investigational products or radiotherapy (for  reasons  other  than  bone  metastases)  while  the  patient  was  on  treatment:  2  (0.4%) patients overall, 1 patient in each arm

The second most frequent important protocol deviation category included patients who did not meet eligibility criteria, including:

- No confirmation that the tumour harboured an EGFR sensitising mutation (Ex19del or L858R): 7 (1.3%) patients (osimertinib: 3 [1.1%]; SoC: 4 [1.4%]).
- o The  investigators'  interpretation  of  inclusion  criterion  5  (Section  5.3.1)  led  them  to classify these 7 patients as not meeting the criterion. However, based on review of the local  and/or  central  test  results,  all  7  patients  did  have  tumours  harbouring  EGFR sensitising mutations. The nature of the deviation was that either the mutation analysis was performed on a biopsy taken from an early disease stage sample (5 patients) or was performed in a local laboratory at a date preceding the laboratory accreditation (2 patients)
- No pathological confirmation that the patient had an adenocarcinoma of the lung: 5 (0.9%) patients (osimertinib: 2 [0.7%]; SoC: 3 [1.1%])
- Patient was not treatment-naïve for locally-advanced or metastatic NSCLC: 3 (0.5%) patients overall (osimertinib: 2 [0.7%]; SoC: 1 [0.4%])
- No lesions not previously irradiated or chosen for biopsy during the screening period that could be accurately measured at baseline as being 10 mm in longest diameter by CT or MRI (except lymph  nodes,  which  had  to  have  a  short  axis  of  15  mm)  and  were  suitable  for  accurate

<div style=\"page-break-after: always\"></div>

repeated measurements: 2 (0.4%) patients, both on osimertinib: 1 patient had no measurable lesion and 1 patient provided measurements, but from a previously irradiated lesion

- During data review, it was discovered that 1 patient in each treatment arm had a mean (from triplicate  measurements)  QTcF  value  above  470  msec  at  study  entry.  In  both  patients (E1403008 in the osimertinib arm and E3603004 in the SoC arm), a mean QTcF value of 483.3 msec was recorded at screening.

## Baseline data

## Demographic characteristics

The  study  enrolled  the  population  intended  by  protocol.  Demographic  characteristics  were  generally well balanced between the treatment arms.

Table 13 : Demographic characteristics (full analysis set).

Percentages are based on the FAS.

| Demographiccharacteristic               | Osimertinib (N=279)   | SoC (N=277)   | Total (N=556)   |
|-----------------------------------------|-----------------------|---------------|-----------------|
| Age (years)                             |                       |               |                 |
| Mean                                    | 62.7                  | 63.3          | 63.0            |
| Standard deviation                      | 10.70                 | 10.90         | 10.79           |
| Median                                  | 64.0                  | 64.0          | 64.0            |
| Min                                     | 26                    | 35            | 26              |
| Max                                     | 85                    | 93            | 93              |
| Age group (years), n (%)                |                       |               |                 |
| <50                                     | 32 (11.5)             | 37 (13.4)     | 69 (12.4)       |
| ≥50-<65                                 | 121 (43.4)            | 108 (39.0)    | 229 (41.2)      |
| ≥65-<75                                 | 90 (32.3)             | 89 (32.1)     | 179 (32.2)      |
| ≥75                                     | 36 (12.9)             | 43 (15.5)     | 79 (14.2)       |
| Sex n (%)                               |                       |               |                 |
| Male                                    | 101 (36.2)            | 105 (37.9)    | 206 (37.1)      |
| Female                                  | 178 (63.8)            | 172 (62.1)    | 350 (62.9)      |
| Race n (%)                              |                       |               |                 |
| Asian                                   | 174 (62.4)            | 173 (62.5)    |                 |
| Black or African American               | 2 (0.7)               | 2 (0.7)       | 4 (0.7)         |
| White                                   | 101 (36.2)            | 100 (36.1)    | 201 (36.2)      |
| AmericanIndian or Alaska Native         | 1 (0.4)               | 1 (0.4)       | 2 (0.4)         |
| Missing                                 | 1 (0.4)               | 1 (0.4)       | 2 (0.4)         |
| Ethnic group n (%)                      |                       |               |                 |
| Asian (other than Chinese and Japanese) | 77 (27.6)             | 94 (33.9)     | 171 (30.8)      |
| Chinese                                 | 32 (11.5)             | 24 (8.7)      | 56 (10.1)       |
| Japanese                                | 65 (23.3)             | 55 (19.9)     | 120 (21.6)      |
| Other                                   | 103 (36.9)            | 104 (37.5)    | 207 (37.2)      |
| Missing                                 | 2 (0.7)               | 0             | 2 (0.4)         |
| Smoking status                          |                       |               |                 |
| Never                                   | 182 (65.2)            | 175 (63.2)    | 357 (64.2)      |
| Current                                 | 8 (2.9)               | 9 (3.2)       | 17 (3.1)        |
| Former                                  | 89 (31.9)             | 93 (33.6)     | 182 (32.7)      |

<div style=\"page-break-after: always\"></div>

## Baseline disease characteristics

All  randomized  patients,  except  for  1  patient  in  the  osimertinib  arm  with  missing  data,  had  locally advanced  NSCLC  that  was  not  amenable  to  curative  surgery  or  radiotherapy  (29  [5.2%]  patients overall) or metastatic NSCLC (526 [94.6%] patients overall).

Per  protocol,  all  patients  were  to  receive  study  treatment  as  first-line  therapy.  However,  3  (0.5%) patients  (osimertinib:  2  [0.7%];  SoC:  1  [0.4%]),  all  enrolled  at  the  same  US  study  site,  were  not treatment-naïve  for  locally-advanced  or  metastatic  NSCLC  at  study  entry,  an  important  protocol deviation. Baseline disease characteristics were generally well balanced between the 2 treatment arms.

Table 14 : Disease characteristics at baseline (full analysis set).

|                                                          | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|----------------------------------------------------------|--------------------------|--------------------------|--------------------------|
|                                                          | Osimertinib              | SoC                      | Total                    |
|                                                          | (N=279)                  | (N=277)                  | (N=556)                  |
| WHO performance status                                   |                          |                          |                          |
| 0 (normal activity)                                      | 112 (40.1)               | 116 (41.9)               | 228 (41.0)               |
| 1 (restricted activity)                                  | 167 (59.9)               | 160 (57.8)               | 327 (58.8)               |
| Missing                                                  | 0                        | 1 (0.4)                  | 1 (0.2)                  |
| Overall disease classification                           |                          |                          |                          |
| Metastatica                                              | 264 (94.6)               | 262 (94.6)               | 526 (94.6)               |
| Locally advancedb                                        | 14 (5.0)                 | 15 (5.4)                 | 29 (5.2)                 |
| Missing                                                  | 1 (0.4)                  | 0                        | 1 (0.2)                  |
| Time from diagnosis/recurrence to randomisation (months) |                          |                          |                          |
| n                                                        | 278                      | 276                      | 554                      |
| Mean                                                     | 1.9                      | 1.8                      | 1.9                      |
| Standard deviation                                       | 5.57                     | 3.24                     | 4.56                     |
| Median                                                   | 1.2                      | 1.2                      | 1.2                      |
| Min                                                      | 0                        | 0                        | 0                        |
| Max                                                      | 82                       | 37                       | 82                       |
| CNS metastases                                           | 53 (19.0)                | 63 (22.7)                | 116 (20.9)               |
| No CNS metastases                                        | 226 (81.0)               | 214 (77.3)               | 440 (79.1)               |
| Extra-thoracic visceral metastases                       | 94 (33.7)                | 103 (37.2)               | 197 (35.4)               |
| Liver metastases                                         | 41 (14.7)                | 37 (13.4)                | 78 (14.0)                |
| Bone&locomotormetastases                                 | 97 (34.8)                | 102 (36.8)               | 199 (35.8)               |
| No extra-thoracic visceral metastases                    | 185 (66.3)               | 174 (62.8)               | 359 (64.6)               |
| Baseline tumour size (mm)d                               |                          |                          |                          |
| n                                                        | 278                      | 277                      | 555                      |
| Mean                                                     | 55.3                     | 56.7                     | 56.0                     |
| Standard deviation                                       | 34.65                    | 33.55                    | 34.08                    |
| Median                                                   | 47.5                     | 50.0                     | 48.0                     |
| Min                                                      | 10                       | 10                       | 10                       |
| Max                                                      | 207                      | 176                      | 207                      |
| Baseline tumour size category (mm), n (%)                |                          |                          |                          |
| 40                                                       | 111 (39.8)               | 104 (37.5)               | 215 (38.7)               |

<div style=\"page-break-after: always\"></div>

| 40 - ≤80                                         | 102 (36.6)   | 107 (38.6)   | 209 (37.6)   |
|--------------------------------------------------|--------------|--------------|--------------|
| 80-≤120                                          | 52 (18.6)    | 49 (17.7)    | 101 (18.2)   |
| ≥120                                             | 13 (4.7)     | 17 (6.1)     | 30 (5.4)     |
| Missing                                          | 1 (0.4)      | 0            | 1 (0.2)      |
| EGFR mutations by cobas central test             |              |              |              |
| EGFR exon 19 deletion                            | 158 (56.6)   | 155 (56.0)   | 313 (56.3)   |
| EGFR exon 21 L858R                               | 97 (34.8)    | 90 (32.5)    | 187 (33.6)   |
| EGFRm not detected                               | 3 (1.1)      | 3 (1.1)      | 6 (1.1)      |
| Invalid test                                     | 4 (1.4)      | 5 (1.8)      | 9 (1.6)      |
| No sample or inadequate sample                   | 17 (6.1)     | 24 (8.7)     | 41 (7.4)     |
| EGFR mutations as used for randomisation strataf |              |              |              |
| EGFR ex0n 21 L858R                               | 104 (37.3)   | 103 (37.2)   | 207 (37.2)   |
| EGFR exon 19 deletion                            | 175 (62.7)   | 174 (62.8)   | 349 (62.8)   |

- Metastatic disease - Patient had any metastatic site of disease.
- Locally advanced - Patient had only locally advanced sites of disease.
- Longest diameter at baseline.
- A patient could have more than one mutation.
- EGFR mutations based on the test (local or central) used to determine randomisation strata (Ex19del or L858R).

## Determination of EGFR mutation status

Of the 994 patients screened in the FLAURA study, 556 were randomised. Of those 556 patients, 267 were randomised based on local testing performed at certified/accredited laboratories. The remaining 289 patients were randomised based on an EGFRm status identified via the cobas® EGFR Mutation Test performed at designated central laboratories (Figure 3).

<!-- image -->

MD.presence ofexon I9 deletion orLs5sRmulition

NMD:absetice ofexon 19 deletion andLS5SRillotatiom

Not tested by central cobus testing: inebading tisspe sannple mot available, insufficient tissue, tissue failed pathology review, insufficient DNA yield

Figure 17 : Summary of EGFR local and central testing results.

Patients who were randomised based on a local EGFRm positive result were also required to provide a tissue specimen for central testing to compare the local testing results with the central cobas® EGFR Mutation Test. Investigators were not required to submit samples for central testing for patients who failed screening based on local EGFR test results.

Of  the  267  patients  randomised  based  on  a  local  result,  226  (85%)  also  had  evaluable  tumour specimens tested  by the central  cobas®  EGFR  Mutation  Test.  Of  these  226  patients,  217  yielded  a

<div style=\"page-break-after: always\"></div>

valid  central  cobas  test  result,  of  whom  211/217  (97%)  patients  were  retrospectively  confirmed  to have EGFRm tumours based on central testing (osimertinib: 110 [52%]; SoC: 101 [48%]). The central test  did  not  confirm  the  presence  of  an  EGFRm  mutation  in  6  patients  (osimertinib:  3;  SoC:  3).  A further 41 patients were not tested by the central cobas® EGFR Mutation Test; this included patients for whom no sample was supplied and patients for whom the supplied sample did not meet the testing requirements.

The  PPA  between  the  cobas®  EGFR  Mutation  Test  and  the  local  tests  was  97.2%  for  the  2  EGFR sensitising  mutations (Ex19del and L858R) in aggregate, 99.2% for Ex19del, and 94.5% for L858R, excluding invalid test results and no or inadequate samples. The cobas® EGFR Mutation Test showed a high percent agreement with the local tests.

Of the 556 patients randomised into the FLAURA study, 500 (89.9%) were confirmed to have EGFR mutation-positive  tumours  according  to  the  cobas  EGFR  Mutation  Test  (performed  centrally).  An additional 41 (7.4%) patients had no or inadequate samples, 9 (1.6%) had invalid tests, and 6 (1.1%) had mutations not detected.

## Prior anti-cancer therapy

Per  protocol,  all  randomised  patients  were  to  be  treatment-naïve  for  their  advanced  NSCLC.  Three patients  (2  in  the  osimertinib  arm,  1  in  the  SoC  arm)  had  received  prior  treatment  for  advanced cancer, an important protocol deviation.

Patients could have received prior adjuvant or neo-adjuvant therapy at an earlier stage of the disease: overall, 37/556 (6.7%) patients had received prior adjuvant or neoadjuvant cytotoxic chemotherapy (osimertinib: 21 [7.5%]; SoC: 16 [5.8%]).

Prior  radiotherapy  had  been  administered  to  104/556  (18.7%)  patients  overall  (osimertinib:  47 [16.8%]; SoC: 57 [20.6%]). Fifteen (2.7%) patients overall had prior brain radiotherapy (osimertinib: 8 [15.1%]; SoC: 7 [11.1%]).

## Use of concomitant medication

The vast majority of patients (274 [98.2%] in the osimertinib arm and 272 [98.2%] in the SoC arm) received concomitant medications during the study. Concomitant medications were generally representative of medications commonly administered to patients with advanced NSCLC, in alignment with the concomitant medical conditions, were well balanced between treatment arms, and were not considered to affect the study results.

Radiotherapy while on treatment was administered to 8 (2.9%) patients in the osimertinib arm and 10 (3.6%) patients in the SoC arm.

Two  (0.4%)  patients  (1  in  each  arm)  received  a  disallowed  concomitant  medication,  an  important protocol deviation.

<div style=\"page-break-after: always\"></div>

Anti-cancer therapy post-treatment discontinuation (including cross-over treatment).

Table 15 : Post-treatment anti-cancer therapy (including cross-over osimertinib)(FAS set)

|                                         | Number (%) of patientsa   | Number (%) of patientsa   |
|-----------------------------------------|---------------------------|---------------------------|
| Classification/ATC dictionary text      | Osimertinib (N=279)       | SoC (N=277)               |
| Discontinued randomised study treatment | 138 (49.5)                | 213 (76.9)                |
| Any post-treatment anti-cancer therapy  | 82 (29.4)                 | 129 (46.6)                |
| No post-treatment anti-cancer therapy   | 56 (20.1)                 | 84 (30.3)                 |
| Ongoing randomised study treatment      | 141 (50.5)                | 64 (23.1)                 |
| EGFR-TKI                                | 38 (13.6) [27.5]          | 99 (35.7) [46.5]          |
| PD1/PDL1                                | 6 (2.2) [4.3]             | 4 (1.4) [1.9]             |
| Non-platinum chemotherapy               | 55 (19.7) [39.9]          | 46 (16.6) [21.6]          |
| Platinum-based chemotherapy             | 53 (19.0) [38.4]          | 42 (15.2) [19.7]          |
| Other targeted therapy                  | 3 (1.1) [2.2]             | 5 (1.8) [2.3]             |
| Anti-VEGF                               | 10 (3.6) [7.2]            | 14 (5.1) [6.6]            |

The number of patients is shown with percentages calculated as the proportion of patients in the FAS and secondly (between brackets) as the proportion of patients who discontinued randomised study treatment.

Post-treatment anti-cancer therapies are those with a start date on or after the last dose date of randomised shudy treatment.

Patients with no post-treatment anti-cancer therapy had discontinued randomised study treatment without starting any other post-treatment anti-cancer therapy.

AZ Drug Dictionary version 17.1

DCO1: 12 June 2017

Patients may be counted in multiple rows if they received more than 1 anti-cancer therapy or a combination therapy that contained drug substances from multiple classifications.

<div style=\"page-break-after: always\"></div>

Table 16 : First and second post-treatment anti-cancer therapy (including cross-over osimertinib) (FAS)

|                                                                             | Number (%) of patientsa                                                     | Number (%) of patientsa                                                     |
|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Classification/ATC dictionary text                                          | Osimertinib (N=279)                                                         | SoC (N=277)                                                                 |
| First post-treatment anti-cancer therapy (including cross-over osimertinib) | First post-treatment anti-cancer therapy (including cross-over osimertinib) | First post-treatment anti-cancer therapy (including cross-over osimertinib) |
| Discontinued randomised study treatment                                     | 138 (49.5)                                                                  | 213 (76.9)                                                                  |
| First post-treatment anti-cancer therapy                                    | 82 (29.4)                                                                   | 129 (46.6)                                                                  |
| No post-treatment anti-cancer therapy                                       | 56 (20.1)                                                                   | 84 (30.3)                                                                   |
| Ongoing randomised study treatment                                          | 141 (50.5)                                                                  | 64 (23.1)                                                                   |
| First post-treatment anti-cancer therapy                                    |                                                                             |                                                                             |
| EGFR-TKI                                                                    | 29 (10.4) [21.0]                                                            | 97 (35.0) [45.5]                                                            |
| PD1/PDL1                                                                    | 3 (1.1) [2.2]                                                               | 2 (0.7) [0.9]                                                               |
| Non-platinum chemotherapy                                                   | 50 (17.9) [36.2]                                                            | 27 (9.7) [12.7]                                                             |
| Platinum-based chemotherapy                                                 | 48 (17.2) [34.8]                                                            | 26 (9.4) [12.2]                                                             |
| Other targeted therapy                                                      | 2 (0.7) [1.4]                                                               | 3 (1.1) [1.4]                                                               |
| Anti-VEGF                                                                   | 7 (2.5) [5.1]                                                               | 4 (1.4) [1.9]                                                               |
| Second post-treatment anti-cancer therapy                                   |                                                                             |                                                                             |
| Second post-treatment anti-cancer therapy                                   | 24 (8.6)                                                                    | 39 (14.1)                                                                   |
| Only 1 post-treatment anti-cancer therapy                                   | 58 (20.8)                                                                   | 90 (32.5)                                                                   |
| Second post-treatment anti-cancer therapy                                   |                                                                             |                                                                             |
| EGFR-TKI                                                                    | 10 (3.6) [7.2]                                                              | 14 (5.1) [6.6]                                                              |
| PD1/PDL1                                                                    | 2 (0.7) [1.4]                                                               | 1 (0.4) [0.5]                                                               |
| Non-platinum chemotherapy                                                   | 11 (3.9) [8.0]                                                              | 19 (6.9) [8.9]                                                              |
| Platinum-based chemotherapy                                                 | 4 (1.4) [2.9]                                                               | 16 (5.8) [7.5]                                                              |
| Other targeted therapy                                                      | 1 (0.4) [0.7]                                                               | 2 (0.7) [0.9]                                                               |
| Anti-VEGF                                                                   | 3 (1.1) [2.2]                                                               | 6 (2.2) [2.8]                                                               |

The number of patients is shown with percentages calculated as the proportion of patients in the FAS and secondly (between brackets) as the proportion of patients who discontinued randomised study treatment.

randomised study treatment. The second post-treatment anti-cancer therapy was the second treatment started on or after the last dose date of randomised study treatment.

Patients with no post-treatment anti-cancer therapy had discontinued randomised study treatment without starting any other post-treatment anti-cancer therapy.

## Numbers analysed

The analysis sets and the number (%) of patients in each analysis set are summarised in the table below.

<div style=\"page-break-after: always\"></div>

Table 17 : Study-level analysis sets (full analysis set).

|                                                               | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|---------------------------------------------------------------|--------------------------|--------------------------|--------------------------|
|                                                               | Osimertinib (N=279)      | SoC (N=277)              | Total (N=550)            |
| Patients included in full analysis set (FAS)                  | 279                      | 277                      | 556                      |
| Patients included in safety analysis set                      | 279                      | 277                      | 556                      |
| Patients included in pharmacokinetic (PK) analysis set        | 261                      | 0                        | 261                      |
| Patients excluded from pharmacokinetic analysis set           | 18                       | 277                      | 295                      |
| Patients not randomised to osimertinib                        | 0                        | 277                      | 277                      |
| Patient had detectable pre-dose osimertinib concentration     | 18                       | 0                        | 18                       |
| Patients included in centrally-confirmed EGFRm analysis set   | 255                      | 245                      | 500                      |
| Patients excluded from centrally-confirmed EGFRm analysis set | 24                       | 32                       | 56                       |
| No sample or inadequate sample                                | 17                       | 24                       | 41                       |
| Invalid sample                                                | 4                        | 5                        | 9                        |
| EGFRm not detected (negative) by central testing              | 3                        | 3                        | 6                        |

a Patients could have been excluded for more than 1 reason.

Full analysis set: all randomised patients Safety analysis set: all patients who received at least 1 dose of treatment; Pharmacokinetic analysis set: patients in the FAS randomised to osimertinib who did not have an osimertinib plasma concentration above LLQ at pre-dose Cycle 1 Day 1 and had at least 1 osimertinib plasma concentration above LLQ. Centrally confirmed EGFRm analysis set: all randomised patients who had centrallyconfirmed positive EGFR mutation. DCO1: 12 June 2017.

The analysis sets used in the CNS efficacy analyses were as follows (Figure 4):

The cFAS (defined as all randomised patients identified by CNS BICR as having at least 1 CNS lesion at baseline,  whether  measurable  or  not)  included  a  total  of  128/556  (23.0%)  patients  (osimertinib: 61/279 [21.9%]; SoC: 67/277 [24.2%]).

- The  cEFR  (defined  as  all  randomised  patients  identified  by  CNS  BICR  as  having  at  least  1  CNS measurable  lesion  at  baseline)  included  a  total  of  41/556  (7.4%)  patients  (osimertinib:  22/279 [7.9%]; SoC: 19/277 [6.9%]).
- The CNS MTS analysis set included a total of 116/556 (20.9%) patients programmatically classified as  having  a  positive  CNS  metastases  status  at  baseline  (CNS  MTS:  \"Yes\")  based  on  baseline characteristics  recorded  by  the  investigators  on  the  eCRF  pages  (osimertinib:  53/279  [19.0%]; SoC:  63/277  [22.7%]);  and  440/556  (79.1%)  patients  determined  to  have  a  negative  CNS metastases  status  at  baseline  (CNS  MTS:  \"No\")  (osimertinib:  226/279  [81.0%];  SoC:  214/277 [77.3%]).

<div style=\"page-break-after: always\"></div>

Figure 18 : Central nervous system analysis sets

<!-- image -->

The patient characteristics for the patients in the CNS full analysis set are summarised below:

Table 18 : Selected baseline characteristics in the CNS full analysis set

|                         | Osimertinib (n=61)   | Soc (n=67)   |
|-------------------------|----------------------|--------------|
| Age (median, range)     | 63.0 (34-83)         | 63.0 (39-85) |
| Male sex                | 23 (37,7 %)          | 26 (38,8 %)  |
| Asian race              | 40 (65,6 %)          | 37 (55,2 %)  |
| WHO performance status  |                      |              |
| 0 (Normal activity)     | 16 (26,2 %)          | 27 (40,3 %)  |
| 1 (Restricted activity) | 45 (73,8 %)          | 39 (58,2 %)  |

## Outcomes and estimation

## Efficacy results

At the time of DCO the median duration of total treatment exposure was 16.2 months (range, 0.1 to 27.4) for patients receiving osimertinib and 11.5 months (range, 0 to 26.2) for patients receiving SoC.

A summary of the key efficacy data from FLAURA at the time of DCO1 is presented in Table 8.

<div style=\"page-break-after: always\"></div>

Table 19 : Summary of key efficacy outcome variables (Full Analysis Set).

DC01:12June 2017

|                                                         | Osimertinib 80 mg (N = 279)    | Standard of Care (N = 277)     |
|---------------------------------------------------------|--------------------------------|--------------------------------|
| Progression-free survival                               |                                |                                |
| Number of events (%)                                    | 136 (48.7)                     | 206 (74.4)                     |
| Hazard ratio (95% CI); 2-sided p-value                  | 0.46 (0.37, 0.57); p<0.0001    | 0.46 (0.37, 0.57); p<0.0001    |
| Median PFS (95% CI), months                             | 18.9 (15.2, 21.4)              | 10.2 (9.6, 11.1)               |
| Overall survival (Interim analysis)                     |                                |                                |
| Number of patients with OS events (%)                   | 58 (20.8)                      | 83 (30.0)                      |
| Hazard ratio (95% CI); 2-sided p-value                  | 0.63 (0.45, 0.88); 0.0068 (NS) | 0.63 (0.45, 0.88); 0.0068 (NS) |
| Median OS (95% CI) (months)                             | Not calculable                 | Not calculable                 |
| Survival at 12 months (%) (95% CI)                      | 89.1 (84.7, 92.2)              | 82.5 (77.4, 86.5)              |
| Survival at 18 months (%) (95% CI)                      | 82.8 (77.7, 86.8)              | 70.9 (64.8, 76.1)              |
| Objective response rate                                 |                                |                                |
| ORR a                                                   |                                |                                |
| Number of patients with response (%)                    | 223 (79.9)                     | 210 (75.8)                     |
| 95% CI for ORR                                          | 74.7, 84.5                     | 70.3, 80.7                     |
| Odds ratio (95% CI); 2-sided p-value                    | 1.27 (0.85,1.90); 0.2421       | 1.27 (0.85,1.90); 0.2421       |
| Confirmed ORR b                                         |                                |                                |
| Number of patients with response (%)                    | 214 (76.7)                     | 191(69.0)                      |
| 95% CI for ORR                                          | 71.3, 81.5                     | 63.1, 74.4                     |
| Odds ratio (95% C1); 2-sided p-value                    | 1.48 (1.02, 2.17); 0.0397      | 1.48 (1.02, 2.17); 0.0397      |
| Duration of response                                    |                                |                                |
| Median DoR (95% CI) (months)                            | 17.2 (13.8, 22.0)              | 8.5 (7.3, 9.8)                 |
| Confirmed Median DoR (95% CI) (months)                  | 17.6 (13.8, 22.0)              | 9.6 (8.3, 11.1)                |
| Disease control rate                                    |                                |                                |
| No (%) patients with disease control (CR+PR+SD≥6 weeks) | 271 (97.1)                     | 256 (92.4)                     |
| 95% CI for DCR                                          | 94.4, 98.8                     | 88.6, 95.2                     |
| Odds ratio (95% CI); 2-sided p-value                    | 2.78 (1.25, 6.78); 0.0110      | 2.78 (1.25, 6.78); 0.0110      |

All the results included in this table are based on investigator assessment unless otherwise stated. PFS, ORR and DoR results by investigator assessment were consistent with those reported via Blinded Independent Central Review (BICR); PFS by BICR assessment was 17.7 months [95% CI: 15.1, 21.4] on osimertinib and 9.7 months [95% CI: 8.5, 11.0] on SoC; ORR by BICR assessment was 78.1% on osimertinib and 70.4% on SoC.

HR = Hazard ratio, CI = confidence interval, NC = Not calculable, NS = Not statistically significant

a Responses were unconfirmed as per RECIST guidelines for Phase III trials (Eisenhauer et al 2009).

b Confirmed responses: subset of unconfirmed responses; CI calculated with the Clopper-Pearson method.

## Primary efficacy endpoint: PFS based on Investigator assessment

At the DCO1 for the primary analysis of PFS (12 June 2017), 342 (61.5%) RECIST progression events had occurred based on Investigator assessment according to RECIST v1.1.

<div style=\"page-break-after: always\"></div>

Table 20 : Analysis of progression-free survival (full analysis set)

DC01: 12 June 2017

|                                      | Nunber (%) patients   | Nunber (%) patients   |
|--------------------------------------|-----------------------|-----------------------|
|                                      | Osimertinib (N=279)   | SoC (N=277)           |
| PFS based on Investigator assessment |                       |                       |
| No. (%) patients with PFS events     | 136 (48.7)            | 206 (74.4)            |
| Hazard ratio (95% CI)                | 0.46 (0.37, 0.57)     | 0.46 (0.37, 0.57)     |
| 2-sided p-value                      | <0.0001               | <0.0001               |
| Median PFS (95% CI), months          | 18.9 (15.2, 21.4)     | 10.2 (9.6, 11.1)      |
| PFS based on BICR assessment         |                       |                       |
| No. (%) of patients with PFS events  | 137 (49.1)            | 198 (71.5)            |
| Hazard ratio (95% CI)                | 0.45 (0.36, 0.57)     | 0.45 (0.36, 0.57)     |
| 2-sided p-value                      | <0.0001               | <0.0001               |
| Median PFS (95% CI), months          | 17.7 (15.1, 21.4)     | 9.7 (8.5, 11.0)       |

A greater proportion of patients treated with osimertinib were alive and progression-free at 6 months (88.4% [95% CI: 83.9, 91.7]), 12 months (68.2% [95% CI: 62.3, 73.5]), and 18 months (50.9% (95% CI: 44.5, 57.0]) compared to those treated with SoC (6 months: 75.2% [95% CI: 69.5, 79.9]; 12 months: 42.3% [95% CI: 36.3, 48.2]; and 18 months: 24.4% [95% CI: 19.2, 30.0]).

Figure 19: Kaplan-Meier plot of progression-free survival - investigator assessment (full analysis set). Most of the PFS events were due to progression by RECIST criteria; 11 (3.9%) patients on osimertinib and 14 (5.1%) patients on SoC died in the absence of RECIST progression.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 21: Progression-free survival analysis - investigator assessment (full analysis set)

|                                          | Number (%) of patients   | Number (%) of patients   |
|------------------------------------------|--------------------------|--------------------------|
| Progression status                       | Osimertinib (N=279)      | SoC (N=277)              |
| Progression status                       |                          |                          |
| Progression                              |                          |                          |
| Total number of patients with PFS events | 136 (48.7)               | 206 (74.4)               |
| RECIST progression*                      | 125 (44.8)               | 192 (69.3)               |
| Target lesionsb                          | 64 (22.9)                | 94 (33.9)                |
| Non-target lesionsb                      | 40 (14.3)                | 70 (25.3)                |
| New lesionsb                             | 52 (18.6)                | 103 (37.2)               |
| Deathc                                   | 11 (3.9)                 | 14 (5.1)                 |
| No progression                           |                          |                          |
| Total                                    | 143 (51.3)               | 71 (25.6)                |
| Censored RECIST progressiond             | 3 (1.1)                  | 2 (0.7)                  |
| Censored deathd                          | 4 (1.4)                  | 5 (1.8)                  |
| Progression-free at time of analysis?    | 129 (46.2)               | 56 (20.2)                |
| Lost to follow-upf                       | 1 (0.4)                  | 0                        |
| Withdrawn consent                        | 6 (2.2)                  | 8 (2.9)                  |
| Discontinued study for other reasons     | 0                        | 0                        |
| New lesions                              |                          |                          |
| Patientswith no newlesions               | 217 (77.8)               | 163 (58.8)               |
| Patients with new lesions                | 62 (22.2)                | 114 (41.2)               |
| Most common sites of new lesions:        |                          |                          |
| CNS                                      | 15 (5.4)                 | 34 (12.3)                |
| Liver                                    | 6 (2.2)                  | 20 (7.2)                 |
| Lung                                     | 20 (7.2)                 | 41 (14.8)                |
| Bone                                     | 11 (3.9)                 | 11 (4.0)                 |
| Comparisonbetween arms                   |                          |                          |
| Hazard ratio (95% CI)                    | 0.46 (0.37, 0.57)        | 0.46 (0.37, 0.57)        |
| 2-sided p-value                          | <0.0001                  | <0.0001                  |

Only included progression events that occurred within 2 scheduled visits (plus visit window) of the last evaluable assessment (or randomisation).

- Target lesions, non-target lesions, and new lesions were not necessarily mutually exclusive categories. New lesions presented with the PFS analysis were only counted if they occurred at the time of first progression (PFS analysis).
- Death in the absence of progression.
- d RECIST progression or death occurred more than 2 scheduled visits (plus visit window) after last evaluable RECIST assessment.
- Included patients known to be alive, with no evaluable baseline RECIST assessment (censored at Day 1) of censored at last evaluableRECIST assessment.
- f Patients censored at last evaluable RECIST assessment orrandomisation.
- Included any new lesions up to DCO, including new lesions that occurred at any time after PD and new lesions in patients who were censored for PFS. The number of new lesions in this analysis is therefore larger than the number of new lesions that contributed to, and were recorded at, PFS.

RECIST version 1.1.

DC01: 12 June 2017

<div style=\"page-break-after: always\"></div>

## Sensitivity analysis of PFS based on BICR

Table 22 : Progression-free survival analysis -BICR assessment (full analysis set)

|                                          | Number (%) of patients   | Number (%) of patients   |
|------------------------------------------|--------------------------|--------------------------|
|                                          | Osimertinib              | SoC                      |
| Progression status                       | (N=279)                  | (N=277)                  |
| Progression status                       |                          |                          |
| Progression                              |                          |                          |
| Total number of patients with PFS events | 137 (49.1)               | 198 (71.5)               |
| RECIST progressiona                      | 122 (43.7)               | 182 (65.7)               |
| Target lesionsb                          | 66 (23.7)                | 87 (31.4)                |
| Non-target lesionsb                      | 39 (14.0)                | 67 (24.2)                |
| New lesionsb                             | 21 (7.5)                 | 39 (14.1)                |
| Deathc                                   | 15 (5.4)                 | 16 (5.8)                 |
| No progression                           |                          |                          |
| Total                                    | 142 (50.9)               | 79 (28.5)                |
| Censored RECIST progressiond             | 0                        | 0                        |
| Censored deathd                          | 4 (1.4)                  | 6 (2.2)                  |
| Progression-free at time of analysis?    | 131 (47.0)               | 64 (23.1)                |
| Lost to follow-upf                       | 1 (0.4)                  | 0                        |
| Withdrawn consent                        | 6 (2.2)                  | 9 (3.2)                  |
| Discontinued study for other reasonsf    | 0                        | 0                        |
| New lesionss                             |                          |                          |
| Patients with no new lesions             | 236 (84.6)               | 206 (74.4)               |
| Patients with newlesions                 | 43 (15.4)                | 71 (25.6)                |
| Comparison between arms                  |                          |                          |
| Hazard ratio (95% CI)                    | 0.45 (0.36, 0.57)        | 0.45 (0.36, 0.57)        |
| 2-sided p-value                          | <0.0001                  | <0.0001                  |

evaluable assessment (or randomisation)

Target lesions, non-target lesions, and new lesions were not necessarily mutually exclusive categories.

Death in the absence of progression.

d RECIST progression or death occurred more than 2 scheduled visits (plus visit window) after last evaluableRECIST assessment.

- Included patients known to be alive, with no evaluable baseline RECIST assessment (censored at Day O)
- Included all new lesions up to DCO, including new lesions that occurred after PD and new lesions in patients who were censored for PFS.

f Patients censored at last evaluable RECIST assessment of randomisation.

RECIST version 1.1.

DCO1: 12 June 2017

## Other sensitivity analyses of progression-free survival

Further sensitivity analyses to assess bias were found to be consistent with the primary PFS analysis, demonstrating the robustness of the primary outcome.

- There was no evidence of evaluation-time bias affecting PFS, which could occur if scans were not performed at the protocol-scheduled time intervals. The HR of 0.46 (95% CI: 0.37, 0.57; p-value &lt;0.0001) was consistent with the primary analysis.
- The results of the attrition bias sensitivity analysis indicated that the censoring rules applied did not introduce a bias in the outcome of the primary analysis of PFS. The HR was 0.47 (95% CI: 0.37, 0.58; p &lt;0.0001).

<div style=\"page-break-after: always\"></div>

- An additional sensitivity analysis was conducted to assess the impact of the change in RECIST scanning schedule at Month 18 from every 6 weeks to every 12 months, which fell close to the median PFS of 18.9 months in the osimertinib arm. The impact of the change in visit schedule was very minor. The median PFS in the osimertinib arm decreased to 18.4 months (95% CI: 15.2, 22.1) from 18.9 months, with no change in the median for the SoC arm. The HR and 95% CI remained unchanged. The median total number of RECIST assessments per patient after Month 18 was 1.0 (range: 1-5).

## Secondary efficacy endpoint: Overall survival (interim analysis)

The first of 2 analyses of OS was conducted at the DCO1 for the primary analysis of PFS. A survival status check was conducted on all randomised patients without a death reported 7 days after database DCO  date  (12  June  2017).  A  second  and  final  OS  analysis  will  be  conducted  when  data  are approximately 60% mature (~334 deaths).

The  maturity  for  OS  was  25.4%  overall.  A  majority  of  patients  (osimertinib:  51/58  [87.9%];  SoC 65/83 [78.3%]) died of the disease under study.

Table 23 : Overall survival analysis (full analysis set)

|                                      | Osimertinib (N=279)   | SoC (N=277)       |
|--------------------------------------|-----------------------|-------------------|
| Survival status                      |                       |                   |
| Death                                | 58 (20.8)             | 83 (30.0)         |
| Still in survival follow-up*         | 208 (74.6)            | 177 (63.9)        |
| Terminated prior to deathb           | 13 (4.7)              | 17 (6.1)          |
| Voluntary discontinuation by patient | 11 (3.9)              | 17 (6.1)          |
| Patient lost to follow-up            | 2 (0.7)               | 0                 |
| Comparison between arms              |                       |                   |
| Hazard ratio (95% CI)                | 0.63 (0.45, 0.88)     | 0.63 (0.45, 0.88) |
| Adjusted CI (99.85%)                 | 0.37, 1.08            | 0.37, 1.08        |
| 2-sided p-value                      | 0.0068                | 0.0068            |

The analysis was performed using a log rank test stratified by stratification factors.

Compared to patients treated with SoC, a greater proportion of patients treated with osimertinib were alive at 12 months (osimertinib: 89.1% [95% CI: 84.7, 92.2]; SoC: 82.5% [95% CI: 77.4, 86.5]) and 18 months (osimertinib: 82.8% [95% CI: 77.7, 86.8]; SoC: 70.9% [95% CI: 64.8, 76.1]). At the time of DCO1, every patient had the opportunity for a minimum of 15-month follow-up.

<div style=\"page-break-after: always\"></div>

Figure 20 : Kaplan-Meier plot of overall survival (full analysis set)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Secondary efficacy endpoint: ORR based on Investigator assessment

Table 24 : Best objective response analysis - investigator assessment (full analysis set)

|                                                                      | Number (%) of patients   | Number (%) of patients   |
|----------------------------------------------------------------------|--------------------------|--------------------------|
| Best objective response                                              | Osimertinib (N=279)      | SoC (N=277)              |
| Response status?                                                     |                          |                          |
| Response                                                             |                          |                          |
| Total                                                                | 223 (79.9)               | 210 (75.8)               |
| Complete response                                                    | 7 (2.5)                  | 4 (1.4)                  |
| Partial response                                                     | 216 (77.4)               | 206 (74.4)               |
| Non-response                                                         |                          |                          |
| Total                                                                | 56 (20.1)                | 67 (24.2)                |
| Stabledisease≥6weeks                                                 | 47 (16.8)                | 46 (16.6)                |
| Progression                                                          | 3 (1.1)                  | 14 (5.1)                 |
| RECIST progression                                                   | 3 (1.1)                  | 9 (3.2)                  |
| Death                                                                | 0                        | 5 (1.8)                  |
| Not evaluable                                                        | 6 (2.2)                  | 7 (2.5)                  |
| Incomplete post baseline assessments                                 | 6 (2.2)                  | 7 (2.5)                  |
| Analysis of ORRb                                                     |                          |                          |
| Objective response rate (%) (95% CI)                                 | 76.7 (71.3, 81.5)        | 69.0 (63.1, 74.4)        |
| Objective response rate adjusted for ethnicity and mutation type (%) | 80.7                     | 76.6                     |
| Comparison between groups                                            |                          |                          |
| Odds ratio (95% CI)                                                  | 1.27 (0.85, 1.90)        | 1.27 (0.85, 1.90)        |
| 2-sided p-value for odds ratio                                       | 0.2421                   | 0.2421                   |
| Adjusted odds ratio (95% CI)                                         | 1.28 (0.85, 1.93)        | 1.28 (0.85, 1.93)        |
| 2-sided p-value for adjusted odds ratio                              | 0.2335                   | 0.2335                   |
| Response status - Confirmed responses                                |                          |                          |
| Response                                                             |                          |                          |
| Total                                                                | 214 (76.7)               | 191 (69.0)               |
| Complete response                                                    | 6 (2.2)                  | 3 (1.1)                  |
| Partial response                                                     | 208 (74.6)               | 188 (67.9)               |
| Non-response                                                         |                          |                          |
| Total                                                                | 65 (23.3)                | 86 (31.0)                |
| Stable disease ≥ 6 weeks                                             | 55 (19.7)                | 65 (23.5)                |
| Progression                                                          | 4 (1.4)                  | 14 (5.1)                 |
| RECIST progression                                                   | 4 (1.4)                  | 9 (3.2)                  |
| Death                                                                | 0                        | 5 (1.8)                  |
| Not evaluable                                                        | 6 (2.2)                  | 7 (2.5)                  |
| No evaluable follow-up assessments                                   | 6 (2.2)                  | 7 (2.5)                  |
| Analysis of ORRb - Confirmed responsesc                              |                          |                          |
| No. (%) of patients with confirmed response                          | 214 (76.7)               | 191 (69.0)               |
| Objective response rate (%) (95% CI)                                 | 76.7 (71.3, 81.5)        | 69.0 (63.1, 74.4)        |
| Objective response rate adjusted for ethnicity and mutation type (%) | 76.0                     | 67.8                     |
| Comparison between arms                                              |                          |                          |
| Odds ratio (95% CI)                                                  | 1.48 (1.02, 2.17)        | 1.48 (1.02, 2.17)        |
| 2-sided p-value for odds ratio                                       | 0.0397                   | 0.0397                   |
| Adjusted odds ratio (95% CI)                                         | 1.51 (1.03, 2.22)        | 1.51 (1.03, 2.22)        |
| 2-sidedp-valuefor adjustedoddsratio                                  | 0.036                    | 0.036                    |

The analysis was performed using a logistic regression stratified by ethnicity (Asian versus Non-Asian) and mutation type (Ex19del versus L85sR). An odds ratio &gt; 1 favours osimertinib.

Response did notrequire confirmation.

Confirmed responses were a subset of the responses. CIs were calculated using the Clopper-Pearson method.

## ORR based on BICR assessment

<div style=\"page-break-after: always\"></div>

The BICR assessment was consistent with the Investigator assessment. The ORR was 78.1% in the osimertinib arm and 70.4% in the SoC arm. Based on assessment by BICR, no patients had CR and 218 (78.1%) had PR in the osimertinib arm vs. 3 (1.1%) patients with CR and 192 (69.3%) patients with  PR  in  the  SoC  arm.  The  ORR  (adjusted  for  ethnicity  and  mutation  type)  was  78.6%  in  the osimertinib arm vs. 70.8% in the SoC arm (OR: 1.52 [95% CI: 1.03, 2.24]; p-value = 0.0344).

## ORR based on Investigator assessment for patients with centrally-confirmed EGFRm

The ORR results based on Investigator assessment in patients with centrally-confirmed EGFRm were consistent with those in the study FAS. The ORR in patients with centrally-confirmed positive EGFRm was 79.6% in the osimertinib arm and 77.1% in the SoC arm. The ORR (adjusted) was 80.5% in the osimertinib  arm  vs.  77.9%  in  the  SoC  arm  (OR  [adjusted]:  1.17  [95%  CI:  0.76,  1.81];  2-sided  pvalue: 0.4728).

## Secondary efficacy endpoint: Duration and onset of response based on Investigator assessment

The median DoR based on Investigator assessment (calculated using KM technique) was 17.2 months (95% CI: 13.8, 22.0) in the osimertinib arm vs. 8.5 months (95% CI: 7.3, 9.8) in the SoC arm.

A  greater  proportion  of  patients  in  the  osimertinib  arm  remained  in  response  at  12  months (osimertinib:  64.4%  [95%  CI:  57.5,  70.5];  SoC:  37.3%  [95%  CI:  30.6,  44.1])  and  18  months (osimertinib: 48.8% [95% CI: 41.1, 56.0]; SoC: 19.1% [95% CI: 13.3, 25.7]) compared to patients in the SoC arm.

The  DoR  analysis  by  BICR  was  consistent  with  the  Investigator  DoR  analysis  and  in  line  with  the improvement in PFS.

Figure 21: Kaplan-Meier plot of duration of response - investigator assessment (full analysis set) The median time to onset of response from randomisation was similarly rapid in both treatment arms and aligned with the first response assessment at Week 6 (osimertinib, 6.1 weeks [95% CI: 6.0, 6.1]; SoC, 6.1 weeks [95% CI: NC, NC]).

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Secondary efficacy endpoint: DCR based on Investigator assessment

The  DCR  (defined  as  complete  response  [CR]+  PR+stable  disease  [SD]  ≥6  weeks)  based  on Investigator assessment was similar and &gt;90% in both arms.

## Secondary efficacy endpoint: Depth of response (tumour shrinkage)

A similar proportion of patients had tumour shrinkage (reduction of the sum of tumour lesion size) in both treatment arms, based on Investigator assessment according to RECIST v1.1, with a similar mean shrinkage of TLs in both arms. The BICR analysis was consistent with the Investigator analysis.

<!-- image -->

Best percentage change in target lesion size was the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction.

*represents imputed values: If it was known that the patient had died, had new lesions or progression of non-target lesions, had withdrawn due to PD and

RECIST version 1.1.

DC01:12June2017

Figure 22: Target lesion size, best percentage change from baseline by investigator assessment - total waterfall plot, osimertinib arm (full analysis set)

<!-- image -->

* represents imputed values: Ifit was known that the patient had died, had new lesions or progression of non-target lesions, had withdrawn due to PD and

RECIST version 1.1.

DC01:12June2017

Figure 23: Target lesion size, best percentage change from baseline by investigator assessment - total waterfall plot, standard of care arm (full analysis set)

<div style=\"page-break-after: always\"></div>

## Secondary endpoint of patient-reported outcomes

Overall, compliance rates for EORTC QLQ-C30 were ≥70% up to Week 96 in the osimertinib arm and up to Week 60 in the SoC arm. Compliance rates for EORTC QLQ-LC13 were ≥70% up to Week 93 in the  osimertinib  arm  and  up  to  Week  75  in  the  SoC  arm  (with  an  exception  for  Week  66  when  the compliance rate was 69.2%).

Table 25: Summary of change from baseline in primary PRO symptoms, MMRM (full analysis set)

|                                                | Cough       | Cough       | Dyspnoea    | Dyspnoea    | Chest pain   | Chest pain   | Appetite loss   | Appetite loss   | Fatigue     | Fatigue     |
|------------------------------------------------|-------------|-------------|-------------|-------------|--------------|--------------|-----------------|-----------------|-------------|-------------|
|                                                | Osi         | SoC         | Osi         | SoC         | Osi          | SoC          | Osi             | SoC             | Osi         | SoC         |
| N                                              | 248         | 252         | 248         | 252         | 248          | 252          | 252             | 247             | 252         | 247         |
| LS mean                                        | -10.97      | -11.65      | -4.04       | -4.14       | -6.62        | -6.41        | -6.15           | -5.64           | -5.48       | -4.72       |
| 95% CI for                                     | -12.77,     | -13.47,     | -5.63,      | -5.73,      | -8.24,       | -8.04,       | -8.39,          | -7.96,          | -7.45,      | -6.74,      |
| LS mean                                        | -9.17       | -9.84       | -2.45       | -2.54       | -5.01        | -4.78        | -3.90           | -3.32           | -3.52       | -2.69       |
| Difference in LS means (osimertinib minus SoC) | 0.68        | 0.68        | 0.10        | 0.10        | -0.21        | -0.21        | -0.50           | -0.50           | -0.77       | -0.77       |
| 95% CI for difference in LS means              | -1.87, 3.24 | -1.87, 3.24 | -2.16, 2.35 | -2.16, 2.35 | -2.51, 2.08  | -2.51, 2.08  | -3.73, 2.73     | -3.73, 2.73     | -3.59, 2.05 | -3.59, 2.05 |

LS = least squares; MMRM = mixed-effects model for repeated measures; Osi = osimertinib.

The analysis was performed using a MMRM analysis on the change from baseline in PRO symptom score at each visit up to 9 month (281 days), including patient (as a random effect), treatment, visit (as fixed effect and repeated measure), and treatment-by-visit interaction as explanatory variables, thebaselinePROscore as a covariate along with the baseline PRO score by visit interaction, using an unstructured covariance structure. Using the first covariance structure (in the order: unstructured, toeplitz with heterogeneity, autoregressive with heterogeneity, toepliz, autoregressive) for which convergence could be achieved for all 5 primary PRO symptoms scores.

DCO1: 12 June 2017

<div style=\"page-break-after: always\"></div>

## Post progression outcomes

Overall, the positive impact of first-line osimertinib therapy continued beyond first RECIST progression, as demonstrated by the analyses of post-progression outcomes.

Table 26: Post-progression outcome endpoints (full analysis set)

Treatment with EGFR-TKIs was to be sequential, without any intervention therapy in between, except for palliative radiotherapy for painful bone metastases.

|                                                                                          | Number (%) patients                                                                      | Number (%) patients                                                                      |
|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
|                                                                                          | Osimertinib                                                                              | SoC                                                                                      |
|                                                                                          | (N=279)                                                                                  | (N=277)                                                                                  |
| Time to discontinuation of randomised treatment or death (TDT)                           | Time to discontinuation of randomised treatment or death (TDT)                           | Time to discontinuation of randomised treatment or death (TDT)                           |
| No. (%) of patients who discontinued treatment or died                                   | 138 (49.5)                                                                               | 213 (76.9)                                                                               |
| Median (95% CI)                                                                          | 20.8 (17.2, 24.1)                                                                        | 11.5 (10.3, 12.8)                                                                        |
| Time from randomisation to first subsequent therapy or death (TFST)                      | Time from randomisation to first subsequent therapy or death (TFST)                      | Time from randomisation to first subsequent therapy or death (TFST)                      |
| No. (%) patients who started first subsequent therapy or died                            | 115 (41.2)                                                                               | 175 (63.2)                                                                               |
| Median TFST (months) (95% CI)                                                            | 23.5 (22.0, NC)                                                                          | 13.8 (12.3, 15.7)                                                                        |
| Hazard ratio (95% CI)                                                                    | 0.51 (0.40, 0.64)                                                                        | 0.51 (0.40, 0.64)                                                                        |
| 2-sided p-value                                                                          | <0.0001                                                                                  | <0.0001                                                                                  |
| Continuation of randomised treatment beyond RECIST progression (Investigator-based)      | Continuation of randomised treatment beyond RECIST progression (Investigator-based)      | Continuation of randomised treatment beyond RECIST progression (Investigator-based)      |
| No. (%) patients who continued treatment beyond RECIST progression                       | 91 (66.9)                                                                                | 145 (70.4)                                                                               |
| Median duration of treatment post-progression (95% CI), weeks                            | 8.1 (6.3, 12.3)                                                                          | 7.0 (5.9, 8,1)                                                                           |
| Best objective response rate to first subsequent therapy                                 | Best objective response rate to first subsequent therapy                                 | Best objective response rate to first subsequent therapy                                 |
| Best objective response rate, % (95% CI)                                                 |                                                                                          | 18.3 (10.6, 28.4)22.5 (15.6, 30.7)                                                       |
| Time on first subsequent therapy                                                         | Time on first subsequent therapy                                                         | Time on first subsequent therapy                                                         |
| No. (%) of patients with first subsequent therapy                                        | 82 (29.4)                                                                                | 129 (46.6)                                                                               |
| Median duration of first subsequent therapy (95% CI), months                             | 3.45 (0-23.5)                                                                            | 4.99 (0-21.8)                                                                            |
| Time from randomisation to second progression after start of subsequent treatment (PFS2) | Time from randomisation to second progression after start of subsequent treatment (PFS2) | Time from randomisation to second progression after start of subsequent treatment (PFS2) |
| No. (%) patients with second progression                                                 | 73 (26.2)                                                                                | 106 (38.3)                                                                               |
| Median PFS2 (months) (95% CI)                                                            | NC (23.7, NC)                                                                            | 20.0 (18.2, NC)                                                                          |
| Hazard ratio (95% CI)                                                                    | 0.58 (0.44, 0.78)                                                                        | 0.58 (0.44, 0.78)                                                                        |
| 2-sided p-value                                                                          | 0.0004                                                                                   | 0.0004                                                                                   |
| Time to second subsequent treatment or death (TSST)                                      | Time to second subsequent treatment or death (TSST)                                      | Time to second subsequent treatment or death (TSST)                                      |
| No. (%) patients with second subsequent therapy or death                                 | 74 (26.5)                                                                                | 110 (39.7)                                                                               |
| Median TSST (months) (95% CI)                                                            | NC (NC, NC)                                                                              | 25.9 (20.0, NC)                                                                          |
| Hazard ratio (95% CI)                                                                    | 0.60 (0.45, 0.80)                                                                        | 0.60 (0.45, 0.80)                                                                        |
| 2-sided p-value                                                                          | 0.0005                                                                                   | 0.0005                                                                                   |
| Time to discontinuation of any EGFR-TKI treatment or deatha                              | Time to discontinuation of any EGFR-TKI treatment or deatha                              | Time to discontinuation of any EGFR-TKI treatment or deatha                              |
| No. (%) of patients who discontinued any EGFR-TKIs or died                               | 128 (45.9)                                                                               | 167 (60.3)                                                                               |
| Median time to discontinuation (months) (95% CI)                                         | 23.0 (19.5, NC)                                                                          | 16.0 (14.8, 18.6)                                                                        |

DCO1: 12 June 2017

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Subgroup analysis of PFS

The  superiority  of  osimertinib  over  SoC  was  maintained  and  consistent  across  the  randomisation stratification factors and all the predefined subgroups with available data for statistical analysis. All PFS HRs were &lt;0.60 in favour of osimertinib for all but the subgroup of patients without a valid EGFRm central test result (HR of 0.85).

<!-- image -->

EGFR mutation results are by the method used at randomisation.

Figure 24: Progression-free survival, Forest plot, by subgroup (full analysis set)

<div style=\"page-break-after: always\"></div>

Table 27: Subgroup analyses of progression-free survival (full analysis set)

ctDNA = circulating tumour deoxyribonucleic acid; EGFRm = epidermal growth factor receptor mutation-positive; NC = not calculable; ND =not done TheanalysiswasperformedusingaCoxproportional hazardsmodelincludingcovariateforsubgroupand atreatment-by-subgroupinteraction term.A hazardratio&lt;1favoursosimertinib.

|                                          |                                                             |                                  | Number (%) of                                                           | Median PFS                                                                                                             | Comparisonbetween arms   | Comparisonbetween arms          | Comparisonbetween arms   |
|------------------------------------------|-------------------------------------------------------------|----------------------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|--------------------------|---------------------------------|--------------------------|
| Subgroup                                 | Group                                                       | N                                | patients with events                                                    | (months) (95% CI)                                                                                                      | Hazard ratio             | 10 %56                          | 2-sided p-value          |
| Gender                                   |                                                             |                                  |                                                                         |                                                                                                                        |                          |                                 |                          |
| Male                                     | Osimertinib                                                 | 101                              | 58 (57.4)                                                               | 16.4 (13.8, 20.5)                                                                                                      | 0.58                     | 0.41, 0.82                      | ND                       |
| Female                                   | SoC Osimertinib                                             | 105 178                          | 76 (72.4) 78 (43.8)                                                     | 11.0 (9.6, 13.8) 20.7 (15.2, NC)                                                                                       | 0.40                     | 0.30, 0.52                      | ND                       |
|                                          | SoC                                                         |                                  | 130 (75.6)                                                              | 9.7 (8.3, 11.1)                                                                                                        | 0.44                     | 0.33,0.58                       |                          |
| Age at screening                         |                                                             |                                  |                                                                         |                                                                                                                        |                          |                                 |                          |
| <65 years                                | Osimertinib SoC                                             | 153                              | 79 (51.6) 113 (77.9)                                                    | 17.8 (14.9, 23.4) 9.7 (9.5, 11.1)                                                                                      |                          |                                 | ND                       |
| ≥65 years Ethnicity Asian                | Osimertinib SoC Osimertinib SoC                             | 132 174 173                      | 57 (45.2) 93 (70.5) 91 (52.3) 125 (72.3)                                | 19.8 (13.9, NC) 11.0 (8.3, 13.8) 16.4 (13.8, 20.7) 11.0 (9.5, 12.6)                                                    | 0.49 0.55 0.34           | 0.35, 0.67 0.42,0.72 0.23,0.48  | ND ND                    |
| Smoking history Yes No No                | Osimertinib SoC Osimertinib SoC Osimertinib SoC Osimertinib | 145 126 97 102 182 175 53 63 226 | 55 (56.7) 80 (78.4) 81 (44.5) 126 (72.0) 29 (54.7) 53 (84.1) 107 (47.3) | 16.5 (13.9, 20.5) 9.7 (8.5, 11.1) 20.7 (14.9, NC) 11.0 (9.0, 12.6) 15.2 (12.1, 21.4) 9.6 (7.0, 12.4) 19.1 (15.2, 23.5) | 0.48 0.45 0.47           | 0.34, 0.68 0.34,0.59 0.30, 0.74 | ND ND 0.0009             |
| Non-Asian CNS metastases at baseline Yes | Osimertinib SoC SoC Osimertinib                             | 172 105 104 214                  | 45 (42.9) 81 (77.9) 153 (71.5) 77 (44.0)                                | 24.3 (16.3, NC) 9.7 (8.2, 11.1) 10.9 (9.6, 12.3) 21.4 (16.5, 24.3)                                                     | 0.46                     | 0.36, 0.59                      | ND <0.0001               |
| L858R                                    | SoC Osimertinib SoC                                         | 174 104 103                      | 129 (74.1) 59 (56.7)                                                    | 11.0 (9.7, 12.6)                                                                                                       |                          |                                 |                          |
| EGFRmutationasusedforrandomisation       |                                                             | 175                              | 77 (74.8)                                                               |                                                                                                                        |                          | 0.32,0.56                       | <0.0001                  |
| Exon 19 deletion                         | Osimertinib SoC                                             | 176                              |                                                                         | 14.4 (11.1, 18.9)                                                                                                      | 0.43                     |                                 |                          |
|                                          | Osimertinib                                                 | 183                              |                                                                         | 9.5 (8.1, 11.0)                                                                                                        | 0.51                     | 0.36, 0.71                      | <0.0001                  |
|                                          |                                                             | 60                               | 100 (54.6)                                                              | 15.2 (13.7,20.7)                                                                                                       |                          |                                 |                          |
| EGFR by ctDNA EGFRm positive             | SoC                                                         | 64                               | 140 (79.5) 22 (36.7)                                                    | 9.7 (8.4, 11.1) 23.5 (17.8, 24.3)                                                                                      | 0.44                     | 0.34, 0.57                      | <0.0001                  |
| EGFRm negative                           | SoC                                                         |                                  | 40 (62.5) 14 (38.9)                                                     | 15.0 (9.7, 18.3)                                                                                                       | 0.48                     | 0.28, 0.80                      | 0.0047                   |
| EGFRm missing                            | Osimertinib                                                 | 36 37                            | 26 (70.3)                                                               | 17.3 (11.1, 21.4) 8.3 (6.8, 10.2)                                                                                      | 0.41                     |                                 |                          |
| Centrally-confirmedEGFRmutation          | Osimertinib                                                 | 255                              | 124 (48.6)                                                              | 18.9 (15.2, 21.4)                                                                                                      |                          | 0.21,0.78                       | 0.0059                   |
| Positive                                 | SoC                                                         | 245                              | 188 (76.7)                                                              | 9.7 (9.5, 11.0)                                                                                                        | 0.43                     | 0.34, 0.54                      | <0.0001                  |
| Negative                                 | Osimertinib Osimertinib                                     | 3 3                              | 1 (33.3) 2 (66.7)                                                       | NC (2.7, NC) 2.8 (1.4, NC)                                                                                             | NC                       | NC, NC                          |                          |
|                                          | SoC                                                         | 21 29                            | 11 (52.4)                                                               |                                                                                                                        | 0.85                     |                                 | NC                       |
| Missing                                  |                                                             |                                  | 16 (55.2)                                                               | 16.5 (11.1, NC)                                                                                                        |                          | 0.38, 1.82                      | 0.6813                   |
|                                          | SoC                                                         |                                  |                                                                         | 16.6 (9.7, 23.0)                                                                                                       |                          |                                 |                          |
|                                          |                                                             |                                  | 45 (40.2)                                                               | 23.5 (18.4, NC)                                                                                                        |                          | 0.27,0.56                       | ND                       |
| WHO performance status                   |                                                             |                                  |                                                                         | 11.1 (9.9, 14.0)                                                                                                       |                          |                                 |                          |
| 0 (normal activity)                      |                                                             |                                  |                                                                         |                                                                                                                        |                          |                                 |                          |
|                                          | SoC                                                         |                                  |                                                                         |                                                                                                                        | 0.39                     |                                 |                          |
|                                          | Osimertinib                                                 | 112 116                          | 85 (73.3)                                                               |                                                                                                                        |                          |                                 |                          |
| 1 (restricted activity)                  | Osimertinib                                                 | 167                              | 91 (54.5)                                                               | 15.2 (12.9, 20.7)                                                                                                      | 0.50                     | 0.38,0.66                       | ND                       |
|                                          | SoC                                                         | 160                              | 120 (75.0)                                                              | 9.5 (8.2, 10.9)                                                                                                        |                          |                                 |                          |
|                                          |                                                             | 1                                | 1 (100.0)                                                               | NC (NC, NC)                                                                                                            |                          |                                 |                          |
| Missing                                  | SoC                                                         |                                  |                                                                         |                                                                                                                        |                          |                                 |                          |

<div style=\"page-break-after: always\"></div>

Table 28 : Progression-free survival analysis based on investigator assessment by age (≥75 years vs. &lt;75 years) (Full analysis set)

|                                    | Number (%) patients   | Number (%) patients   | Number (%) patients   | Number (%) patients   |
|------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
|                                    | <75 years (N=477)     | <75 years (N=477)     | ≥75 year's (N=79)     | ≥75 year's (N=79)     |
|                                    | Osimertinib (n = 243) | SoC (n = 234)         | Osimertinib (m = 36)  | SoC (n = 43)          |
| No. (%) patients with PFS events a | 118 (48.6)            | 174 (74.4)            | 18 (50.0)             | 32 (74.4)             |
| Median PFS, (95%CI), months b      | 19.1 (15.2, 23.4)     | 10.2 (9.6, 11.1)      | 12.1 (7.8, NC)        | 9.9 (7.0, 13.8)       |
| Hazard ratio (95% C1) [c]          | 0.45 (0.35, 0.57)     | 0.45 (0.35, 0.57)     | 0.58 (0.32, 1.02)     | 0.58 (0.32, 1.02)     |

a Progression events that did not occur within 2 scheduled visits (plus visit window) of the last evaluable assessment (or randomisation) are censored and therefore excluded in the number of events.

b Calculated using the Kaplan-Meier method. NC= not calculable

c The analysis was performed using a Cox proportional hazards model including covariate for subgroup and a treatment-bysubgroup interaction term. A hazard ratio &lt; 1 favoured osimertinib DCO1: 12 June 2017

## Subgroup analysis for EGFR mutation status

At baseline, patients were enrolled and stratified by EGFR mutation type, as determined either by local testing or by central testing. Overall, 349 (62.8%) patients had tumours harbouring Ex19del mutation and 207 (37.2%) patients had tumours harbouring L858R mutation.

Progression-free  survival,  as  assessed  by the  Investigator,  was  prolonged  for  patients  who  received osimertinib compared to patients on SoC irrespective of the EGFR mutation type (Figure 10). Patients with NSCLC harbouring Ex19del in the EGFR gene had numerically longer median PFS in both arms, in line with previous observations (Sebastian et al 2014). However, patients with NSCLC harbouring the less  EGFR-TKI  responsive  L858R  treated  with  osimertinib  have  better  outcomes  than  patients  with NSCLC harbouring the more responsive Ex19del when treated with SoC.

Table 29: Progression-free survival based on investigator assessment by baseline EGFR mutation status used for randomisation (Ex19del or L858R [tissue])

|                                  | Number (%) patients   | Number (%) patients   | Number (%) patients   | Number (%) patients   |
|----------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
|                                  | Ex19del (N=349)       | Ex19del (N=349)       | L858R (N=207)         | L858R (N=207)         |
|                                  | Osimertinib (n = 175) | SoC (n =174)          | Osimertinib (n = 104) | SoC (n =103)          |
| No. (%) patients with PFS events | 77 (44.0)             | 129 (74.1)            | 59 (56.7)             | 77 (74.8)             |
| Median PFS (months), 95% CI      | 21.4 (16.5, 24.3)     | 11.0 (9.7, 12.6)      | 14.4 (11.1, 18.9)     | 9.5 (8.1, 11.0)       |
| Hazard ratio (95% CI)            | 0.43 (0.32, 0.56)     | 0.43 (0.32, 0.56)     | 0.51 (0.36, 0.71)     | 0.51 (0.36, 0.71)     |
| 2-sided p-value                  | <0.0001               | <0.0001               | <0.0001               | <0.0001               |

The analysis was performed using a Cox proportional hazards model including covariate for subgroup and a treatment-by-subgroup interaction term. A hazard ratio &lt; 1 favours osimertinib.

<div style=\"page-break-after: always\"></div>

Figure 25: Kaplan-Meier plot of subgroup analyses of PFS by EGFR mutation by Investigator assessment (full analysis set)

<!-- image -->

## Subgroup of patients with locally advanced NSCLC

In  29/556  (5%)  patients  with  locally  advanced  EGFRm  NSCLC  (osimertinib:  14  patients;  SoC:  15 patients),  the  ORR,  as  assessed  by  the  Investigator,  was  92.9%  (95%  CI:  66.1,  99.8)  for  patients receiving osimertinib and 60.0% (95% CI: 32.3, 83.7) for patients receiving SoC.

The duration of response in this population was not assessed.

## Patients with locally advanced disease

Among the 29 patients with locally  advanced  disease,  20  reported  a  PFS  event  by  investigator.  No formal analysis of PFS in this subgroup has been performed. The Applicant provided a summary table (data not shown) with the relevant PFS data. The results are in line with the overall population.

## Central nervous system efficacy analyses

The prespecified CNS analyses conducted on the CNS MTS and CNS BICR (cFAS, cEFR) populations were all prospectively defined.

## Subgroup analysis by CNS metastases status at baseline (CNS MTS)

At baseline, 116/556 (20.9%) patients were determined programmatically from eCRF pages to have a CNS  MTS  status  of  \"Yes\"  based  on  Investigator  assessment:  53/279  (19.0%)  patients  in  the osimertinib arm and 63/277 (22.7%) patients in the SoC arm. Twenty patients were part only of the subgroup with a CNS MTS status of 'Yes' at baseline, but not of the cFAS subgroup, due to either the absence  of  a  CNS  CT  or  MRI  scan  for  CNS  BICR  assessment  or  BICR  not  identifying  CNS  lesions. Conversely, 32 patients were part only of the cFAS as they were not considered by the Investigator to have baseline CNS metastases and, therefore, were not included in the subgroup of patients with a CNS MTS status of 'Yes' at baseline.

<div style=\"page-break-after: always\"></div>

Table 30: Efficacy by CNS metastases status at baseline (CNS MTS analysis set, Investigator assessment)

|                                                                       | Number (%) patients                                                   | Number (%) patients                                                   | Number (%) patients                                                   | Number (%) patients                                                   |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                       | CNS MTS of Yes at baseline (N=116)                                    | CNS MTS of Yes at baseline (N=116)                                    | CNS MTS of No at baseline (N=440)                                     | CNS MTS of No at baseline (N=440)                                     |
|                                                                       | Osimertinib (n = 53)                                                  | SoC (n = 63)                                                          | Osimertinib (n = 226)                                                 | SoC (n = 214)                                                         |
| Progression-free survival based on Investigator assessment            | Progression-free survival based on Investigator assessment            | Progression-free survival based on Investigator assessment            | Progression-free survival based on Investigator assessment            | Progression-free survival based on Investigator assessment            |
| No. (%) patients with eventsa                                         | 29 (54.7)                                                             | 53 (84.1)                                                             | 107 (47.3)                                                            | 153 (71.5)                                                            |
| Median PFS (months), 95% CIb                                          | 15.2 (12.1, 21.4)                                                     | 9.6 (7.0, 12.4)                                                       | 19.1 (15.2, 23.5)                                                     | 10.9 (9.6, 12.2)                                                      |
| Hazard ratio (95% CI)                                                 | 0.47 (0.30, 0.74)                                                     | 0.47 (0.30, 0.74)                                                     | 0.46 (0.36, 0.59)                                                     | 0.46 (0.36, 0.59)                                                     |
| 2-sided p-value                                                       | <0.001                                                                | <0.001                                                                | <0.001                                                                | <0.001                                                                |
| Patients with progression other than death and reason for progression | Patients with progression other than death and reason for progression | Patients with progression other than death and reason for progression | Patients with progression other than death and reason for progression | Patients with progression other than death and reason for progression |
| No. (%) patients with progression other than deathd                   | 25 (47.2)                                                             | 49 (77.8)                                                             | 100 (44.2)                                                            | 143 (66.8)                                                            |
| Progression in TLe                                                    | 12 (22.6)                                                             | 20 (31.7)                                                             | 52 (23.0)                                                             | 74 (34.6)                                                             |
| Progression in NTLe                                                   | 9 (17.0)                                                              | 19 (30.2)                                                             | 31 (13.7)                                                             | 51 (23.8)                                                             |
| Progression in CNS NTL                                                | 7 (13.2)                                                              | 15 (23.8)                                                             | 0                                                                     | 1 (0.5)f                                                              |
| Progression in non-CNS NTL                                            | 9 (17.0)                                                              | 18 (28.6)                                                             | 31 (13.7)                                                             | 51 (23.8)                                                             |
| Presence of NLe                                                       | 11 (20.8)                                                             | 31 (49.2)                                                             | 41 (18.1)                                                             | 72 (33.6)                                                             |
| New CNS lesions                                                       | 4 (7.5)                                                               | 19 (30.2)                                                             | 7 (3.1)                                                               | 15 (7.0)                                                              |
| Non-CNS new lesions                                                   | 7 (13.2)                                                              | 13 (20.6)                                                             | 35 (15.5)                                                             | 59 (27.6)                                                             |
| Reason for CNS progression                                            | Reason for CNS progression                                            | Reason for CNS progression                                            | Reason for CNS progression                                            | Reason for CNS progression                                            |
| No. (%) patients with CNS progressions                                | 10 (18.9)                                                             | 27 (42.9)                                                             | 7 (3.1)                                                               | 15 (7.0)                                                              |
| Progression in CNS only                                               | 3 (5.7)                                                               | 10 (15.9)                                                             | 4 (1.8)                                                               | 12 (5.6)                                                              |
| Progression in CNS NL only                                            | 3 (5.7)                                                               | 9 (14.3)                                                              | 4 (1.8)                                                               | 12 (5.6)                                                              |
| Progression in CNS and non- CNS                                       | 7 (13.2)                                                              | 17 (27.0)                                                             | 3 (1.3)                                                               | 3 (1.4)                                                               |
| No. (%) patients with non-CNS progression onlys                       | 0                                                                     | 4 (6.3)                                                               | 0                                                                     | 0                                                                     |
| Objective response rate based on Investigator assessment              | Objective response rate based on Investigator assessment              | Objective response rate based on Investigator assessment              | Objective response rate based on Investigator assessment              | Objective response rate based on Investigator assessment              |
| No. (%) patients with response                                        | 40 (75.5)                                                             | 183 (81.0)                                                            | 54 (85.7)                                                             | 156 (72.9)                                                            |
| Odds ratio (95% CI)                                                   | 0.5 (0.2, 1.3)                                                        | 0.5 (0.2, 1.3)                                                        | 1.6 (1.0, 2.5)                                                        | 1.6 (1.0, 2.5)                                                        |
| 2-sided p-value                                                       | 0.161                                                                 | 0.161                                                                 | 0.044                                                                 | 0.044                                                                 |
| Duration of response based on Investigator assessment                 | Duration of response based on Investigator assessment                 | Duration of response based on Investigator assessment                 | Duration of response based on Investigator assessment                 | Duration of response based on Investigator assessment                 |
| Number of responders                                                  | 40                                                                    | 54                                                                    | 183                                                                   | 156                                                                   |
| No. (%) ofresponders who subsequently progressed or died              | 22                                                                    | 46                                                                    | 84                                                                    | 112                                                                   |
| Median duration of response from onset of response, months, (95% C1)b | 13.8 (10.8, 20.2)                                                     | 8.3 (5.5, 9.6)                                                        | 17.6 (13.8, 23.0)                                                     | 9.6 (8.1, 11.2)                                                       |

a Only included progression events that occurred within 2 missing visits (+2 weeks) of the last evaluable assessment. If the patient progressed or died after 2 or more missed visits, the patient was censored at the time of the latest evaluable RECIST assessment. Progression included deaths in the absence of RECIST progression.

b Calculated using the Kaplan-Meier method.

<div style=\"page-break-after: always\"></div>

c  Hazard  ratio  was  calculated  from  a  Cox  proportional  hazard  model  with  factors  for  treatment,  CNS  MTS,  and  a  treatment  by  CNS  MTS interaction. A HR &lt;1 favours osimertinib.

d Only includes progression events that occurred within 2 missing visits (+2 weeks) of the last evaluable assessment.

- e Target lesions, non-target lesions, and new lesions were not necessarily mutually exclusive categories.
- f  E1511004: enrolled with liver and respiratory metastatic lesion as only disease extend at baseline, no prior brain surgery and no prior brain radiation and was hence grouped in the CNS MTS='no' subgroup. However, the RECIST baseline by investigator included CNS as NTL and this lesion progressed.
- g Progression events that did not occur within 2 scheduled visits (plus visit window) of the last evaluable assessment (or randomisation) were censored and therefore excluded in the number of events. Excluded deaths.NL = new lesion; NTL = non-target lesion; TL = target lesion

DCO1: 12 June 2017

Figure 26: Kaplan-Meier plot of subgroup analysis of PFS: CNS MTS status at baseline (full analysis set)

<!-- image -->

Irrespective of the CNS MTS status at baseline, based on Investigator assessment, there were fewer patients with new CNS lesions in the osimertinib arm than in the SoC arm.

An analysis of efficacy by CNS MTS status at baseline based on study CNS BICR was consistent with the analysis by the Investigator: the HR for PFS in patients with a CNS MTS status of \"Yes\" based on BICR was 0.48 (95% CI: 0.30, 0.75; p = 0.001) in favour of osimertinib. The HR for PFS in patients with a CNS MTS status of 'No' based on BICR was 0.47 (95% CI: 0.37, 0.61; p&lt;0.0001).

The median DoR and proportion of patients remaining in response at 3 months, 6 months, 9 months, and 12 months favoured osimertinib, irrespective of CNS MTS status at entry. The interpretation of an OR of 0.5 in favour of SoC for patients with a CNS MTS status of 'Yes' should therefore take all data into  account.  Hence,  taking  all  efficacy  assessments  together,  this  subgroup  analysis  demonstrates that  irrespective  of  CNS  MTS  status  at  entry,  patients  receive  greater  benefit  from  osimertinib treatment that from treatment with SoC.

## Efficacy on CNS metastases based on CNS BICR

The  2  analysis  sets  evaluated  by  CNS  BICR  were  the  cFAS  (patients  with  measurable  and  nonmeasurable CNS metastases at baseline); and the cEFR (patients with measurable CNS metastases at baseline).

<div style=\"page-break-after: always\"></div>

Table 31: Efficacy on CNS in cFAS and cEFR analysis sets by CNS BICR

|                                                                    | Number (%) patients                                                | Number (%) patients                                                | Number (%) patients                                                | Number (%) patients   |
|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|-----------------------|
|                                                                    | cFAS (N=128)                                                       | cFAS (N=128)                                                       | cEFR (N=41)                                                        | cEFR (N=41)           |
|                                                                    | Osimertinib (n=61)                                                 | SoC (n= 67)                                                        | Osimertinib (n=22)                                                 | SoC (n =19)           |
| CNS progression-free survival                                      |                                                                    |                                                                    |                                                                    |                       |
| No.(%) patients with CNS PFS events (CNS progression or death)a    | 18 (29.5)                                                          | 30 (44.8)                                                          |                                                                    |                       |
| Median CNS PFS (months) (95% CI)b                                  | NC (16.5, NC)                                                      | 13.9 (8.3, NC)                                                     |                                                                    |                       |
| Hazard ratio (95% CI)c                                             | 0.48 (0.26, 0.86)                                                  |                                                                    |                                                                    |                       |
| 2-sided p-value                                                    | 0.014d                                                             |                                                                    |                                                                    |                       |
| CNS progression-free survival by number of CNS lesions at baseline | CNS progression-free survival by number of CNS lesions at baseline | CNS progression-free survival by number of CNS lesions at baseline | CNS progression-free survival by number of CNS lesions at baseline |                       |
| No. of patients with 1-3 CNS lesions at baseline                   | 47                                                                 | 49                                                                 |                                                                    |                       |
| No. (%) patients with CNS PFS events (CNS progression or death)a   | 11 (23.4)                                                          | 21 (42.9)                                                          |                                                                    |                       |
| Median CNS PFS (months) (95% CI)b                                  | NC (16.6. NC)                                                      | 13.9 (9.7, NC)                                                     |                                                                    |                       |
| No. of patients with >3 CNS lesions at baseline                    | 14                                                                 | 18                                                                 |                                                                    |                       |
| No. (%) patients with CNS PFS events (CNS progression or death)a   | 7 (50.0)                                                           | 9 (50.0)                                                           |                                                                    |                       |
| Median CNS PFS (months) (95% CI)b                                  | 16.5 (7.5, NC)                                                     | 8.3 (4.0, NC)                                                      |                                                                    |                       |
| CNS objective response rate                                        |                                                                    |                                                                    |                                                                    |                       |
| No. (%) patients with CNS response                                 | 40 (65.6)                                                          | 29 (43.3)                                                          | 20 (90.9)                                                          | 13 (68.4)             |
| ORR, % (95% CI)e                                                   | 65.6 (52.3,77.3)                                                   | 43.3 (31.2, 56.0)                                                  | 90.9 (70.8, 98.9)                                                  | 68.4 (43.3, 87.4      |
| CNS confirmed objective response rate                              | CNS confirmed objective response rate                              |                                                                    |                                                                    |                       |
| No. (%) patients with CNS                                          | 35 (57.4)                                                          | 27 (40.3)                                                          | 17 (77.3)                                                          | 12 (63.2)             |
| ORR, % (95% CI)e                                                   | 57.4 (44.1, 70.0)                                                  | 40.3 (28.5, 53.0)                                                  | 77.3 (54.6, 92.2)                                                  | 63.2 (38.4, 83.7)     |
| CNS duration of response*                                          |                                                                    |                                                                    |                                                                    |                       |
| Median CNS DoR (months) (95% CI)b                                  | NC (11.9, NC)                                                      | 14.4 (7.0, 18.7)                                                   | 15.2 (4.1, NC)                                                     | 18.7 (4.2, 18.7)      |
| Patients remaining in response >6 months                           | 30 (75.0)                                                          | 16 (55.2)                                                          | 15 (75.0)                                                          | 6 (46.2)              |
| Patients remaining inresponse >12months                            | 16 (40.0)                                                          | 8 (27.6)                                                           | 8 (40.0)                                                           | 4 (30.8)              |
| CNS duration of response for confirmed responses                   | CNS duration of response for confirmed responses                   |                                                                    |                                                                    |                       |
| Median CNS DoR (months) (95% CI)b                                  | NC (11.9, NC)                                                      | 14.4 (8.3, 18.7)                                                   | NC (8.5, NC)                                                       | 18.7 (4.2, 18.7)      |
| Patients remaining in response >6months                            | 30 (85.7)                                                          | 16 (59.3)                                                          | 15 (88.2)                                                          | 6 (50.0)              |
| Patients remaining inresponse >12months                            | 16 (45.7)                                                          | 8 (29.6)                                                           | 8 (47.1)                                                           | 4 (33.3)              |
| CNS disease control rate                                           |                                                                    |                                                                    |                                                                    |                       |
| DCR% (95% CI)                                                      | 90.2 (79.8, 96.3)                                                  | 83.6 (72.5,91.5)                                                   | 95.5 (77.2, 99.9)                                                  | 89.5 (66.9,98.7)      |

cEFR = central nervous system evaluable-for-response analysis set; cFAS = central nervous system full analysis set.

b CalculatedusingtheKaplan-Meiermethod.

Progression events that did not occur within 2 scheduled visits (plus visit window) of the last evaluable assessment(orrandomisation)werecensoredandthereforeexcludedfromthenumberofevents.

The HR was calculated from a Cox proportional hazards model with a factor for treatment. The CI was calculated using profile likelihood.An HR &lt;1 favours osimertinib.

The CIswerecalculated usingClopper-Pearson exact method forbinomialproportions.

nominally statistically significant.

Durationofresponseisthetimefromfirst documentationofCR/PRuntil thedateofprogressionordeath in absence of disease progression. Responses required confirmation at least 4 weeks after the criteria for first response were met.

DCO1:12June 2017

<div style=\"page-break-after: always\"></div>

There was a greater decrease in CNS TL size in the osimertinib arm compared to the SoC arm in the cEFR.

## Osimertinibarm

<!-- image -->

## SoC arm

<!-- image -->

-100

Best percentage change in target lesion size was the maximum reduction from baseline or the minimum increasefrom baseline in the absenceof a reduction

*represents imputed values: if it was known that a patient had died, had new lesions or progression of nontarget lesions, had withdrawn due to PD and had no evaluable target lesions (before or at progression) assessments, best change was imputed as 20%

RECIST v1.1

DC01: 12 June 2017

Figure 27: CNS target lesion size, best change from baseline, waterfall plot (cEFR analysis set)

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 32: Summary of Efficacy for FLAURA trial

| Title: A Phase III, Double-blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a SoC EGFR TKI as First-line Treatment in Patients with EGFR Mutation-positive, Locally- advanced or Metastatic Non-small-cell Lung Cancer (FLAURA)   | Title: A Phase III, Double-blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a SoC EGFR TKI as First-line Treatment in Patients with EGFR Mutation-positive, Locally- advanced or Metastatic Non-small-cell Lung Cancer (FLAURA)   | Title: A Phase III, Double-blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a SoC EGFR TKI as First-line Treatment in Patients with EGFR Mutation-positive, Locally- advanced or Metastatic Non-small-cell Lung Cancer (FLAURA)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                             | 2014-002694-11                                                                                                                                                                                                                                               | 2014-002694-11                                                                                                                                                                                                                                               |
| Design                                                                                                                                                                                                                                                       | Phase 3, multicentre, double-dummy, controlled, randomized study                                                                                                                                                                                             | Phase 3, multicentre, double-dummy, controlled, randomized study                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                              | Duration of main phase:                                                                                                                                                                                                                                      | From 19-Feb-2015 (FPR) to 12-Jun-2017 (DCO)                                                                                                                                                                                                                  |
| Hypothesis                                                                                                                                                                                                                                                   | Superiority over SoC (erlotinib or gefitinib)                                                                                                                                                                                                                | Superiority over SoC (erlotinib or gefitinib)                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Treatments groups                                                                                               | Osimertinib                                                                                                                                                                                                             | Osimertinib                                                                                                                                                                                                             | Osimertinib                                                                                                                                                                                                             | Osimertinib 80 mg orally once daily; n= 279                                                                                                                                                                             | Osimertinib 80 mg orally once daily; n= 279                                                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatments groups                                                                                               | SoC                                                                                                                                                                                                                     | SoC                                                                                                                                                                                                                     | SoC                                                                                                                                                                                                                     | Gefitinib 250 mg orally once daily or Erlotinib 150 mg                                                                                                                                                                  | Gefitinib 250 mg orally once daily or Erlotinib 150 mg                                                                                                                                                                  |
| Endpoints and definitions                                                                                       | Primary endpoint                                                                                                                                                                                                        | PFS                                                                                                                                                                                                                     | PFS                                                                                                                                                                                                                     | orally once daily; n= 277 Time from randomisation until date of objective disease progression (RECIST v1.1. assessed by investigator) or death by any cause in the absence of progression.                              | orally once daily; n= 277 Time from randomisation until date of objective disease progression (RECIST v1.1. assessed by investigator) or death by any cause in the absence of progression.                              |
| Endpoints and definitions                                                                                       | Secondary endpoint                                                                                                                                                                                                      | OS                                                                                                                                                                                                                      | OS                                                                                                                                                                                                                      | Time from date of randomisation until death from any cause                                                                                                                                                              | Time from date of randomisation until death from any cause                                                                                                                                                              |
| Endpoints and definitions                                                                                       | Secondary endpoint                                                                                                                                                                                                      | ORR                                                                                                                                                                                                                     | ORR                                                                                                                                                                                                                     | Number (%) of randomised patients with at least 1 visit response of CR or PR.                                                                                                                                           | Number (%) of randomised patients with at least 1 visit response of CR or PR.                                                                                                                                           |
| Database lock 12-Jun-2017                                                                                       | Database lock 12-Jun-2017                                                                                                                                                                                               | Database lock 12-Jun-2017                                                                                                                                                                                               | Database lock 12-Jun-2017                                                                                                                                                                                               | Database lock 12-Jun-2017                                                                                                                                                                                               | Database lock 12-Jun-2017                                                                                                                                                                                               |
| Results and Analysis                                                                                            | Results and Analysis                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                    |
| Analysis description Analysis population and time point description Descriptive statistics estimate variability | Primary Analysis                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                        |
| and                                                                                                             | Intent to treat population (Osimertinib n=279; SoC n=277) st                                                                                                                                                            | Intent to treat population (Osimertinib n=279; SoC n=277) st                                                                                                                                                            | Intent to treat population (Osimertinib n=279; SoC n=277) st                                                                                                                                                            | Intent to treat population (Osimertinib n=279; SoC n=277) st                                                                                                                                                            | Intent to treat population (Osimertinib n=279; SoC n=277) st                                                                                                                                                            |
|                                                                                                                 | DCO of main analysis of Treatment group Number of subject                                                                                                                                                               | DCO of main analysis of Treatment group Number of subject                                                                                                                                                               | PFS (1 IA for OS). Osimertinib 279                                                                                                                                                                                      | PFS (1 IA for OS). Osimertinib 279                                                                                                                                                                                      | SoC 277                                                                                                                                                                                                                 |
|                                                                                                                 | Primary endpoint PFS (INV)                                                                                                                                                                                              | Primary endpoint PFS (INV)                                                                                                                                                                                              | 18.9                                                                                                                                                                                                                    | 18.9                                                                                                                                                                                                                    | 10.2                                                                                                                                                                                                                    |
|                                                                                                                 | Median months                                                                                                                                                                                                           | Median months                                                                                                                                                                                                           | (15.2, 21.4)                                                                                                                                                                                                            | (15.2, 21.4)                                                                                                                                                                                                            | (9.6, 11.1)                                                                                                                                                                                                             |
|                                                                                                                 | (95% CI) Secondary endpoint OS Median months NR                                                                                                                                                                         | (95% CI) Secondary endpoint OS Median months NR                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         | NR                                                                                                                                                                                                                      |
|                                                                                                                 | (95% CI) Secondary endpoint ORR n (%)                                                                                                                                                                                   | (95% CI) Secondary endpoint ORR n (%)                                                                                                                                                                                   | - 223 (79.9%)                                                                                                                                                                                                           | - 223 (79.9%)                                                                                                                                                                                                           | -                                                                                                                                                                                                                       |
|                                                                                                                 |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         | 210 (75.8%)                                                                                                                                                                                                             |
|                                                                                                                 | (95% CI)                                                                                                                                                                                                                | (95% CI)                                                                                                                                                                                                                | (71.3, 81.5)                                                                                                                                                                                                            | (71.3, 81.5)                                                                                                                                                                                                            | (63.1, 74.4)                                                                                                                                                                                                            |
|                                                                                                                 | Secondary endpoint DoR Median months                                                                                                                                                                                    | Secondary endpoint DoR Median months                                                                                                                                                                                    | 17.2                                                                                                                                                                                                                    | 17.2                                                                                                                                                                                                                    | 8.5                                                                                                                                                                                                                     |
| Effect estimate per comparison                                                                                  | (95% CI) Primary endpoint PFS                                                                                                                                                                                           | (95% CI) Primary endpoint PFS                                                                                                                                                                                           | (13.8, 22.0) Comparison groups                                                                                                                                                                                          | (13.8, 22.0) Comparison groups                                                                                                                                                                                          | (7.3, 9.8) Osimertinib vs. SoC                                                                                                                                                                                          |
| Effect estimate per comparison                                                                                  | HR                                                                                                                                                                                                                      | HR                                                                                                                                                                                                                      | (stratified) (95% CI)                                                                                                                                                                                                   | (stratified) (95% CI)                                                                                                                                                                                                   | 0.46 (0.37, 0.57)                                                                                                                                                                                                       |
| Effect estimate per comparison                                                                                  | Secondary endpoint OS                                                                                                                                                                                                   | Secondary endpoint OS                                                                                                                                                                                                   | P-value Comparison groups                                                                                                                                                                                               | P-value Comparison groups                                                                                                                                                                                               | <0.0001 Osimertinib vs. SoC                                                                                                                                                                                             |
| Effect estimate per comparison                                                                                  |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         | HR (stratified) (95% CI)                                                                                                                                                                                                | HR (stratified) (95% CI)                                                                                                                                                                                                | 0.63 (0.45, 0.88) 0.0068*                                                                                                                                                                                               |
| Effect estimate per comparison                                                                                  | Secondary endpoint ORR                                                                                                                                                                                                  | Secondary endpoint ORR                                                                                                                                                                                                  | P-value Comparison groups                                                                                                                                                                                               | P-value Comparison groups                                                                                                                                                                                               | Osimertinib vs. SoC                                                                                                                                                                                                     |
| Effect estimate per comparison                                                                                  |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         | Odds ratio**                                                                                                                                                                                                            | Odds ratio**                                                                                                                                                                                                            | 1.27                                                                                                                                                                                                                    |
| Effect estimate per comparison                                                                                  | *NES. OS 1 st IA: For approach) was required.                                                                                                                                                                           | *NES. OS 1 st IA: For approach) was required.                                                                                                                                                                           | (95% CI)                                                                                                                                                                                                                | (95% CI)                                                                                                                                                                                                                | (0.85, 1.90) 0.2421                                                                                                                                                                                                     |
| Notes                                                                                                           |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         | P-value statistical significance a                                                                                                                                                                                      | P-value statistical significance a                                                                                                                                                                                      | p-value<0.0015 (O'Brien-Fleming (95% CI): 1.28 (0.85, 1.93)                                                                                                                                                             |
| Analysis description                                                                                            |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
|                                                                                                                 | **Data corresponds to unadjusted OR. Adjusted OR Efficacy according to CNS metastases status at baseline CNS MTS Yes at baseline n=116 (53 Osimertinib; 63 SoC) CNS MTS No at baseline n=440 (226 Osimertinib; 214 SoC) | **Data corresponds to unadjusted OR. Adjusted OR Efficacy according to CNS metastases status at baseline CNS MTS Yes at baseline n=116 (53 Osimertinib; 63 SoC) CNS MTS No at baseline n=440 (226 Osimertinib; 214 SoC) | **Data corresponds to unadjusted OR. Adjusted OR Efficacy according to CNS metastases status at baseline CNS MTS Yes at baseline n=116 (53 Osimertinib; 63 SoC) CNS MTS No at baseline n=440 (226 Osimertinib; 214 SoC) | **Data corresponds to unadjusted OR. Adjusted OR Efficacy according to CNS metastases status at baseline CNS MTS Yes at baseline n=116 (53 Osimertinib; 63 SoC) CNS MTS No at baseline n=440 (226 Osimertinib; 214 SoC) | **Data corresponds to unadjusted OR. Adjusted OR Efficacy according to CNS metastases status at baseline CNS MTS Yes at baseline n=116 (53 Osimertinib; 63 SoC) CNS MTS No at baseline n=440 (226 Osimertinib; 214 SoC) |
|                                                                                                                 | Treatment group CNS                                                                                                                                                                                                     | Treatment group CNS                                                                                                                                                                                                     | Treatment group CNS                                                                                                                                                                                                     | MTS Yes , Osimertinib n=53                                                                                                                                                                                              | CNS MTS Yes , SoC n=63                                                                                                                                                                                                  |
|                                                                                                                 | PFS Median months (IC 95%)                                                                                                                                                                                              | PFS Median months (IC 95%)                                                                                                                                                                                              | PFS Median months (IC 95%)                                                                                                                                                                                              | 15.2 (12.1, 21.4)                                                                                                                                                                                                       | 9.6 (7.0, 12.4)                                                                                                                                                                                                         |
|                                                                                                                 | ORR                                                                                                                                                                                                                     | ORR                                                                                                                                                                                                                     | ORR                                                                                                                                                                                                                     | (75.5%)                                                                                                                                                                                                                 | 183 (81.0%)                                                                                                                                                                                                             |
|                                                                                                                 | n (%) 40 Treatment group CNS                                                                                                                                                                                            | n (%) 40 Treatment group CNS                                                                                                                                                                                            | n (%) 40 Treatment group CNS                                                                                                                                                                                            | MTS No , Osimertinib n=226                                                                                                                                                                                              | CNS MTS No , SoC n=214                                                                                                                                                                                                  |
|                                                                                                                 | PFS Median months (IC 95%) 19.1                                                                                                                                                                                         | PFS Median months (IC 95%) 19.1                                                                                                                                                                                         | PFS Median months (IC 95%) 19.1                                                                                                                                                                                         | (15.2, 23.5)                                                                                                                                                                                                            | 10.9 (9.6, 12.2)                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| ORR n (%)   | 54 (85.7%)   | 156 (72.9%)   |
|-------------|--------------|---------------|

## Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable

## Clinical studies in special populations

Not applicable

## Supportive study(ies)

Proof-of-concept of the efficacy of osimertinib in the first-line setting came from a cohort of 30 patients with EGFRm NSCLC treated with osimertinib 80 mg in the Phase I component of Study D5160C00001 (AURA Phase I component). At the time the FLAURA study was designed, results from the first DCO date (2 December 2014) were available. Further confirmation of an efficacy signal was observed with longer follow-up in these patients in first-line, showing, at the third DCO (1 November 2016), a median PFS of 22.1 months (95% CI: 13.7, 30.2); an ORR of 66.7% (95% CI: 47.2, 82.7); a reduction in size of target lesions (TLs) in 97% of patients; and a median DoR at 75% maturity of 19.3 months (95% CI: 12.3, 24.7). As this was a Phase I study without a protocol-mandated scheduled collection of OS throughout the study, full survival  follow-up  may  have  been  incomplete; thus,  OS  analysis  was  not conducted.

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

FLAURA is a Phase III, double-blind, randomised study (1:1 ratio) specifically designed to compare the efficacy  of  osimertinib  vs.  SoC  (either  gefinitib  or  erlotinib)  as  first-line  treatment  in  patients  with locally-advanced or metastatic EGFRm NSCLC.

## Patient population

Patients  with  locally  advanced  or  metastatic  NSCLC  (Pathologically-confirmed  adenocarcinoma)  not amenable to curative surgery or radiotherapy with a documented (centrally or locally) EGFR mutation known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), were recruited.  Patients had to be treatment naïve for advanced cancer although adjuvant or neo-adjuvant therapy at an earlier stage of the NSCLC was permitted.

While it is acknowledged that 85 % - 90 % of the patients with activating mutations harbour Ex19del or  L858R  mutations,  no  patients  with  less  common  mutations  were  included  in  FLAURA  trial . All patients  were  to  have  adequate  cardiac,  hepatic  and  renal  function,  WHO-PS  of  0  or  1  with  no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks. Patients were required to have at least 1 measurable lesion at baseline according to the investigator. Patients with CNS metastases were eligible if they were asymptomatic, stable and not requiring steroids for at least 2 weeks prior to start of study treatment, this is relevant as osimertinib is claimed to have superior blood barrier  penetration  than  other  licensed  TKIs  which  are  considered  to  have  limited  efficacy  on CNS metastases.

The exclusion of patients with poor general condition (WHO PS 2 or higher), and short life expectancy is a limitation in the study design.

<div style=\"page-break-after: always\"></div>

## Treatments

Osimertinib was administered at the same dose as that currently authorised one for patients with the T790M mutation, 80 mg once a day.

Erlotinib  and  gefitinib  are  considered  suitable  comparators  as  both  together  with  afatinib  are  the standard of care for first-line EGFRm NSCLC. The absence of afatinib is justified based on the fact that it was not widely available at the time of FLAURA trial start. Study centres had to declare their choice of comparator prior to site initiation. In some regions there was only one drug of choice such as in the US  (where  erlotinib  was  the  only  licensed  drug  at  the  time  of  start  of  the  trial)  or  Japan  (where gefitinib was the only investigator´s choice). Both erlotinib and gefitinib, were administered according to SmPC recommended doses and schedules.

Patients progressing in the SoC arm as determined by the investigator, with confirmation by BICR, who had  not  received  any  subsequent  therapy  after  discontinuation  of  study  therapy  and  who  had confirmation of T790M mutation, were given the opportunity to be treated with osimertinib 80 mg once daily. This is in line with the currently authorised indication of osimertinib and cross-over is considered ethical, although it will affect OS data.

## Endpoints

The  primary  efficacy  endpoint  of  FLAURA  was  PFS  based  on  investigator  assessment  according  to RECIST v1.1. For this first-line setting PFS is an acceptable primary endpoint. OS, ORR, DoR, QoL and post progression outcomes (PFS2) were included as secondary endpoints.

OS data as well as PFS2 data are considered of great value in order to assess how osimertinib acts on the development of secondary resistances and whether the early introduction of osimertinib could have some impact on subsequent lines of therapy..

An analysis in a predefined subgroup of patients presenting CNS metastases at baseline was planned. CNS BIRC assessment of PFS and ORR was also performed.

## Randomisation and SAP

Suitable patients were centrally randomised to receive either osimertinib 80 mg or SoC in a 1:1 ratio. Patients were stratified at randomisation based on EGFR mutation status (Ex19del or L858R) ethnicity (Asian/Non-Asian).

The DCO for the main PFS analysis (after approximately 359 PFS events) was performed at the DCO of 12-Jun-2017. The first IA on OS was performed at that time. The final analysis for OS has not yet been conducted.

## Results

The overall patient population seems reasonably representative for the intended patient population.

As of DCO1 for the primary PFS analysis, 141 (50.5%) patients in the osimertinib arm and 64 (23.1%) patients in the SoC arm patients were ongoing on their randomised treatment.

Two amendments to protocol were carried out, mainly related to the inclusion of the China cohort (as recommended  by  Chinese  regulatory  authority),  and  to  allow  post progression cross-over to osimertinib for patients in the SoC arm and statistical issues. The MAH is recommended to submit data from the Chinese cohort when available.

The number of protocol deviations is overall high (23.3% osimertinib vs 18.1% SoC) however none is considered to have meaningful impact on study results.

- Baseline characteristics

Patient demographic seem to be well-balanced between arms. The median age was 63 years (range 26 to  93  years),  with  79  patients  (14.2%)  aged  ≥75  years.  There  was  a  greater  proportion  of  female

<div style=\"page-break-after: always\"></div>

patients  (62.9%)  and  the  population  was  predominantly  Asian  (62.4%)  and  white  (36.2%).  The proportion  of  Asian  population  is  consistent  with  previous  trials  with  osimertinib  (in  AURA  3  trial (second line of T790M+ NSCLC) 65.4% of patients were Asian). Pivotal trials with first and secondgeneration  TKIs,  on  the  contrary,  were  either  conducted  in  Asian  population  (IPASS  trial)  or  in Caucasic  patients  (EURTAC  trial).  Two-thirds  of  patients  had  never  smoked  (64.2%)  and  a  low percentage of patients (3.1%) were current smokers. This is consistent with the known prevalence of sensitising EGFR mutations.

Most patients had a WHO performance status of 1 (58.8%). As per inclusion criteria all patients should have had histological type of adenocarcinoma (or mixed histology with predominance of adenocarcinoma).  Based  on  confirmation  by  both  central  and  local  test,  the  most  common  EGFR sensitising mutations were exon 19 deletion (62.7% in osimertinib arm vs. 62.8 in SoC) and exon 21 L858R (37.3% osimertinib vs. 37.2% SoC).

Of the 556 patients randomised in the trial 267 (48%) were randomised based on local testing of EGFR mutations and 289 (52%) based on status identified by central laboratories (cobas® EGFR Mutation Test). All patients centrally analysed were positive for EGFR mutations. From the 267 patients locally analysed, samples from 226 patients were also sent for central confirmation of mutations (84.6%). Mutations were centrally confirmed in 211 patients (211/267; 80%) whereas absence of mutation was centrally confirmed for 6 patients and the sample was invalid for testing in 9 patients. Concordance between central and local test sites was high.

EGFR mutations by cobas central test classified 56.6% of patients in the osimertinib arm vs. 56.0% in the SoC as having exon 19 deletion, 34.8% and 32.5% respectively as exon 21 L858R, 1.1% in each study arm (3 patients each) as EGFRm not detected and 1.4% and 1.8% of patients respectively as invalid test.

Most patients had metastatic disease (94.6%) while only 5.2% (n=29) had locally advanced (stage IIIb) NSCLC not suitable for definitive multimodality therapy. The proportion is in line with what was seen in other recent trials in lung cancer.

Sites of metastases were comparable between study arms.

Central  nervous  system  (CNS)  metastases  as  collected  by  investigators  in  the  sCRF  pages  were present in 19% of patients in osimertinib arm (n=53) and 22.7% of patients (n=63) in the SoC arms, however  these  were  required  to  be  asymptomatic,  stable  and  not  requiring  steroids  for  at  least  2 weeks prior to the start of study treatment.

Overall the main demographic and disease characteristics can be considered representative of targeted population.

8.6%  of  patients  (n=24)  from  the  osimertinib  arm  and  14.1%  from  SoC  received  second  posttreatment anticancer therapy.

## Efficacy data and additional analyses

A statistically significant and clinically relevant improvement in terms of the primary endpoint, PFS per investigator assessment (HR: 0.46 [95% CI: 37, 0.57]; p-value: &lt;0.0001), was shown by osimertinib compared  to  the  SoC  arm.  Data  can  be  considered  mature  enough  with  48.7%  of  events  in  the osimertinib  arm  and  74.4%  in  SoC  arm.  Treatment  with  osimertinib  resulted  in  a  8.7-month improvement in median PFS compared to SoC (18.9 months [95% CI: 15.2, 21.4] vs. 10.2 months [95% CI: 9.6, 11.1]). PFS rates consistently favoured osimertinib treatment arm at 6 months (88.4% vs. 75.2%), 12 months (68.2% vs. 42.3%) and 18 months (50.9% vs. 24.4%). K-M curves show a

<div style=\"page-break-after: always\"></div>

clear and early separation almost from the beginning of the trial.

PFS results according to BICR on the FAS are consistent with main analysis, HR: 0.45 (95% CI: 0.36, 0.57; p-value &lt;0.0001). Median estimates were close to those estimated by investigator but slightly lower in both arms, 17.7 months (95% CI: 15.1, 21.4) in the osimertinib arm vs. 9.7 months (95% CI: 8.5,  11.0)  in  the  SoC  arm.  Exploratory  analyses  carried  out  in  order  to  estimate  the  discrepancy degree between BICR and investigator (early discrepancy rate (EDR) and late discrepancy rate (LDR)) did not raise concerns.

Although an analysis in the subgroup of patients presenting at baseline with T790M+ was initially preplanned, it was finally not performed given the low number of patients (4 patients in the osimertinib arm and 1 patient in the SoC arm).  This is compliant with the amended study protocol and SAP.

Different sensitivity analyses were carried out in order to assess robustness of results. They included assessment of ascertainment bias,  evaluation-time bias,  attrition  bias  as  well  as  assessment  of  the impact  of  the  change  in  RECIST  scanning  schedule  at  Month  18  from  every  6  weeks  to  every  12 months,  which  fell  close  to  the  median  PFS  of  18.9  months  in  the  osimertinib  arm.  All  sensitivity analyses  supported  the  main  one  with  HR  between  0.45-0.47  and  upper  bounds  of  the  95%  CI  no greater than 0.58.

A  sensitivity  analysis  comparing  the  differences  in  PFS  data  between  osimertinib  and  gefitinib  vs. osimertinib and erlotinib was not planned or performed. The study was not designed or powered to allow a meaningful interpretation of this analysis: randomization into the two study arms was stratified by ethnicity and EGFR mutations, both factors known to impact outcome, however patients randomized into  the  comparator  arms  were  not  stratified  to  also  generate  an  equal  distribution  of  these  factors over the two SoC choices. Taking into account that a separate analysis for gefitinib and erlotinib was likely  to  be  heavily  confounded  by  the  unequal  distribution  of  ethnicity  and  that  other  previously conducted  head-to-head  studies  of  erlotinib versus  gefitinib showed  no  statistically significant difference  for  efficacy,  this  issue  was  not  further  pursued.    Furthermore,  no  unexpected  change  in WHO performance status was observed in either arm of the study.

Subgroup analyses for PFS showed consistent results in all subgroups analysed. Previous experience with  first  and  second-generation  TKIS  suggested  better  efficacy  in  patients  with  Exon19  mutation compared to those with L858R mutations. A similar trend has been observed in the FLAURA trial and the benefit over the SoC is clear for both subgroups. Regarding the analysis of subgroups according to EFGR mutation by ctDNA was also consistent with main findings although CI in some subgroups are widened likely because of the limited sample size (HR of 0.44 (95% CI: 0.34-0.57) for EGFR m+; HR of 0.48 (95% CI: 0.28-0.80) EGFR m-; HR of 0.41 (95% CI: 0.21-0.78) EGFR missing). The HR in the subgroup of patients with centrally confirmed mutation was 0.43 (95% CI: 0.34-0.54).

There were 14% of patients aged ≥75 years. The treatment effect in patients older than 75 years old is not considered critically dissimilar to that of the overall population. Results in terms of PFS for this subgroup are borderline statistically significant (upper limit 95%CI: 1.02) which could be due to the limited sample size.

Osimertinib performed better in the non-Asian population compared to the Asian population with a PFS of 24.3 months (95%CI: 16.4, NC) vs. 16.6 months (95%CI: 13.8, 20.7), respectively. The existing PFS data demonstrated a statistically and clinically relevant benefit over SoC in both Asians and nonAsians.

PFS in patients with locally advanced disease seemed to be in line with the overall population, although the data set is too small to conclude.

PFS results in the comparator arm observed in the FLAURA trial (10.2 months) can be considered in

<div style=\"page-break-after: always\"></div>

line with data from previous trials of TKI inhibitors, including those of afatinib, where medians ranging from 8.2 to 13.7 months at best were observed. The most recent phase III trial (ARCHER 1050; Wu et al  2017)  compared  a  new  TKI  inhibitor  with  gefitinib  and  a  median  PFS  of  11.0  months  was documented for the latter. PFS results for osimertinib (median 18.9 months) compare favourably to the  best outcomes documented in the literature for TKI alternatives (13.7 months).

The first OS interim analysis was submitted showing a HR of 0.63 (CI 95% 0.45, 0.88) that did not reach  the  pre-specified  threshold  for  statistical  significance.  Superior  rates  at  different  time  points consistently favoured osimertinib arm (OS rates at 12 months: 89.1% vs. 82.5%; 18 months: 82.8% vs. 70.9%).

Results from the final analysis would further support the efficacy including subgroup analyses of OS. The MAH is recommended to submit the final OS analysis expected to be available by Q4 2019.

OS data will be submitted together with updates of other relevant endpoints such as TFST and TSST. Although it is acknowledged that the cross-over of patients will unavoidably confound study results.

Regarding  secondary  endpoints,  the  superiority  in  terms  of  PFS  is  however  not  supported  by  a statistically  significant  difference  in  terms  of  response  rates.  The  ORR  (not  confirmed)  was  79.9% (95% CI: 74.7, 84.5) in the osimertinib arm and 75.8% (95% CI: 70.3, 80.7) in the SoC arm. The confirmed responses were consistent with the unconfirmed ORR data. Acknowledging the limitations of cross-study comparisons, the ORR results observed in this study are in line with the ORRs observed in randomized controlled studies with currently approved EGFR-TKIs (58%-83%, reviewed in Sebastian et al 2014). A longer duration of response has been observed with osimertinib compared to SoC (median 17.2  months  vs.  8.5  months).  The  BICR  assessment  of  ORR  was  consistent  with  the  Investigator assessment as it was the analysis of ORR according to centrally confirmed EGFRm.

## CNS analyses (by BICR and Investigator)

Efficacy analyses were conducted in the subset of patients with CNS metastases at baseline.

Of 556 patients randomized, 200 had available baseline brain scans. CNS efficacy by RECIST v1.1 in FLAURA demonstrated a nominal statistically significant improvement in CNS PFS HR: 0.48 (95% CI: 0.26,  0.86).  An  ORR  of  65.6%  (95%  CI:  52.3,  77.3)  was  documented  in  the  osimertinib  arm  vs. 43.3% (95% CI: 31.2, 56.0) in the SoC arm in the subset of patients with brain metastasis. These findings confirm preclinical investigation suggesting that osimertinib has higher BBB than other TKIs.

## Patients reported outcome data

The overall compliance in terms of PRO data over the first 9 months was similar between treatment arms, and ≥60%.

The  presented  PRO  data  collected  up  to  nine  months  showed  no  significant  differences  between treatment arms. A clinically relevant improvement from baseline in cough in both treatment arms was shown, and a clinically relevant worsening in diarrhoea in both treatments was also observed and could be expected considering the mechanism of action and safety profile of the studied medicinal products.

## Post-progression outcomes (exploratory endpoints)

At  DCO1,  73  (26.2%)  patients  from  osimertinib  and  106  (38.3%)  patients  from  SoC  had  second progression  events  after  the  start  of  subsequent  therapy  or  died.  The  majority  of  patients  in  the osimertinib arm received platinum-based therapy after progression on trial treatment and the majority of patients in SoC arm received EGFR-TKI therapy (including 48 patients that were eligible to crossover to osimertinib). Median PFS2 is longer in the osimertinib arm however data are still immature with low percentage of events.

<div style=\"page-break-after: always\"></div>

TFST and TSST favoured osimertinib arm. Median TSST was not reached in both arms (0.60 (0.45, 0.80);  P=0.0005)  as  data  are  still  immature  (limited  number  of  patients  with  second  subsequent therapy).

The potential mechanisms of resistance to osimertinib have not been investigated in the FLAURA trial. Blood  samples  for  ctDNA  testing  and  optional  tumour  samples  were  collected  from  patients  in  both treatment arms at time of progression to explore the potential mechanisms of resistance, results are anticipated to be available by the 3/4Q 2018 and the MAH is recommended to submit them.

Although  more  mature  OS  data  is  still  awaited,  preliminary  data  together  with  post-progression measures (PFS2, TFST) are in favour of osimertinib treatment. This reflects that osimertinib does not negatively impact next-line therapies. Twenty nine (29) patients received an EFGR-TKI as subsequent therapy  to  osimertinib.  Median  PFS  for  this  subset  of  patients  was  lower  than  for  the  overall population.  No  reliable  conclusion  can  be  made  on  the  possible  impact  of  osimertinib  treatment  on next-line TKI therapies or development of cross-resistances due to the limited sample size.

A broadening of the indication to mutations other than Ex19del or L858R has been considered.

Available evidence, including early preclinical data with mutant cell lines shows activity of osimertinib, against  the  rare  EGFR  mutations  G719S,  L861Q,  and  the  exon  19  insertion  mutations  (Cross  et  al 2014). Publications have also reported activity in exon 20 mutations (Lee et al 2017; Kohsaka et al 2017; Ward et al 2016). Clinical data with osimertinib in other mutations are limited, although ongoing clinical  trials  could  provide  additional  information  in  the  future.  It  is  not  expected  that  osimertinib would  have  a  lower  efficacy  in  other  mutations.  Alternatives  authorised  in  the  treatment  of  EGFR activating mutations do not have a restricted use based on specific EGFR mutations despite very little or no clinical data in rare mutations.

Based on the above, the CHMP considered that the use of Tagrisso should not be restricted to Ex19del or L858R mutations.

## 2.4.4. Conclusions on the clinical efficacy

Osimertinib  prolong  PFS  in  a  clinically  relevant  manner  when  compared  to  SoC  (gain  8.7  months), which  could  likely  translate  into  longer  OS  for  patients  (as  pointed  out  by  preliminary  data).  PFS results are well-above findings of first and second-generation TKIs, and although rather similar results in terms of ORR are observed, the duration of responses was significantly longer for osimertinib.  This could potentially be due to a delay in TKI resistance development, however no data confirming this hypothesis has been submitted and the potential mechanisms of resistance to osimertinib remain to be investigated.

Although more mature OS data are will be available post authorisation (final OS results expected to be provided by Q4 2019), preliminary data together with post-progression measures (PFS2, TFST) are in favour of osimertinib treatment. On the basis of the available data, it is considered that osimertinib does not negatively impact next-line therapies.

The  benefit  of  osimertinib  as  first-line  for  the  overall  population  of  EGFR  mutated  patients  therapy overcomes the  potential  uncertainties  about  treatment  sequencing  as  it  is  currently  not  possible  to predict  in  advance  which  patients  will  develop  T790M  resistance  prior  to  receiving  any  EGFR-TKI therapy.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

The safety review is based primarily on the results of the Phase III study FLAURA (D5160C00007).

FLAURA safety data are based on the DCO date for the primary efficacy analysis of PFS: 12 June 2017. Moreover, updated data, with an additional follow-up of 90 days have been provided (90 DSU DCO 25 September 2017).

Safety  findings  in  FLAURA  (first-line  therapy)  were  supported  by  a  pooled  dataset  (N  =  1142)  that includes  data  from  Phase  I-III  studies  in  patients  treated  with  80  mg  osimertinib  as  first-line  (309 patients)  or  ≥  second-line  therapy  (833  patients)  for  EGFR  mutation-positive  NSCLC:  FLAURA  (N  = 279), AURA3 (N = 279), AURA2 (N = 210), AURA extension (N = 201), and AURA Phase 1 (N =173). The  pooled  population  did  not  include  patients  who  crossed  over  to  osimertinib  after  disease progression on their initial treatment.

<div style=\"page-break-after: always\"></div>

Table 33 : Summary of key clinical studies contributing to the evaluation of the safety of osimertinib

| Study                                                                   | Design                                                                                                                                                                                                                                                                                                                                                                                                           | Number of patients                                                                                                                                                             | Patient population                                                                                                                                                                                                                                                                                                                                                                        | report inModule5                                                         |
|-------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| D5160C00007 PhaseII (FLAURA) DCO1: 12 June 2017                         | A Phase Ill, double-blind, randomisedstudyto assessthe efficacyandsafetyofosimertinib versusastandard-of-careEGFRTKI asfirst-line treatment Primary objective: To assess the efficacy of single-agent osimertinibcomparedwithSoC EGFR-TKI therapy as measured by progression-free survival (PFS) Key safety objective: Toassessthesafetyandtolerability profile ofosimertinib compared with SoC EGFR-TKI therapy | 556 first-line patients: 279treatedwith osimertinib 80 mg 277 treated with SoC: 94 erlotinib 150 mg 183 gefitinib 250 mg                                                       | PatientswithEGFRmutation- positive (Exon 19 deletion or L858R),locallyadvancedor metastatic NSCLC                                                                                                                                                                                                                                                                                         | Module 5.3.5.1                                                           |
| D5160C00003 (AURA3) DCO1: 15 April 2016                                 | PhaseIll,open-label,randomised studyofosimertinibvs.platinum- based doublet chemotherapy Primary objective: Toassesstheefficacyofosimertinib comparedwithplatinum-based doubletchemotherapyby assessment ofPFS. Key safety objective: Toassessthesafety andtolerability profile of osimertinib comparedwith platinum-based doublet                                                                               | 415second-line patients: 279 treated with osimertinib 80 mg 136treatedwith pemetrexed plus cisplatin or pemetrexed plus carboplatinfollowed by optional pemetrexed maintenance | Patientswith advancedEGFR T790Mmutation-positive, locallyadvancedormetastatic NSCLCwhosediseasehas progressed following treatment with an approved EGFR TKI (second-line).                                                                                                                                                                                                                | Edition 2 dated 9 Nov 2016 (AURA3 DCO1 of15 Apr 2016), in Module 5.3.5.1 |
| D5160C00002 (AURA2) DC04: 1 November 2016                               | chemotherapy. Phase II, single-arm, open-label, non-randomised study. Primary objective: To assess the efficacy of osimertinib by assessmentofORR. Key secondarysafety objective: Toassessthesafetyandtolerability profile of osimertinib.                                                                                                                                                                       | 210 second-line (n=68) and ≥third-line (n=142) patients treated with osimertinib 80 mg                                                                                         | PatientswithadvancedEGFR T79oMmutationpositive NSCLCwhose disease has progressed following either 1 prior therapy with an EGFR TKI (second-line chemotherapy- naive, n=68) or following treatmentwithatleast1EGFR TKIand1priorplatinum-based doublet chemotherapy third- line,n=142),in addition further lines of therapy were permitted such as cytotoxic chemotherapy or immunotherapy. | 5.3.5.2                                                                  |
| D5160C00001 (Phase II component) (AURA extension) DC04: 1 November 2016 | Phase II, single-arm, open-label, non-randomised study extension to AURA Primary objective: Toinvestigatethesafety,tolerability and efficacy (objective response rate [ORR]]ofosimertinib Keysecondarysafetyobjective: To investigate the safety and tolerabilityofosimertinibgiven orally as first-line therapy to patients whoaretreatment-naive.                                                              | 201 second-line (n=61) and ≥third-line (n=140) patients treated with osimertinib80mg                                                                                           | PatientswithadvancedEGFR T790M mutation positive NSCLC whose disease has progressed following either 1 prior therapy with an EGFR TKI or following treatmentwithbothEGFRTKI and atleast1otherpriorlineof therapy, such as cytotoxic doublet chemotherapy or immunotherapy.                                                                                                                | 5.3.5.2                                                                  |
| D5160C00001 AURA PhaseI (Phase I component) DCO3: 1 November 2016       | Phase I component (dose-escalation and dose expansion)of Study D5160C00001. Primaryobjective: Toinvestigatethesafety,tolerability, andefficacy(ORRbyBICR)oforal osimertinib Key secondary objectives: TocharacterisethePKofosimertinib anditsmetabolites(AZ5104and AZ7550)aftermultipleoraldoses To obtain additionalassessments of theanti-tumouractivity of osimertinibbyevaluationofDoR                       | Thestudyevaluated31 pre-treated patients in the dose-escalation portion and 371 patients (311 pre-treated, 60 first-line*)in the dose- expansion portion                       | PatientswithadvancedEGFR- mutation-positive NSCLC who aretreatment-naive(firstline, n=60)orwhose diseasehas progressed following prior therapy with an EGFR TKI secondline,n=342)*                                                                                                                                                                                                        | 5.3.5.2                                                                  |

BICR=blinded independent central review;DCO= data cut-off;DCR = disease control rate;DoR= duration of response;EGFR= epidermal growth factorreceptor;NSCLC=non-small cell lung cancer;ORR=objective responserate;PFS=progression-freesurvival;PK=pharmacokinetics;TKI =tyrosinekinaseinhibitor

whoreceived80mgosimertinibas&gt;=second-line therapy

<div style=\"page-break-after: always\"></div>

## Patient exposure

## Study FLAURA

All patients randomised to osimertinib or SoC received at least 1 dose of study medication. At the time of the 12 June 2017 DCO1, 141/279 (50.5%) patients were still on treatment in the osimertinib arm and 64/277 (23.1%) were still on treatment in the SoC arm. In comparison, at the time of the 90 DSU DCO, 25 September 2017, 127 (45.5%) patients were still on treatment in the osimertinib arm and 50 (18.1%) were still on treatment in the SoC arm.

Exposure to osimertinib and SoC is summarized in the table below.

Table 34: Duration of exposure in FLAURA (Safety analysis set)

|                               |                       | Number (%) of patients    | Number (%) of patients    | Number (%) of patients   | Number (%) of patients   |
|-------------------------------|-----------------------|---------------------------|---------------------------|--------------------------|--------------------------|
|                               |                       | Osimertinib 80 mg (N=279) | Osimertinib 80 mg (N=279) | Standardof Care (N=277)  | Standardof Care (N=277)  |
|                               |                       | DC01                      | 90 DSU                    | DC01                     | 90 DSU                   |
| Total exposure (months)a      | Mean (SD)             | 15.05 (6.6)               | 16.73 (7.9)               | 11.78 (6.8)              | 12.47 (7.7)              |
|                               | Median                | 16.20                     | 18.79                     | 11.53                    | 11.53                    |
|                               | Minimum               | 0.1                       | 0.1                       | 0.0                      | 0.0                      |
|                               | Maximum               | 27.4                      | 30.9                      | 26.2                     | 29.6                     |
|                               | Total treatment years | 349.9                     | 389.0                     | 271.9                    | 287.9                    |
| Actual exposure (months) b    | Mean (SD)             | 14.88 (6.6)               | 16.55 (7.9)               | 11.56 (6.8)              | 12.25 (7.7)              |
|                               | Median                | 16.10                     | 18.56                     | 11.50                    | 11.50                    |
|                               | Minimum               | 0.1                       | 0.1                       | 0.0                      | 0.0                      |
|                               | Maximum               | 27.4                      | 30.9                      | 26.2                     | 29.6                     |
|                               | Total treatment years | 346.0                     | 384.9                     | 266.9                    | 282.7                    |
| Cumulative exposure over time | ≥9 months             | 220 (78.9)                | 220 (78.9)                | 177 (63.9)               | 177 (63.9)               |
|                               | ≥12 months            | 194 (69.5)                | 194 (69.5)                | 131 (47.3)               | 131 (47.3)               |
|                               | ≥15 months            | 162 (58.1)                | 167 (59.9)                | 99 (35.7)                | 103 (37.2)               |
|                               | ≥18 months            | 106 (38.0)                | 150 (53.8)                | 55 (19.9)                | 74 (26.7)                |
|                               | ≥21 months            | 53 (19.0)                 | 99 (35.5)                 | 25 (9.0)                 | 46 (16.6)                |
|                               | ≥24 months            | 13 (4.7)                  | 54 (19.4)                 | 7 (2.5)                  | 20 (7.2)                 |
|                               | ≥27 months            | 1 (0.4)                   | 16 (5.7)                  | 0                        | 5 (1.8)                  |
|                               | ≥30months             |                           | 1 (0.4)                   |                          | 0                        |

a Total exposure = [(last dose date where dose &gt;0 mg -first dose date) + 1] / 30.4375.

b Actual exposure =[(last dose date where dose &gt;0 mg-first dose date)+ 1)-total duration of dose interruption (ie, number of days with dose = 0 mg)]/30.4375.

Includes exposure to randomised study treatment during the double-blind treatment phase, not including crossovertreatment.

Ifapatient hasnot discontinued,then thedatacut-offdateisusedinplace oflastdosedate.

Datacut-offdate:DCO1=12June2017;90DSUDCO=25September2017

Source: see Table 5, Module 2.7.4 dated 4 October 2017 and see Table 11.3.1.1, Appendix A

## Pooled dataset

In the pooled population, the median duration of osimertinib therapy was 12.9 months (mean, 13.9 months;  range,  &lt;0.1  -  40.1  months).  Actual  exposure  was  similar  to  intended  exposure  (median: 12.7; range: 0.0-17.6 months), indicating that the frequency and median duration interruptions had low impact on exposure.

<div style=\"page-break-after: always\"></div>

## Dose modifications

Table 35: Treatment interruptions and dose reductions in FLAURA (Safety analysis set)

|                                            |                                              | Number (%) of patients    | Number (%) of patients   |
|--------------------------------------------|----------------------------------------------|---------------------------|--------------------------|
|                                            |                                              | Osimertinib 80 mg (N=279) | Standardof Care (N=277)  |
| Total patients with any dose modification? | Any                                          | 108 (38.7)                | 107 (38.6)               |
| Reasons for any modification               | Adverse event                                | 71 (25.4)                 | 89 (32.1)                |
| Reasons for any modification               | Patientforgottotakedose                      | 31 (11.1)                 | 23 (8.3)                 |
| Reasons for any modification               | Surgery                                      | 4 (1.4)                   | 5 (1.8)                  |
| Reasons for any modification               | Laboratory abnormality not reported as an AE | 3 (1.1)                   | 0                        |
| Reasons for any modification               | Other reason                                 | 15 (5.4)                  | 10 (3.6)                 |
| Patients with a dosing interruption        | Any                                          | 107 (38.4)                | 106 (38.3)               |
| Patients with a dosing interruption        | 1 interruption                               | 65 (23.3)                 | 67 (24.2)                |
| Patients with a dosing interruption        | 2 intenruptions                              | 17 (6.1)                  | 17 (6.1)                 |
| Patients with a dosing interruption        | > 2 interruptions                            | 25 (9.0)                  | 22 (7.9)                 |
| Reasons for interruption                   | Adverse event                                | 71 (25.4)                 | 88 (31.8)                |
| Reasons for interruption                   | Patientforgottotakedose                      | 31 (11.1)                 | 23 (8.3)                 |
| Reasons for interruption                   | Surgery                                      | 4 (1.4)                   | 5 (1.8)                  |
| Reasons for interruption                   | Laboratory abnormality not reported as an AE | 3 (1.1)                   | 0                        |
| Reasons for interruption                   | Other reason                                 | 13 (4.7)                  | 10 (3.6)                 |
| Patients with a dose reduction             | Any                                          | 17 (6.1)                  | 19 (6.9)                 |
| Reasons for dose reduction²                | Adverse event                                | 15 (5.4)                  | 19 (6.9)                 |
| Reasons for dose reduction²                | Other                                        | 2 (0.7)                   | 0                        |

Datacut-offdate:12June2017

Number ofpatientswitha doseinterruption and/or a dosereduction.Reasonsfordosemodifications are not mutually exclusive for patients with multiple modifications although patients are counted only once per category.

Source:Table11.3.1.2,FLAURA CSR,Module5.3.5.1

## Adverse events

## Study FLAURA

This analysis included AEs with an onset date on or after the date of the first dose, up to and including 28  days  following  discontinuation  of  randomised  treatment  or  the  day  before  administration  of osimertinib as crossover treatment.

<div style=\"page-break-after: always\"></div>

Table 36: Adverse events in any category in FLAURA (Safety analysis set)

|                                                                                 | Number (%) of patients a    | Number (%) of patients a    | Number (%) of patients a   | Number (%) of patients a   |
|---------------------------------------------------------------------------------|-----------------------------|-----------------------------|----------------------------|----------------------------|
|                                                                                 | Osimertinib 80 mg (N = 279) | Osimertinib 80 mg (N = 279) | Standard of Care (N =277)  | Standard of Care (N =277)  |
|                                                                                 | DC01                        | 90 DSU                      | DC01                       | 90 DSU                     |
| Median duration of exposure (months)                                            | 16.2                        | 18.8                        | 11.5                       | 11.5                       |
| Any AE                                                                          | 273 (97.8)                  | 273 (97.8)                  | 271 (97.8)                 | 271 (97.8)                 |
| Any AE causally related to treatment b                                          | 253 (90.7)                  | 253 (90.7)                  | 255 (92.1)                 | 254 (91.7)                 |
| Any AE of CTCAE grade 3 or higher                                               | 95 (34.1)                   | 103 (36.9)                  | 124 (44.8)                 | 125 (45.1)                 |
| Any AE of CTCAE grade 3 or higher, causally related to treatment b              | 49 (17.6)                   | 51 (18.3)                   | 78 (28.2)                  | 78 (28.2)                  |
| Any AE with outcome = death                                                     | 6 (2.2)                     | 8 (2.9)                     | 10 (3.6)                   | 9 (3.2) c                  |
| Any AE with outcome = death, causally related to treatment                      | 0                           | 0                           | 1 (0.4)                    | 1 (0.4)                    |
| Any SAE (including events with outcome = death)                                 | 60 (21.5)                   | 63 (22.6)                   | 70 (25.3)                  | 72 (26.0)                  |
| Any SAE (including events with outcome = death), causally related to treatmentb | 22 (7.9)                    | 22 (7.9)                    | 23 (8.3)                   | 24 (8.7)                   |
| Any AE leading to dose interruption                                             | 70 (25.1)                   | 72 (25.8)                   | 66 (23.8)                  | 70 (25.3)                  |
| Any AE leading to dose reduction                                                | 11 (3.9)                    | 11 (3.9)                    | 15 (5.4)                   | 17 (6.1)                   |
| AnyAE leading todiscontinuation of treatment                                    | 37 (13.3)                   | 37 (13.3)                   | 49 (17.7)                  | 49 (17.7)                  |
| AnyAE leading to discontinuation of treatment, causally related to treatmentb   | 27 (9.7)                    | 27 (9.7)                    | 38 (13.7)                  | 38 (13.7)                  |

b As assessed by the Investigator.

a Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

C One fatal AE reported as a SoC patient at DCO1 was determined to be a cross-over patient at the 90 DSU andisreportedinSection 6.

Includes AEs with an onset date on or after the date of first dose and up to and including 28 days following the date of last dose of studymedication or the day before first administration of crossover treatment.

AE = adverse event; CTCAE = Common Terminology Criteria for Adverse Events version 4.03; SAE = serious adverseevent

Datacut-offdate:DCO1=12June2017;90DSUDCO=25September2017

Source:seeTable9,Module2.7.4dated40ctober2017andTable11.3.1.1,Table11.3.2.1.1,Table11.3.2.9.1 Table 11.3.2.9.3 and Table 11.3.5.2.1, Appendix A

## Pooled dataset

<div style=\"page-break-after: always\"></div>

Table 37: Summary of categorical safety data in patients receiving osimertinib 80 mg in FLAURA and Phase I-III pooled datasets (Safety analysis set)

|                                                                                 | AURA Phase I A&B (N =143)   | AURA2 &AURA1C (N = 411)   | AURA3 (N = 279)   | AURA Phase I first-line (N=30)   | FLAURA (N=279)   | Total (N=1142)   |
|---------------------------------------------------------------------------------|-----------------------------|---------------------------|-------------------|----------------------------------|------------------|------------------|
| Duration of exposure (months)a                                                  |                             |                           |                   |                                  |                  |                  |
| Mean (standard deviation)                                                       | 13.9 (10.96)                | 15.9 (8.99)               | 8.8 (4.05)        | 22.3 (11.52)                     | 15.0 (6.64)      | 13.9 (8.50)      |
| Median                                                                          | 11.1                        | 16.4                      | 8.2               | 27.1                             | 16.2             | 12.9             |
| Range                                                                           | 0.1-40.1                    | 0.0-29.7                  | 0.2-18.5          | 0.5-34.5                         | 0.1-27.4         | 0.0-40.1         |
| Any adverse event b                                                             | 142 (99.3)                  | 408 (99.3)                | 273 (97.8)        | 30 (100)                         | 273 (97.8)       | 1126 (98.6)      |
| Any AE causally related to osimertinibc                                         | 131 (91.6)                  | 366 (89.1)                | 231 (82.8)        | 29 (96.7)                        | 253 (90.7)       | 1010 (88.4)      |
| AnyAEofCTCAE≥grade3                                                             | 78 (54.5)                   | 180 (43.8)                | 63 (22.6)         | 18 (60.0)                        | 95 (34.1)        | 434 (38.0)       |
| Any AE of CTCAE ≥grade 3, causally related to osimertinibc                      | 28 (19.6)                   | 64 (15.6)                 | 16 (5.7)          | 4 (13.3)                         | 49 (17.6)        | 161 (14.1)       |
| Any AE with outcome of death                                                    | 9 (6.3)                     | 22 (5.4)                  | 4 (1.4)           | 0                                | 6 (2.2)          | 41 (3.6)         |
| Any AE with outcome of death, causally related to osimertinibc                  | 0                           | 4 (1.0)                   | 1 (0.4)           | 0                                | 0                | 5 (0.4)          |
| AnySAE(includingAEswithoutcome of death)                                        | 52 (36.4)                   | 145 (35.3)                | 50 (17.9)         | 14 (46.7)                        | 60 (21.5)        | 321 (28.1)       |
| Any SAE (including AEs with outcome of death), causally related to osimertinibc | 8 (5.6)                     | 28 (6.8)                  | 8 (2.9)           | 4 (13.3)                         | 22 (7.9)         | 70 (6.1)         |
| AnyAEleadingtodiscontinuationofstudy drug                                       | 17 (11.9)                   | 33 (8.0)                  | 19 (6.8)          | 3 (10.0)                         | 37 (13.3)        | 109 (9.5)        |
| AnyAEleadingtodiscontinuationofstudy drug, causally related to osimertinibb     | 7 (4.9)                     | 18 (4.4)                  | 10 (3.6)          | 2 (6.7)                          | 27 (9.7)         | 64 (5.6)         |

a Total treatment duration=(last dose date - first dose date +1)/(365.25/12).

b Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

C As assessed by the Investigator.

IncludesAEswithanonsetdateonorafterthedateoffirstdoseanduptoandincluding28daysfollowingthedateoflastdoseofstudymedication. AE=adverseevent;CTCAE=CommonTerminology CriteriaforAdverseEvents version 4.03;SAE=serious adverseevent

Data cut-off dates: 12 June 2017 for FLAURA, 15 April 2016 for AURA3, 1 November 2016 for the Phase I-II studies

Source:Table2.7.4.1.1andTable2.7.4.2.1.1,PooledSafety,Module5.3.5.3

<div style=\"page-break-after: always\"></div>

## Common adverse events

## Study FLAURA

Table 38: Most common adverse events (frequency of ≥ 10% in either treatment arm) (Safety analysis set)

|                                      | Nunber (%) of patients a   | Nunber (%) of patients a   | Nunber (%) of patients a   | Nunber (%) of patients a   |
|--------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                      | Osimertinib S0 mg (N=279)  | Osimertinib S0 mg (N=279)  | Standard of Care (N =277)  | Standard of Care (N =277)  |
| MedDRApreferred term                 | DC01                       | 90 DSU                     | DC01                       | 90 DSU                     |
| Median duration of exposure (months) | 16.2                       | 18.8                       | 11.5                       | 11.5                       |
| Patients with any adverse event      | 273 (97.8)                 | 273 (97.8)                 | 271 (97.8)                 | 271 (97.8)                 |
| Diarrhoea                            | 161 (57.7)                 | 162 (58.1)                 | 159 (57.4)                 | 161 (58.1)                 |
| Dry skin                             | 88 (31.5)                  | 88 (31.5)                  | 90 (32.5)                  | 90 (32.5)                  |
| Paronychia                           | 81 (29.0)                  | 82 (29.4)                  | 80 (28.9)                  | 82 (29.6)                  |
| Stomatitis                           | 80 (28.7)                  | 80 (28.7)                  | 56 (20.2)                  | 56 (20.2)                  |
| Dermatitis acneiform                 | 71 (25.4)                  | 71 (25.4)                  | 134 (48.4)                 | 134 (48.4)                 |
| Decreased appetite                   | 56 (20.1)                  | 62 (22.2)                  | 52 (18.8)                  | 54 (19.5)                  |
| Pruritus                             | 48 (17.2)                  | 48 (17.2)                  | 43 (15.5)                  | 43 (15.5)                  |
| Cough                                | 46 (16.5)                  | 51 (18.3)                  | 42 (15.2)                  | 42 (15.2)                  |
| Constipation                         | 42 (15.1)                  | 45 (16.1)                  | 35 (12.6)                  | 36 (13.0)                  |
| Nausea                               | 39 (14.0)                  | 45 (16.1)                  | 52 (18.8)                  | 54 (19.5)                  |
| Fatigue                              | 38 (13.6)                  | 39 (14.0)                  | 33 (11.9)                  | 33 (11.9)                  |
| Rash maculopapular                   | 37 (13.3)                  | 37 (13.3)                  | 45 (16.2)                  | 45 (16.2)                  |
| Dyspnoea                             | 35 (12.5)                  | 36 (12.9)                  | 20 (7.2)                   | 21 (7.6)                   |
| Anaemia                              | 34 (12.2)                  | 37 (13.3)                  | 25 (9.0)                   | 26 (9.4)                   |
| Headache                             | 33 (11.8)                  | 33 (11.8)                  | 19 (6.9)                   | 19 (6.9)                   |
| Vomiting                             | 31 (11.1)                  | 36 (12.9)                  | 29 (10.5)                  | 29 (10.5)                  |
| Upper respiratory tract infection    | 28 (10.0)                  | 30 (10.8)                  | 18 (6.5)                   | 18 (6.5)                   |
| Electrocardiogram QT prolonged       | 28 (10.0)                  | 28 (10.0)                  | 11 (4.0)                   | 12 (4.3)                   |
| Pyrexia                              | 28 (10.0)                  | 29 (10.4)                  | 11 (4.0)                   | 11 (4.0)                   |
| ASTincreased                         | 26 (9.3)                   | 26 (9.3)                   | 68 (24.5)                  | 68 (24.5)                  |
| Back pain                            | 26 (9.3)                   | 31 (11.1)                  | 23 (8.3)                   | 23 (8.3)                   |
| Alopecia                             | 20 (7.2)                   | 20 (7.2)                   | 35 (12.6)                  | 35 (12.6)                  |
| ALTincreased                         | 18 (6.5)                   | 18 (6.5)                   | 75 (27.1)                  | 75 (27.1)                  |

Number (%) of patients with AEs, sorted in descending frequency of PT in the osimertinib arm at DCO1 Includes AEs with an onset date on or after the date of first dose and up to and including 28 days following the date oflast dose of study medication.

ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; MedDRA = Medical Dictionary for RegulatoryActivitiesversion 20.0

Datacut-offdate:DCO1=12June2017;90DSUDCO=25September2017

Source: see Table 10, Module 2.7.4 dated 4 October 2017 and see Table 11.3.1.1 and Table 11.3.2.6, Appendix A

## Pooled dataset

Among 1142 patients in the pooled dataset, 1126 (98.6%) reported AEs. The most commonly reported PTs  were  diarrhoea  (555  [48.6%]),  dry  skin  (295  [25.8%]),  paronychia  (276  [24.2%]),  decreased appetite (253 [22.2%]) and stomatitis (229 [20.1%].

Adverse events of CTCAE grade 3 or higher

## Study FLAURA

Table 39: Adverse events of CTCAE grade 3 or higher in at least 1% of patients in either treatment arm in FLAURA, by preferred term (Safety analysis set)

<div style=\"page-break-after: always\"></div>

|                                      | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|--------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                      | Osimertinib 80 mg (N =279) | Osimertinib 80 mg (N =279) | Standardof Care (N =277)   | Standardof Care (N =277)   |
|                                      | DC01                       | 90 DSU                     | DC01                       | 90 DSU                     |
| Median duration of exposure (months) | 16.2                       | 18.8                       | 11.5                       | 11.5                       |
| Any CTCAE ≥grade 3 AE                | 95 (34.1)                  | 103 (36.9)                 | 124 (44.8)                 | 125 (45.1)                 |
| Decreased appetite                   | 7 (2.5)                    | 7 (2.5)                    | 5 (1.8)                    | 5 (1.8)                    |
| Diarrhoea                            | 6 (2.2)                    | 6 (2.2)                    | 7 (2.5)                    | 7 (2.5)                    |
| Pneumonia                            | 6 (2.2)                    | 6 (2.2)                    | 6 (2.2)                    | 7 (2.5)                    |
| Electrocardiogram QT prolonged       | 6 (2.2)                    | 6 (2.2)                    | 2 (0.7)                    | 2 (0.7)                    |
| Hyponatraemia                        | 4 (1.4)                    | 5 (1.8)                    | 4 (1.4)                    | 4 (1.4)                    |
| Pulmonary embolism                   | 4 (1.4)                    | 4 (1.4)                    | 1 (0.4)                    | 1 (0.4)                    |
| Neutrophil count decreased           | 4 (1.4)                    | 5 (1.8)                    | 1 (0.4)                    | 1 (0.4)                    |
| Gamma-glutamyltransferase increased  | 4 (1.4)                    | 4 (1.4)                    | 0                          | 0                          |
| Lymphocyte count decreased           | 4 (1.4)                    | 4 (1.4)                    | 0                          | 0                          |
| Anaemia                              | 3 (1.1)                    | 4 (1.4)                    | 3 (1.1)                    | 3 (1.1)                    |
| Hypokalaemia                         | 3 (1.1)                    | 3 (1.1)                    | 3 (1.1)                    | 3 (1.1)                    |
| Interstitial lung disease            | 3 (1.1)                    | 3 (1.1)                    | 3 (1.1)                    | 3 (1.1)                    |
| Weight decreased                     | 3 (1.1)                    | 3 (1.1)                    | 0                          | 0                          |
| Cataract                             | 2 (0.7)                    | 3 (1.1)                    | 1 (0.4)                    | 1 (0.4)                    |
| Ejectionfraction decreased           | 2 (0.7)                    | 3 (1.1)                    | 1 (0.4)                    | 1 (0.4)                    |
| Aspartate aminotransferaseincreased  | 2 (0.7)                    | 2 (0.7)                    | 12 (4.3)                   | 12 (4.3)                   |
| Alanineaminotransferaseincreased     | 1 (0.4)                    | 1 (0.4)                    | 25 (9.0)                   | 25 (9.0)                   |
| Rash maculopapular                   | 1 (0.4)                    | 1 (0.4)                    | 5 (1.8)                    | 5 (1.8)                    |
| Dyspnoea                             | 1 (0.4)                    | 1 (0.4)                    | 4 (1.4)                    | 4 (1.4)                    |
| Dry skin                             | 1 (0.4)                    | 1 (0.4)                    | 3 (1.1)                    | 3 (1.1)                    |
| Dermatitis acneiform                 | 0                          | 0                          | 13 (4.7)                   | 13 (4.7)                   |
| Vomiting                             | 0                          | 0                          | 4 (1.4)                    | 4 (1.4)                    |
| Drug-induced liver injury            | 0                          | 0                          | 3 (1.1)                    | 3 (1.1)                    |
| Hepatic function abnormal            | 0                          | 0                          | 3 (1.1)                    | 3 (1.1)                    |
| Blood alkaline phosphatase increased | 0                          | 0                          | 3 (1.1)                    | 3 (1.1)                    |

a Number(%) of patients with AEs of CTCAE grade 3 or higher, sorted by decreasing order of AEs within the osimertinib arm at DCO1.

PatientswithmultipleAEsofCTCAEgrade3orhigherarecountedonceforeachpreferred term

Includes AEs with an onset date on or after the date of first dose and up to and including 28 days following discontinuationofrandomisedtreatmentorthedaybeforefirstadministrationofcrossovertreatment.

CTCAE = Common Terminology Criteria for Adverse Events (version 4.03); MedDRA = Medical Dictionary for RegulatoryActivitiesversion 20.0

Data cut-offdate:DCO1=12June 2017;90DSUDCO=25September2017

Source:seeTable 13,Module2.7.4 dated4 0ctober2017andseeTable11.3.1.1 andTable11.3.2.4.1, Appendix A

## Pooled dataset

The incidence of CTCAE ≥ grade 3 AEs in the osimertinib arm in FLAURA was similar to the pooled population (34.1% vs. 38%, respectively). The following AEs of CTCAE ≥ grade 3 were reported in ≥ 1% of patients:  pneumonia  (32  [2.8%]),  pulmonary  embolism  (32  [2.8%]),  anaemia  (24  [2.1%]), neutrophil count decreased (23 [2.0%]), neutropenia (20 [1.8%]), alanine aminotransferase increased (17  [1.5%]),  decreased  appetite  (16  [1.4%]),  dyspnoea  (15  [1.3%]),  hyponatraemia  (15  [1.3%]), diarrhoea (14 [1.2%]), electrocardiogram QT prolonged (13 [1.1%]), asthenia (12 [1.1%]), aspartate aminotranferase increased (11 [1.0%]) and white blood cell count decreased (11 [1.0%]).

<div style=\"page-break-after: always\"></div>

## Adverse Drug reactions (ADRs)

## Table 40 : Adverse reactions reported in FLAURA a  study

| MedDRA SOC                                                       | TAGRISSO (N=279)                                                 | TAGRISSO (N=279)                                                 | EGFR TKI comparator (gefitinib or erlotinib) (N=277)             | EGFR TKI comparator (gefitinib or erlotinib) (N=277)             |
|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| NCI Grade b                                                      | Any Grade (%)                                                    | Grade 3 or higher (%)                                            | Any Grade (%)                                                    | Grade 3 or higher (%)                                            |
| MedDRA Preferred Term                                            | MedDRA Preferred Term                                            | MedDRA Preferred Term                                            | MedDRA Preferred Term                                            | MedDRA Preferred Term                                            |
| Respiratory, thoracic and mediastinal disorders                  | Respiratory, thoracic and mediastinal disorders                  | Respiratory, thoracic and mediastinal disorders                  | Respiratory, thoracic and mediastinal disorders                  | Respiratory, thoracic and mediastinal disorders                  |
| Interstitial Lung Disease c                                      | 3.9                                                              | 1.1                                                              | 2.2                                                              | 1.4                                                              |
| Eye disorders                                                    | Eye disorders                                                    | Eye disorders                                                    | Eye disorders                                                    | Eye disorders                                                    |
| Keratitis d                                                      | 0.4                                                              | 0                                                                | 1.4                                                              | 0                                                                |
| Gastrointestinal disorders                                       | Gastrointestinal disorders                                       | Gastrointestinal disorders                                       | Gastrointestinal disorders                                       | Gastrointestinal disorders                                       |
| Diarrhoea e                                                      | 58                                                               | 2.2                                                              | 57                                                               | 2.5                                                              |
| Stomatitis                                                       | 29                                                               | 0.7                                                              | 20                                                               | 0.4                                                              |
| Skin and subcutaneous tissue disorders                           | Skin and subcutaneous tissue disorders                           | Skin and subcutaneous tissue disorders                           | Skin and subcutaneous tissue disorders                           | Skin and subcutaneous tissue disorders                           |
| Rash f                                                           | 58                                                               | 1.1                                                              | 78                                                               | 6.9                                                              |
| Dry skin g                                                       | 36                                                               | 0.4                                                              | 36                                                               | 1.1                                                              |
| Paronychia h                                                     | 35                                                               | 0.4                                                              | 33                                                               | 0.7                                                              |
| Pruritus i                                                       | 17                                                               | 0.4                                                              | 17                                                               | 0                                                                |
| Investigations                                                   | Investigations                                                   | Investigations                                                   | Investigations                                                   | Investigations                                                   |
| QTc interval prolongation j                                      | 1.1                                                              | 1.1                                                              | 0.7                                                              | 0.7                                                              |
| (Findings based on test results presented as CTCAE grade shifts) | (Findings based on test results presented as CTCAE grade shifts) | (Findings based on test results presented as CTCAE grade shifts) | (Findings based on test results presented as CTCAE grade shifts) | (Findings based on test results presented as CTCAE grade shifts) |
| Platelet count decreased k                                       | 51                                                               | 0.7                                                              | 12                                                               | 0.4                                                              |
| Leukocytes decreased k                                           | 72                                                               | 0.4                                                              | 31                                                               | 0.4                                                              |
| Lymphocytes decreased k                                          | 63                                                               | 5.6                                                              | 36                                                               | 4.2                                                              |
| Neutrophils decreased k                                          | 41                                                               | 3.0                                                              | 10                                                               | 0                                                                |

In FLAURA, the median duration of study treatment was 16.2 months for patients in the TAGRISSO arm and 11.5 months for patients in the EGFR TKI comparator arm.

a Only events for patients receiving at least one dose of TAGRISSO as their randomised treatment are summarised.

- b National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0

c Cases reported within the clustered terms: Interstitial lung disease, pneumonitis.

d Cases reported within the clustered terms: Keratitis, punctate keratitis, corneal erosion, corneal epithelium defect.

e 1 CTCAE grade 5 event (fatal) was reported in the EGFR TKI comparator arm.

f Cases reported within the clustered terms for rash AEs: Rash, rash generalised, rash erythematous, rash macular, rash maculopapular, rash papular, rash pustular, rash pruritic, rash vesicular, rash follicular, erythema, folliculitis, acne, dermatitis, dermatitis acneiform, drug eruption, skin erosion.

- g Cases reported within the clustered terms: Dry skin, skin fissures, xerosis, eczema, xeroderma.
- h Cases reported within the clustered terms: Nail bed disorder, nail bed inflammation, nail bed infection, nail discolouration, nail pigmentation, nail disorder, nail toxicity, nail dystrophy, nail infection, nail ridging, onychoclasis, onycholysis, onychomadesis, onychomalacia, paronychia.
- i Cases reported within the clustered terms: Pruritus, pruritus generalised, eyelid pruritus.

j Represents   the incidence of patients who had a QTcF prolongation &gt;500 msec.

k Represents the incidence of laboratory findings, not of reported adverse events.

<div style=\"page-break-after: always\"></div>

Table 41: Adverse reactions reported in FLAURA and AURA studies a

| MedDRA SOC                                                       | MedDRA term                 | CIOMS descriptor/ overall frequency (all CTCAE grades) b   | Frequency of CTCAE grade 3-4   |
|------------------------------------------------------------------|-----------------------------|------------------------------------------------------------|--------------------------------|
| Respiratory, thoracic and mediastinal disorders                  | Interstitial lung disease c | Common (3.9%) d                                            | 1.5%                           |
| Gastrointestinal disorders                                       | Diarrhoea                   | Very common (49%)                                          | 1.2%                           |
| Gastrointestinal disorders                                       | Stomatitis                  | Very common (20%)                                          | 0.2%                           |
| Eye disorders                                                    | Keratitis e                 | Uncommon (0.7%)                                            | 0.1%                           |
| Skin and subcutaneous tissue disorders                           | Rash f                      | Very common (47%)                                          | 0.9%                           |
| Skin and subcutaneous tissue disorders                           | Dry skin g                  | Very common (31%)                                          | 0%                             |
| Skin and subcutaneous tissue disorders                           | Paronychia h                | Very common (25%)                                          | 0%                             |
| Skin and subcutaneous tissue disorders                           | Pruritus i                  | Very common (14%)                                          | 0%                             |
| Investigations                                                   | QTc interval prolongation j | Uncommon (0.9%)                                            | Uncommon (0.9%)                |
| (Findings based on test results presented as CTCAE grade shifts) | Platelet count decreased k  | Very common (54%)                                          | 1.6%                           |
| (Findings based on test results presented as CTCAE grade shifts) | Leucocytes decreased k      | Very common (68%)                                          | 1.5%                           |
| (Findings based on test results presented as CTCAE grade shifts) | Lymphocytes decreased k     | Very common (67%)                                          | 7.2%                           |
| (Findings based on test results presented as CTCAE grade shifts) | Neutrophils decreased k     | Very common (35%)                                          | 4.1%                           |

- a) Data is cumulative from FLAURA and AURA (AURA3, AURAex, AURA 2 and AURA1) studies; only events for patients receiving at least one dose of TAGRISSO as their randomised treatment are summarised.
- b) National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
- c) Includes cases reported within the clustered terms: Interstitial lung disease, pneumonitis.
- d) 5 CTCAE grade 5 events (fatal) were reported.
- e) Includes cases reported within the clustered terms: Keratitis, punctate keratitis, corneal erosion, corneal epithelium defect.
- f) Includes cases reported within the clustered terms for rash AEs: Rash, rash generalised, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pustular, rash pruritic, rash vesicular, rash follicular, erythema, folliculitis, acne, dermatitis, dermatitis acneiform, drug eruption, skin erosion.
- g) Includes cases reported within the clustered terms: Dry skin, skin fissures, xerosis, eczema, xeroderma.
- h) Includes cases reported within the clustered terms: Nail bed disorder, nail bed inflammation, nail bed infection, nail discolouration, nail pigmentation, nail disorder, nail toxicity, nail dystrophy, nail infection, nail ridging, onychoclasis, onycholysis, onychomadesis, onychomalacia, paronychia.
- i) Includes cases reported within the clustered terms: pruritus, pruritus generalised, eyelid pruritus.
- j) Represents the incidence of patients who had a QTcF prolongation &gt;500msec.
- k) Represents the incidence of laboratory findings, not of reported adverse events.

<div style=\"page-break-after: always\"></div>

## Adverse events of special interest (AESIs)

## Adverse events by organ system or syndrome: key safety topics

AESI findings from this study are consistent with known data in terms of the frequency of occurrence, nature, severity, clinical course and outcome of the event.

Table 42: Summary of adverse events of special interest by grouped term and subgrouped term (safety analysis set)

|                                                           | Number (%) of patients   | Number (%) of patients   |
|-----------------------------------------------------------|--------------------------|--------------------------|
| Grouped term                                              | Osimertinib              | SoC                      |
| Subgrouped term                                           | (N=279)                  | (N=277)                  |
| Cardiac effects (QT)                                      | 29 (10.4)                | 13 (4.7)                 |
| Cardiac arrhythmia terms, non-specific (SMQ)              | 0                        | 1 (0.4)                  |
| ICH QT terms                                              | 1 (0.4)                  | 2 (0.7)                  |
| Torsade de pointes/QT prolongation                        | 28 (10.0)                | 11 (4.0)                 |
| Cardiac effects (cardiac failure)                         | 12 (4.3)                 | 6 (2.2)                  |
| Cardiac failure (SMQ)                                     | 12 (4.3)                 | 5 (1.8)                  |
| Cardiomyopathy (SMQ)                                      | 10 (3.6)                 | 6 (2.2)                  |
| Diarrhoea                                                 | 161 (57.7)               | 159 (57.4)               |
| Diarrhoea                                                 | 161 (57.7)               | 159 (57.4)               |
| Hepatic                                                   | 40 (14.3)                | 101 (36.5)               |
| Hepatic from Investigations (SOC)                         | 34 (12.2)                | 86 (31.0)                |
| Hepatobiliary disorders (SOC)                             | 7 (2.5)                  | 16 (5.8)                 |
| ILD and pneumonitis                                       | 11 (3.9)                 | 6 (2.2)                  |
| ILD grouped terms                                         | 11 (3.9)                 | 6 (2.2)                  |
| Nail effects                                              | 97 (34.8)                | 91 (32.9)                |
| General nail&nail bed conditions                          | 97 (34.8)                | 91 (32.9)                |
| Ocular effects                                            | 48 (17.2)                | 63 (22.7)                |
| Conjunctival disorders (SMQ)                              | 37 (13.3)                | 46 (16.6)                |
| Corneal disorders (SMQ)                                   | 1 (0.4)                  | 4 (1.4)                  |
| Keratitis                                                 | 1 (0.4)                  | 4 (1.4)                  |
| Lacrimal disorders (SMQ)                                  | 22 (7.9)                 | 22 (7.9)                 |
| Miscellaneous ocular terms                                | 9 (3.2)                  | 14 (5.1)                 |
| Periorbital & eyelid disorders (SMQ)                      | 6 (2.2)                  | 14 (5.1)                 |
| Renal                                                     | 36 (12.9)                | 27 (9.7)                 |
| Renal & urinary disorders (SOC)                           | 26 (9.3)                 | 24 (8.7)                 |
| Renal fromInvestigations SOC                              | 12 (14.3)                | 5 (1.8)                  |
| Skin effects                                              | 207 (74.2)               | 236 (85.2)               |
| Dry skin                                                  | 100 (35.8)               | 100 (36.1)               |
| Exfoliative rash                                          | 8 (2.9)                  | 4 (1.4)                  |
|                                                           | 48 (17.2)                | 46 (16.6)                |
| Rashes & Acnes                                            | 161 (57.7)               | 216 (78.0)               |
| Upper gastrointestinal tract inflammatory events          | 115 (41.2)               | 89 (32.1)                |
| Gastrointestinaltractinflammationofunspecifiedlocation    | 1 (0.4)                  | 2 (0.7)                  |
| Non-oral upper gastrointestinal tract inflammatory events | 35 (12.5)                | 33 (11.9)                |
| Oral inflammation                                         | 94 (33.7)                | 63 (22.7)                |

Included AEs with onset date on or after date of first dose up to and including 28 days following discontinuation ofrandomisedtreatmentorthedaybeforefirstadministrationofcrossovertreatment.

s = o a  = ai =s

DC01:12June2017

Source:Table 11.3.2.12.1.1

<div style=\"page-break-after: always\"></div>

## Interstitial lung disease

## Study FLAURA

ILD  (grouped  term)  was  reported  in  a  low  but  numerically  higher  proportion  of  patients  in  the osimertinib  arm  than  the  SoC  arm:  12/279  (4.3%)  patients  vs.  6/277  (2.2%)  patients.  The  overall event rate per 100 patient-years was similar between the 2 treatment arms: 3.14 in the osimertinib arm and 2.21 in the SoC arm.

In all 11 patients with ILD in the osimertinib arm, the outcome was reported as either resolved (7/11 [63.6%]) or resolving (4/11 [36.4%]) at the time of DCO1. ILD grouped terms were reported as SAEs in 6 (2.2%) patients in the osimertinib arm and 4 (1.4%) patients in the SoC arm.

The median time to onset of ILD grouped-term events (first occurrence per patient) was 106.0 days (range:  9-425)  in  the  11  patients  in  the  osimertinib  arm  and  83.5  days  (range:  11-253)  in  the  6 patients in the SoC arm.

Table 43: ILD grouped term adverse events in FLAURA, by preferred term and maximum CTCAE grade (Safety analysis set)

|                     | Number(%)ofpatients    | Number(%)ofpatients    | Number(%)ofpatients    | Number(%)ofpatients    | Number(%)ofpatients     | Number(%)ofpatients     | Number(%)ofpatients     | Number(%)ofpatients     |
|---------------------|------------------------|------------------------|------------------------|------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                     | Osimertinib80mg(N=279) | Osimertinib80mg(N=279) | Osimertinib80mg(N=279) | Osimertinib80mg(N=279) | Standard of Care(N=277) | Standard of Care(N=277) | Standard of Care(N=277) | Standard of Care(N=277) |
| Groupedterm         | DC01                   | DC01                   | 90DSU                  | 90DSU                  | DC01                    | DC01                    | 90DSU                   | 90DSU                   |
| MedDRApreferredterm | Any grade              | ≥Grade 3               | Any grade              | ≥Grade3                | Any grade               | ≥Grade3                 | Any grade               | ≥Grade 3                |
| ILD                 | 11 (3.9)               | 3 (1.1)                | 12 (4.3)               | 3 (1.1)                | 6 (2.2)                 | 4 (1.4)                 | 6 (2.2)                 | 4 (1.4)                 |
| ILD                 | 6 (2.2)                | 3 (1.1)                | 6 (2.2)                | 3 (1.1)                | 4 (1.4)                 | 3 (1.1)                 | 4 (1.4)                 | 3 (1.1)                 |
| Pneumonitis         | 5 (1.8)                | 0                      | 5 (1.8)                | 0                      | 2 (0.7)                 | 1 (0.4)                 | 2 (0.7)                 | 1 (0.4)                 |
| Lung disorder       | 0                      | 0                      | 1 (0.4)                | 0                      | 0                       | 0                       | 0                       | 0                       |

Number(%)ofpatientswithAEs ofspecialinterest,sortedonAESIgrouped term and descendingfrequencyforpreferred term.IncludesAEwithan onset dateonorafterthedateoffirstdoseanduptoandincluding28daysfollowingdiscontinuationofrandomisedtreatmentorthedaybeforefirst administration of crossover treatment. Specific AEs of interest may either be grouped MedDRA preferred terms or individual MedDRA preferred terms.

ILD=interstitiallung disease;MedDRA=Medical DictionaryforRegulatoryActivities version 20.0;SMQ=Standardised MedDRA query,CTCAE= CommonTerminologyCriteriaforAdverseEventsversion4.03;PT=preferred term

Datacut-offdate:DCO1=12June2017;90DSUDCO=25September2017

Source:seeTable19,Module2.7.4dated40ctober2017andseeTable11.3.2.12.10.1,AppendixA

## Pooled dataset

The ILD events reported in FLAURA were generally similar to those in the pooled population in terms of incidence  (11  [3.9%]  and  45  [3.9%],  respectively)  and  severity,  with  most  events  being  of  CTCAE grade 1 or grade 2 in each arm. There were 4 patients with CTCAE grade 5 AEs in AURA2/AURA1C and 1 patient with grade 5 ILD in AURA3. The incidence of ILD reported in Japanese patients in FLAURA (12.3%) was similar to that seen in previous studies (10.4%), with events remained primarily CTCAE grade 1 or grade 2 with evidence of reversibility.

<div style=\"page-break-after: always\"></div>

## Cardiac effects

## Study FLAURA

Cardiac effects (QT)

Table 44: Cardiac effects adverse events, by grouped term, MedDRA preferred term, and maximum CTCAE grade in FLAURA at Safety analysis set)

|                                               | Number (%) of patients    | Number (%) of patients    | Number (%) of patients    | Number (%) of patients    | Number (%) of patients     | Number (%) of patients     | Number (%) of patients     | Number (%) of patients     |
|-----------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                               | Osimertinib 80 mg (N=279) | Osimertinib 80 mg (N=279) | Osimertinib 80 mg (N=279) | Osimertinib 80 mg (N=279) | Standard of Care (N = 277) | Standard of Care (N = 277) | Standard of Care (N = 277) | Standard of Care (N = 277) |
| Grouped term Subgrouped term MedDRA preferred | DC01                      | DC01                      | 90 DSU                    | 90 DSU                    | DC01                       | DC01                       | 90 DSU                     | 90 DSU                     |
| term                                          | Any grade                 | ≥Grade 3                  | Any grade                 | ≥Grade3                   | Any grade                  | ≥Grade 3                   | Any grade                  | ≥Grade 3                   |
| Cardiac effects (QT)                          | 29 (10.4)                 | 6 (2.2)                   | 32 (11.5)                 | 6 (2.2)                   | 13 (4.7)                   | 3 (1.1)                    | 15 (5.4)                   | 4 (1.4)                    |
| Torsade de pointes/QT prolongation (SMQ)      | 28 (10.0)                 | 6 (2.2)                   | 28 (10.0)                 | 6 (2.2)                   | 11 (4.0)                   | 2 (0.7)                    | 12 (4.3)                   | 2 (0.7)                    |
| ECG QT prolonged                              | 28 (10.0)                 | 6 (2.2)                   | 28 (10.0)                 | 6 (2.2)                   | 11 (4.0)                   | 2 (0.7)                    | 12 (4.3)                   | 2 (0.7)                    |
| Arrhythmias (SMQ)                             | 0                         | 0                         | 0                         | 0                         | 1 (0.4)                    | 0                          | 1 (0.4)                    | 0                          |
| Heart rate irregular                          | 0                         | 0                         | 0                         | 0                         | 1 (0.4)                    | 0                          | 1 (0.4)                    | 0                          |
| ICH E14 terms                                 | 1 (0.4)                   | 0                         | 4 (1.4)                   | 0                         | 2 (0.7)                    | 1 (0.4)                    | 3 (1.1)                    | 2 (0.7)                    |
| Syncope                                       | 1 (0.4)                   | 0                         | 4 (1.4)                   | 0                         | 0                          | 0                          | 0                          | 0                          |
| Seizure                                       | 0                         | 0                         | 0                         | 0                         | 2 (0.7)                    | 1 (0.4)                    | 2 (0.7)                    | 1 (0.4)                    |
| Epilepsy                                      | 0                         | 0                         | 0                         | 0                         | 0                          | 0                          | 1 (0.4)                    | 1 (0.4)                    |

Includes AE with an onset date on or after the date of first dose and up to and including 28 days following discontinuation of randomised treatment or the day beforefirst administrationofcrossovertreatment.

Number (%) of patients with AEs of special interest, sorted on AESI grouped term and descending frequency for preferred term.

Specific AEs of interest may either be grouped MedDRA preferred terms or individual MedDRA preferred terms.

CTCAE = Common Terminology Criteria for Adverse Events version 4.03; MedDRA = Medical Dictionary for Regulatory Activities version 20.0; SMQ = Standardised MedDRA query.

Data cut-offdate:DCO1=12June2017;90DSUDCO=25September2017

Source: see Table 21, Module 2.7.4 dated 4 October 2017 and see Table 11.3.2.12.10.1, Appendix A

Dose interruptions for AEs of ECG QT prolonged were reported in 8 (2.9%) patients in the osimertinib arm  and  6  (2.2%)  patients  in  the  SoC  arm.  Dose  reductions  for  AEs  of  ECG  QT  prolonged  were reported in 5 (1.8%) patients in the osimertinib arm and 1 (0.4%) patient in the SoC arm.

<div style=\"page-break-after: always\"></div>

Table 45: QTcF intervals above pre-specified thresholds in FLAURA (Safety analysis set)

|                                                                                                    | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|----------------------------------------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                                                                                    | Osimertinib 80 mg (N=279)  | Osimertinib 80 mg (N=279)  | Standard of Care (N=277)   | Standard of Care (N=277)   |
|                                                                                                    | DC01                       | 90 DSU                     | DC01                       | 90 DSU                     |
| QTcF value above 450/480/500 msec at any time during treatment                                     |                            |                            |                            |                            |
| >450 msec                                                                                          | 98 (35.1)                  | 99 (35.5)                  | 47 (17.0)                  | 47 (17.0)                  |
| >480 msec                                                                                          | 17 (6.1)                   | 17 (6.1)                   | 5 (1.8)                    | 5 (1.8)                    |
| >500 msec                                                                                          | 3 (1.1)                    | 3 (1.1)                    | 2 (0.7)                    | 2 (0.7)                    |
| QTcF increase b by more than 30/60/90 msec at any time during treatment                            |                            |                            |                            |                            |
| >30 msec                                                                                           | 116 (41.6)                 | 116 (41.6)                 | 66 (23.8)                  | 67 (24.2)                  |
| >60 msec                                                                                           | 14 (5.0)                   | 14 (5.0)                   | 6 (2.2)                    | 6 (2.2)                    |
| >90 msec                                                                                           | 1 (0.4)                    | 1 (0.4)                    | 0                          | 0                          |
| QTcFvalue above450/500msec andQTcF increase b by more than 30/60 msec at any time during treatment |                            |                            |                            |                            |
| Value >450 (msec) and increase >30 (msec) b                                                        | 62 (22.2)                  | 62 (22.2)                  | 31 (11.2)                  | 31 (11.2)                  |
| Value >500 (msec) and increase >60 (msec) b                                                        | 1 (0.4)                    | 1 (0.4)                    | 1 (0.4)                    | 1 (0.4)                    |
| QTcF decrease b by more than 30/60/90 msec at any time during treatment                            |                            |                            |                            |                            |
| >30 msec                                                                                           | 11 (3.9)                   | 13 (4.7)                   | 27 (9.7)                   | 28 (10.1)                  |
| >60 msec                                                                                           | 0                          | 0                          | 1 (0.4)                    | 1 (0.4)                    |
| >90 msec                                                                                           | 0                          | 0                          | 0                          | 0                          |

## Cardiac effects (cardiac failure)

Table 46: Cardiac effects adverse events, by grouped term, MedDRA preferred term, and maximum CTCAE grade in FLAURA at Safety analysis set)

|                                   | Number (%) of patients    | Number (%) of patients    | Number (%) of patients    | Number (%) of patients    | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|-----------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                   | Osimertinib 80 mg (N=279) | Osimertinib 80 mg (N=279) | Osimertinib 80 mg (N=279) | Osimertinib 80 mg (N=279) | Standard of Care (N=277) | Standard of Care (N=277) | Standard of Care (N=277) | Standard of Care (N=277) |
| Grouped term Subgrouped term      | DC01                      | DC01                      | 90 DSU                    | 90 DSU                    | DC01                     | DC01                     | 90 DSU                   | 90 DSU                   |
| MedDRA preferred term             | Any grade                 | ≥Grade 3                  | Any grade                 | ≥Grade 3                  | Any grade                | ≥Grade 3                 | Any grade                | ≥Grade 3                 |
| Cardiac effects (cardiac failure) | 12 (4.3)                  | 3 (1.1)                   | 13 (4.7)                  | 4 (1.4)                   | 6 (2.2)                  | 1 (0.4)                  | 6 (2.2)                  | 1 (0.4)                  |
| Cardiac failure (SMQ)             | 12 (4.3)                  | 3 (1.1)                   | 13 (4.7)                  | 4 (1.4)                   | 5 (1.8)                  | 1 (0.4)                  | 5 (1.8)                  | 1 (0.4)                  |
| Ejection fraction decreased       | 10 (3.6)                  | 2 (0.7)                   | 11 (3.9)                  | 3 (1.1)                   | 5 (1.8)                  | 1 (0.4)                  | 5 (1.8)                  | 1 (0.4)                  |
| Cardiac failure                   | 1 (0.4)                   | 0                         | 1 (0.1)                   | 0                         | 0                        | 0                        | 0                        | 0                        |
| Cardiac failure chronic           | 1 (0.4)                   | 1 (0.4)                   | 1 (0.4)                   | 1 (0.4)                   | 0                        | 0                        | 0                        | 0                        |
| Cardiomyopathy (SMQ)              | 10 (3.6)                  | 2 (0.7)                   | 11 (3.9)                  | 3 (1.1)                   | 6 (2.2)                  | 1 (0.4)                  | 6 (2.2)                  | 1 (0.4)                  |
| Ejection fraction decreased       | 10 (3.6)                  | 2 (0.7)                   | 11 (3.9)                  | 3 (1.1)                   | 5 (1.8)                  | 1 (0.4)                  | 5 (1.8)                  | 1 (0.4)                  |
| Metabolic cardiomyopathy          | 0                         | 0                         | 0                         | 0                         | 1 (0.4)                  | 0                        | 1 (0.4)                  | 0                        |

Includes AE with an onset date on or after the date of first dose and up to and including 28days following discontinuation of randomised treatment or the day

Number(%) ofpatients withAEsof special interest,sortedon AESI grouped term and descending frequency forpreferred term in the osimertinib arm.

beforefirstadministrationofcrossovertreatment.

Specific AEs of interest may either be grouped MedDRA preferred terms or individual MedDRA preferred terms.

MedDRA = Medical Dictionary for Regulatory Activities version 20.0; SMQ = Standardised MedDRA query; CTCAE = Common Terminology Criteria for AdverseEventsversion4.03

Datacut-off date:DCO1=12June2017;90DSUDCO=25September2017

Source: see Table 21, Module 2.7.4 dated 4 October 2017 and see Table 11.3.2.12.10.1,Appendix A

A total of 257 (92.1%) patients in the osimertinib arm vs. 253 (91.3%) patients in the SoC arm had both a baseline and a post-baseline assessment. The median maximum change from baseline in LVEF was -3.0% in both treatment arms: in the osimertinib arm at Week 48 and Week 72 (range: -3% to 1%) and in the SoC arm at Week 96 (range: -3% to 0%).

<div style=\"page-break-after: always\"></div>

Among all patients who had baseline and post-baseline LVEF assessment (regardless of whether the assessments were within the ±7-day visit window), 8/257 (3.1%) patients in the osimertinib arm and 3/253 (1.2%) patients in the SoC arm had a LVEF decrease from baseline of ≥10 pp, to an LVEF value of &lt;50%. An LVEF decrease of ≥15 pp to an absolute value of ≥50% was seen in 26/257 (10.1%) patients in the osimertinib arm vs. 18/253 (7.1%) patients in the SoC arm.

Patients treated in FLAURA who experienced asymptomatic decreases in LVEF while taking osimertinib recovered  from  these  decreases  whilst  on  full  dose  of  osimertinib,  without  occurrence  of  cardiac symptoms.

The  median  time  to  onset  for  AEs  in  the  Cardiac  effects  (cardiac  failure)  category  was  166.0  days (range: 18-504) in the osimertinib arm and 109.5 days (range: 84-750) in the SoC arm.

## Cardiac effects outside the cardiac failure and cardiomyopathy SMQs

Adverse  events  in  the  Cardiac  Disorders  MedDRA  SOC  were  reported  for  24  (8.6%)  patients  in  the osimertinib  arm  and  19  (6.9%)  patients  in  the  SoC  arm  at  DCO1.  Most  of  the  AEs  in  the  Cardiac Disorders  SOC  at  the  90  DSU  DCO  were  either  CTCAE  grade  1  (14/26  [53.8%]  osimertinib;  15/21 [71.4%] SoC) or CTCAE grade 2 (7/26 [26.9%] osimertinib and 2/21 [9.5%] SoC). CTCAE ≥grade 3 cardiac AEs were reported in 4 (1.4%) patients in the osimertinib arm and 4 (0.4%) patients in the SoC arm. In the osimertinib arm, 2 patients had CTCAE grade 3 AEs (acute myocardial infarction, atrial fibrillation); 1 patient had a CTCAE grade 4 AE (cardiac arrest) and 1 patient had a CTCAE grade 5 AE (myocardial  infarction).  In  the  SoC  arm,  4  patients  had  CTCAE  grade  3  AEs  (angina  pectoris,  left bundle branch block, pericardial effusion, and ventricular extrasystoles).

## Pooled dataset

There was a similar incidence of AEs of ECG QT prolongation in FLAURA than in the pooled population (28/279 [10.0%] vs. 70/142 [6.1%], respectively) and LVEF decreases (10/279 [3.6%] vs. 22/1142 [1.9%]).  In  both  populations,  the  events  were  primarily  CTCAE  grade  1  or  grade  2.  One  (&lt;0.1%) patient had CTCAE grade 5 cardiac failure reported in AURA2/AURA1C. Similar proportions of patients had a QTcF value ≥500 msec (10 (0.9%) pooled population and 3 (1.1%) FLAURA), QTcF increase &gt; 60 msec (41 [3.6%] pooled population and 14 [5%] FLAURA) or an LVEF value with a ≥10 pp change from  baseline  and  an  absolute  value  &lt;50%  (35  (3.9%)  pooled  population  vs.  8  (3.1%)  FLAURA). Therefore, the differences between the 2 populations are not considered to constitute a change in this safety topic when FLAURA results are included in the pooled population.

## Diarrhoea

## Study FLAURA

Diarrhoea was the most commonly reported AESI in FLAURA. The incidence of diarrhoea was similar between the 2 treatment arms: 161 (57.7%) patients in the osimertinib arm and 161 (58.1%) patients in the SoC arm.

<div style=\"page-break-after: always\"></div>

Table 47: Diarrhoea adverse events by treatment arm and CTCAE grade (safety analysis set)

| Event                     | Any grade                 | Grade 1                   | Grade 2                   | Grade 3                   | Grade 4                   | Grade 5                   |
|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Osimertinib arm (N = 279) | Osimertinib arm (N = 279) | Osimertinib arm (N = 279) | Osimertinib arm (N = 279) | Osimertinib arm (N = 279) | Osimertinib arm (N = 279) | Osimertinib arm (N = 279) |
| Diairhoea                 | 161 (57.7)                | 120 (43.0)                | 35 (12.5)                 | 6 (2.2)                   | 0                         | 0                         |
| SoC arm (N = 277)         | SoC arm (N = 277)         | SoC arm (N = 277)         | SoC arm (N = 277)         | SoC arm (N = 277)         | SoC arm (N = 277)         | SoC arm (N = 277)         |
| Diarrhoea?                | 159 (57.4)                | 116 (41.9)                | 35 (12.6)                 | 6 (2.2)                   | 0                         | 1 (0.4)                   |

Includes an AE ofunknown severity (CTCAE grade).

Included AE with an onset date on or after the date of first dose and up to and including 28 days following discontinuationofrandomisedtreatmentorthedaybeforefirstadministrationofcross-overtreatment.

MedDRA = Medical Dictionary for Regulatory Activities version 20.0; SMQ = standardised MedDRA query;

CTCAE = Common Terminology Criteria for Adverse Events version 4.03

DC01:12Jume2017

Diarrhoea led to dose interruption in 7 (2.5%) patients in the osimertinib arm and 4 (1.4%) patients in the SoC arm. No AEs of diarrhoea led to dose reduction or treatment discontinuation in the osimertinib arm. In the SoC arm, 1 (0.4%) patient had a dose reduction due to an AE of diarrhoea, and 5 (1.8%) patients discontinued SoC dosing due to diarrhoea

The median time to onset of first event of diarrhoea was similar between the 2 treatment arms: 17 days (range: 1 to 536) in the osimertinib arm vs. 19 days (range: 1 to 631 days) in the SoC arm.

Events of diarrhoea were of same duration between the 2 treatment arms (median of 44.0 days).

On an episode level, 233 events of diarrhoea were reported among the 161 patients who experienced diarrhoea  in  the  osimertinib  arm  and  236  events  were  reported  among  the  159  patients  who experienced  diarrhoea  in  the  SoC  arm  at  DCO1.  After  3  months,  the  diarrhoea  event  rate  in  both treatment arms remained relatively constant (&lt;5%). The overall event rate per 100 patient years was lower in the osimertinib arm compared to the SoC arm: 46.0 and 58.5, respectively.

The majority of episodes of diarrhoea resolved without treatment.

## Pooled dataset

Incidence was higher in FLAURA (161 [57.7%]) than in the pooled population (555 [48.6%]). Nearly all events in the 2 populations were either CTCAE grade 1 or grade 2: 155/161 (96.3%) patients with diarrhoea in FLAURA and 541/555 (97.5%) patients with the event in the pooled population. CTCAE grade 3-4 was reported in 6 patients (2.2%) in the osimertinib arm in FLAURA and 14 patients (1.2%) in the pooled population.

Diarrhoea  led  to  dose  reductions  in  no  patients  in  FLAURA  and  0.2%  of  patients  in  the  pooled population; to dose interruption in 2.5% and 1.4% of patients, respectively; and to discontinuation in no patients and 0.1% of patients, respectively. No events of haemorrhagic diarrhoea or GI perforation were reported in the osimertinib arm.

## Skin effects

## Study FLAURA

The AESI of Skin effects was evaluated by review of 4 subgroups: Rashes &amp; acnes, Pruritus, Dry skin, and Exfoliative rash.

No  severe  bullous,  severe  blistering  or  severe  exfoliative  skin  events,  or  severe  hypersensitivity reactions, including Stevens-Johnson Syndrome, were reported in either treatment arm. One CTCAE grade 4 SAE of toxic epidermal necrolysis was reported in the SoC arm.

<div style=\"page-break-after: always\"></div>

Table 48: Skin effects grouped term adverse events in FLAURA, by subgrouped term and maximum CTCAE grade (safety analysis set)

|                            | Number(%)ofpatients      | Number(%)ofpatients      | Number(%)ofpatients      | Number(%)ofpatients      | Number(%)ofpatients        | Number(%)ofpatients        | Number(%)ofpatients        | Number(%)ofpatients        |
|----------------------------|--------------------------|--------------------------|--------------------------|--------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                            | Osimertinib80 mg (N=279) | Osimertinib80 mg (N=279) | Osimertinib80 mg (N=279) | Osimertinib80 mg (N=279) | Standard of Care (N = 277) | Standard of Care (N = 277) | Standard of Care (N = 277) | Standard of Care (N = 277) |
|                            | DC01                     | DC01                     | 90DSU                    | 90DSU                    | DC01                       | DC01                       | 90DSU                      | 90DSU                      |
| Groupedterm Subgroupedterm | Any grade                | ≥Grade 3                 | Any grade                | ≥Grade 3                 | Any grade                  | ≥Grade 3                   | Any grade                  | ≥Grade 3                   |
| Skin effects               | 207 (74.2)               | 4 (1.4)                  | 207 (74.2)               | 4 (1.4)                  | 236 (85.2)                 | 21 (7.6)                   | 236 (85.2)                 | 21 (7.6)                   |
| Rashes & acnes             | 161 (57.7)               | 3 (1.1)                  | 162 (58.1)               | 3 (1.1)                  | 216 (78.0)                 | 19 (6.9)                   | 217 (78.3)                 | 19 (6.9)                   |
| Dry skin                   | 100 (35.8)               | 1 (0.4)                  | 101 (36.2)               | 1 (0.4)                  | 100 (36.1)                 | 3 (1.1)                    | 100 (36.1)                 | 3 (1.1)                    |
| Pruritus                   | 48 (17.2)                | 1 (0.4)                  | 48 (17.2)                | 1 (0.4)                  | 46 (16.6)                  | 0                          | 46 (16.6)                  | 0                          |
| Exfoliative rash           | 8 (2.9)                  | 0                        | 8 (2.9)                  | 0                        | 4 (1.4)                    | 0                          | 4 (1.4)                    | 0                          |

Number (%) of patients with AEs of special interest, sorted on AESI grouped term and descending frequency.

IncludesAEwithanonsetdateonorafterthedateoffirstdoseanduptoandincluding28daysfollowingdiscontinuationofrandomisedtreatmentortheday beforefirstadministrationofcrossovertreatment.

Specific AEs of interest may either be grouped MedDRA preferred terms or individual MedDRA preferred terms.

MedDRA = Medical Dictionary for Regulatory Activities version 20.0; CTCAE = Common Terminology Criteria for Adverse Events version 4.03

Datacut-off date:DCO1=12June2017;90DSUDCO=25September2017

Source: see Table 28, Module 2.7.4 dated 4 0ctober 2017 and see Table 11.3.2.12.10.1, Appendix A

## Rashes and acnes

The  most  commonly  reported  PTs  were  dermatitis  acneiform  and  rash  maculo-papular.  The  median time to onset of first event in the Rashes and acnes subgroup was 18.0 days (range: 1 to 709 days) in the osimertinib arm vs. 14.5 days (range: 1-379 days) in the SoC arm.

A majority of the episodes of rash required medication (59.6% in the osimertinib arm and 79.5% in the SoC arm). None of the untreated AEs of rash resulted in dose modification. In the osimertinib arm 173 (67.8%) of the AEs of rash resolved and 82 (32.2%) were ongoing at DCO1.

## Dry skin

The  only  PT  in  this  subgroup  reported  by  at  least  10%  of  patients  was  dry  skin  (osimertinib:  88 [31.5%] patients; SoC: 90 [32.5%] patients.

The median time to onset of first event in the Dry skin subgroup was 33.5 days (range: 1 to 667 days) in the osimertinib arm vs. 26.0 days (range: 1 to 492 days) in the SoC arm.

## Pruritus

The median time to onset of first event of Pruritus (grouped term) AEs was lower in the osimertinib arm than the SoC arm: 16.5 days (range: 1 to 616 days) vs. 48 days (range: 5 to 676 days).

One (0.4%) patient in the osimertinib arm and no patient in the SoC arm had an AE in the Pruritus subgrouped term reported as an SAE. Events led to discontinuation of treatment in 1 (0.4%) patient in the osimertinib arm and no patients in the SoC arm.

## Pooled dataset

The incidence of AEs in the Skin Effects (grouped term) was higher in the osimertinib arm of FLAURA (207 [74.2%]) than in the pooled population (746 [65.3%]). The incidence of Rashes &amp; acnes was higher in the osimertinib arm in FLAURA (57.7%) than in the pooled population (46.8%) whereas the incidence  of  Dry  skin  was  similar  between  the  osimertinib  arm  in  FLAURA  (35.8%)  and  the  pooled population (32.6%). The other two subgroups were similar among both arms.

In the majority of patients Skin Effects AEs were CTCAE grade 1: 168 (60.2%) patients in FLAURA and 605 (53.0%) in the pooled population and grade 2: 35 patients (12.5%) in FLAURA and 130 (11.4%) in the pooled population. CTCAE grade 3 were reported in 4 patients (1.4%) in the osimertinib arm in FLAURA and 11 patients (1.0%) in the pooled population. The CTCAE grade 3 events in the pooled population consisted on erythema (3 patients [0.3%]), rash maculo-papular (3 patients [0.3%]), rash erythematous (2 patients [0.2%]), rash macular (2 patients [0.1%]) and dry skin (1 [0.4%]).

<div style=\"page-break-after: always\"></div>

## Upper gastrointestinal tract inflammatory events

## Study FLAURA

The Upper GI Tract Inflammatory Events grouped term included 3 subgroup terms: Oral inflammation, Non-oral upper GI tract inflammatory events, and GI tract inflammation of unspecified location.

The median time to onset of first event of Upper GI Tract Inflammatory Events (grouped term) was similar in the osimertinib arm (26.0 days [range: 2 to 603]) and the SoC arm (20.0 days [range: 1 to540 days]).

The CTCAE grade 4 AE of stomatitis in the osimertinib arm was classified as an SAE; it was considered to  be  unrelated  to  osimertinib  by  the  Investigator.  None  of  the  other  AEs  in  the  Upper  Gi  tract inflammatory events category were SAEs. In the SoC arm, 2 AEs of mouth ulceration were classified as SAEs.

Table 49: Upper GI tract inflammatory events grouped term adverse events in FLAURA, by subgroup and maximum CTCAE grade (Safety analysis set)

|                                               | Number (%) of patients    | Number (%) of patients    | Number (%) of patients    | Number (%) of patients    | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|-----------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                               | Osimertinib 80 mg (N=279) | Osimertinib 80 mg (N=279) | Osimertinib 80 mg (N=279) | Osimertinib 80 mg (N=279) | Standard of Care(N=277)  | Standard of Care(N=277)  | Standard of Care(N=277)  | Standard of Care(N=277)  |
| Grouped term Subgrouped term                  | DC01                      | DC01                      | 90 DSU                    | 90 DSU                    | DC01                     | DC01                     | 90 DSU                   | 90 DSU                   |
| MedDRA PT                                     | Any grade                 | ≥Grade 3                  | Any grade                 | ≥Grade 3                  | Any grade                | ≥Grade 3                 | Any grade                | ≥Grade3                  |
| Upper GI tract inflammatory events            | 115 (41.2)                | 3 (1.1)                   | 115 (41.2)                | 3 (1.1)                   | 89 (32.1)                | 3 (1.1)                  | 90 (32.5)                | 3 (1.1)                  |
| Oralinflammation                              | 94 (33.7)                 | 2 (0.7)                   | 94 (33.7)                 | 2 (0.7)                   | 63 (22.7)                | 3 (1.1)                  | 64 (23.1)                | 3 (1.1)                  |
| Stomatitis                                    | 80 (28.7)                 | 2 (0.7)                   | 80 (28.7)                 | 2 (0.7)                   | 56 (20.2)                | 1 (0.4)                  | 56 (20.2)                | 1 (0.4)                  |
| Mouth ulceration                              | 9 (3.2)                   | 0                         | 9 (3.2)                   | 0                         | 5 (1.8)                  | 2 (0.7)                  | 6 (2.2)                  | 2 (0.7)                  |
| Aphthous ulcer                                | 4 (1.4)                   | 0                         | 4 (1.4)                   | 0                         | 2 (0.7)                  | 0                        | 2 (0.7)                  | 0                        |
| Glossitis                                     | 1 (0.4)                   | 0                         | 1 (0.4)                   | 0                         | 0                        | 0                        | 0                        | 0                        |
| Oral pain                                     | 1 (0.4)                   | 0                         | 1 (0.4)                   | 0                         | 0                        | 0                        | 0                        | 0                        |
| Atrophic glossitis                            | 0                         | 0                         | 0                         | 0                         | 1 (0.4)                  | 0                        | 1 (0.4)                  | 0                        |
| Non-oral upper GI tract inflammatory events   | 35 (12.5)                 | 1 (0.4)                   | 38 (13.6)                 | 1 (0.4)                   | 33 (11.9)                | 0                        | 34 (12.3)                | 0                        |
| Epistaxis                                     | 17 (6.1)                  | 0                         | 18 (6.5)                  | 0                         | 14 (5.1)                 | 0                        | 14 (5.1)                 | 0                        |
| Oropharyngeal pain                            | 12 (4.3)                  | 0                         | 13 (4.7)                  | 0                         | 9 (3.2)                  | 0                        | 9 (3.2)                  | 0                        |
| Dysphagia                                     | 4 (1.4)                   | 1 (0.4)                   | 4 (1.4)                   | 1 (0.4)                   | 4 (1.4)                  | 0                        | 4 (1.4)                  | 0                        |
| Gastritis                                     | 2 (0.7)                   | 0                         | 2 (0.7)                   | 0                         | 3 (1.1)                  | 0                        | 4 (1.4)                  | 0                        |
| Gastric ulcer                                 | 1 (0.4)                   | 0                         | 2 (0.4)                   | 0                         | 0                        | 0                        | 0                        | 0                        |
| Oesophagitis                                  | 0                         | 0                         | 0                         | 0                         | 3 (1.1)                  | 0                        | 3 (1.1)                  | 0                        |
| Odynophagia                                   | 0                         | 0                         | 0                         | 0                         | 2 (0.7)                  | 0                        | 2 (0.7)                  | 0                        |
| GI tract inflammation of unspecified location | 1 (0.4)                   | 0                         | 1 (0.4)                   |                           | 2 (0.7)                  | 0                        | 2 (0.7)                  | 0                        |

Number (%) of patients

|                              | Osimertinib 80 mg (N=279)   | Osimertinib 80 mg (N=279)   | Osimertinib 80 mg (N=279)   | Osimertinib 80 mg (N=279)   | Standard of Care (N = 277)   | Standard of Care (N = 277)   | Standard of Care (N = 277)   | Standard of Care (N = 277)   |
|------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
| Grouped term Subgrouped term | DC01                        | DC01                        | 90DSU                       | 90DSU                       | DC01                         | DC01                         | 90DSU                        | 90DSU                        |
| MedDRA PT                    | Any grade                   | ≥Grade 3                    | Any grade                   | ≥Grade3                     | Any grade                    | ≥Grade 3                     | Any grade                    | ≥Grade 3                     |
| Mucosal dryness              | 1 (0.4)                     | 0                           | 1 (0.4)                     | 0                           | 1 (0.4)                      | 0                            | 1 (0.4)                      | 0                            |
| Mucosalinflammation          | 0                           | 0                           | 0                           | 0                           | 1 (0.4)                      | 0                            | 1 (0.4)                      | 0                            |

Number(%)of patientswithAEs of specialinterest,sortedonAESIgrouped term anddescendingfrequencyin the osimertinib arm.

SpecificAEsofinterestmayeitherbegroupedMedDRApreferred termsorindividual MedDRApreferredterms.

Includes AE with an onset date on or after the date of first dose and up to and including 28 days following discontinuation of randomised treatment or the day before first administration of crossover treatment.

MedDRA =MedicalDictionaryforRegulatoryActivitiesversion 20.0;CTCAE=CommonTerminology CriteriaforAdverseEvents version 4.03

Datacut-offdate:DCO1=12June 2017;90DSUDCO=25September2017

Source: seeTable 33,Table 34,and Table 35,Module 2.7.4 dated4 October 2017 and see Table 11.3.2.12.10.1,Appendix A

The  median  time  to  onset  of  first  event  of  Oral  inflammation  events  (grouped  term)  was similar between the 2 treatment arms: 22.0 days (range: 2 to 595 days) and 16.0 days (range: 1  to  383 days).

One patient in the osimertinib arm discontinued treatment due to oral pain; no patient in the SoC arm discontinued due to an AE in this grouped term.

<div style=\"page-break-after: always\"></div>

The median time to onset of first event of Non-oral upper GI inflammatory events (grouped term) was higher in the osimertinib arm (133 days [range: 6 to 603]) than in the SoC arm (66.0 days [range: 1 to 540 days]).

## Pooled dataset

AEs in the grouped term of Upper GI inflammatory events were reported in 115 patients (41.2%) in the osimertinib arm in FLAURA and 381 patients (33.4%) in the pooled population. The incidence of oral  inflammation  was  higher  in  the  osimertinib  arm  in  FLAURA  than  in  the  pooled  population  (94 [33.7%] vs. 277 [24.3%]). In both populations, the incidence of Oral inflammation events was driven primarily by the PT of stomatitis, which was reported in 80 (28.7%) of patients in the osimertinib arm in FLAURA and 229 (20.1%) of patients in the overall pooled population. However, incidence of CTCAE ≥ 3 was similar in both treatment arms (0.2% pooled population vs. 0,7% FLAURA).

AEs reported within the other subgroups were: Non-oral upper GI tract inflammatory events (12.5% FLAURA vs. 14.0% pooled population) and GI Tract Inflammation Of Unspecified Location (0.4% vs. 1.1%).

## Nail effects

## Study FLAURA

Adverse  events  in  the  Nail  effects  grouped  term  were  reported  in  100  (35.8%)  patients  in  the osimertinib arm and 93 (33.6%) patients in the SoC arm, with a lower event rate per 100 patientyears in the osimertinib arm than in the SoC arm: 27.7 and 33.5, respectively.

The vast majority of Nail effects AEs were either CTCAE grade 1 (osimertinib: 52 [18.6%] patients; SoC: 55 [19.9%] patients) or CTCAE grade 2 (osimertinib: 44 [15.8%]; SoC: 34 [12.3%]). CTCAE grade  3  events  in  the  Nail  effects  grouped  term  were  reported  in  only  1  (0.4%)  patient  in  the osimertinib arm and 2 (0.7%) patients in the SoC arm. There was no AE greater than CTCAE grade 3 in severity in either treatment arm. No event was reported as an SAE in either treatment arm. One (0.4%) patient in the osimertinib arm discontinued treatment due to an AE of paronychia; no patient in the SoC arm discontinued due to an AE in this grouped term.

The median time to onset of first event of Nail effects (grouped term) was similar in the osimertinib arm (104.0 days [range: 7 to 632]) and the SoC arm (120.0 days [range: 10 to 588 days]).

## Pooled dataset

The  incidence  of  Nail  effects  was  similar  between  the  osimertinib  arm  in  FLAURA  (34.8%)  and  the pooled population (31.3%), with the majority of events being CTCAE grade 1 or grade 2 in each arm.

## Ocular effects

## Study FLAURA

The Ocular effects grouped term was evaluated by review of 4 narrow SMQs (Conjunctival disorders, Corneal  disorders,  Lacrimal  disorders,  and  Periorbital  &amp;  eyelid  disorders)  and  the  grouped  terms  of Keratitis and Miscellanous ocular terms.

Adverse events in the Ocular effects grouped term were reported in fewer patients in the osimertinib arm  than  the  SoC  arm:  48/279  (17.2%)  patients  and  64/277  (23.1%)  patients,  respectively.  The event rate per 100 patient-years was lower in the osimertinib arm than in the SoC arm: 13.7 and 23.2 respectively.

There was 1/279 (0.4%) patient in the osimertinib arm that reported grade 1 AE of keratitis grouped term (corneal erosion PT) and 4/277 (1.4%) patients in the SoC arm reported one grade 1 (corneal erosion PT) and three grade 2 AEs of keratitis.

<div style=\"page-break-after: always\"></div>

The severity of the events was similar to those of the SoC arm. In most patients, the events were either  CTCAE  grade  1  (14.7%  osimertinib  vs.  17.3%  SoC)  or  CTCAE  grade  2  (2.5% osimertinib  vs. 5.1% SoC).  CTCAE  grade  3  events  in  the  Ocular  effects  grouped  term  were  similar  between  the  2 treatment  arms:  0  patients  in  the  osimertinib  arm  and  1/277  (0.4%)  patient  in  the  SoC  arm.  No CTCAE grade 4 or grade 5 events were reported in either treatment arm.

The  median  time  to  onset  of  first  event  of  Ocular  effects  AEs  (grouped  term)  was  lower  in  the osimertinib  arm  (48.0  days  [range:  1  to  681])  than  in  the  SoC  arm  (103.0  days  [range:  7  to  585 days]).

No patient in either treatment had an AE in this grouped term that was reported as an SAE or led to discontinuation of treatment.

Within  the  MedDRA  SOC  of  Eye  Disorders,  at  DCO1  AEs  were  reported  in  a  similar  proportion  of patients  in  the  osimertinib  arm  (45  [16.1%])  than  in  the  SoC  arm  (55  [19.9%]),  with  the  most common PT being dry eye (21 [7.5%] osimertinib vs. 18 [6.5%] SoC) and conjunctivitis (14 [5.0%] osimertinib  vs.  20  [7.2%]  SoC).  Except  for  2  (0.7%)  patients  in  the  osimertinib  arm  with  a  CTCAE grade  3  cataract  and  1  (0.4%)  patients  each  in  the  SoC  arm  with  CTCAE  grade  3  blepharitis  and vitreous detachment, no events of CTCAE ≥grade 3, no SAEs, and no treatment discontinuations or dose reductions due to AEs in the Eye Disorders SOC were reported in either treatment arm. Dose interruptions  due  to  Eye  disorders  AEs  were  reported  in  1  (0.4%)  patient  with  cataract  in  the osimertinib arm and 2 (0.7%) patients (1 with blepharitis and 1 with vitreous detachment) in the SoC arm.

## Pooled dataset

The incidence of Ocular effects grouped term was 48 (17.2%) in the osimertinib arm in FLAURA and 201 (17.6%) in the pooled population. The majority of events were CTCAE grade 1 (14.7% FLAURA vs. 14.0% pooled population) or grade 2 (2.5% FLAURA vs. 3.5% pooled population). One patient (0.1%) in  the  pooled  population  had  a  CTCAE  grade  3  adverse  event  (2  patients  in  osimertinib  arm  in FLAURA).

## Hepatobiliary

## Study FLAURA

Overall, hepatic-related AEs (in the Hepatobiliary disorders SOC or Investigations SOC) were reported in  a  lower  proportion  of  patients  in  the  osimertinib  arm  than  the  SoC  arm:  41  (14.7%)  vs  101 (36.5%).

Table 16. Hepatic grouped term adverse events in at least 2 patients in either treatment arm in FLAURA, by subgrouped term, preferred term and maximum CTCAE grade (Safety analysis set)

<div style=\"page-break-after: always\"></div>

|                                       | Number (%)ofpatientsa     | Number (%)ofpatientsa     | Number (%)ofpatientsa     | Number (%)ofpatientsa     | Number (%)ofpatientsa      | Number (%)ofpatientsa      | Number (%)ofpatientsa      | Number (%)ofpatientsa      |
|---------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                       | Osimertinib 80 mg (N=279) | Osimertinib 80 mg (N=279) | Osimertinib 80 mg (N=279) | Osimertinib 80 mg (N=279) | Standard of Care (N = 277) | Standard of Care (N = 277) | Standard of Care (N = 277) | Standard of Care (N = 277) |
| Grouped term                          | DC01                      | DC01                      | 90DSU                     | 90DSU                     | DC01                       | DC01                       | 90 DSU                     | 90 DSU                     |
| Subgrouped term MedDRA PT             | Any grade                 | ≥Grade 3                  | Any grade                 | ≥Grade 3                  | Any grade                  | ≥Grade 3                   | Any grade                  | ≥Grade 3                   |
| Hepatic                               | 40 (14.3)                 | 6 (2.2)                   | 41 (14.7)                 | 6 (2.2)                   | 101 (36.5)                 | 32 (11.6)                  | 101 (36.5)                 | 32 (11.6)                  |
| Hepatobiliary disorders SOC           | 7 (2.5)                   | 0                         | 6 (2.2)a                  | 0                         | 16 (5.8)                   | 7 (2.5)                    | 16 (5.8)                   | 7 (2.5)                    |
| Hepaticfunction abnormal              | 2 (0.7)                   | 0                         | 2 (0.7)                   | 0                         | 7 (2.5)                    | 3 (1.1)                    | 7 (2.5)                    | 3 (1.1)                    |
| Hyperbilirubinaemia                   | 2 (0.7)                   | 0                         | 1 (0.4)                   | 0                         | 0                          | 0                          | 0                          | 0                          |
| Drug-induced liver injury             | 0                         | 0                         | 0                         | 0                         | 5 (1.8)                    | 3 (1.1)                    | 5 (1.8)                    | 3 (1.1)                    |
| Hepatotoxicity                        | 0                         | 0                         | 0                         | 0                         | 2 (0.7)                    | 0                          | 2 (0.7)                    | 0                          |
| Hepatic eventsfrom Investigations SOC | 34 (12.2)                 | 6 (2.2)                   | 35 (12.5)                 | 6 (2.2)                   | 86 (31.0)                  | 26 (9.4)                   | 86 (31.0)                  | 26 (9.4)                   |
| AST increased                         | 26(9.3)                   | 2 (0.7)                   | 26 (9.3)                  | 2 (0.7)                   | 68 (24.5)                  | 12 (4.3)                   | 68 (24.5)                  | 12 (4.3)                   |
| ALTincreased                          | 18 (6.5)                  | 1 (0.4)                   | 18 (6.5)                  | 1 (0.4)                   | 75 (27.1)                  | 25 (9.0)                   | 75 (27.1)                  | 25 (9.0)                   |
| GGT increased                         | 10 (3.6)                  | 4 (1.4)                   | 10 (3.6)                  | 4 (1.4)                   | 2(0.7)                     | 0                          | 2 (0.7)                    | 0                          |
| Blood bilirubin increased             | 6 (2.2)                   | 0                         | 7 (2.5)                   | 0                         | 12 (4.3)                   | 1 (0.4)                    | 12 (4.3)                   | 1 (0.4)                    |
| Transaminasesincreased                | 1 (0.4)                   | 1 (0.4)                   | 1 (0.4)                   | 1 (0.4)                   | 3 (1.1)                    | 0                          | 3 (1.1)                    | 0                          |

?

Anevent ofhyperbilirubinaemia(E2005002)wasremovedfromthedatabaseat the90DSUDcO

Number (%) of patients with AEs of special interest, sorted on AESI grouped term and descending frequency for preferred term in the osimertinib arm.

SpecificAEs ofinterest mayeitherbegrouped MedDRApreferred terms orindividual MedDRApreferred terms.

Includes AE with an onset date on or after the date of first dose and up to and including 28 days following discontinuation of randomised treatment or the day beforefirst administration of crossover treatment.

ALT = alanine aminotransferase; AST = aspartate aminotransferase; GGT= gamma glutamyltranspeptidase; CTCAE = Common Terminology Criteria for Adverse Events version 4.03; MedDRA = Medical Dictionary for Regulatory Activities version 20.0; PT=preferred term; SOC = system organ class. Datacut-offdate:DCO1=12June2017;90DSUDCO=25September2017

Source: see Table 47, Module 2.7.4 dated 4 October 2017 and see Table 11.3.2.12.10.1, Appendix A

Additional AEs related to hepatic function from the Investigations SOC were also reported in a lower proportion  of  patients  in  the  osimertinib  arm  than  the  SoC  arm:  35  (12.5%)  vs  86  (31.0%), respectively. The majority of the events were either CTCAE grade 1 or grade 2, with CTCAE grade 4 events reported in no patients in the osimertinib arm and in 4 (1.4%) patients in the SoC arm (all in the PT of ALT increased).

Dose  reductions  due  to  hepatic-related  AEs  in  this  SOC  were  reported  in  1  (0.4%)  patient  in  the osimertinib arm (GGT increased) and 2 (0.7%) patients in the SoC arm (1 ALT increased and 1 AST increased). Dose interruptions for hepatic AEs in the Investigations SOC were reported as follows: ALT increased (osimertinib: 3 [1.1%] patients; SoC: 18 [6.5%] patients); AST increased (osimertinib: 3 [1.1%];  SoC:  12  [4.3%]);  and  blood  bilirubin  increased  (osimertinib:  1  [0.4%];  SoC:  0).  In  the osimertinib arm, no patients discontinued treatment due to hepatic AEs in this SOC. In contrast, in the SoC  arm,  8  (2.9%)  patients  discontinued  due  to  AEs  of  both  ALT  increased  and  AST  increased,  4 (1.4%) patients due to an AE of ALT increased, and 1 (0.4%) patient due to an AE of blood bilirubin increased.

In  the  osimertinib  arm,  2  (0.7%)  patients  had  hepatic  AEs  that  were  classified  as  SAEs:  1  (0.4%) patient  had  SAEs  of  both  ALT  increased  and  AST  increased,  and  1  (0.4%)  patient  had  an  SAE  of transaminase increased. In the SoC arm, 5 (1.8%) patients had hepatic events that were classified as SAEs: 1 (0.4%) patient had SAEs of both AST increased and ALT increased, 1 (0.4%) had an SAE of ALT increased, and 3 (1.1%) patients had SAEs of drug induced liver injury.

## Pooled dataset

The incidence of hepatic related AEs events in the osimertinib arm in FLAURA (14.3%) was similar to the pooled population (13.9%); with the majority of events being CTCAE grade 1 or grade 2 in each arm. Proportion of CTCAE grade 3 adverse events were similar between both arms (2.2% FLAURA vs. 2.7% pooled population).  In  the  pooled  population,  2  patients  (0.2%)  had  a  CTCAE  grade  4  and  2 patients  (0.2%)  had  CTCAE  grade  5.  No  patient  reported  CTCAE  grade  4  in  the  osimertinib  arm  in FLAURA.

<div style=\"page-break-after: always\"></div>

## Renal effects

## Study FLAURA

A total of 21 (7.5%) patients in the osimertinib arm and 33 (11.9%) patients in the SoC arm had a history of Renal and urinary disorders at baseline. No patient in either treatment arm had a history of renal metastases.

Renal-related  AEs  were  reported  in  42/279  (15.1%)  patients  in  the  osimertinib  arm  and  27/277 (9.7%)  patients  in  the  SoC  arm,  with  a  similar  event  rate  per  100  patient  years:  10.3  and  9.9, respectively.

In both treatment arms, the vast majority of Renal AEs were either CTCAE grade 1 (osimertinib: 27 [9.7%] patients; SoC: 20 [7.2%] patients) or CTCAE grade 2 (osimertinib: 12 [4.3%] patients; SoC: 6 [2.2%] patients). Two patients (0.7%) in the osimertinib arm (acute kidney injury and proteinuria) and one patient in the SoC arm (proteinuria) had a CTCAE grade 3 Renal AE. One patient in the osimertinib arm experienced a CTCAE grade 5 of renal failure.

Two  (0.7%)  patients  in  the  osimertinib  arm  and  1  (0.4%)  patient  in  the  SoC  arm  had  Renal  AEs classified  as  SAEs,  which  included  acute  kidney  injury  and  renal  failure  in  1  patient  each  in  the osimertinib arm, and ureterolithiasis in 1 patient in the SoC arm.

Renal  AEs  did  not  lead  to  dose  reductions  in  either  arm.  The  following  Renal  AEs  led  to  dosing interruptions: acute kidney injury and creatinine renal clearance decreased (1 [0.4%] patient each) in the  osimertinib  arm;  and  blood  creatinine  increased  (1  [0.4%]  patient)  in  the  SoC  arm.  One  AE  of proteinuria in the SoC arm led to treatment discontinuation; no Renal AE led to discontinuation in the osimertinib arm.

Patients with grade shifts in creatinine were identified by applying the CTCAE version 4.03 definition of creatinine increases. At DCO1, grade shifts in creatinine (increased) from baseline were seen in the majority of patients during treatment: 263 (96.7%) patients in the osimertinib arm and 256 (95.2%) patients in the SoC arm. A total of 214 (78.7%) patients in the osimertinib arm and 238 (88.5%) in the  SoC  arm  had  a  1-grade  shift;  48  (17.6%)  and  16  (59%),  respectively,  had  a  2-grade  shift;  1 (0.4%) patient and 2 (0.7%), respectively, had a 3-grade shift.

## Pooled dataset

Renal effects were reported in 36 patients (12.9%) in the osimertinib arm in FLAURA and 166 patients (14.5%) in the pooled population: with most of the events being CTCAE grade 1 (8.2% FLAURA vs. 9.5% pooled population) or grade 2 (4.3% FLAURA vs. 4.2% pooled population). Incidence of CTCAE grade 3 in the pooled population was 7 (0.6%).

## Other AESI

## Asthenic conditions

## Study FLAURA

AEs in the Asthenic conditions grouped term (DCO1) were reported in a slightly greater proportion of patients in the osimertinib arm (69 [24.7%]) than in the SoC arm (50 [18.1%]). The event rate per 100 patient-years was similar between the 2 treatments: 19.7 and 18.4, respectively.

In  the  osimertinib  arm,  AEs  were  generally  mild,  with  no  CTCAE  grade  4  or  grade  5  events.  The frequency and severity of events were similar to those in the SoC arm.

Two (0.7%) patients in the osimertinib arm and 3 (1.1%) in the SoC arm had AEs in the Asthenic conditions  grouped  term  reported  as  SAEs.  Events  led  to  discontinuation  of  treatment  in  2  (0.7%) patients in the osimertinib arm (PT of asthenia) and 1 (0.4%) patient in the SoC arm (PT of fatigue).

<div style=\"page-break-after: always\"></div>

## Anorexia

## Study FLAURA

Adverse events in the Anorexia grouped term (DCO1) were reported in a similar proportion of patients in the 2 treatment arms: 56 (20.1%) patients in the osimertinib arm and 52 (18.8%) patients in the SoC arm. The event rate per 100 patient-years was lower in the osimertinib arm than the SoC arm: 16.0 and 19.1, respectively.

In the osimertinib arm, AEs in the Anorexia grouped term were generally mild, with no CTCAE grade 4 or grade 5 events. The frequency and severity of events were similar to those in the SoC arm.

Two (0.7%) patients in each treatment arm had AEs in the Anorexia grouped term reported as an SAE, neither of which led to treatment discontinuation.

## Nausea

## Study FLAURA

Nausea  was  a  single-PT  AESI  in  this  evaluation  and  was  reported  in  39  (14.0%)  patients  in  the osimertinib arm and 52 (18.8%) patients in the SoC arm, with a lower event rate per 100 patientyears in the osimertinib arm than in the SoC arm: 11.2 and 19.1, respectively. In the osimertinib arm, reports of nausea were generally mild (all CTCAE grade 1 or grade 2). The frequency and severity of events were similar to those in the SoC arm. None of the events was classified as an SAE.

Nausea led to dosing interruption in 2 (0.7%) patients on osimertinib vs. 1 (0.4%) patient on SoC. No patient  had  a  dosing  reduction  due  to  an  AE  of  nausea  in  either  arm.  Nausea  led  to  treatment discontinuation in 1 (0.4%) patient in each treatment arm.

## Vomiting

## Study FLAURA

Vomiting  was  a  single-PT  AESI  in  this  evaluation  and  was  reported  in  31  (11.1%)  patients  in  the osimertinib arm and 29 (10.5%) patients in the SoC arm (DCO1), with a similar event rate per 100 patient-years: 8.9 and 10.7, respectively. In the osimertinib arm, reports of vomiting were generally mild (all CTCAE grade 1 or grade 2). The frequency and severity of the events were similar to those in the SoC arm.

One (0.4%) patient in the osimertinib arm and 5 (1.8%) patients in the SoC arm had vomiting AEs reported as an SAE.

Vomiting led to dosing interruption in 1 (0.4%) patient in the osimertinib arm and 3 (1.1%) patients in the SoC arm, and to treatment discontinuation in 1 (0.4%) and 2 (0.7%) patients, respectively.

## Pancreatitis

## Study FLAURA

No event of Pancreatitis (HLT of Acute and chronic pancreatitis) was reported in either treatment arm.

## Dry mouth

## Study FLAURA

Dry mouth was a single-PT AESI in this evaluation and was reported in a similar proportion of the 2 treatment arms: 12 (4.3%) patients in the osimertinib arm and 14 (5.1%) patients in the SoC arm, with a similar event rate per 100 patient-years: 3.4 and 5.2, respectively (DCO1).

In  the  osimertinib  arm,  reports  of  dry  mouth  were  mild  (all  CTCAE  grade  1).  The  frequency  and severity of the events were similar to those in the SoC arm.

No patients in either treatment arm had an AE of dry mouth reported as an SAE. and no events led to dose interruption, dose reduction, or discontinuation of treatment in either arm.

<div style=\"page-break-after: always\"></div>

## Abdominal pain

## Study FLAURA

AEs in the GI and abdominal pains HLT were reported in a similar proportion of the 2 treatment arms: 23 (8.2%) patients in the osimertinib arm and 23 (8.3%) patients in the SoC arm (DCO1). The event rate per 100 patient-years was also similar: 6.6 and 8.5, respectively. In the osimertinib arm, reports of this HLT were generally mild, with no CTCAE grade 4 or grade 5 events, and led to dose interruption in 1 patient, no dose reductions, and no discontinuation of treatment. The frequency and severity of events were similar to those in the SoC arm.

One (0.4%) patient in the osimertinib arm had an event of abdominal pain reported as an SAE that led to  dose  interruption  but  not  discontinuation  of  treatment.  No  patient  in  the  SoC  arm  had  an  event reported as an SAE.

## Pyrexia

## Study FLAURA

Pyrexia  was  a  single-PT  AESI  in  this  evaluation  and  was  reported  in  28  (10.0%)  patients  in  the osimertinib arm and 11 (4.0%) patients in the SoC arm (DCO1).

In the osimertinib arm, reports of pyrexia were generally mild (all CTCAE grade 1 or grade 2), and led to dose interruption in 1 patient, no dose reductions or discontinuation of treatment.

One (0.4%) patient in the osimertinib arm and no patients in the SoC arm had a dose interruption due to pyrexia. Two (0.7%) patients in each treatment arm had an AE of pyrexia reported as an SAE; no events led to discontinuation of treatment in either arm.

## Infections and infestations

## Study FLAURA

The Infections and Infestations SOC is a large AESI grouping that includes over 100 PTs that cover a wide range of common conditions.

Within this SOC, AEs reported in the osimertinib arm and in the SoC arm were: 185 (66.3%) and 168 (60.6%)  patients,  respectively  (DCO1).  The  most  commonly  reported  AEs  (≥5%  of  patients)  were paronychia  (osimertinib:  81  [29%]  patients;  SoC:  80  [28.9%]  patients);  upper  respiratory  tract infection (osimertinib: 28 [10.0%]; SoC: 18 [6.5%]); viral upper respiratory infection (osimertinib: 27 [9.7%]; SoC: 20 [7.2%]); pneumonia (osimertinib: 18 [6.5%]; SoC: 9 [3.2%]); and conjunctivitis (osimertinib: 14 [5.0%]; SoC: 20 [7.2%]).The overall event rate per 100 patient-years of AEs in the Infections and Infestations SOC was lower in the osimertinib arm than in the SoC arm: 52.9 and 61.8, respectively. In both treatment arms, the vast majority of infectious AEs were CTCAE grade 1 or grade 2. CTCAE grade 3 AEs were reported in 16 (5.7%) patients on osimertinib and 17 (6.1%) patients on SoC. There was 1 (0.4%) patient with CTCAE grade 4 AE of pneumonia in the SoC arm. CTCAE grade 5 AEs in the Infections &amp; Infestations SOC were reported in 2 (0.7%) patients on osimertinib (pneumonia [1] and respiratory tract infection [1], both unrelated to osimertinib) and 5 (1.8%) patients on SoC (pneumonia and sepsis [2 each], and endocarditis).

A total of 18 (6.5%) patients in the osimertinib arm and 26 (9.4%) patients in the SoC arm had AEs in this SOC reported as an SAE, with the most common SAE being pneumonia (7 [2.5%] patients in each treatment arm).

Dose interruptions due to AEs in the Infections &amp; Infestations SOC were reported in 21 (7.5%) patients in  the  osimertinib  arm  and  14  (5.1%)  patients  in  the  SoC  arm.  Events  led  to  dose  reduction  in  1 (0.4%)  patient  in  the  osimertinib  arm  (AE  of  paronychia)  and  no  patients  in  the  SoC  arm.  Three (1.1%) patients in the osimertinib arm and 5 (1.8%) patients in the SoC arm discontinued treatment due to AEs in the Infections &amp; Infestations SOC.

<div style=\"page-break-after: always\"></div>

## Pooled population

Adverse  events  of  Infections  and  infestations  (SOC)  in  the  pooled  population  were  reported  in  712 (62.3%) patients. The most commonly reported AEs (≥ 3%) were: paronychia (276 [24.2%] vs. 81 [29.0%] in FLAURA), Upper respiratory tract infection (142 [12.4%] vs. 28 [10.0%] in FLAURA), Viral upper respiratory tract infection (132 [11.6%] vs. 27 [9.7%] in FLAURA), Urinary tract infection (89 [7.8%] vs. 12 [4.3%] in FLAURA), pneumonia (67 [5.9%] vs. 18 [6.5%] FLAURA), conjunctivitis (46 [4.0%] vs. 14 [5.0%] in FLAURA) and pharyngitis (35 [3.1%] vs. 10 [3.6%] in FLAURA). Most of the AEs were grade 1 (26.3% vs. 23.7% FLAURA) or grade 2 (28.1% vs. 35.8%). CTAE grade 5 AEs were reported in 13 (1.1%) patients in the pooled population and 2 (0.7%) patients in the osimertinib arm in FLAURA.

## Haemorrhages

## Study FLAURA

Adverse events in the Haemorrhages SMQ were reported in a similar proportion of patients in the 2 treatment arms: 39 (14.0%) patients in the osimertinib arm and 51 (18.4%) patients in the SoC arm (DCO1). The event rate per 100 patient-years was lower in the osimertinib arm than in the SoC arm: 11.2 and 18.8, respectively. Aside from epistaxis (17 [6.1%] osimertinib vs. 14 [5.1%] SoC), no single PT in this SMQ was reported in &gt;5% of patients in either treatment arm.

In most patients, the events were either CTCAE grade 1 or CTCAE grade 2, with 1 (0.4%) patient in the osimertinib arm having a CTCAE grade 4 subdural haematoma. In the SoC arm, 1 (0.4%) patient had a CTCAE grade 4 pulmonary haemorrhage and 2 (0.7%) patients had grade 5 events (1 each of GI haemorrhage and haemoptysis).

Haemorrhages  AEs  were  classified  as  SAEs  in  3  (1.1%)  patients  in  the  osimertinib  arm  (PTs  of haemorrhagic stroke, haemorrhoidal haemorrhage, and subdural haematoma) and 5 (1.8%) patients in  the  SoC  arm  (PTs  of  GI  haemorrhage,  haemoptysis,  melena,  pulmonary  haemorrhage,  and subarachnoidal haemorrhage).

The  AE  of  subarachnoidal  haemorrhage  in  the  SoC  arm  led  to  dosing  interruption;  no  other Haemorrhages AEs led to dose interruption. There were no dose reductions due to events in this SMQ. Events led to discontinuation of 1 (0.4%) patient in the osimertinib arm (PT of subdural haematoma reported the same day as a head injury) and of 3 (1.1%) patients in the SoC arm (PTs of haemoptysis, GI haemorrhage, and Henoch-Schonlein purpura).

## Pooled population

The incidence of Hemorrhages SOC AEs in the osimertinib arm in FLAURA was similar to the pooled population: 39 (14.0%) and 191 (16.7%), respectively. Epistaxis (63 (5.5%) pooled population vs. 17 (6.1%) FLAURA) was the only PT reported in ≥ 5% of patients.

## Serious adverse event/deaths/other significant events

## SAEs in FLAURA

Table 50: Serious adverse events, by preferred term in ≥ 2 patients in either treatment arm in FLAURA (Safety analysis set)

<div style=\"page-break-after: always\"></div>

|                                   | Number (%) of patients a    | Number (%) of patients a    | Number (%) of patients a   | Number (%) of patients a   |
|-----------------------------------|-----------------------------|-----------------------------|----------------------------|----------------------------|
|                                   | Osimertinib 80 mg (N = 279) | Osimertinib 80 mg (N = 279) | Standard of Care (N = 277) | Standard of Care (N = 277) |
| MedDRA Preferred term             | DC01                        | 90 DSU                      | DC01                       | 90 DSU                     |
| Pafients with any SAE             | 60 (21.5)                   | 63 (22.6)                   | 70 (25.3)                  | 72 (26.0)                  |
| Pneumonia                         | 7 (2.5)                     | 7 (2.5)                     | 7 (2.5)                    | 7 (2.5)                    |
| Interstitial lung disease         | 4(1.4)                      | 4 (1.4)                     | 3 (1.1)                    | 3 (1.1)                    |
| Pulmonary embolism                | 4 (1.4)                     | 4 (1.4)                     | 1 (0.4)                    | 1 (0.4)                    |
| Plewral effusion                  | 3 (1.1)                     | 4 (1.4)                     | 3 (1.1)                    | 4 (1.4)                    |
| Dianhoea                          | 2 (0.7)                     | 2 (0.7)                     | 4 (1.4)                    | 4 (1.4)                    |
| Decreased appetite                | 2 (0.7)                     | 2 (0.7)                     | 2 (0.7)                    | 2 (0.7)                    |
| Asthenia                          | 2 (0.7)                     | 2 (0.7)                     | 2 (0.7)                    | 2 (0.7)                    |
| Pyrexia                           | 2 (0.7)                     | 3 (1.1)                     | 2 (0.7)                    | 2 (0.7)                    |
| Gashoenteritis                    | 2 (0.7)                     | 2 (0.7)                     | 1 (0.4)                    | 1(0.4)                     |
| Pneumonitis                       | 2 (0.7)                     | 2 (0.7)                     | 1 (0.4)                    | 1 (0.4)                    |
| Deep vein thrombosis              | 2 (0.7)                     | 2 (0.7)                     | 0                          | 0                          |
| Enterocolitis                     | 2 (0.7)                     | 2 (0.7)                     | 0                          | 0                          |
| Vomiting                          | 1 (0.4)                     | 1 (0.4)                     | 5 (1.8)                    | 5 (1.8)                    |
| Sepsis                            | 1 (0.4)                     | 1 (0.4)                     | 3 (1.1)                    | 3 (1.1)                    |
| Dyspnoea                          | 1 (0.4)                     | 1 (0.4)                     | 3 (1.1)                    | 2 (0.7)                    |
| Alanine aminotansferase increased | 1 (0.4)                     | 1 (0.4)                     | 2 (0.7)                    | 2 (0.7)                    |
| Drug-induced liver injuy          | 0                           | 0                           | 3 (1.1)                    | 3 (1.1)                    |
| Pneumothorax                      | 0                           | 1 (0.4)                     | 2 (0.7)                    | 2 (0.7)                    |
| Respiratory failure               |                             | 0                           | 2 (0.7)                    | 2 (0.7)                    |
| Mouth ulceration                  | 0                           | 0                           | 2 (0.7)                    | 2 (0.7)                    |
| Dermatitis acneiform              | 0                           | 0                           | 2 (0.7)                    | 2 (0.7)                    |
| Haemoptysis                       | 0                           | 0                           | 1(0.4)                     | 2 (0.7)                    |

a Number (%6) of patients with SAEs, sorted in decreasing frequency of PT in the osimertinib arm at DCO1.

## Deaths in FLAURA

Among patients who died due to AE in the osimertinib arm, primary causes of death were: pneumonia, respiratory  tract  infection,  intestinal  ischaemia,  myocardial  infarction,  cerebral  infarction,  pulmonary embolism, multiple organ dysfunction syndrome and sudden death.

Death was reported in 9 of the 48 (18.8%) patients who crossed over to the osimertinib arm.

<div style=\"page-break-after: always\"></div>

Table 51: Summary of deaths in FLAURA

|                                                                                  | Number (%o) of patients    | Number (%o) of patients    | Number (%o) of patients    | Number (%o) of patients    |
|----------------------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                                                                  | Osimertinib S0 mg (N= 279) | Osimertinib S0 mg (N= 279) | Standard of Care (N = 277) | Standard of Care (N = 277) |
|                                                                                  | DC01                       | 90 DSU                     | DC01                       | 90 DSU                     |
| Total number of deaths                                                           | 58 (20.8)                  | 71 (25.4)                  | 83 (30.0)                  | 97 (35.0)                  |
| Cause of death                                                                   |                            |                            |                            |                            |
| Disease under investigation only                                                 | 51 (18.3)                  | 61 (21.9)                  | 65 (23.5)                  | 78 (28.2)                  |
| AE with fatal outcome only                                                       | 6 (2.2)                    | 8 (2.9)                    | 8 (2.9) 4                  | 8 (2.9) *                  |
| AE with fatal outeome only (AE start date falling after 28-day follow-up period) | 0                          | 0                          | 1 (0.4)                    | 1 (0.4)                    |
| Disease under investigation and AE with fatal outcome                            | 0                          | 0                          | 4(1.4)                     | 4(1.4)                     |
| Other reasonb                                                                    | 0                          | 1 (0.4)                    | 3 (1.1)                    | 4 (1.4)                    |
| Reason unknown/missing                                                           | 1 (0.4)                    | 1 (0.4)                    | 2 (0.7)                    | 2 (0.7)                    |

Includes 3 patients who had AEs leading to death after crossover to osimertinib

Death related to disease umder investigation was determined by the Investigator.

b Includes patients who died and are not captured in the earlier categories: osimertinib anm: E2113001 (acute (disseminated intravascular coagulation, 1 day after last dose), E2900021 (acute respiratory failure, 55 days (asop ise raye sfep 1 moissaond aoueo 2m) to0605le pne (asop rse iaye

Rows are mutually exchusive: patients are reported in only I category.

Data cut-off date: DC01=12 Jume 2017; 90 DSU DC0=25 September 2017

Includes all deaths on or after the date of the first dose of randomised study teatment.

Source: see Table 14, Module 2.7.4 dated 4 0ctober 2017 and see Table 11.3.3.1, Appendix A

## Laboratory findings

## Study FLAURA

## Haematology

Decreases  from  baseline  in  median  values  for  platelets,  neutrophils,  and  leukocytes  were  observed early in treatment with osimertinib. Median values appeared to stabilise after the initial drop, with the majority of patients experiencing no change in CTCAE grade, or a single grade change.

## Haemoglobin

For  haemoglobin-related  changes  reported  as  AEs  (anaemia  and  haemoglobin  decreased),  the incidence and severity of AEs were similar in the 2 treatment arms, with no CTCAE grade 4 or grade 5 events and only 1 AE reported as an SAE (CTCAE grade 3 anaemia in the SoC arm). In both treatment arms, there were few dose modifications or discontinuation of treatment.

Worsening in CTCAE grade shifts in haemoglobin was recorded in a higher proportion of patients in the osimertinib arm (60.1%) than in the SoC arm (47.0%), with no 4-grade shifts reported in either arm.

## Platelets

Worsening in CTCAE grade shifts in platelets was recorded in a higher proportion of patients in the osimertinib arm (51.6%) than in the SoC arm (11.9%). Almost all shifts in both treatment arms were 1-grade  (osimertinib:  134  [49.1%]  patients;  SoC:  30  [11.2%]  patients).  CTCAE  2-grade  shifts occurred in 4 (1.5%) patients on osimertinib and 1 (0.4%) patient on SoC, and 3-grade shifts in 1 (0.4%) patient in each arm. One (0.4%) osimertinib patient had a 4-grade shift in platelets.

A higher proportion of patients in the osimertinib arm experienced platelet counts below the LLN: 151 (54.1%) osimertinib, 36 (13.0%) SoC. Of the patients who had a shift from baseline in grade of the laboratory  parameter  of  platelets  (decreased),  134/141  (95.0%)  in  the  osimertinib  arm  and  30/32 (93.8%) in the SoC arm were CTCAE grade 1.

<div style=\"page-break-after: always\"></div>

Adverse  events  related  to  a  reduction  in  platelet  count  (ie,  thrombocytopenia  and  platelet  count decreased) were reported in a higher proportion of patients in the osimertinib arm than the SoC arm: 14.7% vs 1.8%, respectively.  Most  of  the  events  in  both  treatment  arms  were  reported  as  CTCAE grade  1.  CTCAE  grade  3  events  were  reported  in  2  (0.7%)  patients  in  the  osimertinib  arm  and  no patients in the SoC arm. No CTCAE ≥grade 4 events were reported in the osimertinib arm vs. 1 (0.4%) in the SoC arm. One SAE event of platelet count decreased was reported in each treatment arm.

AEs of bleeding, bruising or haemorrhage were reported concomitantly with platelet count below the LLN  in  9  (3.2%)  patients  in  the  osimertinib  arm  and  in  6  (2.2%)  patients  in  the  SoC  arm.  In  the osimertinib arm, the patients with bleeding AEs included 3 patients with epistaxis; and 1 patient each with  conjunctival  haemorrhage,  contusion,  gingival  bleeding,  haematoma,  haematuria,  haemoptysis, haemorrhoidal  haemorrhage,  and  vaginal  haemorrhage.  In  the  SoC  arm,  bleeding  AEs  occurring concomitantly  with  platelet  counts  below  the  LLN  were  haemoptysis  (2  patients);  and  diarrhoea haemorrhagic,  disseminated  intravascular  coagulation,  epistaxis,  haematochezia,  haematuria,  and purpura (1 patient each).

## Leucocytes

Worsening in CTCAE grade shifts in leukocytes values were reported in a higher proportion of patients in the osimertinib arm (72.6%) than in the SoC arm (32.2%). A majority of grade shifts in leukocytes were  1-grade  shifts  (osimertinib:  133  [50.0%]  patients;  SoC:  72  [27.6%]  patients),  with  2-grade shifts reported in 58 (21.8%) patients on osimertinib and 11 (4.2%) patients on SoC. One patient in the osimertinib arm had a 3-grade shift and one patient in each treatment arm had a 4-grade shift in leukocytes.

Adverse events of leukopenia or WBC count decreased were reported in a higher proportion of patients in the osimertinib arm (45 [16.1%]) than the SoC arm (8 [2.9%]). Most patients in both treatment arms had events that were CTCAE grade 1 or grade 2, with no SAEs and only 1 (0.4%) patient in the osimertinib arm reporting a CTCAE ≥ grade 3 event. The majority of the AEs (71/80 [88.8%] in the osimertinib arm and 8/9 [88.9%] in the SoC arm) did not require medication. Three events required dose  interruption  and  1  event  required  dose  reduction  in  the  osimertinib  arm;  no  event  led  to discontinuation. No event required dose interruption, modification or led to discontinuation in the SoC arm.

Adverse  events  in  the  Infections  &amp;  Infestations  SOC  occurred  concomitantly  with  leukocyte  counts below the LLN in 35.1% of patients on osimertinib and 7.9% of patients on SoC.

## Neutrophils

Worsening  in  CTCAE  grade  shifts  in  neutrophils  was  recorded  in  110  (41.2%)  patients  in  the osimertinib arm vs. 26 (9.9%) patients in the SoC arm. The vast majority of grade shifts in neutrophils were 1-grade shifts (osimertinib: 52 [19.5%] patients; SoC: 15 [5.7%] patients) and 2-grade shifts (osimertinib: 50 [18.7%]; SoC: 10 [3.8%]). Eight (3.0%) patients on osimertinib (one patient on SoC) had 3-grade shifts in neutrophils. There were no 4-grade shifts in neutrophils in either arm.

Adverse events of neutropenia or neutrophil count decreased were reported in a higher proportion of patients in the osimertinib arm (31 [11.1%]) than in the SoC arm (3 [1.1%]). Six (2.2%) patients in the osimertinib arm and one (0.4%) patient in the SoC arm had a CTCAE ≥ grade 3 event. No event was reported as an SAE.

Adverse  events  in  the  Infections  &amp;  Infestations  SOC  occurred  concomitantly  with  neutrophil  counts below the LLN in 33 (11.8%) patients on osimertinib and 5 (1.8%) patients on SoC.

<div style=\"page-break-after: always\"></div>

## Lymphocytes

Adverse events of lymphocyte count decreased were reported in a higher proportion of patients in the osimertinib  arm  (3.2%)  than  the  SoC  arm  (0.4%),  as  were  AEs  of  lymphopenia  (2.2%  and  1.1%, respectively). No serious AEs of lymphocyte count decreased or lymphopenia were reported.

Worsening CTCAE grade shifts in lymphocyte values were reported in higher percentage of patients in the osimertinib arm than the SoC arm (65.2% vs. 35.7%, respectively). The vast majority of grade shifts in lymphocytes were either 1-grade shifts (osimertinib: 82 [30.7%] patients; SoC: 44 [16.7%]) or 2-grade shifts (osimertinib: 76 [28.5%]; SoC: 39 [14.8%]). 14 (5.2%) patients in the osimertinib arm and 11 (4.2%) patients in the SoC arm had 3-grade shifts in lymphocytes. Two (0.7%) patients in the osimertinib arm had 4-grade shifts in lymphocytes (no patients in the SoC arm).

## Pooled population

Results from the pooled dataset show a consistent safety profile for osimertinib as that demonstrated in FLAURA.

The most commonly reported haematology-related AEs PTs were anaemia (13.1% pooled population vs. 12.2%  FLAURA), platelet count decreased  (8.9% pooled population vs. 5.0%  FLAURA), thrombocytopenia (8.1% pooled population vs. 9.3% FLAURA), white blood cell count decreased (7.7% pooled population vs. 8.6% FLAURA) and neutropenia (6.5% pooled population vs. 6.8%).

In the pooled population, neutrophils decreased grade shifts incidence was 34.7%, mostly grade 1 and grade  2  [15%]  each;  Lymphocytes  decreased  was  67.1%,  mostly  grade  1  (33.3%)  and  grade  2 (26.6%); leukocytes decreased grade shifts incidence was 67.8% mostly grade 1 (47.8%) and platelet count decreased events grade shifts incidence was 54.1%, mostly grade 1 (49.9%).

## General clinical chemistry

Analysis of reported clinical chemistry values have been considered in conjunction with any relevant or related clinical biochemistry AEs.

In  the  osimertinib  arm,  values  remained generally consistent over time and there were no clinically significant changes in median values of albumin, calcium, glucose, magnesium, potassium or sodium observed during treatment in the majority of patients. The majority of CTCAE grade shifts seen were 1-grade shifts, with only a small percentage of patients in the osimertinib arm developing a 3-grade or 4-grade shift.

There was a low frequency of reports of abnormal clinical biochemistry AEs. As would be expected with the small magnitude of these changes, no clinically significant sequelae were observed.

## Safety in special populations

## Effect of gender

## Study FLAURA

The 2 groups were broadly consistent in terms of the most commonly reported PTs, with only vomiting (4.0% males vs. 15.2% females) and ECG QT prolonged (3 [3.0%] males vs. 25 [14.0%] females) having a difference of ≥10 pp between genders. There was a doubling of incidence between genders for the PTs pneumonia (11.9% male vs. 3.4% female) and anaemia (6.9% male vs. 15.2% female).

The  only  key  safety  topic  grouped  term  of  interest  with  a  difference  of  &gt;10  pp  between  male  and female patients was Cardiac effects (QT) (4.0% males vs. 14.0% females). This difference was driven largely by the PT of ECG QT prolonged.

<div style=\"page-break-after: always\"></div>

Table 52: Adverse events in any category, by gender among patients in the osimertinib arm in FLAURA (Safety analysis set)

|                                                                                    | Nunber (%) of patientsa   | Nunber (%) of patientsa   |
|------------------------------------------------------------------------------------|---------------------------|---------------------------|
| Atlverse event category                                                            | Male (N=101)              | Female (N =178)           |
| Any AE                                                                             | 100 (99.0)                | 173 (97.2)                |
| Any AE causally related to osimertinibb                                            | 92 (91.1)                 | 161 (90.4)                |
| Any AE of CTCAE grade 3 or higher                                                  | 27 (26.7)                 | 68 (38.2)                 |
| Any AE of CTCAE grade 3 or higher, causally related to osimertinibb                | 10 (9.9)                  | 39 (21.9)                 |
| Any AE with outcome = death                                                        | 3 (3.0)                   | 3 (1.7)                   |
| Any AE with outcome = death, causally related to osimertinibb                      | 0                         | 0                         |
| Any SAE (including events with outcome = death)                                    | 20 (19.8)                 | 40 (22.5)                 |
| Any SAE (including events with outcome = death), causally related to osimertinibb  | 4 (4.0)                   | 18 (10.1)                 |
| AnySAEleadingtodiscontinuationofosimertinib                                        | 6 (5.9)                   | 14 (7.9)                  |
| AnyAEleadingtodiscontinuation ofosimertinib                                        | 12 (11.9)                 | 25 (14.0)                 |
| Any AE leading to discontinuation of osimertinib, causally related to osimertinibb | 8 (7.9)                   | 19 (10.7)                 |

b As assessed by theInvestigator assessment and programmatically derived from individual causality assessments.

a Patients with multiple events in the same category are counted only once in that category.Patients with eventsinmore than1 category are countedonceineachof thosecategories.

Includes AEs with an onset date on or after the date of first dose and up to and including 28 days following discontinuation of randomised treatment or the day before start of new anticancer treatment (including crossover treatment for FLAURA patients).

CTCAE = Common Terminology Criteria for Adverse Events version 4.03. MedDRA version 20.0.

## Pooled population

Consistent  with  FLAURA,  the  overall  incidence  of  AEs  was  similar  across  male  (N=400)  and  female (N=742) patients (98.5% vs. 98.7%, respectively) as well as the incidence of AEs of CTCAE ≥ grade 3 (37.3% vs. 38.4%). AEs of CTCAE ≥ grade 3 that were considered by the investigator to be causally related to treatment were slightly higher among female patients (10.5% vs. 16%).

## Effect of race

## Study FLAURA

<div style=\"page-break-after: always\"></div>

Table 53: Adverse events in any category, by race among patients in the osimertinib arm in FLAURA (Safety analysis set)

|                                                                                    | Nunber (%) of patientsa   | Nunber (%) of patientsa   |
|------------------------------------------------------------------------------------|---------------------------|---------------------------|
| Adlverse event category                                                            | White (N =101)            | Asian (N =174)            |
| Any AE                                                                             | 96 (95.0)                 | 173 (99.4)                |
| Any AE causally related to osimertinibb                                            | 84 (83.2)                 | 165 (94.8)                |
| Any AE of CTCAE grade 3 or higher                                                  | 29 (28.7)                 | 66 (37.9)                 |
| Any AE of CTCAE grade 3 or higher, causally related to osimertinibb                | 14 (13.9)                 | 35 (20.1)                 |
| Any AE with outcome = death                                                        | 4 (4.0)                   | 2 (1.1)                   |
| Any AE with outcome = death, causally related to osimertinibb                      | 0                         | 0                         |
| Any SAE (including events with outcome = death)                                    | 22 (21.8)                 | 38 (21.8)                 |
| Any SAE (including events with outcome = death), causally related to osimertinibb  | 8 (7.9)                   | 14 (8.0)                  |
| AnySAEleadingtodiscontinuationof osimertinib                                       | 8 (7.9)                   | 12 (6.9)                  |
| AnyAEleadingtodiscontinuation of osimertinib                                       | 13 (12.9)                 | 24 (13.8)                 |
| Any AE leading to discontinuation of osimertinib, causally related to osimertinibb | 9 (8.9)                   | 18 (10.3)                 |

b As assessedby theInvestigatorassessment andprogrammatically derivedfromindividual causality assessments.

a Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Includes AEs with an onset date on or after the date of first dose and up to and including 28 days following discontinuationofrandomised treatment orthedaybeforestartof newanticancer treatment(including crossover treatment forFLAURApatients).

CTCAE =CommonTerminology Criteria forAdverseEvents version4.03. MedDRA version20.0.

Data cut-off: 12 June 2017

Source:Table 2.7.4.s2cs,Pooled safety,Module 5.3.5.3.

<div style=\"page-break-after: always\"></div>

Table 54: Most common adverse event, by race among patients in the osimertinib arm in FLAURA (frequency ≥ 10% in either race) (Safety analysis set)

|                                         | Nunber (%) of patients   | Nunber (%) of patients   |
|-----------------------------------------|--------------------------|--------------------------|
| MedDRA preferred term                   | White (N =101)           | Asian (N =174)           |
| Paronychia                              | 15 (14.9)                | 65 (37.4)                |
| Diarrhoea                               | 63 (62.4)                | 96 (55.2)                |
| Dry skin                                | 29 (28.7)                | 57 (32.8)                |
| Decreased appetite                      | 24 (23.8)                | 32 (18.4)                |
| Cough                                   | 24 (23.8)                | 22 (12.6)                |
| Fatigue                                 | 22 (21.8)                | 15 (8.6)                 |
| Dyspnoea                                | 22 (21.8)                | 13 (7.5)                 |
|                                         | 21 (20.8)                | 27 (15.5)                |
| Nausea                                  | 21 (20.8)                | 17 (9.8)                 |
| Vomiting                                | 20 (19.8)                | 11 (6.3)                 |
| Stomatitis                              | 19 (18.8)                | 59 (33.9)                |
| Thrombocytopenia                        | 19 (18.8)                | 7 (4.0)                  |
| Dermatitisacneiform                     | 18 (17.8)                | 51 (29.3)                |
| Asthenia                                | 17 (16.8)                | 4 (2.3)                  |
| Headache                                | 15 (14.9)                | 18 (10.3)                |
| Back pain                               | 15 (14.9)                | 11 (6.3)                 |
| Alopecia                                | 13 (12.9)                | 7 (4.0)                  |
| Pain in extremity                       | 13 (12.9)                | 4 (2.3)                  |
| Constipation                            | 12 (11.9)                | 28 (16.1)                |
| Dizziness                               | 11 (10.9)                | 8 (4.6)                  |
| Rash maculopapular                      | 11 (10.9)                | 26 (14.9)                |
| Anaemia                                 | 11 (10.9)                | 23 (13.2)                |
| Arthralgia                              | 11 (10.9)                | 6 (3.4)                  |
| Muscle spasms                           | 11 (10.9)                | 5 (2.9)                  |
| ASTincreased                            | 7 (6.9)                  | 19 (10.9)                |
| Upper respiratory tract infection       | 6 (5.9)                  | 22 (12.6)                |
| Insomnia                                | 6 (5.9)                  | 19 (10.9)                |
| Viral upper respiratory tract infection | 4 (4.0)                  | 22 (12.6)                |
| Electrocardiogram QT prolonged          | 3 (3.0)                  | 25 (14.4)                |
| Whitebloodcell count decreased          | 0                        | 24 (13.8)                |

Bolding indicates that the PT has a &gt; 10 pp difference between the races.

a Number (%) of patients with AEs, sorted in descending frequency of PT in White patients

Includes AEs with an onset date on or after the date of first dose and up to and including 28 days following the date of last dose of study medication.

## Pooled population

Consistent with FLAURA, the overall incidence of AEs was similar between White and Asian patients (97.2%  vs.  99.3%,  respectively),  while  the  incidence  of  AEs  considered  by  the  investigator  to  be possibly related to osimertinib was higher for Asian patients (90.8%) than for White patients (83.1%). The  incidence  of  AEs  CTCAE  grade  ≥  3  causally  related  to  osimertinib  was  also  higher  for  Asian patients  (10.3%  vs.  16.3%)  whereas  SAE  were  more  frequent  among  White  patients  (34.6%  vs. 24.3%).

<div style=\"page-break-after: always\"></div>

## Effect of age

## Table 55: Adverse events in any category, by age group at baseline among patients in the osimertinib

Study FLAURA arm in FLAURA (Safety analysis set)

|                                                                                   | Nunber (%) of patientsa   | Nunber (%) of patientsa   | Nunber (%) of patientsa   |
|-----------------------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|
| Adlverse event category                                                           | <65 years (N = 153)       | 65-74 years (N = 90)      | ≥75 years (N = 36)        |
| Any AE                                                                            | 151 (98.7)                | 87 (96.7)                 | 35 (97.2)                 |
| Any AE causally related to osimertinibb                                           | 141 (92.2)                | 79 (87.8)                 | 33 (91.7)                 |
| Any AEofCTCAEgrade 3or higher                                                     | 39 (25.5)                 | 34 (37.8)                 | 22 (61.1)                 |
| Any AE of CTCAE grade 3 or higher, causally related to osimertinibb               | 18 (11.8)                 | 21 (23.3)                 | 10 (27.8)                 |
| Any AE with outcome = death                                                       | 0                         | 2 (2.2)                   | 4 (11.1)                  |
| Any AEwith outcome = death, causally related to osimertinibb                      | 0                         | 0                         | 0                         |
| Any SAE (including events with outcome = death)                                   | 24 (15.7)                 | 21 (23.3)                 | 15 (41.7)                 |
| Any SAE (including events with outcome = death), causally related to osimertinibb | 7 (4.6)                   | 9 (10.0)                  | 6 (16.7)                  |
| AnySAE leading to discontinuation of osimertinib                                  | 3 (2.0)                   | 7 (7.8)                   | 10 (27.8)                 |
| AnyAEleadingtodiscontinuationofosimertinib                                        | 10 (6.5)                  | 14 (15.6)                 | 13 (36.1)                 |
| AnyAE leading to discontinuation of osimertinib, causally related to osimertinibb | 9 (5.9)                   | 11 (12.2)                 | 7 (19.4)                  |

a events in more than 1 category are counted once in each of those categories.

Includes AEs with an onset date on or after the date of first dose and up to and including 28 days following discontinuationofrandomisedtreatment orthedaybeforestartofnewanticancertreatment(including crossover treatment for FLAURA patients).

b As assessedby theInvestigator assessment and programmaticallyderivedfrom individual causality assessments.

CTCAE =Common Terminology Criteria forAdverse Events version 4.03. MedDRA version 20.0.

Data cut-off: 12 June 2017

Source:Table 2.7.4.s2bs,Pooled safety,Module 5.3.5.3

There was at least a 10-pp difference in incidence among patients &lt; 65 years, patients 65-74 years and patients ≥ 75 years of age in the following PTs: diarrhoea (58.8%, 50.0%, 72.2%, respectively), dermatitis  acneiform  (30.7%,  23.3%,  8.3%),  headache  (17.0%,  4.4%,  8.3%),  dyspnoea  (15.7%, 10.0%, 5.6%), decreased appetite (13.1%, 28.9%, 27.8%), weight decreased (4.6%, 1.1%, 16.7%) conjunctivitis (3.9%, 3.3%, 13.9%) and pulmonary embolism (1.3%, 2.2, 13.9%).

The  key  safety  topics  grouped  terms  of  interest  with  a  difference  of  &gt;10  pp  between  patients  &lt;65 years of age, patients 64-75 years, and patients ≥75 years, respectively, were: diarrhoea (58.8% vs. 50.0% vs. 72.2% ≥75), nail effects (33.3% vs. 40.0% vs. 27.8%), renal effects (13.7% vs. 7.8% vs. 22.2%, with the PT of acute kidney injury reported in no patients &lt;65 or 65-74 and in 8.3% patients ≥75),  skin  effects  (78.4%  vs.  71.1%  vs.  63.9%,  with  the  difference  driven  primarily  by  the  PT  of dermatitis  acneiform:  30.7%  vs.  23.3%  vs.  8.3%)  upper  GI  tract  inflammatory  events  (46.4%  vs. 34.4% vs. 36.1%).

## Pooled population

Consistent  with  FLAURA,  the  overall  incidence  of  AEs  was  similar  (&gt;  98%)  among  the  3  groups: patients &lt; 65 years (N=657), patients 65-74 years (N=338) and patients ≥ 75 years (N=147). As well as in FLAURA study, the incidence of AEs in each category, except AEs causally related to osimertinib, appeared to be age-dependent: AEs of CTCAE grade ≥ 3 (33.3%, 40.5%, 53.1%, respectively), AEs of CTCAE grade ≥ 3 considered by the Investigator to be possibly related to osimertinib (10.7%, 16.3% 24.5%),  SAE  (25.6%,  29.3%,  36.7%)  and  SAE  considered  to  be  possibly  causally  related  to osimertinib (4.0%, 8.9%, 9.5%).

## Effect of baseline performance status

<div style=\"page-break-after: always\"></div>

## Study FLAURA

Assessment  of  the  safety  profile  of  osimertinib  at  the  AE  category  level  among  patients  with  WHO performance status (PS) at baseline of 0 (N=112) and WHO score of 1 (N=167) in FLAURA showed alignment with the overall safety profile. With the exception of a higher incidence of AEs of CTCAE ≥ grade 3 in patients with the higher baseline WHO score (29.5% score 0 vs. 37.1% score 1).

The only key safety topic grouped terms of interest with a difference of &gt;10 pp between WHO score of 0 and WHO score or 1 patients was Upper GI tract inflammatory events (50.9% for patients with a WHO score of 0 vs. 34.7% for patients with a WHO score of 1). The difference was driven primarily by the  PT  of  stomatitis,  which  was  reported  in  39.3%  of  WHO  score  of  0  patients  and  21.6%  of  WHO score of 1 patients.

## Pooled population

Consistent  with  FLAURA,  the  overall  incidence  of  AEs  was  similar  (&gt;  98%)  among  the  2  groups: patients with WHO PS of 0 (N=420) and PS of 1 (N=721). The incidence of CTCAE grade ≥ 3 AEs (31.2% score 0  vs.  41.9%  score  1)  and  the  incidence  of  CTCAE  grade  ≥  3  AEs  considered  by  the Investigator  possibly  related  to  osimertinib  (10.0%  vs.  16.5%)  was  higher  in  patients  with  higher baseline WHO score. The incidence of SAE was also higher in patients with WHO score 1 (23.6% vs. 30.7%). SAE considered to be possibly related to osimertinib were similar between both groups (5.0% WHO score 0 vs. 6.8% WHO score 1).

## Effect of comorbidity of hypertension

## Study FLAURA

Assessment of the safety profile of osimertinib at the AE category level among patients with a history of hypertension (N=109) and those with no hypertension (N=170) in FLAURA showed alignment with the overall safety profile. The overall incidence of AEs was similar between the 2 groups; AEs causally related to osimertinib were broadly similar for patients with and those without hypertension (89% vs. 91.8%,  respectively).  A  greater  proportion  of  patients  with  hypertension  than  patients  without hypertension had AEs that were CTCAE ≥ grade 3 (39.8% hypertension vs. 30.6% no hypertension) or were reported as SAEs (29.4% hypertension vs. 16.5% no hypertension).

The  2  groups  were  broadly  consistent  in  terms  of  the  most  commonly  reported  PTs,  with  only decreased appetite (26.6% hypertension vs. 15.9% no hypertension) and headache (3.7% hypertension vs. 17.1% no hypertension) having a difference of ≥ 10 pp. The only key safety topic grouped  terms  of  interest  with  a  difference  of  &gt;10  pp  between  patients  with  a  co-morbidity  of hypertension  and  those  without  was  Upper  GI  tract  inflammatory  events  (33.9%  co-morbidity  of hypertension vs. 45.9% those without). The difference was driven primarily by the PT of stomatitis, which  was  reported  in  27  (24.8%)  patients  with  a  co-morbidity  of  hypertension  and  53  (31.2%) patients without.

## Pooled population

Consistent  with  FLAURA  the  overall  incidence  of  AEs  was  similar  (&gt;  98%)  between  patients  with comorbidity of hypertension (N=393) and patients without comorbidity of hypertension (N=746). The incidence of AEs that were CTCAE ≥ grade 3 was slightly higher in patients with hypertension than patients  without  hypertension  (42.4%  vs.  35.7%,  respectively).  There  were  no  notable  differences between the 2 groups in any other of the categorical parameters.

<div style=\"page-break-after: always\"></div>

## Effect of baseline renal function

## Study FLAURA

Table 56: Adverse events in any category, by baseline renal function among patients in the osimertinib arm in FLAURA (Safety analysis set)

|                                                                                   | Number (%) of patientsa       | Number (%) of patientsa         | Number (%) of patientsa           |
|-----------------------------------------------------------------------------------|-------------------------------|---------------------------------|-----------------------------------|
| Adverseevent category                                                             | Normalrenal function (N = 99) | Mild renal impairment (N = 122) | Moderate renal impairment (N= 46) |
| Any AE                                                                            | 97 (98.0)                     | 120 (98.4)                      | 45 (97.8)                         |
| Any AE causally related to osimertinibb                                           | 91 (91.9)                     | 113 (92.6)                      | 40 (87.0)                         |
| Any AEof CTCAE grade 3 or higher                                                  | 22 (22.2)                     | 48 (39.3)                       | 23 (50.0)                         |
| Any AE of CTCAE grade 3 or higher, causally related to osimertinibb               | 12 (12.1)                     | 24 (19.7)                       | 12 (26.1)                         |
| Any AE with outcome = death                                                       | 2 (2.0)                       | 3 (2.5)                         | 1 (2.2)                           |
| Any AE with outcome = death, causally related to osimertinibb                     | 0                             | 0                               | 0                                 |
| Any SAE (including events with outcome = death)                                   | 17 (17.2)                     | 24 (19.7)                       | 16 (34.8)                         |
| Any SAE (including events with outcome = death), causally related to osimertinibb | 4 (4.0)                       | 10 (8.2)                        | 6 (13.0)                          |
| AnySAE leading todiscontinuation of osimertinib                                   | 4 (4.0)                       | 10 (8.2)                        | 5 (10.9)                          |
| AnyAE leadingtodiscontinuation of osimertinib                                     | 9 (9.1)                       | 20 (16.4)                       | 7 (15.2)                          |
| AnyAEleadingtodiscontinuation of osimertinib, causally related to osimertinibb    | 8 (8.1)                       | 14 (11.5)                       | 5 (10.9)                          |

b As assessed by theInvestigator assessment and programmatically derived from individual causality assessments

a Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Includes AEs with an onset date on or after the date of first dose and up to and including 28 days following discontinuation of randomised treatment or the day before start of new anticancer treatment (including crossover treatment for FLAURA patients).

CTCAE = Common Terminology Criteria for Adverse Events version 4.03.

MedDRA version 20.0.

Data cut-off: 12 June 2017

Source:Table 2.7.4.s2fs,Pooled safety,Module 5.3.5.3.

## Pooled population

Consistent  with  FLAURA  the  overall  incidence  of  AEs  was  similar  (&gt;  98%)  between  patients  with normal renal  function  (N=407),  mild  renal  function  (N=497)  and  moderate  renal  function  (N=220). The  incidence  of  AEs  of  CTCAE  ≥  grade  3  considered  by  the  Investigator  to  be  posibly  related  to osimertinib was higher in patiens with moderate impairment (19.5%) than in patiens with normal renal function  (10.3%)  or  mild  renal  function  (14.9%).  SAE  were  numerically  higher  in  patients  with moderate renal impairment (32.7%) than in patients with normal function (28%) or mild renal function (26.4%).

## Effect of baseline hepatic function

## Study FLAURA

Table 24. Adverse events in any category, by baseline function among patients in the osimertinib arm in FLAURA (Safety analysis set)

<div style=\"page-break-after: always\"></div>

|                                                                                   | Nunber (%) of patientsa           | Nunber (%) of patientsa          |
|-----------------------------------------------------------------------------------|-----------------------------------|----------------------------------|
| Adverse event category                                                            | Normal hepatic function (N = 233) | Mild hepatic impairment (N = 40) |
| Any AE                                                                            | 228 (97.9)                        | 40 (100)                         |
| Any AE causally related to osimertinibb                                           | 211 (90.6)                        | 38 (95.0)                        |
| Any AE of CTCAE grade 3 or higher                                                 | 72 (30.9)                         | 22 (55.0)                        |
| Any AE of CTCAE grade 3 or higher, causally related to osimertinibb               | 37 (15.9)                         | 11 (27.5)                        |
| Any AE with outcome = death                                                       | 5 (2.1)                           | 1 (2.5)                          |
| Any AE with outcome = death, causally related to osimertinibb                     | 0                                 | 0                                |
| Any SAE (including events with outcome = death)                                   | 45 (19.3)                         | 13 (32.5)                        |
| Any SAE (including events with outcome = death), causally related to osimertinibb | 14 (6.0)                          | 6 (15.0)                         |
| Any SAE leading to discontinuation of osimertinib                                 | 14 (6.0)                          | 6 (15.0)                         |
| Any AE leading to discontinuation of osimertinib                                  | 27 (11.6)                         | 10 (25.0)                        |
| AnyAEleadingtodiscontinuationofosimertinib,causally related to osimertinibb       | 19 (8.2)                          | 8 (20.0)                         |

a Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

Includes AEs with an onset date on or after the date of first dose and up to and including 28 days following discontinuation of randomised treatment or the day before start of new anticancer treatment (including crossover treatment for FLAURA patients).

b As assessed by the Investigator assessment and programmatically derived from individual causality assessments.

CTCAE = Common Terminology Criteria for Adverse Events version 4.03. MedDRA version 20.0.

Data cut-off: 12 June 2017

Source: Table 2.7.4.s2gs,Pooled safety, Module 5.3.5.3.

## Pooled population

Consistent  with  FLAURA,  the  overall  incidence  of  AEs  was  similar  (&gt;98%)  in  patients  with  normal hepatic  function  (N=955)  and  mild  hepatic  function  (N=169).  There  were  no  notable  differences between the 2 groups in most of the categorical parameters, apart from the incidence of AEs of CTCAE ≥ grade 3 (37.0% normal function vs. 43.8% mild function).

<div style=\"page-break-after: always\"></div>

## Effect of smoking status

## Table 57: Adverse events in any category, by baseline smoking status among patients in the osimertinib

Study FLAURA arm in FLAURA (Safety analysis set)

|                                                                                    | Nunber (%) of patientsa   | Nunber (%) of patientsa   |
|------------------------------------------------------------------------------------|---------------------------|---------------------------|
| Adverse event category                                                             | Ever smoked (N =97)       | Never smokedl (N = 182)   |
| Any AE                                                                             | 96 (99.0)                 | 177 (97.3)                |
| Any AE causally related to osimertinibb                                            | 90 (92.8)                 | 163 (89.6)                |
| Any AE ofCTCAE grade 3 or higher                                                   | 30 (30.9)                 | 65 (35.7)                 |
| Any AE of CTCAE grade 3 or higher, causally related to osimertinibb                | 13 (13.4)                 | 36 (19.8)                 |
| Any AE with outcome = death                                                        | 1 (1.0)                   | 5 (2.7)                   |
| Any AE with outcome = death, causally related to osimertinibb                      | 0                         | 0                         |
| Any SAE (including events with outcome = death)                                    | 19 (19.6)                 | 41 (22.5)                 |
| Any SAE (including events with outcome = death), causally related to osimertinibb  | 6 (6.2)                   | 16 (8.8)                  |
| AnySAE leading to discontinuation of osimertinib                                   | 7 (7.2)                   | 13 (7.1)                  |
| Any AE leading to discontinuation of osimertinib                                   | 16 (16.5)                 | 21 (11.5)                 |
| Any AE leading to discontinuation of osimertinib, causally related to osimertinibb | 12 (12.4)                 | 15 (8.2)                  |

2 Patients with multiple events in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Includes AEs with an onset date on or after the date of first dose and up to and including 28 days following discontinuation of randomised treatment or the day before start of new anticancer treatment (including crossover treatment for FLAURApatients).

b AsassessedbytheInvestigatorassessmentandprogrammaticallyderivedfromindividualcausality assessments.

CTCAE = Common Terminology Criteria for Adverse Events version 4.03.

MedDRA version 20.0.

Data cut-off:12June2017

Source:Table 2.7.4.s2hs,Pooled safety, Module 5.3.5.3.

## Pooled population

The overall incidence of AEs was similar (&gt; 98%) between Ever smoked patients (N=366) and Never smoked  patients  (N=776).  No  differences  were  observed  between  the  2  groups  in  any  of  the categorical parameters.

## Effect of body weight

## Study FLAURA

Table 58: Adverse events in any category, by body weight among patients in the osimertinib arm in FLAURA (Safety analysis set)

|                                                                                | Number (%) of patients ab   | Number (%) of patients ab   |
|--------------------------------------------------------------------------------|-----------------------------|-----------------------------|
| Adverse event category                                                         | Body weight <43 kg (N=15)   | Body weight >= 43kg (N=256) |
| Any AE                                                                         | 15 (100)                    | 251 (98.0)                  |
| Any AE causally related to AZD9291 c                                           | 15 (100)                    | 232 (90.6)                  |
| Any AE of CTCAE grade 3 or higher                                              | 10 (66.7)                   | 84 (32.8)                   |
| Any AE of CTCAE grade 3 or higher, causally related to AZD9291 b               | 6 (40.0)                    | 43 (16.8)                   |
| Any AE with outcome = death                                                    | 0                           | 6 (2.3)                     |
| Any AE with outcome = death, causally related to AZD9291 b                     | 0                           | 0                           |
| Any SAE (including events with outcome = death)                                | 3 (20.0)                    | 56 (21.9)                   |
| Any SAE (including events with outcome = death), causally related to AZD9291 b | 2 (13.3)                    | 20 (7.8)                    |

<div style=\"page-break-after: always\"></div>

|                                                                             | Number (%) of patients ab   | Number (%) of patients ab   |
|-----------------------------------------------------------------------------|-----------------------------|-----------------------------|
| Adverse event category                                                      | Body weight <43 kg (N=15)   | Body weight >= 43kg (N=256) |
| Any SAE leading to discontinuation of AZD9291                               | 1 (6.7)                     | 18 (7.0)                    |
| Any AE leading to discontinuation of AZD9291                                | 1 (6.7)                     | 35 (13.7)                   |
| Any AE leading to discontinuation of AZD9291, causally related to AZD9291 b | 1 (6.7)                     | 26 (10.2)                   |

a Patients with multiple events in the same category were counted only once in that category. Patients with events in more than one category were counted once in each of those categories.

There were 8 patients who did not have a baseline weight and were excluded from the table.

As assessed by the investigator assessment, and programmatically derived from individual causality assessments.

Included adverse events with an onset date on or after the date of first dose and up to and including 28 days following discontinuation of randomised treatment or the day before start of new anticancer treatment

CTCAE = Common Terminology Criteria for Adverse Events (version 4.0). MedDRA version 20.0.

Table 59: Most common adverse events, by body weight among patients in the osimertinib arm in FLAURA (frequency of ≥10% in either body weight category) (Safety analysis set) a

|                                         | Number (%) of patients   | Number (%) of patients    |
|-----------------------------------------|--------------------------|---------------------------|
| MedDRA PT                               | Body weight <43kg (N=15) | Body weight ≥43kg (N=256) |
| Diarrhoea                               | 7 (46.7)                 | 149 (58.2)                |
| Stomatitis                              | 9 (60.0)                 | 69 (27.0)                 |
| Dry skin                                | 5 (33.3)                 | 82 (32.0)                 |
| Decreased appetite                      | 6 (40.0)                 | 50 (19.5)                 |
| Dermatitis acneiform                    | 6 (40.0)                 | 63 (24.6)                 |
| Paronychia                              | 8 (53.3)                 | 73 (28.5)                 |
| Electrocardiogram QT prolonged          | 8 (53.3)                 | 20 (7.8)                  |
| Nausea                                  | 2 (13.3)                 | 35 (13.7)                 |
| Alanine aminotransferase increased      | 2 (13.3)                 | 15 (5.9)                  |
| Anaemia                                 | 4 (26.7)                 | 28 (10.9)                 |
| Aspartate aminotransferase increased    | 2 (13.3)                 | 23 (9.0)                  |
| Rash maculo-papular                     | 3 (20.0)                 | 34 (13.3)                 |
| Upper respiratory tract infection       | 4 (26.7)                 | 24 (9.4)                  |
| Viral upper respiratory tract infection | 2 (13.3)                 | 25 (9.8)                  |
| Constipation                            | 3 (20.0)                 | 39 (15.2)                 |
| Fatigue                                 | 2 (13.3)                 | 36 (14.1)                 |
| Skin fissures                           | 4 (26.7)                 | 12 (4.7)                  |
| Vomiting                                | 1 (6.7)                  | 29 (11.3)                 |
| White blood cell count decreased        | 6 (40.0)                 | 18 (7.0)                  |
| Alopecia                                | 2 (13.3)                 | 18 (7.0)                  |
| Conjunctivitis                          | 2 (13.3)                 | 12 (4.7)                  |
| Cough                                   | 1 (6.7)                  | 43 (16.8)                 |
| Insomnia                                | 2 (13.3)                 | 24 (9.4)                  |
| Malaise                                 | 3 (20.0)                 | 7 (2.7)                   |
| Rash                                    | 2 (13.3)                 | 14 (5.5)                  |
| Vertigo                                 | 2 (13.3)                 | 1 (0.4)                   |
| Weight decreased                        | 4 (26.7)                 | 9 (3.5)                   |

<div style=\"page-break-after: always\"></div>

|                               | Number (%) of patients   | Number (%) of patients    |
|-------------------------------|--------------------------|---------------------------|
| MedDRA PT                     | Body weight <43kg (N=15) | Body weight ≥43kg (N=256) |
| Blood bilirubin increased     | 2 (13.3)                 | 4 (1.6)                   |
| Dizziness                     | 2 (13.3)                 | 16 (6.3)                  |
| Dysgeusia                     | 2 (13.3)                 | 16 (6.3)                  |
| Dyspnoea                      | 0                        | 33 (12.9)                 |
| Headache                      | 1 (6.7)                  | 31 (12.1)                 |
| Hypokalaemia                  | 2 (13.3)                 | 10 (3.9)                  |
| Hyponatraemia                 | 2 (13.3)                 | 10 (3.9)                  |
| Lymphopenia                   | 3 (20.0)                 | 3 (1.2)                   |
| Pruritus                      | 0                        | 46 (18.0)                 |
| Pyrexia                       | 2 (13.3)                 | 26 (10.2)                 |
| Urinary tract infection       | 2 (13.3)                 | 9 (3.5)                   |
| Leukopenia                    | 2 (13.3)                 | 16 (6.3)                  |
| Lymphocyte count decreased    | 2 (13.3)                 | 4 (1.6)                   |
| Onychomadesis                 | 2 (13.3)                 | 2 (0.8)                   |
| Peripheral sensory neuropathy | 2 (13.3)                 | 6 (2.3)                   |

b Number (%) of subjects with AEs. Included AEs with onset date on or after the date of first dose up to and including 28 days following discontinuation of randomised treatment or the day before first administration of treatment

MedDRA version 20.0

## Safety related to drug-drug interactions and other interactions

No new data on drug-drug interactions were reported.

## Discontinuation due to adverse events

At DCO1 A total of 351 (63.1%) patients had discontinued their randomised treatment: 138 (49.5%) in the osimertinib arm and 213 (76.9%) in the SoC arm. In both treatment arms, the most frequent reason for treatment discontinuation was worsening of the condition under investigation (osimertinib: 87 patients [31.2%]; SoC: 151 patients [54.5%]). Other reasons for treatment discontinuation, summarised by primary reason, were: adverse events (osimertinib: 36 [12.9%]; SoC: 50 [18.1%]); subject decision: (osimertinib: 12 [4.3%]; SoC: 8 [2.9%]); severe non-compliance to protocol (osimertinib: 0; SoC: 1 [0.4%]); other reasons: 6 (1.1%) patients (osimertinib: 3 [1.1%]; SoC: 3 [1.1%]).

## Adverse events leading to discontinuation

## Study FLAURA

The majority of discontinuations were due to single events.

<div style=\"page-break-after: always\"></div>

Table 60: Adverse events leading to discontinuation of study drug in more than 1% of patients in either treatment arm in FLAURA, by preferred term (Safety analysis set)

|                                      | Number (%) of patients *   | Number (%) of patients *   | Number (%) of patients *   | Number (%) of patients *   |
|--------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                      | Osimertinib S0 mg (N=279)  | Osimertinib S0 mg (N=279)  | Standard of Care (N=177)   | Standard of Care (N=177)   |
| MfedDRA preferred term               | DC01                       | 90 DSU                     | DC01                       | 90 DSU                     |
| Any AE leading to discontimuation    | 37 (13.3)                  | 37 (13.3)                  | 49 (17.7)                  | 49 (17.7)                  |
| Interstitial lmg disease             | 6 (2.2)                    | 6 (2.2)                    | 3 (1.1)b                   | 3 (1.1)b                   |
| Pneumonitis                          | 5 (1.8)                    | 5 (1.8)                    | 1 (0.4) b                  | 1 (0.4) b                  |
| ECG QT prolonged                     | 4 (1.4)                    | 4 (1.4)                    | 1 (0.4)                    | 1 (0.4)                    |
| Pneumonia                            | 1 (0.4)                    | 1 (0.4)                    | 3 (1.1)                    | 3 (1.1)                    |
| Alanine aminotransferase increased   | 0                          | 0                          | 12 (4.3)                   | 12 (4.3)                   |
| Aspartate aminotransferase imcreased | 0                          | 0                          | 8 (2.9)                    | 8 (2.9)                    |
| Dianhoea                             | 0                          | 0                          | 5 (1.8)                    | 5 (1.8)                    |
| Hepatic fimction abnormal            | 0                          | 0                          | 4(1.4)                     | 4 (1.4)                    |
| Drug-induced liver injury            | 0                          | 0                          | 3 (1.1)                    | 3 (1.1)                    |

a Number (%o) of patients with an AE leading to discontinuation of study drug (action taken penmamently stopped), with preferred tenms sorted in descending order within the osimertinib arm.

b Although the protocol mandated discontinuation of study treatment for patients who had ILD, 2 patients in the SoC arm had AEs (IL D and pneumonitis [l patient each]) but continued on treatment.

PatientswithmultipleAEswere couwtedonceforeachprefered temm.

Includes AEs with an onset date on or after the date of first dose and up to and including 28 days following discontinuation of randomised treatment or the day before first administration of crossover teahment.

MedDRA=Medical Dictionary forRegulatoryActivitiesversion 20.0.

Data cut-off date: DC01=12 Jume 2017; 90 DSU DC0=25 September 2017

Souce: see Table 17, Module 2.7.4 dated 4 0ctober 2017 and see Table 11.3.5.1.1, Appendix A

## Pooled population

AEs leading to discontinuation of osimertinib in the pooled population was reported by 109 patients (9.5%). AEs events leading of study discontinuation causally related to osimertinib were 64 (5.6%).

## Adverse events leading to dose reduction

## FLAURA

AEs leading to dose reduction were reported in a low proportion of patients in each treatment arm, although the SoC arm had a numerically higher proportion: 11 (3.9%) osimertinib vs. 17 (6.1%) SoC. Adverse events leading to dose interruption

## FLAURA

Adverse  events  with  an  action  taken  of  dose  interruption  were  reported  in  similar  proportion  of patients: 72 (25.8%) patients in the osimertinib arm and 70 (25.3%) patients in the SoC arm. There did not appear to be any single AE driving the interruption rate in the osimertinib arm, as 17 events led to dose interruption in more than 1 patient each in the osimertinib arm, none of which was reported in more than 3% of patients. In the SoC arm, increases in transaminases were the primary reason for drug interruptions.

## Analysis of safety after crossover in Phase III study FLAURA

48 (17.3%) patients in FLAURA crossed over to osimertinib treatment after BICR-confirmed objective progression on SoC and a T790M positive test result based on tissue or plasma. A new baseline was determined at the start of osimertinib treatment for these patients.

## Common adverse events

Adverse  events  were  reported  in  37  (77.1%)  of  the  48  patients  randomised  to  the  SoC  arm  who crossed over to osimertinib following confirmed objective progression on SoC.

The  most  frequently  reported  PTs  (≥10%  of  crossover  patients)  were  diarrhoea  (9  [18.8%]),  and paronychia,  cough,  dry  skin,  and  nausea  (5  [10.4%]).  Adverse  events  of  CTCAE  ≥grade  3  were

<div style=\"page-break-after: always\"></div>

reported in 6/48 (12.5%) patients. The CTCAE ≥grade 3 AEs included pneumonia in 2 (4.2%) patients; and bacteraemia, febrile infection, oesophageal candidiasis, oral candidiasis, anxiety, atrial thrombosis, and  septic  shock  in  1  (2.1%)  patient  each.  There  were  no  CTCAE  grade  4  AEs  in  patients  after crossover.  One  case  of  pneumonia  and  the  case  of  septic  shock  were  CTCAE  grade  5  AEs,  both  of which were considered to be unrelated to osimertinib.

## Adverse events of special interest

In general, no new safety findings were seen in AESIs after crossover. Within the key safety topic AEs, the only PTs reported in &gt;10% of patients after crossover were diarrhoea (9 [18.8%]) and paronychia and  dry  skin  (5  [10.4%]  each).  No  CTCAE  ≥grade  3  key  safety  topic  AESIs  were  reported  in  any patient after crossover.

## Serious adverse events

Serious AEs were reported for 8 (16.7%) of the 48 crossover patients. The only SAE reported in more than 1 patient was pneumonia, in 2 (4.2%) patients. In neither patient was the SAE considered by the Investigator to be possibly related to osimertinib.

## Deaths

A  total  of  9  deaths  were  reported  after  patients  crossed  over  to  osimertinib  following  confirmed objective disease progression on the SoC treatment, either during the crossover period or its 28-day follow-up.  Seven  (77.8%) of the 9 deaths were considered by the Investigator to be related to the disease under investigation only. In 2 (22.2%) of the 9 patients, the death was considered to be due to an AE only.

## Clinical laboratory results

Adverse events in the Blood &amp; lymphatic disorders SOC included CTCAE grade 2 anaemia in 1 (2.1%) patient. Adverse events related to haematology tests in the Investigations SOC were neutrophil count decreased in 2 (4.2%) patients (both CTCAE grade 2) and WBC count decreased (CTCAE grade 2) in 1 (2.1%) patient. No SAEs were reported in these SOCs.

## Discontinuations and dose modification

Adverse events led to permanent discontinuation of osimertinib in 2 (4.2%) of the 48 patients who crossed  over  to  osimertinib  after  PD:  pneumonia  in  Patient  E2205008  and  septic  shock  in  Patient E3402006, each of which led to the patient's death. Neither AE was considered by the Investigator to be possibly related to osimertinib.

In the 48 SoC patients who crossed over to osimertinib therapy after PD, only 1 patient had a dose interruption due to an AE (weight decreased). Adverse events of rash and oral candidiasis each led to dose reduction to 40 mg osimertinib in 1 (2.1%) patient after crossover.

<div style=\"page-break-after: always\"></div>

## Results of analyses on pooled dataset

Table 61: Summary of key safety topics across pooled safety datasets

|                                                            | Percentageofpatientsreceiving osimertinibS0mginFLAURA? (N=279)   | Percentageofpatientsreceiving osimertinibS0mginFLAURA? (N=279)   | Percentageofpatientsreceiving osimertinibS0mginFLAURA? (N=279)   | Percentageofpatientsreceiving osimertinibS0mginFLAURA? (N=279)   | Percentage ofpatientsreceiving osimertinib 80 mg in Phase I, II or II studiesb (N=1142)   | Percentage ofpatientsreceiving osimertinib 80 mg in Phase I, II or II studiesb (N=1142)   | Percentage ofpatientsreceiving osimertinib 80 mg in Phase I, II or II studiesb (N=1142)   | Percentage ofpatientsreceiving osimertinib 80 mg in Phase I, II or II studiesb (N=1142)   |
|------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Topice                                                     | Any CTCAE grade                                                  | CTCAE grade 1                                                    | CICAE grade 2                                                    | CTCAE grade 3-4                                                  | Any CTCAE grade                                                                           | CICAE grade 1                                                                             | CTCAE grade 2                                                                             | CTCAE grade3-4                                                                            |
| ILD (grouped term)                                         | 11 (3.9)                                                         | 2 (0.7)                                                          | 6 (2.2)                                                          | 3 (1.1)                                                          | 45 (3.9)                                                                                  | 11 (1.0)                                                                                  | 17 (1.5)                                                                                  | 12 (1.1)d                                                                                 |
| Torsade de pointes (TdP)/QT prolongation (SMQ)             | 28 (10.0)                                                        | 11 (3.9)                                                         | 11 (3.9)                                                         | 6 (2.2)                                                          | 70 (6.1)                                                                                  | 35 (3.1)                                                                                  | 22 (1.9)                                                                                  | 13 (1.1)                                                                                  |
| Arrhythmias (SMQ)                                          | 0                                                                | 0                                                                | 0                                                                | 0                                                                | 1 (0.1)                                                                                   | 1 (0.1)                                                                                   | 0                                                                                         | 0                                                                                         |
| Cardiomyopathy (SMQ)                                       | 10 (3.6)                                                         | 3 (1.1)                                                          | 5 (1.8)                                                          | 2 (0.7)                                                          | 22 (1.9)                                                                                  | 3 (0.3)                                                                                   | 14 (1.2)                                                                                  | 5 (0.4)                                                                                   |
| Cardiac failure (SMQ)                                      | 12 (4.3)                                                         | 3 (1.1)                                                          | 6 (2.2)                                                          | 3 (1.1)                                                          | 30 (2.6)                                                                                  | 3 (0.3)                                                                                   | 19 (1.7)                                                                                  | 7 (0.6)d                                                                                  |
| Rashes & acnes (grouped term)                              | 161 (57.7)                                                       | 134 (48.0)                                                       | 24 (8.6)                                                         | 3 (1.1)                                                          | 535 (46.8)                                                                                | 447 (39.1)                                                                                | 78 (6.8)                                                                                  | 10 (0.9)                                                                                  |
| Dry skin (grouped term)                                    | 100 (35.8)                                                       | 87 (31.2)                                                        | 12 (4.3)                                                         | 1 (0.4)                                                          | 372 (32.6)                                                                                | 324 (28.4)                                                                                | 47 (4.1)                                                                                  | 1 (0.1)                                                                                   |
| Pruritus (grouped term)                                    | 48 (17.2)                                                        | 40 (14.3)                                                        | 7 (2.5)                                                          | 1 (0.4)                                                          | 194 (17.0)                                                                                | 162 (14.2)                                                                                | 31 (2.7)                                                                                  | 1 (0.1)                                                                                   |
| Exfoliativerash(groupedterm)                               | 8 (2.9)                                                          | 6 (2.2)                                                          | 2 (0.7)                                                          | 0                                                                | 26 (2.3)                                                                                  | 21 (1.8)                                                                                  | 5 (0.4)                                                                                   | 0                                                                                         |
| Skin&subcutaneoustissue disorders (grouped term)           | 20 (7.2)                                                         | 17 (6.1)                                                         | 3 (1.1)                                                          | 0                                                                | 53 (4.6)                                                                                  | 47 (4.1)                                                                                  | 6 (0.5)                                                                                   | 0                                                                                         |
| Diarrhoea (PT)                                             | 161 (57.7)                                                       | 120 (43.0)                                                       | 35 (12.5)                                                        | 6 (2.2)                                                          | 555 (48.6)                                                                                | 450 (39.4)                                                                                | 91 (8.0)                                                                                  | 14 (1.2)                                                                                  |
| Oralinflammationevents (grouped term)                      | 94 (33.7)                                                        | 75 (26.9)                                                        | 17 (6.1)                                                         | 2 (0.7)                                                          | 277 (24.3)                                                                                | 214 (18.7)                                                                                | 61 (5.3)                                                                                  | 2 (0.2)                                                                                   |
| Non-oral upper GI tract inflammatory events (grouped term) | 35 (12.5)                                                        | 30 (10.8)                                                        | 4 (1.4)                                                          | 1 (0.4)                                                          | 160 (14.0)                                                                                | 133 (11.6)                                                                                | 23 (2.0)                                                                                  | 4 (0.4)                                                                                   |
| GI tractinflammationofunspecified location (grouped term)  | 1 (0.4)                                                          | 1 (0.4)                                                          | 0                                                                | 0                                                                | 12 (1.1)                                                                                  | 11 (1.0)                                                                                  | 1 (0.1)                                                                                   | 0                                                                                         |
| Nail effects (grouped term)                                | 97 (34.8)                                                        | 52 (18.6)                                                        | 44 (15.8)                                                        | 1 (0.4)                                                          | 357 (31.3)                                                                                | 242 (21.2)                                                                                | 112 (9.8)                                                                                 | 3 (0.3)                                                                                   |
| Keratitis (grouped term)                                   | 1 (0.4)                                                          | 1 (0.4)                                                          | 0                                                                | 0                                                                | 8 (0.7)                                                                                   | 3 (0.3)                                                                                   | 4 (0.4)                                                                                   | 1 (0.1)                                                                                   |

Table 62: Summary of key safety topics across pooled safety datasets

|                                                                                                      | Percentageofpatientsreceiving osimertinibS0mginFLAURAa (N=279)                                       | Percentageofpatientsreceiving osimertinibS0mginFLAURAa (N=279)                                       | Percentageofpatientsreceiving osimertinibS0mginFLAURAa (N=279)                                       | Percentageofpatientsreceiving osimertinibS0mginFLAURAa (N=279)                                       | Percentageofpatientsreceiving osimertinib S0 mg in Phase I, II or III studiesb (N=1142)              | Percentageofpatientsreceiving osimertinib S0 mg in Phase I, II or III studiesb (N=1142)              | Percentageofpatientsreceiving osimertinib S0 mg in Phase I, II or III studiesb (N=1142)              | Percentageofpatientsreceiving osimertinib S0 mg in Phase I, II or III studiesb (N=1142)              |
|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Topice                                                                                               | Any CTCAE grade                                                                                      | CTCAE grade1                                                                                         | CTCAE grade 2                                                                                        | CTCAE grade 3-4                                                                                      | Any CTCAE grade                                                                                      | CTCAE grade1                                                                                         | CTCAE grade2                                                                                         | CTCAE grade 3-4                                                                                      |
| Conjunctival disorders (SMQ)                                                                         | 37 (13.3)                                                                                            | 31 (11.1)                                                                                            | 6 (2.2)                                                                                              | 0                                                                                                    | 128 (11.2)                                                                                           | 98 (8.6)                                                                                             | 30 (2.6)                                                                                             | 0                                                                                                    |
| Cormeal disorders (SMQ)                                                                              | 1 (0.4)                                                                                              | 1 (0.4)                                                                                              | 0                                                                                                    | 0                                                                                                    | 10 (0.9)                                                                                             | 5 (0.4)                                                                                              | 4 (0.4)                                                                                              | 1 (0.1)                                                                                              |
| Lacrimal disorders (SMQ)                                                                             | 22 (7.9)                                                                                             | 20 (7.2)                                                                                             | 2 (0.7)                                                                                              | 0                                                                                                    | 77 (6.7)                                                                                             | 69 (6.0)                                                                                             | 8 (0.7)                                                                                              | 0                                                                                                    |
| Periorbitalandeyeliddisorders (SMQ)                                                                  | 6 (2.2)                                                                                              | 5 (1.8)                                                                                              | 1 (0.4)                                                                                              | 0                                                                                                    | 32 (2.8)                                                                                             | 25 (2.2)                                                                                             | 7 (0.6)                                                                                              | 0                                                                                                    |
| Misc ocularterms(grouped term)                                                                       | 9 (3.2)                                                                                              | 9 (3.2)                                                                                              | 0                                                                                                    | 0                                                                                                    | 62 (5.4)                                                                                             | 57 (5.0)                                                                                             | 5 (0.4)                                                                                              | 0                                                                                                    |
| Investigations ^ (findings are based on CTCAE grade shifts from baseline in laboratory test results) | Investigations ^ (findings are based on CTCAE grade shifts from baseline in laboratory test results) | Investigations ^ (findings are based on CTCAE grade shifts from baseline in laboratory test results) | Investigations ^ (findings are based on CTCAE grade shifts from baseline in laboratory test results) | Investigations ^ (findings are based on CTCAE grade shifts from baseline in laboratory test results) | Investigations ^ (findings are based on CTCAE grade shifts from baseline in laboratory test results) | Investigations ^ (findings are based on CTCAE grade shifts from baseline in laboratory test results) | Investigations ^ (findings are based on CTCAE grade shifts from baseline in laboratory test results) | Investigations ^ (findings are based on CTCAE grade shifts from baseline in laboratory test results) |
| Plateletcountdecreased (n=1135 for pooled dataset)                                                   | 138 (50.5)                                                                                           | 132 (48.4)                                                                                           | 4 (1.5)                                                                                              | 2 (0.7)                                                                                              | 614 (54.1)                                                                                           | 566 (49.9)                                                                                           | 30 (2.6)                                                                                             | 18 (1.6)                                                                                             |
| Leukocyte count decreased (n=1128forpooled dataset)                                                  | 191 (71.8)                                                                                           | 133 (50.0)                                                                                           | 57 (21.4)                                                                                            | 1 (0.4)                                                                                              | 765 (67.8)                                                                                           | 539 (47.8)                                                                                           | 209 (18.5)                                                                                           | 17 (1.5)                                                                                             |
| Neutrophil count decreased (n=1128forpooleddataset)                                                  | 109 (40.8)                                                                                           | 53 (19.9)                                                                                            | 48 (18.0)                                                                                            | 8 (3.0)                                                                                              | 391 (34.7)                                                                                           | 171 (15.2)                                                                                           | 174 (15.4)                                                                                           | 46 (4.1)                                                                                             |
| Lymphocytecount decreased (n=1127 for pooled dataset)                                                | 168 (62.9)                                                                                           | 79 (29.6)                                                                                            | 74 (27.7)                                                                                            | 15 (5.6)                                                                                             | 756 (67.1)                                                                                           | 375 (33.3)                                                                                           | 300 (26.6)                                                                                           | 81 (7.2)                                                                                             |
| Electrocardiogramandechocardiogramresults                                                            | Electrocardiogramandechocardiogramresults                                                            | Electrocardiogramandechocardiogramresults                                                            | Electrocardiogramandechocardiogramresults                                                            | Electrocardiogramandechocardiogramresults                                                            | Electrocardiogramandechocardiogramresults                                                            | Electrocardiogramandechocardiogramresults                                                            | Electrocardiogramandechocardiogramresults                                                            | Electrocardiogramandechocardiogramresults                                                            |
| QTcFincrease>500msec                                                                                 | 3/279 (1.1)                                                                                          | 3/279 (1.1)                                                                                          | 3/279 (1.1)                                                                                          | 3/279 (1.1)                                                                                          | 10/1142 (0.9)                                                                                        | 10/1142 (0.9)                                                                                        | 10/1142 (0.9)                                                                                        | 10/1142 (0.9)                                                                                        |
| QTcFincrease>60sec                                                                                   | 14/279 (5.0)                                                                                         | 14/279 (5.0)                                                                                         | 14/279 (5.0)                                                                                         | 14/279 (5.0)                                                                                         | 41/1142 (3.6)                                                                                        | 41/1142 (3.6)                                                                                        | 41/1142 (3.6)                                                                                        | 41/1142 (3.6)                                                                                        |
| LVEF values with >10% pp decreasefrombaselinetoan absolute value<50%)                                | 8/257 (3.1)                                                                                          | 8/257 (3.1)                                                                                          | 8/257 (3.1)                                                                                          | 8/257 (3.1)                                                                                          | 35/908 (3.9)                                                                                         | 35/908 (3.9)                                                                                         | 35/908 (3.9)                                                                                         | 35/908 (3.9)                                                                                         |

a EachpatienthasonlybeenrepresentedwiththemaximumreportedCTCAEgradeforeachpreferredterm.

b Includespatientsfromthefollowingstudies:FLAURA,AURA3,AURA2,AURAextension,andAURAPhase1

P Inadditiontothepatientsshownhere,therewere5patientswithaCTCAEgrade5eventofILD(groupedterm)(4inAURA2/AURA1Cand1in AURA3)and1patientwithaCTCAEgrade5eventofcardiacfailureinAURA3.

C Baselineisdefinedasthelastresultobtainedpriortothestartof studytreatment.Percentageshavebeencalculatedusingthenumberofpatients(n)with abaselinevalueandanon-treatmentvalue.OnlyworseningshiftsinCTCgradeareincluded(wherethemaximumontreatmentCTCgrade&gt;baseline CTCgrade).

Includesadverseeventsorassessmentswithanonsetdateonorafterthedateoffirstdoseanduptoandincluding28daysfollowingdiscontinuationof randomisedtreatmentorthedaybeforestartofnewanticancertreatment(includingcrossovertreatmentforAURA3andFLAURApatients). CTCAE=CommonTerminologyCriteriaforAdverseEvents(version4.03);MedDRA=MedicalDictionaryforRegulatoryActivities,version20.0. Datacut-offdates:12June2017forFLAURA,15April2016forAURA3,1November2016forthePhaseI-IIstudies

Source:Table 2.7.4.2.2,Table 2.7.4.2.2.2,Table 2.7.4.6.3,Table 2.7.4.6.6 andTable 2.7.4.7.3,Pooled Safety,Module 5.3.5.3.

<div style=\"page-break-after: always\"></div>

## Post marketing experience

Post-marketing  data  have  been  summarised  in  the  latest  PBRER,  which  included  data  from  13 November  2016  to  12  May  2017.  In  this  PBRER,  the  total  cumulative  post-marketing  exposure  to osimertinib for all doses and all countries as of 12 May 2017 was 7295.5 patient-years.

In the PBRER period from 13 November 2016 to 12 May 2017, the majority of postmarketing cases received  were  in  keeping  with  the  patient  population  being  treated  and  the  known  safety  profile  of osimertinib. Cumulatively, the most frequent spontaneously reported events were from the Investigations  SOC  (n=188), the majority of which were non-serious (n=164). The most frequently reported event in this SOC was platelet count decreased (n=38), of which 37 were non-serious. Events in the Gastrointestinal disorders SOC were the next most frequently reported (n=179), the majority of which  were  non-serious  (n=147).  The  most  commonly  reported  event  was  dry  mouth  (n=73;  nonserious =61). The third most frequent SOC in terms of reported events was Skin and subcutaneous tissue  disorders  (n=178;  non-serious  =  169),  with  rash  being  the  most  commonly  reported  event (n=59; non-serious = 54).

No further changes to the reference safety information have been made since marketing approval of osimertinib.

## 2.5.1. Discussion on clinical safety

The safety profile assessment is based mainly on 556 patients from the FLAURA study (279 received 80 mg osimertinib [DCO 12 June 2017] and 277 patients received SoC). All patients randomised to the SoC  arm  in  the  US  received  erlotinib  and  all  patients  randomised  in  Japan  received  gefitinib.  The results have not been split on gefitinib and erlotinib, but are combined to SoC group.

The accumulated safety population consists of 1142 patients from Phase I-III studies treated with 80 mg osimertinib, including the 279 patients in the FLAURA study.

A total of 48 patients crossed over to osimertinib treatment within the study after confirmed objective disease progression on SoC and a T790M positive test result based on tissue or plasma.

## Adverse events (AEs)

No new safety signals have been detected from the FLAURA study. The safety profile reported is in line with the adverse reactions that have previously been described.

Generally, the safety profile of osimertinib appears similar to that of the SoC (erlotinib and gefitinib). However, osimertinib had a more favourable profile regarding severity of AEs with a lower frequency of AEs CTCAE grade 3 or higher causally related to treatment of 18.3% compared to 28.2% for SoC.

The most frequently reported AEs (≥ 50%) in either arm were in the SOCs of Gastrointestinal disorders (78.5% vs. 87.0%, osimertinib and SoC respectively), Skin &amp; subcutaneous tissue disorders (77.4% vs.  87.0%) and Infections and Infestations (66.3% vs. 60.6%). The incidence of AEs was generally similar  between  the  two  treatment  arms,  except  for  the  AEs  in  the  skin  &amp;  subcutaneous  tissue disorders, which were reported in a greater proportion of patients in the SoC arm.

The most commonly reported PTs in the osimertinib arm (≥ 20%) were diarrhoea (58.1% vs. 58.1%, osimertinib  and  SoC  respectively),  dry  skin  (31.5  vs.  32.5%),  paronychia  (29.4%  vs.  29.6%), stomatitis  (28.7%  vs.  20.2%),  dermatitis  acneiform  (25.4%  vs.  48.4%)  and  decreased  appetite (22.2% vs. 19.5%).

Among  these  most  common  AEs  stomatitis  was  more  frequent  in  the  osimertinib  arm  whereas dermatitis acneiform was more frequent in the SoC. Other PTs more frequent in the osimertinib arm

<div style=\"page-break-after: always\"></div>

were:  ECG  QT  prolonged  (10.0%  vs.  4.3%),  pyrexia  (10.4%  vs.  4.0%)  and  dyspnoea  (12.9%  vs. 7.6%). In the SoC arm the incidence of AST increased (9.3% vs. 24.5%), ALT increased (6.5% vs. 27.1%)  and  alopecia  (7.2%  vs.  12.6%)  was  higher  than  in  the  osimertinib  arm.  In  general,  the incidence  of  most  common AEs was similar in both treatment arms. Other differences of notice are decrease in platelet count, leucocytes, lymphocytes and neutrophils (some associated with AEs) and cardiac failure (4.7% osimertinib vs 2.2% SoC).

AEs of CTCAE ≥ grade 3 was lower in the osimertinib arm t han in the SoC arm (36.9% vs. 45.1%, respectively) as well as those AEs of CTCAE ≥ grade 3 considered by the Investigator to be possibly related to study treatment (18.3% vs. 28.2%). Differences observed between treatment arms seem to be driven to a great extent by hepatic (transaminases increased) and skin related events (dermatitis acneiform mainly), more frequent in the SoC arm. The most frequently reported AEs of CTCAE ≥ grade 3 considered to be possibly related to osimertinib were diarrhoea (2.2%), decreased apetite and ECG QT  prolonged  (1.8%  each),  ILD  and  GGT  increased  (1.1%  each),  asthenia,  fatigue,  AST  increased, ejection fraction decreased, neutrophil count decreased and platelet count decreased (0.7% each).

## Adverse events of special interest (AESIs)

ILD/pneumonitis : ILD grouped term (ILD and pneumonitis) has a low but numerically higher incidence in the osimertinib arm than in the SoC arm (4.3% vs. 2.2%, respectively).

Cardiac effects (QT) : adverse events in the overall cardiac effect grouped term (QT) were reported in a higher  proportion  of  patients  in  the  osimertinib  arm  than  in  the  SoC  arm  (11.5%  vs.  5.4%, respectively).

Cardiac  effects  (cardiac  failure) :  cardiac  failure  AEs  were  reported  in  a  low  but  numerically  higher proportion in the osimertinib arm (4.7%) than in the SoC arm (2.2%).

None of the comparators gefitinib and erlotinib have included cardiac effects as adverse reaction in the SmPCs (section 4.8) or mentioned it in special warnings and precautions (section 4.4). Cardiac failure is  included  in  the  RMP  of  osimertinib  as  an  important  potential  risk,  QT  prolongation  is  listed  as  an adverse reaction and left ventricular ejection fraction (LVEF) decrease is mentioned in section 4.4 of the SmPC. QT prolongation is much higher for females compared to males (14.0% females vs. 3.0% males) and Asian compared to white population (14.4% Asian vs. 3.0% white). The analysis of a large number of potential risk factors using the LVEF decrease data together with osimertinib PK exposure did  not  identify  any  covariates  potentially  confounding  the  exposure-to-LVEF  event  probability relationship.

Diarrhoea : diarrhoea was the most commonly reported AE in either treatment arm (58.1%, each), with a low incidence of AEs of CTCAE ≥ grade 3 (2.2% osimertinib vs. 2.5% SoC).

Skin effects : incidence of Skin Effects grouped term was lower in the osimertinib arm than in the SoC arm  (74.2%  vs.  85.2%,  respectively);  differences  observed  between  treatment  arms  were  driven mainly by PT dermatitis acneiform.

Upper gastrointestinal tract inflammatory events : incidence of AEs in this grouped term was higher in the osimertinib arm than in the SoC arm (41.2% vs. 32.5%, respectively).

Nail  effects :  AEs  in  this  grouped  term  were  reported  in  35.8%  patients  in  the  osimertinib  arm  and 33.6% patients in the SoC arm.

Ocular effects : incidence of AEs ocular effects grouped term was lower in the osimertinib arm than in the SoC arm (17.2% vs. 23.1%), being all of them grade 1 or grade 2 in the osimertinib arm. No SAEs were reported.

<div style=\"page-break-after: always\"></div>

Renal  effects :  renal-related  AEs  were  reported  in  15.1%  patients  in  the  osimertinib  arm  and  9.7% patients in the SoC arm.

Hepatobiliary  effects :  hepatic-related  AEs  were  reported  in  a  lower  proportion  of  patients  in  the osimertinib arm than in the SoC arm (14.7% vs. 36.5%, respectively), driven most of them by the Investigations SOC (12.5% vs. 31.0%, osimertinib and SoC respectively).

Infections and infestations :  infections and infestations were reported in 185 (66.3%) patients in the osimertinib arm and 168 (60.6%) in the SoC arm.

## Serious Adverse Events (SAEs)

The  incidence  of  SAEs  was  similar  between  the  osimertinib  and  SoC  arms  (22.6%  vs.  26.0%, respectively). The most frequently reported SAEs considered to be possibly related to osimertinib were interstitial lung disease, pneumonitis, diarrhoea, enterocolitis and pyrexia.

## Deaths

Overall  71  patients  (25.4%)  in  the  osimertinib  arm  and  97  patients  (35.0%)  in  the  SoC  arm  died. There  were  16  deaths  reported  as  AEs  (8  osimerinib,  8  SoC)  of  which  one  in  the  SoC  arm  was considered possibly related to study drug. None of the deaths in the osimertinib arm were considered to be possibly related to study treatment.

## Laboratory findings

Early reductions in the median laboratory counts of leukocytes, lymphocytes, neutrophils and platelets have been observed in patients treated with TAGRISSO, which stabilised over time and then remained above  the  lower  limit  of  normal.  Adverse  events  of  leukopenia,  lymphopenia,  neutropenia  and thrombocytopenia have been reported, most of which were mild or moderate in severity and did not lead to dose interruptions.

## Special populations

The MAH has conducted additional analyses based on updated data from 1142 patients, of which 197 patients  were  below  50  kg.  Low  weight  (&lt;50  kg)  and  high  age  (&gt;65  years)  were  identified  as significant  predictors  of  developing  AEs  of  CTCAE  grade≥  3.  Gender  and  race  were  not  significant predictors after these effects were accounted for.

According to logistic regression analyses, a patient weighing &lt;50 kg is approximately twice as likely to develop  CTCAE  grade≥  3  AE  and  2-4  times  as  likely  to  develop  QT  prolongation  compared  with patients in  the  higher  weight  categories.  In  the  QT  prolongation  analysis,  there  was  also  a  genderrelated difference, with the probability of QT prolongation being 2.3 higher in females compared with males. This gender-related QT prolongation difference is well described in the literature. No effect of race was seen.

At 80 mg dose, patients with low body weight (&lt;50 kg) had higher frequencies of Grade ≥3 adverse events (52% vs. 35%) and QT prolongation (14% vs. 4%) than patients with higher body weight (≥50 kg).

Patients  with  high  age  (&gt;65  years)  and/or  low  body  weight  (&lt;50  kg)  are  at  increased  risk  of developing adverse events of Grade 3 or higher. Closer monitoring is recommended in these patients.

It  is  reported  that  renal  events  are  more  than  doubled  when  normal  renal  function  is  compared  to moderate renal impairment.

Given the low grade of severity of events (mostly grade 1 or 2) and the limited number of cases at this time no further changes to the product information is warranted. The MAH is currently running a phase I study in patients with advanced solid tumours and normal as well as severe renal impairment where PK,  safety  and  tolerability  of  osimertinib  are  investigated.  The  MAH  is  recommended  to  submit  the results which will provide additional data on patients with renal impairment.

<div style=\"page-break-after: always\"></div>

Discontinuation of study treatment due to AEs appears similar among treatment arms: 37 (13.3%) in the  osimertinib  arm  and  49  (17.7%)  in  the  SoC  arm.  In  the  osimertinib  arm,  27  (9.7%)  were considered to be possibly related to study treatment. In relation to dose modifications (interruptions and dose reductions), no differences were reported between osimertinib arm and SoC arm (38.7% vs. 38.6%), however, modifications due to AEs were lower in the osimertinib arm than in SoC arm (25.4% vs. 32.1%).

Overall, safety profile and tolerability of osimertinib in FLAURA study seems similar to that reported from previous studies. No new signals have been identified.

## 2.5.2. Conclusions on clinical safety

Overall the safety profile of osimertinib in first line locally advanced or metastatic NSCLC with EGFR mutations (exon 19 deletions or exon 21 substitution) is consistent with the known safety profile in patients with the T790M mutation. No new safety signals have been identified in the FLAURA study.

Cardiac effects, QT prolongation, cardiac failure and cardiomyopathy seem to be reported at a higher frequency in FLAURA compared to the pooled population, both regarding total number and numbers with grade 3-4. Cardiac and haematological effects associated with a decrease in counts of platelets, leucocytes,  neutrophils  and  lymphocytes  are  consistently  reported  at  higher  frequencies  in  the osimertinib arm compared to the gefitinib or erlotinib arm. The majority of these effects were of lower grade and manageable with few SAEs.

AEs that led to discontinuation of treatment and AEs of CTCAE grade 3 or higher causally related to treatment were reported in a lower proportion of patients in the osimertinib arm than in the SoC arm. The proportion of SAEs were similar between treatment arms. The totality of the safety data indicate that osimertinib was at least as well tolerated as the SoC comparator.

The present data confirms that osimertinib is well tolerated considering the disease being treated.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 10 is acceptable.

The CHMP endorsed the Risk Management Plan version 10 with the following content:

## Safety concerns

## List of safety concerns

## Important Identified Risks

- Interstitial lung disease
- QT prolongation

<div style=\"page-break-after: always\"></div>

## List of safety concerns

| Important Potential Risks   | • Developmental toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing Information         | • Hepatotoxicity • Long term exposure to osimertinib • Use during lactation • Use in patients with moderate or severe hepatic impairment • Use in patients with severe renal impairment • Use in patients with ECOG performance status ≥2 • Use in patients with symptomatic brain metastases • Potential for drug-drug interactions between osimertinib and non-CYP3A4 mediated PXR substrates • Potential for P-gp inhibition • Use in very elderly patients (≥75 years old) |

No new safety concerns were identified  as  a  result  of  this  extension  of  indication,  but  some  of  the existing safety concerns were deleted based on:

-  the  results  of   the  FLAURA and the re-evaluation of the overall safety profile of osimertinib (using updated pooled datasets comprising integrated safety data from cross-programme osimertinib Phase I to III studies).
- the revised GVP module V guideline and RMP template (rev.2)

The important identified risk 'QT prolongation', while also observed in the Flaura study, was removed from the list because there was no evidence to suggest that the effects of osimertinib on QT interval leads to any undesirable clinical outcomes. Extensive information on risk of QT prolongations will still be provided in the product information.

## Pharmacovigilance plan

## Ongoing and planned additional pharmacovigilance activities

| Study name and description Study Status                       | Summary of objectives                                                                                      | Safety concerns addressed                                     | Milestones                                                    | Due dates (planned/ actual)                                   |
|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities                                              | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| D5165C00001 (CAURAL) A phase III, multi-                      | Primary Objective: • To investigate the safety and tolerability profile of osimertinib in combination with | • ILD                                                         | Protocol submission                                           | 21 May 2015 (actual)                                          |

<div style=\"page-break-after: always\"></div>

## Ongoing and planned additional pharmacovigilance activities

| Study name and description                                                                                                                                                                                                                                                                                      | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Safety concerns addressed    | Milestones                                 | Due dates (planned/ actual)            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|--------------------------------------------|----------------------------------------|
| Study Status centre, open label, randomized study to assess the efficacy and safety of osimertinib in combination with MEDI4736 versus osimertinib monotherapy in patients with locally advanced or metastatic EGFR T790M mutation- positive NSCLC who have received prior EGFR TKI therapy. • Status : Ongoing | MEDI4736. Exploratory Objectives (applicable to osimertinib) : • To assess the safety and tolerability of osimertinib as a single agent • To obtain a preliminary assessment of the efficacy of osimertinib in combination with MEDI4736 and osimertinib monotherapy • To assess the PK of osimertinib as a single agent and in combination with MEDI4736. • To collect and store deoxyribonucleic acid (DNA) for future exploratory research into genes/genetic variation that may influence PK or response osimertinib as a single agent and in combination with MEDI4736 (i.e. absorption, distribution, metabolism, excretion, safety and efficacy) and/or susceptibility to/development of cancers. • To collect and store tumour samples and blood-based (plasma and serum) samples for potential exploratory research into factors that may influence susceptibility to/development of NSCLC/cancer and/or osimertinib as a single agent and in combination with MEDI4736 (where response is defined broadly to include efficacy, tolerability or safety). |                              | CSR (primary analysis)                     | May 2018 (planned)                     |
| D5160C00022 (ASTRIS) Open label, multinational,                                                                                                                                                                                                                                                                 | Primary Objective: • To assess the efficacy and safety of single agent osimertinib in a real world setting in adult patients with advanced or metastatic, EGFR T790M mutation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | • ILD                        | Protocol submission CSR (primary           | 08 Jun 2015 (actual) Q1 2020           |
| D5160C00008 An open-label, non-randomised, multicentre, comparative, phase                                                                                                                                                                                                                                      | Primary Objective: • To characterise the effect of hepatic impairment on the PK of osimertinib after a single oral dose of 80 mg to patients with advanced solid tumours and mild or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | • Use patients with moderate | Protocol submission CSR (primary analysis) | 22 Jul 2014 (actual) Q1 2018 (planned) |

<div style=\"page-break-after: always\"></div>

## Ongoing and planned additional pharmacovigilance activities

| Study name and description Study Status                                                                                                                                                                                                      | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Safety concerns addressed   | Milestones   | Due dates (planned/ actual)   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------------|-------------------------------|
| I study to determine the pharmacokinetics, safety and tolerability of osimertinib following a single oral dose to patients with advanced solid tumours and normal hepatic function or mild or moderate hepatic impairment • Status : Ongoing | moderate hepatic impairment or normal hepatic function. Secondary Objectives: • To characterise the effect of hepatic impairment on the PK of osimertinib metabolites AZ5104 and AZ7550 after a single oral dose of 80 mg to patients with advanced solid tumours and mild or moderate hepatic impairment or normal hepatic function. • To investigate the safety and tolerability of single and multiple oral doses of osimertinib in advanced solid tumour patients with mild or moderate hepatic impairment and in those with normal hepatic function. | severe hepatic impairment   |              |                               |

## D5160C00035

An open-label, non-randomised, multicentre, Phase I  study  to  assess the Pharmacokinetics, safety and tolerability of osimertinib following a single oral 80 mg dose to patients with advanced solid tumours and normal renal function  or  severe renal impairment.

## · Status :

Ongoing

## Primary Objective:

- To investigate the PK of osimertinib after a  single  oral  dose  of  80  mg  in  patients with  advanced solid  tumours  and  normal renal function or severe renal impairment.

## Secondary Objectives:

- To  investigate  the  PK  of  osimertinib  and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.
- To  investigate  the  safety  and  tolerability of  a  single  oral  dose  of  osimertinib  in patients with advanced solid tumours and normal  renal function or severe renal impairment.
- Use in patients with severe renal impairment Protocol submission 28 Oct 2016 (actual) CSR (primary analysis) Dec 2018 (planned)

<div style=\"page-break-after: always\"></div>

## Ongoing and planned additional pharmacovigilance activities

| Study name and description Study Status                                                                                                                                                                             | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Safety concerns addressed                                                                              | Milestones                                    | Due dates (planned/ actual)         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-----------------------------------------------|-------------------------------------|
| D5160C00036 (BLOOM) A Phase I, open- label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of osimertinib in patients with EGFRm advanced stage NSCLC. | Primary Objective: • To investigate the safety and tolerability of AZD3759 (both Part A and Part B) when given orally to patients with advanced stage EGFR m+ NSCLC who have progressed following prior therapy, including Maximum Tolerated Dose (MTD) determination, if possible (Part A only) Secondary Objectives: • To evaluate anti-tumour efficacy and safety in patients treated with osimertinib • To determine the PK of osimertinib and metabolites in blood and CSF following multiple oral dosing • To evaluate the changes from baseline in CNS symptoms (analysed from BN20) in patients with BM and/or LM | • Use in patients with ECOG performance status ≥2 • Use in patients with symptomati c brain metastases | CSR (primary analysis) CSR (primary analysis) | Q2 2018 (planned) Q1 2018 (planned) |

No new safety studies were proposed. Existing routine and additional pharmacovigilance activities remain sufficient to characterise the risks of the product.

## Risk minimisation measures

| Safety concern             | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Pharmacovigilance activities                                                                                                                                                                                                          |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks | Important identified risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Important identified risks                                                                                                                                                                                                            |
| ILD                        | Routine risk minimisation measures: • ILD (grouped term) is listed as an ADR in Section 4.8 ( Undesirable effects ) if the current SmPC. • Appropriate wording in Section 4.2 ( Posology and method of administration ) and Section 4.4 ( Special warnings and special precautions for use ) of the current SmPC relating to the importance of detection and subsequent management of this important identified risk. • Advice to patients to report relevant medical history prior to starting treatment, and/or report any relevant symptoms during treatment is provided in the PL. Additional risk minimisation measures : • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : • Targeted follow-up questionnaire Additional pharmacovigilance activities : • Study D5165C00001 (CAURAL) • Study D5160C00022 (ASTRIS) |

<div style=\"page-break-after: always\"></div>

## Safety concern

## Risk minimisation measures

## Important potential risks

Cardiac failure

## Routine risk minimisation measures:

- Appropriate wording Section 4.4 ( Special warnings and special precautions for use) of the current SmPC advising prescribers to consider monitoring of patients with cardiac risk factors or those who develop relevant cardiac signs/symptoms during treatment.
- Advice to patients to report relevant cardiac history prior to starting treatment, and/or report any relevant symptoms during treatment is provided in the PL.

## Additional risk minimisation measures :

- None

## Missing information

Use in patients with moderate or severe hepatic impairment

## Routine risk minimisation measures:

- Appropriate wording in Section 4.2 ( Posology and method of administration ) and Section 5.2 ( Pharmacokinetic properties ) of the SmPC relating to the administration of osimertinib in this patient population.

## Additional risk minimisation measures :

- None

## Routine risk minimisation measures:

- Appropriate wording in Section 4.2 ( Posology and method of administration ) and Section 5.2 ( Pharmacokinetic properties ) of the SmPC relating to the administration of osimertinib in this patient population.

## Additional risk minimisation measures :

- None

## Routine risk minimisation measures:

- Appropriate wording in Section 4.5 ( Interaction with other medicinal products and other forms of interaction ) and Section 5.2 ( Pharmacokinetic properties ) of the current SmPC states that PXR regulated enzyme interactions other than CYP3A4 have not been studied.

## Additional risk minimisation measures :

- None

## Routine risk minimisation measures:

- Appropriate wording in Section 5.2 ( Pharmacokinetic properties ) of the current SmPC states that osimertinib is an inhibitor P gp.

## Additional risk minimisation measures :

- None

Use in patients severe with renal impairment

Potential for drug-drug interactions between osimertinib and non-CYP3A4 mediated PXR substrates

Potential for P-gp inhibition

## Pharmacovigilance activities

## Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection :

- Targeted follow-up questionnaire

## Additional pharmacovigilance activities :

- None

## Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection :

- None

## Additional pharmacovigilance activities :

- Study D5160C00008

Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection :

- None

## Additional pharmacovigilance activities :

- Study D5160C00035

Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection :

- None

## Additional pharmacovigilance activities :

- Study D5160C00036

Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection :

- None

## Additional pharmacovigilance

## activities :

- Study D5160C00036

<div style=\"page-break-after: always\"></div>

| Safety concern                                    | Risk minimisation measures                                                                | Pharmacovigilance activities                                                                                                                                                |
|---------------------------------------------------|-------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use in patients with ECOG performance status ≥2   | Routine risk minimisation measures: • None Additional risk minimisation measures : • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : • None Additional pharmacovigilance activities :                             |
| Use in patients with symptomatic brain metastases | Routine risk minimisation measures: • None Additional risk minimisation measures : • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : • None Additional pharmacovigilance activities : • Study D6030C00001 (BLOOM) |

Abbreviations: ECOG, Eastern Co-operative Oncology Group; ILD, interstitial lung disease; SmPC, Summary of Product Characteristics; PL, Package leaflet; P-gp, P-glycoprotein; PXR, Pregnane X receptor

Routine risk minimisation activities remain sufficient to manage the safety concerns of osimertinib also in this indication.

This section was updated in line with the amendments proposed for the safety specification, and was also brought in line with the new RMP template.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. Particularly, a new warning with regard to increased risk of developing adverse events of Grade 3 or higher in patients &gt; 65 years and &lt;50 kg has been added to the product information. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

No justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH. However, the changes to the package leaflet are minimal and do not require user consultation with target patient groups.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The claimed indication of osimertinib is for first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have EGFR exon 19 deletions (Ex19del) or substitution of a leucine with an arginine at position 858 in exon 21 (L858R) mutations.

Lung cancer is the fourth most frequently diagnosed cancer in the EU, but remains the leading cause of cancer related deaths. Despite progress in early detection and treatment, in 70% to 80% of patients, NSCLC is diagnosed at a locally advanced or metastatic stage, when it is no longer amenable to curative surgery or chemoradiation (Besse et al 2014).

Recent advances in the knowledge of tumour-specific genomic abnormalities have enabled the identification of specific molecular targets for NSCLC treatment in the current clinical practice (Keedy et al 2011, Leighl et al 2014, NCCN 2017, Novello et al 2016, Travis et al 2011). Several biomarkers have shown to be predictive of therapeutic efficacy of molecularly targeted agents and immune-oncology agents, including the presence of sensitising EGFR mutations.

Sensitising mutations in the EGF-receptor are found in 10% of patients with lung cancer in the European Economic Area and 30% to 50% of patients with lung cancer in Asia. In addition to the higher prevalence of EGFR mutations in Asian patients, overall, EGFR mutations have been found to be more frequent in patients with the adenocarcinoma histological subtype and in women. Smoking is the main cause of lung cancer in general, but is not a risk factor for developing activating mutations in the EGF-receptor, in fact the incidence seems higher in never-smokers than in smokers.

In summary, locally advanced or metastatic NSCLC with EGFR activating mutations is an incurable condition with poor prognosis.

## 3.1.2. Available therapies and unmet medical need

Epidermal growth factor receptor- TKIs such as such as gefitinib (Iressa), erlotinib (Tarceva), afatinib (Giotrif) are the current standard of care as first-line therapy for EGFR mutation-positive NSCLC. Such treatments result in improved response rate (RR) and progression free survival (PFS), better tolerability and superior quality of life (QoL) compared with platinum-based chemotherapy in the first line setting, as demonstrated in several randomised trials.

Although most tumours initially respond well systemically to the currently approved EGFR TKIs in firstline setting, the vast majority of patients develop TKI resistance with a median PFS of 9 to 13 months. In approximately 50% to 65% of the patients the resistance is due to the development of a secondsite EGFR-TKI resistance-conferring 'gatekeeper' point mutation, T790M leading to treatment failure and disease progression.

Limited data are available on the efficacy of EGFR-TKIs against CNS metastases in first-line setting, given that CNS metastases have been a typical exclusion criterion in historical studies involving these agents. A selection of trials studying the activity of EGFR-TKIs in patients with NSCLC harbouring EGFR mutations and CNS metastases report response rates of 70-85%, but these trials were of limited quality.

<div style=\"page-break-after: always\"></div>

Despite the progress in treating lung cancer patients with activating mutations in the EGF-receptor, the prognosis of patients with this indication is still poor, demonstrating the need for improved treatment in these patients.

## 3.1.3. Main clinical studies

To support the application, the MAH submitted efficacy data from one single clinical study. FLAURA is a Phase III, double-blind, randomised study (1:1 ratio) designed to compare the efficacy of osimertinib vs. SoC (either gefinitib or erlotinib) as first-line treatment in patients with locally-advanced or metastatic EGFRm NSCLC.

Stratification factors included EGFR mutation status (Ex19del or L858R) ethnicity (Asian/Non-Asian). The primary efficacy endpoint of FLAURA was PFS based on investigator assessment (RECIST v1.1). OS, ORR, DoR, QoL and post progression outcomes (PFS2) were included as secondary endpoints.

## 3.2. Favourable effects

At the time of the primary analysis for PFS (per investigator assessment; 48.7% of events in the osimertinib arm and 74.4% in SoC arm) a statistically significant and clinically relevant improvement was shown for osimertinib compared to the SoC arm (HR: 0.46 [95% CI: 37, 0.575]; p-value: &lt;0.0001). Treatment with osimertinib resulted in a 8.7-month improvement in median PFS compared to SoC.

PFS results according to BICR on the FAS are consistent with main analysis. Different sensitivity analyses also support robustness of results. Subgroup analyses for PFS showed consistent results in all subgroups analysed.

Regarding OS, a HR of 0.63 (CI 95% 0.45, 0.88) that did not reach the pre-specified threshold for statistical significance at this interim analysis was observed. Superior rates at different time points consistently favoured osimertinib arm (OS rates at 12 months: 89.1% vs. 82.5%; 18 months: 82.8% vs. 70.9%).

A numerical trend favouring osimertinib was observed for ORR (79.9% (95% CI: 74.7, 84.5) in the osimertinib arm and 75.8% (95% CI: 70.3, 80.7) in the SoC arm). Responses were twice longer in the osimertinib arm than in SoC (median 17.2 months vs. 8.5 months).

CNS efficacy by RECIST v1.1 in FLAURA demonstrated an improvement in CNS PFS HR: 0.48 (95% CI: 0.26, 0.86). An ORR of 65.6% (95% CI: 52.3, 77.3) was documented in the osimertinib arm vs. 43.3% (95% CI: 31.2, 56.0) in the SoC arm in the subset of patients with brain metastasis.

The median PFS2 on subsequent treatment was not reached in the osimertinib arm, with a lower limit of the 95% CI of 23.7 months, and was 20.0 months (95% CI: 18.2, NR) in the SoC arm. A HR of 0.58 (95% CI: 0.44, 0.78; p-value = 0.0004), was observed.

## 3.3. Uncertainties and limitations about favourable effects

Os data submitted were immature. Final OS data will be submitted together with other relevant endpoints such as TFST and TSST when available.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

Generally, the safety profile of osimertinib appears similar to that of the SoC (erlotinib and gefitinib). Overall incidence of AEs was 97.8% in both treatment arms, with most of the AEs being considered by the Investigator to be possibly related to study treatment.

The most commonly reported PTs in the osimertinib arm (≥ 20%) were diarrhoea (57.7% vs. 57.4%, osimertinib and SoC respectively), dry skin (31.5 vs. 32.5%), paronychia (29.0% vs. 28.9%), stomatitis (28.7% vs. 20.2%), dermatitis acneiform (25.4% vs. 48.4%) and decreased appetite (20.1% vs. 18.8%). Other PTs more frequent in the osimertinib arm were: ECG QT prolonged (10.0% vs. 4.0%), pyrexia (10.0% vs. 4.0%) and dyspnoea (12.5% vs. 7.2%).

The most frequently reported AEs of CTCAE ≥ grade 3 considered to be possibly related to osimertinib were diarrhoea (2.2%), decreased apetite and ECG QT prolonged (1.8% each), ILD and GGT increased (1.1% each), asthenia, fatigue, AST increased, ejection fraction decreased, neutrophil count decreased and platelet count decreased (0.7% each).

ILD grouped term (ILD and pneumonitis) in the osimertinib was 3.9%, AEs grade 3 was 1.1%.

Adverse events in the overall cardiac effect grouped term (QT) were reported in 10.4% of patients.

Incidence of Skin Effects grouped term was 74.2% of patients.

The incidence of AEs in the Upper gastrointestinal tract inflammatory events was 41.2% of patients. Stomatitis was the most frequent PT in the osimertinib arm (28.7%).

The incidence of SAEs was 21.5% with osimertinib. The most frequently reported SAEs (≥ 1%) were pneumonia (7 [2.5%] patients), ILD and pulmonary embolism (4 [1.4%] each), and pleural effusion (3 [1.1%]).

The majority of deaths in the osimertinib arm were considered to be related to the disease under investigation. None of deaths in the osimertinib arm were considered to be possibly related to study treatment.

Safety profile in males and females was overall similar, although AEs ≥ grade 3 was higher in females than in males. A higher incidence of ECG QT prolonged was also reported in female patients (3.0% vs. 14%). Incidence of AEs causally related to osimertinib was higher in Asian patients than in White patients as well as AE of CTCAE ≥ grade 3. Moreover, a higher incidence of ECG QT prolonged (3.0% vs. 14.4%) and dermatitis acneiform (17.8% vs. 29.3%) was also reported in Asian patients than in White patients. In patients ≥ 75 years incidence of AE of CTCAE ≥ grade 3, SAEs and SAEs possibly related to osimertinib was higher.

Discontinuation of study treatment due to AEs was 13.3% in the osimertinib arm, and 9.7% were considered to be possibly related to study treatment. AEs leading to dose interruption were 25.1%, AEs leading to dose reduction were 3.9%. No new signals have been identified.

Patients aged &gt;65 years and/or low body weight (&lt;50 kg) are at increased risk of developing adverse events of Grade 3 or higher.

## 3.5. Uncertainties and limitations about unfavourable effects

No additional key uncertainties and limitations have been identified.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 63: Effects Table for osimertinib in first-line treatment in patients with locally-advanced or metastatic NSCLC with exon 19 deletions or exon 21 substitution (data cut-off: 12 June 2017)

| Effect               | Short description                                     | Unit                 | Treatment            | Control              | Uncertainties / Strength of evidence                        | References           |
|----------------------|-------------------------------------------------------|----------------------|----------------------|----------------------|-------------------------------------------------------------|----------------------|
| Favourable Effects   | Favourable Effects                                    | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                                          | Favourable Effects   |
| PFS INV              | Progression free survival by investigator             | Months               | 18.9                 | 10.2                 | HR 0.46 (95% CI 0.37, 0.57)                                 | CSR                  |
| OS                   | Overall survival                                      | Months               | NR                   | NR                   | HR 0.63 (95% CI 0.45, 0.88) NES at the time of this 1 st IA | CSR                  |
| ORR INV              | Overall response rate per invesigator (not confirmed) | %                    | 79.9                 | 75.8                 |                                                             |                      |
| Unfavourable Effects | Unfavourable Effects                                  | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                        | Unfavourable Effects |
| AEs grade ≥3         | Adverse events of CTCAE grade ≥3                      | %                    | 34.1                 | 44.8                 |                                                             |                      |
| SAEs                 | Serious AEs regardless causality                      | %                    | 21.5                 | 25.3                 |                                                             |                      |
| Deaths               | Number of deaths                                      | Absolute value       | 2.2                  | 3.6                  |                                                             |                      |
| ILD and pneumonitis  | AE of special interest                                | %                    | 3.9                  | 2.2                  |                                                             |                      |
| Cadiac effects       | AE of special interest                                | %                    | 4.3                  | 2.2                  |                                                             |                      |
| QT prolongation      | AE of special interest                                | %                    | 10.0                 | 4.0                  |                                                             |                      |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The use of EGFR TKIs in patients with activating (sensitising) EGFR mutations NSCLC, have improved the clinical outcomes of these patients, with higher antitumor activity, greater delay in the tumour progression and better quality of life as compared to traditional platinum based chemotherapy. TKIs of first or second generation have been considered the SoC in this patient population.

Osimertinib has now proven to prolong PFS in a clinically relevant manner when compared to SoC, erlotinib or gefitinib, which could likely translate into longer OS for patients (as pointed out by preliminary data). The efficacy was observed regardless of CNS metastases, and across other subgroups. The better clinical outcomes could be a new milestone in the SoC, moving the first choice in the current treatment armamentarium. The uncertainties related to the FLAURA study, lack of mature OS data, do not overcome the benefits associated to this therapy as a clear effect is evident from the preliminary data.

Generally, the safety profile of osimertinib appears similar to that of the SoC (erlotinib and gefitinib). Overall the safety profile of osimertinib in first line locally advanced or metastatic NSCLC with EGFR mutations (exon 19 deletions or exon 21 substitution) is consistent with the known safety profile in the currently authorised indication, in patient harbouring the T790M mutation. No new signals have been identified. Additionally, safety profile and tolerability of osimertinib appear similar to other TKIs (erlotinib and gefitinib), with a lower incidence of severe (CTCAE ≥ grade 3) AEs reported with osimertinib.

Although only patients with Ex19del or L858R mutations were included in the FLAURA study, the available preclinical data and limited clinical data support a broad indication regardless of the type of activating EGFR mutations.

<div style=\"page-break-after: always\"></div>

## 3.7.2. Balance of benefits and risks

Results from FLAURA trial are considered to demonstrate a clinically relevant and significant advantage over the current SoC as first-line treatment of patients with EGFR+ NSCLC whereas the safety profile remains in line with what has been previously described.

## 3.8. Conclusions

The overall B/R of Tagrisso as first-line therapy in EGFR mutation-positive patients with metastatic or locally advanced NSCLC is considered to be positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include (as monotherapy) first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations, based on data from the FLAURA study (D5160C00007): a phase III, double-blind, randomised study to assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor-Tyrosine Kinase Inhibitor as first-line treatment in patients with epidermal growth factor receptor mutation-positive, locally-advanced or metastatic non-small-cell lung cancer; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 of the SmPC have been updated and the Package Leaflet has been updated accordingly. Further, sections 4.4 and 4.8 of the SmPC have been updated with a new warning with regard to increased risk of developing adverse events of Grade 3 or higher in patients &gt; 65 years and &lt;50 kg. In addition, the MAH took the opportunity to update sections 2 and 4.4 of the SmPC with information regarding the excipient sodium, and to implement editorial changes in the SmPC and Package Leaflet. An updated RMP version 10.0 was agreed during the procedure.

## Additional market protection

Furthermore, the CHMP reviewed the data submitted by the MAH, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies.